CAMPYLOBACTER A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2004 by ICON Group International, Inc. Copyright 2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Campylobacter: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-497-00200-0 1. Campylobacter-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International, Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on campylobacter. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON CAMPYLOBACTER ..................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Campylobacter............................................................................... 4 E-Journals: PubMed Central ....................................................................................................... 26 The National Library of Medicine: PubMed ................................................................................ 65 CHAPTER 2. NUTRITION AND CAMPYLOBACTER ......................................................................... 111 Overview.................................................................................................................................... 111 Finding Nutrition Studies on Campylobacter ........................................................................... 111 Federal Resources on Nutrition ................................................................................................. 117 Additional Web Resources ......................................................................................................... 118 CHAPTER 3. ALTERNATIVE MEDICINE AND CAMPYLOBACTER ................................................... 119 Overview.................................................................................................................................... 119 National Center for Complementary and Alternative Medicine................................................ 119 Additional Web Resources ......................................................................................................... 125 General References ..................................................................................................................... 126 CHAPTER 4. DISSERTATIONS ON CAMPYLOBACTER ..................................................................... 127 Overview.................................................................................................................................... 127 Dissertations on Campylobacter ................................................................................................ 127 Keeping Current ........................................................................................................................ 128 CHAPTER 5. PATENTS ON CAMPYLOBACTER ................................................................................ 129 Overview.................................................................................................................................... 129 Patents on Campylobacter ......................................................................................................... 129 Patent Applications on Campylobacter...................................................................................... 148 Keeping Current ........................................................................................................................ 159 CHAPTER 6. BOOKS ON CAMPYLOBACTER ................................................................................... 161 Overview.................................................................................................................................... 161 Book Summaries: Federal Agencies............................................................................................ 161 Book Summaries: Online Booksellers......................................................................................... 162 Chapters on Campylobacter ....................................................................................................... 162 CHAPTER 7. MULTIMEDIA ON CAMPYLOBACTER......................................................................... 167 Overview.................................................................................................................................... 167 Video Recordings ....................................................................................................................... 167 CHAPTER 8. PERIODICALS AND NEWS ON CAMPYLOBACTER ...................................................... 169 Overview.................................................................................................................................... 169 News Services and Press Releases.............................................................................................. 169 Newsletter Articles .................................................................................................................... 171 Academic Periodicals covering Campylobacter.......................................................................... 172 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 175 Overview.................................................................................................................................... 175 NIH Guidelines.......................................................................................................................... 175 NIH Databases........................................................................................................................... 177 Other Commercial Databases..................................................................................................... 179 APPENDIX B. PATIENT RESOURCES ............................................................................................... 181 Overview.................................................................................................................................... 181 Patient Guideline Sources.......................................................................................................... 181 Finding Associations.................................................................................................................. 187 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 189 Overview.................................................................................................................................... 189 Preparation................................................................................................................................. 189
viii Contents
Finding a Local Medical Library................................................................................................ 189 Medical Libraries in the U.S. and Canada ................................................................................. 189 ONLINE GLOSSARIES................................................................................................................ 195 Online Dictionary Directories ................................................................................................... 197 CAMPYLOBACTER DICTIONARY .......................................................................................... 199 INDEX .............................................................................................................................................. 257
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with campylobacter is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about campylobacter, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to campylobacter, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on campylobacter. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to campylobacter, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on campylobacter. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON CAMPYLOBACTER Overview In this chapter, we will show you how to locate peer-reviewed references and studies on campylobacter.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and campylobacter, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “campylobacter” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Campylobacter: Low-Profile Bug is Food Poisoning Leader Source: FDA Consumer. 33(5): 14-17. September-October 1999. Contact: Available from Food and Drug Administration (HFI-40). 5600 Fishers Lane, Rockville, MD 20857. Summary: This article educates readers about campylobacter infections, a bacterial infection that rarely makes the news but that is responsible for up to 4 million human infections a year. Campylobacter bacteria is commonly found in the intestinal tracts of people or animals without causing any symptoms of illness. But eating contaminated or undercooked poultry or meat, or drinking raw milk or contaminated water, may cause Campylobacter infection (campylobacteriosis). Symptoms of this infection include mild to severe diarrhea, fever, nausea, vomiting, and abdominal pain. Most people infected
4
Campylobacter
with Campylobacter can get well on their own without treatment, though antibiotics may be prescribed for severe cases. Complications can occur, such as urinary tract infections, and meningitis, and the bacterial infection has been identified as a trigger for Guillain Barre syndrome (the most common cause of acute paralysis in both children and adults). The article discusses the safeguards in place in the poultry industry, problems with antibiotic resistance, research into a vaccine against Campylobacter, and consumer responsibilities, including appropriate food handling strategies. One sidebar lists the bacteria that cause food borne illness, along with the number of cases caused by each in 1997 in five states. 1 figure. •
Peptic Ulcer Disease and Helicobacter (Campylobacter) Pylori Infection Source: Current Opinion in Gastroenterology. 6(1): 72-78. February 1990. Summary: This article reviews the current evidence connecting peptic ulcer disease and Helicobacter (formerly grouped with Campylobacter) pylori infection. Topics include the bacteria's name change, major review articles studying the correlation of the bacteria with peptic ulcer disease, clinical studies supporting the theory, studies into the role of Helicobacter pylori (H. pylori), gastric ulceration, putative virulence factors, biotypes of H. pylori, Barrett's esophagus, Meckel's diverticulum, and antibacterial treatment. 1 figure. 26 annotated references.
Federally Funded Research on Campylobacter The U.S. Government supports a variety of research studies relating to campylobacter. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to campylobacter. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore campylobacter. The following is typical of the type of information found when searching the CRISP database for campylobacter: •
Project Title: A INSTRUMENT
HIGH-PERFORMANCE
FOOD
PATHOGEN
DETECTION
Principal Investigator & Institution: Su, Xiao-Li; Biodetection Instruments, Inc. Suite 122, M/S 300 Fayetteville, Ar 72701 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 29-JUN-2004 Summary: (provided by applicant): Food safety remains a critical issue for human health in our society. The food system in our nation is vulnerable to contamination from 2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies
5
natural pathogens and from bio-terrorist attack. Current detection methods are inadequate due to the time-consuming and laboratory-centered approaches presently in use. Instruments for rapid on-site detection of pathogens in food are urgently needed. The objective of this project is to evaluate an innovative capillary bioseparator / bioreactor-based optical biosensor technology for rapid detection of E. coli O157:H7. The detection limit, specificity and detection time possible with this approach will be evaluated. It is expected that the technology will provide <100 cells/ml detection limit, <1 h detection time, and high specificity to E. coli O157:H7 (<1% false positive/negative data). Although the initial work will focus on food safety, similar technology can be utilized for rapid, on-site screening of human E. coli infections. Rapid screening of human infections is also very important because life-threatening E. coli infections are increasing especially in susceptible groups such as premature babies. Preliminary data indicate that the proposed approach has good potential to significantly improve the state-of-the-art in rapid, sensitive, and specific detection of E. coli O157:H7 and eventually other biological pathogens. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTIBACTERIAL PEPTIDOGLYCAN RECOGNITION PROTEINS Principal Investigator & Institution: Dziarski, Roman; Professor of Microbiology and Immunology; Microbiology and Immunology; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2003; Project Start 15-SEP-2003; Project End 29-FEB-2008 Summary: (provided by applicant): Bacterial infections are still a major cause of morbidity and mortality, and biodefense category A and B pathogens include at least 18 bacteria that are potential threats to public health in case of their use in biological warfare or bioterrorism attack. The exposure from such an attack may not involve natural ways of transmission of these bacteria, but rather would likely involve contaminated air, objects, food, or water supply. Furthermore, the biological warfare or bioterrorism agent that will be used may not be initially known or may be a mixture of several agents. Therefore, an immediate and broad-based protection, effective against many bacteria, would be most beneficial in early stages of host defense against such an attack, to prevent or stop the infection at the portal of entry (which is likely to be skin, eyes, gastrointestinal tract, and upper respiratory tract). Because of broad specificity of innate immunity mechanisms for many bacteria (through their pattern recognition receptors), innate immunity is likely to be the most effective first line of defense to combat such bacterial infections immediately after the initial exposure. Thus, enhancing host antibacterial innate immunity at the site of contact with bacteria, including category A and B pathogens, could prevent establishment of infection or complement other therapies, and thus save lives in a biological warfare or a bioterrorism attack. Therefore, the goal of this project is to determine if human peptidoglycan recognition proteins (PGRPs), a newly discovered family of antibacterial pattern recognition molecules, can be applied to enhance host defenses against bacterial infections (including biodefense category A and B bacterial pathogens). Such an application will first require understanding of the mechanism of their antibacterial effect. This project will: first, determine the extent of antibacterial activity of PGRPs against a variety of bacteria (including category A and B bacterial pathogens); second, look for alternative splice forms of PGRPs with higher antibacterial activity; third, determine the mechanism of antibacterial effect of PGRPs and optimize the in vitro conditions for the antibacterial effect of PGRPs; and fourth, determine if PGRPs have protective or therapeutic effects in
6
Campylobacter
mouse infection models, when applied to the initial site of contact with selected category A and B bacterial pathogens. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DETECTION
BACTERIAL
PATHOGEN
AMPLIFICATION
&
REAL-TIME
Principal Investigator & Institution: U'ren, Jack R.; Director of Research; Saigene Corporation 7126 180Th Ave Ne, Ste C-104 Redmond, Wa 980524971 Timing: Fiscal Year 2003; Project Start 01-MAY-2003; Project End 30-NOV-2003 Summary: (provided by applicant): As we all know, bio-terrorism in America is a reality. However in addition to the Category A agents like anthrax, Yersinia pestis and smallpox, which are difficult to safely grow and disseminate, exist the Category B agents that could be used to infect our food or water supply. These organisms include bacterial pathogens, protozoa, and viruses. In addition to these natural pathogenic organisms they could also be genetically engineered to increase their virulence or to resist standard antibiotic treatments. Therefore new methods for rapid sensitive food and waterborne pathogen detection are greatly needed, especially if they can also be used to identify drug sensitivity within these organisms. Bio-terrorism using a food pathogen is not just a hypothetical threat to America. A religious cult in Dalles Oregon sickened at least 751 people by contaminating food in grocery stores and restaurants in the fall of 1984. The group simply grew cultures of the food pathogen Salmonella typhimurium that they obtained from their local scientific supply house and sprinkled the cultures on produce in the grocery stores and the restaurant salad bars. If the group had used a more deadly pathogen like Salmonella typhi that causes typhoid fever many people would certainly have died. The overall goal of this program is to develop an integrated isothermal DNA amplification and a probe array detection slide capable of rapidly identifying a variety of food and waterborne pathogens. All of the NIAID Biodefense Category B food and waterborne bacterial pathogens E. coli, Vibrio cholera, Shigella dysentery, Salmonella species, Listeria monocytogenes, Camphylobacter jejuni, and Yersinia enterocolitica will be detected in this program. A single integrated slide capable of isothermal amplifying and detecting all of these organisms in real-time in a closed sealed device is proposed. The program can also distinguish live organisms from dead organisms killed by the food or water sanitation process. Also, the test can be used to identify the antibiotic sensitivity of the pathogen to identify genetically altered organisms. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BROADLY ACTIVE INHIBITORS OF HIGH PRIORITY PATHOGENS Principal Investigator & Institution: Gulnik, Sergei; Professor; Sequoia Pharmaceuticals, Inc. 401 Professional Dr, Ste 100 Gaithersburg, Md 20879 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2005 Summary: (provided by applicant): The recent anthrax attack of 2001 underscored the reality of large-scale aerosol bioweapons attack by terrorist groups. It also revealed that there is an urgent and pressing need to discover and develop novel and potent antimicrobials that can be used therapeutically and prophylactically for biodefense against new bioattacks. The NIH and CDC have identified a number of High Priority pathogens based on their likelihood of causing widespread contagious disease and/or death to the general population. The long range goal of this Phase I SBIR is to discover and develop potent, broad-spectrum, and mechanistically-novel antimicrobials suitable for treating and/or preventing outbreaks of diseases like anthrax, plague, cholera,
Studies
7
gastroenteritis, multidrug-resistant tuberculosis (MDR TB), and for tackling the growing problem of antibiotic resistant bacteria strains. This Phase I application aims to generate novel inhibitors of a bacterial enzyme-3-dehydroquinate dehydratase (DHQase) using molecular target- and structure-based approaches. DHQase is a key enzyme in the shikimate pathway that is essential for the biosynthesis of aromatic amino acids in microorganisms, plants and fungi. Specific aims of the application include: 1) cloning, expression and purification of recombinant DHQases from Bacillus anthracis, Yersinia pestis, Campylobacter jejuni, Vibrio cholera and Mycobacteria tuberculosis; 2) establishing DHQase inhibitor assays using the recombinant enzymes; 3) identifying small molecule chemical leads using experimental and computational screening methods; and 4) validating binding modes of inhibitor leads using X-ray crystallography of inhibitor/enzyme complexes. High resolution crystal structures of DHQase, with and without inhibitors, are available from preliminary studies, and crystallization conditions are well established in the laboratory of the PI. The commercial goal of this SBIR is the invention of one or more patentable molecular entities with broad cross-reactivity against DHQases and the pathogens from which they are derived. Enzyme inhibitors identified in the Phase I portion of this work will serve as leads for launching into a Phase II study, the goal of which will be to translate potent and selective inhibitors of High Priority pathogens into safe and effective clinical drug candidates for use as biodefense agents. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: C. INTERACTIONS
JEJUNI
CYTOLETHAL
DISTENDING
TOXIN
CELL
Principal Investigator & Institution: Blanke, Steven R.; Associate Professor; Biology and Biochemistry; University of Houston 316 E Cullen Houston, Tx 772042015 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2006 Summary: (provided by applicant): Campylobacter jejuni is a food and water borne pathogen responsible for severe inflammatory diarrhea in humans. C. jejuni is a NIAID Category B Priority Pathogen because, in part, of the potential of this pathogen to be used as a biowarfare agent to contaminate food- and water supplies over large geographical areas. It is important to understand the basic biology of C. jejuni pathogenesis, which may lead to novel strategies for circumventing the use of this bacterium as a biowarfare agent. However, the pathogenic mechanisms used by C. jejuni to colonize and cause disease in the host are poorly understood. This application is a collaborative proposal between investigators at the University of Houston and UCLA to study the only known exotoxin secreted by C. jejuni. We will investigate the cellular mechanisms of the C. jejuni cytolethal distending toxin (CDT), which causes cell cycle arrest and eventual death of intoxicated mammalian cells, and has been proposed to assist in remodeling the in vivo environment to facilitate colonization of the intestinal tract. In this R21 application, we will begin to explore the hypothesis that CDT discriminates for and binds to a specific plasma membrane receptor on the surface of sensitive cells as an essential early step during cellular intoxication. In this application, we propose experiments for investigating at the molecular level the interactions of CDT with target cells. In Specific Aim 1, University of Houston researchers will characterize the interactions of CDT with sensitive mammalian cell lines. We will determine the specific and non-specific components as well as the affinity of CDT-receptor interactions. In addition, we will establish many how receptors are present per mammalian cell. Moreover, because CDT is a tri-partite toxin comprising three discrete subunits (CdtA, CdtB, and CdtC), we will establish the contribution of each subunit to
8
Campylobacter
binding of the toxin. Finally, we will begin to characterize the nature of the CDT receptor. These experiments will be important for establishing the framework for future experiments to identify the molecular basis for CDT receptor discrimination and binding. In Specific Aim 2, we will identify and characterize mutant cell lines that are resistant to CDT. UCLA researchers will use a genetic approach involving two fundamental phases. In phase 1, cell lines will be mutagenized and screened for a loss of sensitivity to CDT. In phase 2, the loss of sensitivity will be characterized, with the goal being the identification of a cell line that is deficient in binding to CDT. These experiments will be crucial for future work to complement the cell-binding defect, which will identify the putative CDT receptor. Results from this research will provide important information about the mechanism of CDT cellular intoxication, and will provide the basis for future work to develop strategies for blocking the action of CDT as an approach for attenuating C. jejuni pathogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CAMPYLOBACTER Principal Investigator & Institution: Ruiz-Palacios, Guillermo; Eastern Virginia Medical School Norfolk, Va 23507 Timing: Fiscal Year 2002 Summary: Campylobacter is one of the most common cause of diarrhea worldwide. Human milk protects young infants against Campylobacter diarrhea by several factors including fucosylated oligosaccharides. However, there is a lack of understanding of the chemical structure of these components and their mechanism of interaction with Campylobacter virulence traits associated with attachment to gut mucosa. The specific aims of this project are: 1) define the virulence markers of Campylobacter associated with attachment to epithelial cells; 2) characterize and purify milk glycoconjugates that inhibit Campylobacter infection; 3) assess passive protection in breast- fed children and experimentally in transgenic mice carrying a human fucoslytransferase gene expressed mainly in mammary tissue; 4) develop strategies for large-scale synthesis of fucosylated glycoconjugates active against Campylobacter infection; and 5) conduct clinical trials on safety and protection of fucosylated glycoconjugates against Campylobacter diarrhea. The long-term goal of this project is to develop methods for prevention and treatment of Campylobacter infection through understanding at the cellular and molecular level the mechanism of protection conferred by human milk against Campylobacter infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CAMPYLOBACTER DETERMINANTS
COLONIZATION
AND
VIRULENCE
Principal Investigator & Institution: Stintzi, Alain C.; Assistant Professor; Veterinary Pathobiology; Oklahoma State University Stillwater Stillwater, Ok 74078 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-JAN-2008 Summary: (provided by applicant): Campylobacter spp, generally food-borne, are the leading cause of gastroenteritis worldwide, surpassing the number of cases of Salmonella and Shigella combined. Campylobacter spp. are also associated with the development of Guillain-Barre syndrome, which is the most common cause of acute neuromuscular paralysis. In addition, since Campylobacter could be easily acquired and spread through our food supply, it constitutes a potential bioterrorism threat. Currently, no vaccine is available against Campylobacter infection, and despite an intensive research effort to understand Campylobacter pathophysiology, conclusions on
Studies
9
the exact mechanism of infection are extremely difficult to draw. C. jejuni is adapted to survive both in the environment (mainly water and milk) and in its host organisms (mammals and birds). Upon entrance into the human host, Campylobacter must survive in the intestinal tract, either as a free bacterium in the mucus layer or intracellularly in gut epithelial ceils. To colonize the intestinal tract, C. jejuni must successfully transit through the gastric acid barrier of the stomach to the more alkaline environment of the intestine. While up to 500 commensal species as well as other foodborne pathogens must similarly surmount these host barriers and adapt to the gut environment, very little is known about this process. This proposal focuses on the characterization of Campylobacter jejuni colonization and virulence factors. This proposal is based on the following hypothesis: there are numerous genes expressed in rivo that are influenced by environmental factors, and several of these genes are required for gut colonization and ultimately disease development. C. jejuni colonization and virulence determinants will be identified by in vitro and in vivo survival analysis of insertional mutants using DNA microarray. First, a functional genomic tool will be developed to identify conditionally essential genes in C. jejuni, and validated to examine the mechanism of C. jejuni survival to acid stress. Second, this functional genomic tool will be used to characterize the interactions of C. jejuni with the host gastrointestinal tract using the newborn piglet as an animal model of human infection. Finally, the role of the colonization and virulence determinants in disease and Campylobacter physiology will be assessed using a battery of in vitro biological assays. The identification of these Campylobacter determinants could significantly contribute to the development of more effective methods to diagnose, manage and ultimately prevent Campylobacter infections. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CAMPYLOBACTER JEJUNI PROTEINS INDUCED AT 37C Principal Investigator & Institution: Thompson, Stuart A.; Assistant Professor; Biochem and Molecular Biology; Medical College of Georgia 1120 15Th St Augusta, Ga 30912 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-JAN-2008 Summary: (provided by applicant): Campylobacter jejuni is the leading cause of severe bacterial gastroenteritis in the U.S., and has been classified as a food-borne Category B Bioterrorism agent by the NIH. In addition to the tremendous burden of disease due to severe gastroenteritis (>2.4 million cases/yr, in the U.S.), C. jejuni infection is highly associated with the development of Guillain-Barre syndrome, an acute motor paralysis that may result from autoimmune antibodies against C. jejuni antigens. Poultry flocks are ubiquitously and asymptomatically colonized with C. jejuni, and the most probable route of transmission of C. jejuni to humans is probably via consumption of contaminated poultry meat. In its natural habitats, C. jejuni is able to thrive at two different temperatures, 42C (the core temperature of chickens) and 37C (in humans). Consequently, there is likely to be temperature regulation of C. jejuni proteins to facilitate the optimal expression of the subset of proteins appropriate for its current environment (i.e., poultry or humans). Using complementary microarray and proteomics approaches, we have evidence that such temperature regulation occurs. Furthermore, C. jejuni temperature regulation may increase the expression at 37C of proteins that may be important in the course of human disease, and appear to define global regulatory networks that allow the simultaneous regulation of many C. jejuni proteins. We now propose further study of temperature regulation in C. jejuni, focusing on those proteins that are induced at 37C and which may be required for C. jejuni to cause disease in humans. We will achieve these goals using the following 3 specific
10
Campylobacter
aims: Specific Aim 1. Using proteomics and microarray, identify and localize C. jejuni proteins that are induced at 37C, and examine interstrain variability in 37C-induced proteins. Specific Aim 2. Characterize the functions and regulation of C. jejuni proteins that are induced at 37C.Specific Aim 3. Elucidate the roles of specific 37C-induced proteins in human epithelial cell binding and invasion in vitro, and in colonization in a mouse model. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VIRULENCE
CELL-SURFACE
PROTEINS
IN
CAMPYLOBACTER
FETUS
Principal Investigator & Institution: Blaser, Martin J.; Dir, Division of Infectious Diseases; Medicine; New York University School of Medicine 550 1St Ave New York, Ny 10016 Timing: Fiscal Year 2002; Project Start 01-SEP-1989; Project End 31-MAY-2005 Summary: (Adapted from the Applicant's Abstract): Campylobacter fetus is a pathogen of humans and animals. All wildtype C. fetus strains possess regular, paracrystalline high molecular weight (97, 127, or 149kDa) surface layer proteins (SLPs) that are critical for virulence. The SLPs inhibit complement binding, which leads to both serum and phagocytosis resistance, and they undergo antigenic variation. C. fetus cells possess 8 or 9 homologs of sapA, which encodes a 97 kDa SLP. The homologs share multiple areas of homology with each other, are clustered on the bacterial genome, and together with an invertible region (IR) of 6kb form the sap locus. The investigators previously showed that the DNA rearrangement (inversion) plays a major (if not exclusive) role in the antigenic variation, and that mutation of recA removed all detectable variation. They now have developed animal models to examine SLP variation, have shown that antigenic variation due to sap locus recombination occurs in recA strains, and have moved the IR onto the E. coli chromosome. The first aim of the proposed work is to identify the recombination pathways that permit the sap locus inversion. Their hypothesis is that the inversion depends on conserved recombination genes including those in the RecBCD, RecE, and RecF pathways. Alternatively, they might find that C. fetus has species-specific recombination pathways. The ultimate goal will be to define and mutate the recombination genes in C. fetus and examine the phenotypes of mutants. Their second aim is to define the structural features present in the sapA homologs that are required for recombination to occur. They propose to complete the map of the sap locus and to create mutants that will permit assessment of the necessary structural features. As part of this goal, they plan to identify the sites of double strand breaks that are the initial sites for DNA strand exchange. The third aim is to examine sap rearrangement in vivo in mice. After establishing the model, they can examine the role of host responses in directing the evolution of antigenic variation, and the fitness of defined mutants. Finally, the data generated can be used to develop a mathematical model of antigenic variation that focuses on the relationship between microbial recombination generating diversity and host selection determining the direction of change. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHEMOKINES IN HOST DEFENSE TO CAMPYLOBACTER JEJUNI Principal Investigator & Institution: Dwinell, Michael B.; Microbiol & Molecular Genetics; Medical College of Wisconsin Po Box26509 Milwaukee, Wi 532260509 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2005
Studies
11
Summary: (provided by applicant): This R21 research proposal, submitted in response to "Biodefense and Emerging Infectious Diseases Research Opportunities", NOT-AI-02023, has two specific aims designed to increase our understanding of the pathogenesis of Campylobacter jejuni enterocolitis. The intestinal epithelium comprises a dynamic physical barrier that maintains an active repertoire of innate host defense responses to limit entry of clinically significant food- and water-borne pathogens. These mechanisms include the regulated production of chemokines to coordinate the appropriate innate and adaptive immune effector response. C. jejuni is a leading cause of bacterial diarrheal disease in the world. However, while relatively little is known of the pathophysiologic mechanisms employed to infect the human intestinal tract and elicit disease, interaction at the intestinal epithelium is the most common pathogenic feature of infection. The overall objective of this research proposal is to obtain novel information on the mechanisms of pathogenesis to C. jejuni enterocolitis and will, as an important first step, focus on the coordinated production of chemokines by the cells of the intestinal epithelium as a significant host defense mechanism. Studies in Aim 1 will test the hypothesis that C. jejuni infection of human intestinal epithelial cells stimulates production of chemokines for neutrophils, dendritic cells and T lymphocytes, effectors cells that we postulate act in concert to limit C. jejuni entry in vivo. A culture model intestinal epithelium will be infected with C. jejuni and the signaling mechanisms regulating epithelial chemokine production assessed. To define bacterial pathogenicity, studies in Aim 2 will utilize C. jejuni mutants to test the hypothesis that specific Campylobacter virulence factors induce host epithelial cell chemokine expression. Induction of epithelial chemokine expression will be tested in C. jejuni flagella mutants, as well as mutants selected from candidates revealed from a promoter trap-based approach to define novel virulence factors. Together, these studies will provide new insights into the cellular signaling mechanisms and bacterial gene products regulating intestinal epithelial chemokine production as a central host defense function to C. jejuni. Understanding the cellular and biochemical mechanisms of intestinal epithelial host defense to human C. jejuni infection are central to the development of preventative therapeutic strategies to modulate host-pathogen interactions to favor the host. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHINESE PARALYTIC SYNDROME - MECHANISMS AND RELEVANCE Principal Investigator & Institution: Mc Khann, Guy M.; Professor; None; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2001; Project Start 01-MAY-1993; Project End 31-AUG-2004 Summary: Guillain-Barre syndrome (GBS), an autoimmune post-infectious disorder, is a frequent cause of acute flaccid paralysis in the post-polio era. Recently, two major types of GBS have been described: acute inflammatory demyelinating polyneuropathy (AIDP) characterized by lymphocytic inflammatory demyelination; and acute motor axonal neuropathy (AMAN) characterized by noninflammatory axonal degeneration of motor nerves. Both forms can be associated with preceding infections with Campylobacter jejuni. The immunopathology in these two forms is quite different. In AMAN the initial immunological attack is at the node of Ranvier of motor axons and appears to be associated with antibodies against GD1a ganglioside; in AIDP it is at the external membrane of the Schwann cell. Our studies suggest that molecular mimicry , in which a shared epitope on C. jejuni induces an autoimmune response against nerve, may play an important role in the pathogenesis of GBS. Types of GBS that develop may be influenced by several factors including 1) Anti- glycoconjugate antibody production; 2) Chemokine
12
Campylobacter
production; 3) Neuritogenic factors on Campylobacter, 4) Host factors. In this study, the molecular mimicry hypothesis and the factors that may influence the pathogenesis will be evaluated. Aims are designed to 1) study the role of antiglycoconjugate antibody in AMAN and AIDP; 2) localize the relevant epitopes on motor nerves; 3) study the pattern of chemokine production AMAN and AIDP; 4) determine the bacterial factors that may influence the development of GBS and demonstrate the relevant epitopes; 5) study HLA class I and II haplotypes in AMAN and AIDP. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DETECTION OF PATHOGENS IN AVIAN FECAL POLLUTION Principal Investigator & Institution: Mclellan, Sandra L.; Assistant Scientist; Great Lakes Water Institute; University of Wisconsin Milwaukee Graduate School Milwaukee, Wi 532010340 Timing: Fiscal Year 2003; Project Start 11-JUL-2003; Project End 10-JUL-2005 Summary: (provided by applicant): Nationwide, beach closings constitute a major environmental and public health concern. Recreational water quality is evaluated by measuring levels of bacteria such as enterococci, fecal coliforms, or E. coli, all of which indicate the presence of fecal contamination. In freshwater, the EPA recommends that water quality advisories be issued when levels exceed the guideline of 235 E. coli/100 ml; these levels have been established by epidemiological studies that have shown a correlation between concentrations of indicator organisms and gastroenteritis. The health risks associated with exposure to fecal pollution are different depending on the source of contamination. We have found that levels of E. coli in recreational water are highly influenced by localized contamination from roosting birds, and many times are not a reflection of serious contamination events that present a known health risk, such as human sewage overflows. Gulls, the most prevalent type of coastal aquatic bird and waterfowl, are known to carry human pathogens such as Salmonella and Campylobacter. The potential for beach areas to act as reservoirs for human pathogens is not known. In addition, the relationship between levels of human pathogens introduced into surface water by gulls or waterfowl and those of indicator bacteria is not well established. We will evaluate human health risk at beach sites that have experienced chronic beach closings due to localized contamination. In these studies we will 1) determine pathogen occurrence in gull populations that inhabit beach areas, 2) develop direct detection methodology for pathogens that can be applied to recreational water samples, and 3) perform pilot studies to determine the potential for avian adenovirus to be used as a specific marker for avian fecal pollution. Basic information as to the occurrence of human pathogens in beach ecosystems is essential in order to design further studies to assess human health risk, determine parameters that influence transport and fate of these pathogens in the nearshore environment, and finally, develop assessment tools that can discern the sources of fecal pollution. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EXPERIMENTAL NEUROPATHY (AM
MODELS
OF
ACUTE
MOTOR
AXONAL
Principal Investigator & Institution: Sheikh, Kazim A.; Assistant Professor; None; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2002; Project Start 03-JUL-2002; Project End 30-JUN-2006 Summary: (provided by applicant): Guillain-Barre syndrome (GBS), an autoimmune post-infectious neuropathy, is the most frequent cause of acute flaccid paralysis since the
Studies
13
eradication of polio. It is now widely accepted that there are two major forms of the disease, acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and acute motor axonal neuropathy (AMAN). Molecular mimicry has been proposed as a pathogenic mechanism for AMAN because it mostly follows Campylobacter jejuni infection, the LPS of AMAN associated C. jejuni contain ganglioside-like moieties, patients with AMAN have specific IgG anti-ganglioside antibodies including those against GD1a, and pathological studies demonstrate deposition of IgG and complement on motor axons and specific motor fiber injury. However, a direct relationship between anti-ganglioside antibodies and nerve fiber injury has not been established. Further, in vitro or animal models of antibody mediated motor axonal injury are not available. This largely reflects difficulties in generating high affinity IgG complement fixing antiganglioside antibodies similar to those seen in AMAN. We propose to use mice lacking complex gangliosides, which are immune naive to complex gangliosides, to generate the desired monoclonal (mAb) anti-ganglioside antibodies. These mAbs will be used to reproduce motor axonal injury in passive transfer animal models and in an in vitro spinal cord culture system. mAbs will also be used for localization and biochemical studies to probe the basis of the preferential motor axonal damage seen in AMAN. The ganglioside nature of antigens targeted by anti-ganglioside antibodies will be established by genetic and or pharmacologic manipulation of ganglioside expression in in vitro and animal models. An in vitro system will also be used to investigate the components of complement cascade involved in antibody-mediated axonal degeneration. Finally, affinity purified anti-ganglioside antibodies from patients with AMAN will be used in parallel to establish the causal relationship between the human antibodies and motor axonal degeneration. These studies will prove the hypothesis of molecular mimicry as an underlying mechanism for the pathogenesis of AMAN. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FUNCTIONAL GENOMIC/PROTEOMIC ANALYSIS OF BACTERIALHOST Principal Investigator & Institution: Iandolo, John J.; Professor & Chairman; Microbiology and Immunology; University of Oklahoma Hlth Sciences Ctr Health Sciences Center Oklahoma City, Ok 73126 Timing: Fiscal Year 2002; Project Start 15-SEP-2000; Project End 31-AUG-2005 Summary: The purpose off the Institutional Development Award (IdeA) Program is to foster health-related research and increase the competitiveness of investigators through support of faculty development and enhancement of the research infrastructure of institution located in states with historically low aggregate success rates of grant awards from the NIH (RFA +RR-00- 003). Thus, we propose to establish a Center for Biomedical Research Excellence (COBRE), with the thematic focus of Functional genomic/Proteomic Analysis of Bacterial-Host Interactions. This COBRE will exploit one of the few areas of biomedical research where Oklahoma has been in the forefront in recent years, which is the genome-scale analysis of bacterial pathogenesis. Currently, there are five ongoing NIH- supported pathogen genome sequencing programs conducted within the state, including the soon-to-be-completed genome sequence of Neisseria gonorrhoeae, which was the first pathogen genome sequencing project funded by NIH. We therefore propose to build on this unique opportunity by exploring functional genomic and proteome analysis to examine the pathogenesis of five major human pathogens: 1) Neisseria gonorrhoeae, 2) Borrelia burgdorferi, 3) Escherichia coli 0157:H7, 4) Campylobacter jejuni and 5) Bacillus anthracis. The proposed COBRE will be headed by an established NIH-funded investigator and includes three new
14
Campylobacter
investigators and an established investigator who do not have a prior history of NIH R01 support. This is a state-wide initiative that includes the thre major publiclysupported research institutions in the state of Oklahoma: 1) the University of Oklahoma (OU), 2) the Oklahoma University Health Sciences Center (OUHSC), institute located near the OUHSC campus. The project is organized similarly to a typical program project grant, facilities on each campus to support the five participating investigators. This strategy will allow each investigator to sufficiently develop their research program to become competitive for additional NIH R01 support. The proposed core facilities also will provide other investigators in Oklahoma with the technical support necessary to expand their own research programs into the burgeoning area of genome-scale analysis of problems of biomedical interest. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC COLONIZATION
ANALYSIS
OF
CAMPYLOBACTER
JEJUNI
Principal Investigator & Institution: Hendrixson, David R.; Laboratory Animal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2002; Project Start 01-APR-2002 Summary: (provided by applicant): Campylobacter jejuni is the leading cause of bacterial gastroenteritis in developed countries and a major cause of bacterial diarrhea throughout the world. The gastrointestinal tracts of many birds serve as a natural reservoir for the bacterium and humans most often come into contact with the organism by consuming contaminated chicken meats. Despite the prevalence of C. jejuni in human disease, our understanding of pathogenic mechanisms and virulence factors of the bacterium is sparse compared to other enteric pathogens. This lack of knowledge is mainly due to the relative scarcity of available genetic tools to study the organism. We have developed a system of random transposon mutagenesis for C. jejuni and used the derived isogenic mutants to identify genes required for flagellar motility, including carB and carC (encoding proteins with homology to bacterial chemotaxis proteins and the aerotaxis receptor of E. coli, respectively) and rpoN (encoding sigma 54). The aims in this proposal are to understand the roles of the Car proteins and sigma 54 in C. jejuni motility, a phenotype required for efficient colonization of chickens. In addition, we will modify the transposon and perform signature-tagged mutagenesis in C. jejuni to identify genes required for chicken colonization. This last aim will allow us to begin to understand requirements of C. jejuni for colonization of a natural host. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLYCOSYLATION OF CAMPYLOBACTER FLAGELLA Principal Investigator & Institution: Guerry, Patricia; Section Head; Henry M. Jackson Fdn for the Adv Mil/Med Rockville, Md 20852 Timing: Fiscal Year 2003; Project Start 01-JUL-1999; Project End 31-MAR-2008 Summary: (provided by applicant): Campylobacter jejuni is the leading cause of foodborne illness in North America and is among the major causes of bacterial diarrhea worldwide. Flagella and motility are required for intestinal colonization and invasion of intestinal epithelial cells by C. jejuni, and flagellin is an immunodominant and possibly a protective antigen. Flagellin from C. jejuni strain 81-176 and Campylobacter coli strain VC167 are glycosylated at 19 and 16 serine or threonine residues, respectively, with a 9 carbon sugar called pseudaminic acid and derivatives of pseudaminic acid. The
Studies
15
modifications, which account for approximately 10% of the weight of these glycoproteins, are surface exposed on the flagella filament and are likely involved in interaction of flagellin with the eukaryotic host. Genetic analyses indicate that the pathway for biosynthesis of pseudaminic acid is conserved in both 81-176 and VC167. Flagellins from both strains contain minor modifications that are acetamidino forms of pseudaminic acid (mass 315 Da). However, the 315 Da group synthesized by 81-176 and VC 167 are structurally and immunologically distinct and are synthesized by independent pathways in each organism. The data suggest that campylobacter flagellin needs to be glycosylated in order to be exported and/or assembled into a filament. A mutant in 81-176 that is unable to synthesize the acetamidino form of pseudaminic acid appears to be attenuated in virulence. The aim of this study is to further elucidate the pathways by which the different forms of pseudaminic acid are synthesized and to study unique aspects of the regulation of these glycosylation genes. Site-specific mutagenesis will be done on flagellin to eliminate modification sites sequentially in order to determine sites that are critical for flagella function and the rules of site occupancy. The biological role of flagella glycosylation will be studied by examining a series of mutants in in vitro and in vivo assays of virulence. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GUT TO BRAIN PATHWAYS FOR INFECTION-INDUCED ANXIETY Principal Investigator & Institution: Lyte, Mark; Professor; Minneapolis Medical Research Fdn, Inc. 600 Hfa Bldg Minneapolis, Mn 55404 Timing: Fiscal Year 2002; Project Start 01-APR-1994; Project End 30-JUN-2006 Summary: (provided by applicant): The experiments proposed in this application examine the effects of infectious microorganisms in the gastrointestinal tract on affect and behavior, effects posited to be mediated by stimulation of a visceral sensory pathway to the central nervous system (CNS). This proposal is based on the demonstration that a low-dose ("subclinical") infection with the food-borne pathogen Campylobacter jejuni induces anxiety-like behavior in orally challenged mice. As such, it differs from the current understanding of the mechanisms that govern the ability of infection to influence behavior since these infection-induced behavioral alterations occur in absence of obvious physical sickness symptoms that usually accompany infectioninduced behavioral alterations. Further, new data demonstrate that such subclinical infection results in the specific activation of regions within the brain associated with anxiety and that interruption of gut-brain pathways inhibits C. jejuni infection-induced brain activation. Thus, our Specific Aims are: 1) To determine the peripheral concomitants involved at the gut level that may be responsible for the ability of subclinical C. jejuni infection to induce anxiety-like behavior in mice. The degree of behavioral alterations induced in response to oral challenge with C. jejuni will be assessed in conjunction with histochemical and immune analysis of infected animals to extend previous work. We will also examine whether a localized immune activation occurs in the absence of a systemic response; 2) To identify the specific visceral sensory pathways leading from the gut to the CNS that are activated following oral bacterial challenge. We will assess the expression of the activation marker c-fos in enteric and vagal sensory neurons as well as sensory neurons in the spinal chord, and determine the impact of selective hepatic and celiac vagotomy; and 3) To determine connectivity and neurochemical identities of neurons driven by C. jejuni infection that form a specific neurocircuitry leading to infection-induced alterations of behavior. Collectively, the above aims will seek to establish that certain behaviors may be modulated, in part, by infectious microorganisms within the gut through the "gut-to-brain" axis involving
16
Campylobacter
visceral sensory input. A link between the common occurrence of gastrointestinal infections, especially those which do not produce overt clinical symptoms indicative of infection, with anxiety may therefore identify a previously unidentified circumstance which may play a contributing role in regulating behavior. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HOST FACTORS MEDIATE INVASION BY CAMPYLOBACTER JEJUNI Principal Investigator & Institution: Mansfield, Linda S.; Professor; Large Animal Clinical Sciences; Michigan State University 301 Administration Bldg East Lansing, Mi 48824 Timing: Fiscal Year 2002; Project Start 01-DEC-1997; Project End 30-NOV-2002 Summary: (Adapted from the applicant's abstract): Campylobacter jejuni is the leading cause of intestinal infection in humans in the US and the world, and has been designated as an emerging disease by the US CDC. This bacterium opportunistically invades the gastrointestinal tract, especially the colon, causing gastroenteritis, proctitis, and occasionally other problems, but the factors controlling this invasion are largely unknown. Long-range goal: to understand the mechanisms of resistance to opportunistic invasion of the gastrointestinal tract by C. jejuni; to provide a new animal model for testing cytokine and vaccine therapies for C. jejuni disease in humans. The proposal is based on the investigators previous work with a swine model wherein subsequent to intestinal infection with Trichuris suis, C. jejuni invades the swine colon. Mechanisms of resistance to mucosal invasion by C. jejuni are unknown. The objective is to determine the mechanism whereby T. suis facilitates the invasion of host cells by C. jejuni in piglet colons. The hypothesis to be tested is that T. suis allows C. jejuni to invade 1) by acting directly on cells with a secreted mediator to facilitate uptake of C. jejuni, or 2) acting indirectly through stereotypic immune or proinflammatory responses to downregulate resistance of host cells to C. jejuni invasion. Specific Aims: 1) Determine what cell types are invaded by C. jejuni in T. suis induced C. jejuni infections in swine, 2) Determine whether serotype cytokine patterns are associated with C. jejuni invasion of host cells, 3) Determine whether C. jejuni invasion is facilitated due to a direct effect of some secreted/excreted product of the worms, and 4) Determine what host cell genes are differentially expressed during C. jejuni invasion. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MECHANISMS OF ANTIBIOTIC EFFLUX IN CAMPYLOBACTER Principal Investigator & Institution: Zhang, Qijing; Associate Professor; Vet Microbiol & Prev Medicine; Iowa State University Ames, Ia 500112207 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2006 Summary: (provided by applicant): Campylobacter jejuni, an important foodborne pathogen causing gastroenteritis in humans, has evolved multiple mechanisms to counteract the action of various antibiotics, which has posed a serious threat to public health, Many of these resistance mechanisms, such as gyrA mutations and betalactamase production, confer Campylobacter resistance to specific antibiotics. However, the active efflux systems, which extrude structurally diverse antibiotics out of bacterial cells, contribute to the intrinsic and acquired resistance to multiple drugs. Although previous studies suggested the possible presence of functional efflux systems m C. jejuni, the antibiotic efflux machinery in this pathogen has not been defined. Using transposon mutagenesis in conjunction with other approaches, we have recently
Studies
17
characterized a three-gene operon (named cmeABC) encoding a tripartite antibiotic efflux pump that contributes to C. jejuni resistance to structurally unrelated antibiotics, heavy metals, bile salts, and other toxic compounds. Our preliminary data and the genomic sequence of C. jejuni NCTC 11168 suggested the presence of an additional antibiotic efflux system (name cmeDEF) and the possible regulation of cmeABC and cmeDEF by transcriptional repressors. Based on these observations and the known features of bacterial antibiotic efflux systems, we hypothesize that CmeDEF in conjunction with CmeABC plays an important role in extruding various agents, and the modulated expression of the efflux pumps by regulatory proteins contributes significantly to the intrinsic and acquired resistance of Campylobacter to multiple antimicrobials. To test our hypothesis, we plan to i) determine the role of CmeDEF and its interplay with CmeABC in mediating Campylobacter resistance to multiple drugs and ii) to identify and characterize the transcriptional repressors that modulate the expression of the antibiotic efflux systems. Various genetic and biochemical approaches, including random and site-specific mutagenesis, recombinant proteins, substrate accumulation assay, and DNA binding assays will be utilized to define the functions of the efflux systems and their interplay with regulatory proteins. It is anticipated that the proposed studies will close a major gap in our understanding of the antibiotic resistance mechanisms in C. jejuni and may open new avenues for the design of effective means to prevent and treat antibiotics-resistant Campylobacter. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MICRONUTRIENTS AND ENTERIC INFECTION IN AFRICAN CHILDREN Principal Investigator & Institution: Bennish, Michael L.; Director; New England Medical Center Hospitals 750 Washington St Boston, Ma 021111533 Timing: Fiscal Year 2003; Project Start 15-SEP-1999; Project End 30-JUN-2005 Summary: Enteric infections remain a leading cause of childhood mortality in developing countries. In regions where HIV infection is prevalent, enteric infections and persistent diarrhea have even greater public health importance. Little is known, however, about the pattern of enteric infection in children in regions where HIV infection is common, and how infection is related to HIV activity as measured by plasma HIV RNA, or host immunocompetence, as determined by CD4 counts. Although micronutrient supplementation, including provision of vitamin A and zinc, are being promoted as effective means of reducing infectious diarrhea morbidity and prevalence, little is know about their efficacy in achieving these goals in African children, or in children who are HIV infected. This study had the following specific aims: 1) To determine the pathogen-specific pattern of enteric infections in HIV-infected and uninfected children living in rural South Africa, with a particular focus on infection with Cryptosporidium parvum and other protozoan pathogens. 2) To determine if infection with specific pathogens is associated with the development of persistent diarrhea lasting greater than 14 days; 3) To determine the efficacy of two micronutrient supplements; a) a mixture containing Vitamins A, C, E, and selenium; and b) the same micronutrient supplement with the addition of zinc, on the prevalent days of diarrhea in both HIVinfected and HIV- uninfected children.; 4) To determine if micronutrient supplementation improves gut integrity as measured by the mannitol-lactulose permeability test. 5) Based upon these findings to develop recommendations for use of micronutrient supplements in Africa and other regions with a high HIV- seroprevalence. To answer these questions we propose enrolling and studying three cohorts of children living in a rural region of South Africa over a three-year period; 1) 78 HIV-infected
18
Campylobacter
children; 2) 120 HIV-uninfected children born to HIV-infected mothers; 3) 120 HIVuninfected children born to mothers without HIV infection. Children will be ascertained at three months of age and followed until age 2 years. Micronutrient supplementation will be given from enrollment until age 12 months. Children will be visited weekly by field staff, and diarrhea and other morbidity recorded. Stool for detection of enteric pathogens, including Salmonella, Shigella, Campylobacter, diarrheagenic E. coli (determined using probes for virulence genes), rotavirus, enteric adenoviruses 40/41, astroviruses and Norwalk virus, and the protozoan pathogens C. parvum (including genotyping of strains), Cyclospora cayetanensis, and Enterocytozoon bieneusi will be obtained from children when they have diarrhea, and from a subset of well children. Anthropometry will be measured regularly, and bioimpedance will be performed to determine body composition. A non-invasive test of gut permeability (the lactulosemannitol test) will be performed on all children while they are receiving micronutrient supplementation. The study sample size is calculated to allow a determination of a 20 percent difference in prevalent days of diarrhea between the placebo treated group and the two micronutrient supplemented groups. This study will also allow us to determine risk factors for persistent diarrhea, and to develop algorithms for the management of infectious diarrhea in a region where HIV infection is common. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR ANALYSIS OF THE CYTOLETHAL DISTENDING TOXIN Principal Investigator & Institution: Dreyfus, Lawrence A.; Professor & Dean; Cell Biology and Biophyscis; University of Missouri Kansas City Kansas City, Mo 64110 Timing: Fiscal Year 2002; Project Start 01-JUL-2001; Project End 31-MAY-2006 Summary: The cytolethal distending toxin (CDT) is a potent bacterial toxin produced by a growing list of unrelated bacterial pathogens including scattered isolates of E. coli and Shigella isolates, Campylobacter spp., Haemophilus ducreyi, Actinobacillus actinomycetemcomitans, and enteropathogenic Helicobacter spp. Initially, CDT was characterized by its capacity to induce massive cellular distension and cell death. Cells treated with CDT undergo an irreversible block in cell division caused by disruption of the cell cycle in G2. The specific events leading to CDT-mediated growth arrest parallel those following induction of the mitotic DNA damage checkpoint. CDT is the product of three genes designated cdtA, cdtB, and cdtC, which encode proteins with molecular masses of 30, 32, and 20 kDa. Genetic and biochemical evidence indicate that all three polypeptides are required for cellular intoxication. We recently reported that CdtB bears sidnificance position-specific sequence relatedness to mammalian type I DNase. Mutational analysis indicates that the DNase-related active site residues in CdtB are required for biological activity. In preliminary studies show that purified CdtB possesses Mg2plus- dependent DNase activity. We also present evidence indicating that CDT damages chromosomal DNA followed by activation of elements of the DNA damage checkpoint cascade. Although not toxic when added alone to cells, introduction of CdtB into cells results in the entire spectrum of CDT activities. We therefore hypothesize that CdtB mediates the cytolethal effects of CDT while CdtA and CdtC are required for cell binding and/or translocation of CdtB. In this application we propose to: 1) define the role of each of the three CDT polypeptides in cell binding and CdtB entry, 2) determine the mechanism by which CdtB traffics through the cell and translocates into nucleus (the apparent site of CdtB action, and 3) define the series of events leading to CDT-mediated growth arrest and death. Completion of these aims will provide new insights into the novel action of this potent bacterial toxin.
Studies
19
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR GENETICS OF ENTEROPATHOGENIC E. COLI ADHESION Principal Investigator & Institution: Kaper, James B.; Professor; Microbiology and Immunology; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2004; Project Start 01-JUL-1986; Project End 31-MAR-2009 Summary: (provided by applicant): Enteropathogenic Escherichia coli (EPEC) are an important cause of diarrhea in infants. The long-term objectives of this project are to understand the pathogenesis of disease due to this organism. Previous work on this project has resulted in the discovery of a 35 kb pathogenicity island called the Locus of Enterocyte Effacement (LEE) that is responsible for the attaching and effacing (AE) histopathology on intestinal epithelial cells that is the hallmark of EPEC infections. The LEE island encodes the epithelial cell adhesin named intimin, a type III protein secretion system, and several effector proteins that are translocated into epithelial cells to mediate the AE lesion. Typical EPEC strains possess the LEE plus the EAF plasmid that encodes a type IV pilus (BFP) that contributes to epithelial cell adherence and a positive regulator of EPEC virulence factors called Per. Typical EPEC strains are an important cause of infant diarrhea in developing countries but are infrequent causes of disease in the U.S. Atypical EPEC strains contain the LEE but lack the EAF plasmid. In contrast to typical EPEC strains, atypical EPEC appear to cause outbreaks and sporadic disease in adults in industrialized countries such as the U.S., Finland, and Japan. Recent studies of atypical EPEC in children with diarrhea in the U.S. suggest that the incidence of infections with this pathogen may equal or exceed that of Salmonella, Shigella, Campylobacter, or E. coli O157:H7. The proposed research goals for the next period of support include continued characterization of pathogenic mechanisms of typical EPEC strains, particularly genes encoded outside the LEE, and a new focus on potential pathogenic mechanisms of atypical EPEC. The specific aims are 1) Characterize the Long Polar Fimbriae (LPF) of EPEC and assess in vivo expression of this and other potential adhesins; 2) Identify and characterize genes regulated by the Ler and Per regulators of EPEC virulence factors using genomic arrays; 3) Characterize human host epithelial cell transcriptional responses to EPEC infection using in vitro organ culture (IVOC); and 4) Characterize potential virulence factors in atypical EPEC strains. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PATHOGENESIS OF CAMPYLOBACTER ENTERITIS: Principal Investigator & Institution: Konkel, Michael E.; School/Molecular Biosciences; Washington State University 423 Neill Hall Pullman, Wa 99164 Timing: Fiscal Year 2002; Project Start 01-AUG-2001; Project End 31-MAY-2006 Summary: (provided by the applicant): The ultimate goal of this research is to use the knowledge gained from the identification and characterization of Campylobacter jejuni virulence determinants to reduce morbidity and mortality resulting from C. jejuni infections. C. jejuni is a leading cause of human gastrointestinal disease worldwide, causing approximately 3.5 million cases of diarrheal illness per year in the United States. Infection with C. jejuni is characterized by fever, severe abdominal cramps, and diarrhea containing blood and leukocytes. The dysenteric nature of Campylobacter infection, coupled with experimental evidence, supports the notion that C. jejuni must invade the cells lining the gastrointestinal tract for the development of C. jejuni-mediated enteritis. The focus of this proposal is to identify and functionally characterize the bacterial
20
Campylobacter
proteins necessary for C. jejuni internalization. Previous work in my laboratory has revealed that C. jejuni synthesize and secrete proteins upon co-cultivation with mammalian cells. These secreted bacterial proteins have been collectively called Campylobacter invasion antigens (Cia). A mutation in a gene encoding the 73 kDa CiaB secreted protein results in a non-invasive phenotype. I hypothesize that Cia proteins are secreted via a Type III export pathway from C. jejuni. The results of this research will better define the pathogenic mechanisms and virulence determinants of one enteric pathogen, C. jejuni, and will be useful in the development of intervention and control methods to reduce the number of cases of human campylobacteriosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RAPID DETECTION OF MAJOR FOOD-BORNE PATHOGENS Principal Investigator & Institution: Zhu, Peixuan; Creatv Microtech, Inc. 11609 Lake Potomac Dr Potomac, Md 20854 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2004 Summary: (provided by applicant): Our food is a major source of illness. The Centers for Disease Control (CDC) estimates that food-borne diseases cause approximately 76 million incidents of illness, resulting in 325,000 hospitalizations and 5,000 deaths annually in the U.S. Known pathogens were implicated in 14 million of these incidents, 60,000 associated hospitalizations, and 1,800 deaths. Four pathogens alone (E. coli, Salmonella, Listeria, and Campylobacter) are believed to account for over two-thirds of deaths caused by known pathogens. The goal of our research is to achieve rapid, sensitive, and simple detection of pathogenic bacteria and toxins commonly found in foods by applying a new, very sensitive technology known as the "Integrating Waveguide Biosensor". This technology was recently developed by the Naval Research Laboratory (NRL) and is being licensed to Creatv MicroTech for application in the fields of water and food safety testing. NRL's initial experimental results for two molecules showed the Integrating Waveguide Biosensor to be 100 times more sensitive than the previous generation of biosensors based on optical fibers and planar arrays. We expect to achieve a similar improvement in sensitivity for detection of pathogens in food in a test that can be completed in less than 30 minutes. The resulting device will be ideally suited to the prevention of food-borne diseases. The initial scope in Phase I will focus on E. coli O157:H7 and Salmonella bacteria in ground beef and apple juice. A test instrument will be constructed incorporating the biosensor technology, assays will be developed and verified for the specified pathogens, and tests performed on food samples. In Phase II the scope will be expanded to include the pathogens Listeria monocytogenes and Campylobacter jejuni and the food groups poultry and fresh produce. The instrument will be redesigned to be more compact and portable, and assays developed for use outside a laboratory setting. Tests will be performed on location where these foods are produced, transported and/or prepared. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ROLE OF CHEMOTAXIS IN CAMPYLOBACTER COLONIZATION Principal Investigator & Institution: Chang, Christopher H.; Medicine; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2007 Summary: (provided by applicant) Campylobacter jejuni has become the most frequently identified cause of acute infectious diarrhea in the developed world and is the most commonly reported bacterial cause of foodborne infection in the U.S.(1).
Studies
21
Despite its global importance and economic impact, little is known regarding mechanisms of pathogenesis. This is due in large part to the paucity of high resolution experimental systems for studying infection in vivo. We have recently developed murine models that are characterized by the efficient establishment of gastrointestinal infection following oral inoculation, high levels of colonization and long term persistence. We propose to exploit these models to study determinants of pathogenicity, with an emphasis on chemotaxis. We hypothesize that chemotaxis is required for both the establishment and maintenance of infection and this contention is supported by our preliminary data and reports by other investigators. Despite its obvious importance, the chemotactic system of C. jejuni has remained almost entirely uncharacterized. Similarities between the predicted chemotaxis proteins of C. jejuni and H. pylori suggest that our analysis will have broad implications. An understanding of the signal transduction pathways that guide bacterial movement in vivo may have practical applications for the development of antimicrobial therapeutics as well as vaccines. Specifically, we propose to: 1. Characterize the interactions between Campylobacter and the mouse gastrointestinal tract in our murine models of C. jejuni colonization. 2. Characterize the role of chemotaxis genes identified by genome sequence analysis in chemotactic responses measured in vitro and infection measured in vivo. 3. Conduct a biochemical characterization of the central signaling pathway that controls Campylobacter chemotaxis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE OF G PROTEIN COUPLING IN FE(LL)-UPTAKE IN BACTERIA Principal Investigator & Institution: Unger, Vinzenz M.; Assistant Professor; Molecular Biophysics & Biochem; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): Iron is essential for cell function causing competition for it between pathogens and their hosts. In the gut and stomach, pathogens like Helicobacter, Salmonella and Campylobacter rely on the uptake of Fe(II). Although Fe(II)-uptake is critical for virulence, little is known about the mechanisms of its uptake. The goal of this project is to understand the function of the membrane protein FeoB which is essential for Fe(II)-uptake in bacteria. FeoB is both novel and unique. Notably, the amino acid sequence of FeoB predicts a GTP-binding domain that is connected to a bundle of several putative transmembrane alpha-helices. Based on this design, we hypothesize that FeoB may have served as primordial ancestor for G protein-coupled receptors and/or channels. We will employ biochemical, genetic and biophysical tools to test this hypothesis and to establish the role of FeoB for Fe(II) uptake. The results of our work are important for understanding iron homeostasis in pathogens and may enable us to identify new strategies for treating microbial infections. The first aim is to determine the function of FeoB in Fe(II) uptake. We show that the N-terminal domain of FeoB acts as a regulatory GTP alpha-binding protein. However, the function of the membrane embedded domain remains unknown. We will combine in vivo Fe(II) uptake experiments with in vitro measurements of FeoB's Fe(II)-binding and Fe(II)-transport properties to establish whether FeoB functions as transporter/channel or acts as a receptor protein. The second aim is to determine the function of FeoB's G protein in Fe(II)-uptake, and how the activity of the G protein is regulated. We will determine whether FeoB itself rather than a downstream target is regulated by the N-terminal domain and whether Fe(II) can modify the activity of the G protein. The third aim is to identify the molecular basis for a guanine-nucleotide-exchange-factor like activity that
22
Campylobacter
we discovered in FeoB's N-terminal domain. We will disable this activity by mutagenesis and determine the importance of nucleotide exchange for Fe(II) uptake in vivo. The fourth aim is to generate crystals of FeoB embedded in a lipid bilayer. Ultimately, this will allow visualization of FeoB, and reveal whether its structure is related to other G protein-coupled membrane proteins. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE OF HUMAN MILK IN INFANT NUTRITION AND HEALTH Principal Investigator & Institution: Morrow, Ardythe L.; Professor; Children's Hospital Med Ctr (Cincinnati) 3333 Burnet Ave Cincinnati, Oh 452293039 Timing: Fiscal Year 2002; Project Start 01-JUL-1979; Project End 31-MAR-2003 Summary: The competitive renewal of our program project grant application is submitted by investigators who propose to continue their studies on the unique properties of human milk. All projects address the biologic consequences through protocols which utilize in vitro assays, animal models, and humans. The projects generally seek to define and characterize factors in human milk that protect newborn infants from disease. Certain consequences of the luminal milk gastrointestinal tract interactions that pertain to protection of the infant will continue to be examined. Animal models will be utilized with study of human subjects is not possible, but human infants will be studied whenever appropriate. The respective projects and subcontracts will consider: 1) the role of soluble milk factors in the prevention of shigellosis; 2) the antiinflammatory characteristics of human milk; 3) the role of the secretory immune system in viral enteric pathogen infection; 4) isolation, characterization and testing of the protective factor(s) in human milk against heat-stable enterotoxin of E. coli; and 5) the role of human milk in the prevention of Campylobacter infection. Each of the projects will be supported by epidemiology/statistical, biochemical, and molecular biology core sections. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ROLES PATHOGENESIS
FOR
MOTILITY
IN
HELICOBACTOR
PYLORI
Principal Investigator & Institution: Ottemann, Karen M.; Ecology and Evolutionary Biol; University of California Santa Cruz 1156 High St Santa Cruz, Ca 95064 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2007 Summary: The bacterium Helicobacter pylori inhabits the stomachs of a full 3 billion people--half the world's population. Infections with this bacterium cause significant morbidity and mortality around the globe. In the majority of cases, the bacterium establishes chronic infections that lead to diverse outcomes ranging from asymptomatic carriage to ulcer disease to gastric cancer. Conservative estimates suggest that 5 percent of those infected-150 million people-develop some form of disease. H. pylori has the dubious distinction of being the only bacterium classified as a Group I carcinogen by the International Agency for Research on Cancer of the World Health Organization. Infection by this bacterium is a risk factor for several types of gastric cancer including gastric adenocarcinoma and mucosa- associated lymphoid tissue (MALT) lymphoma. The processes used by H. pylori to establish and maintain infection are just beginning to be worked out. One such process is the ability to swim. H. pylori is motile via organelles called flagella, and it must have functional versions of these organelles in order to colonize animal stomachs. In addition, H. pylori does not swim randomly but instead directs its motility in response to environmental cues in a process called chemotaxis. We
Studies
23
are interested in understanding how chemotactic motility is used for infection by this bacterium. Towards this we propose three aims: (i) Ascertain at what points during infection chemotactic motility is used by H. pylori. (ii) Determine how H. pylori chemotaxis is directed by pinpointing which of its chemoreceptors are used for mouse stomach colonization, and to what they respond. (iii) Dissect how information is relayed from the chemoreceptors to the flagellar motor during chemotactic signal transduction in H. pylori by analyzing how a family of proteins, the CheVs, function. Chemotaxis is observed in a number of bacterial pathogens but little is known about its role during infection. What we learn from these studies may apply to other bacteria. For example, the Campylobacter group of bacteria are leading causes of food-borne diarrheal disease, and similarly require motility and chemotaxis for infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: S. TYPHIMIURIUM ENTEROPATHOGENS
VACCINE
AGAINST
BACTERIAL
Principal Investigator & Institution: Curtiss, Roy Iii.; Professor; Biology; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-MAR-2008 Summary: Of the 18.9 million annual deaths (1997) due to infectious diseases, about 2 million are the result of infections by Salmonella and other related bacterial enteropathogens including Escherichia coli and Shigella species, and less closely related enteropathogens such as Vibrio cholerae, Campylobacter jejuni and Listeria monocytogenes. In addition, these bacteria are responsible are responsible for significant morbidity causing diarrheal and systemic diseases that can be transmitted to humans by contamination of food products and/or the water supply and such contamination can be willful. In the belief that improving health, nutrition and economic well-being (the latter dependent on the first two) provide the best means to enhance the quality of life globally and thus reduce conditions that result in warlike and terrorist behavior, we propose a vaccine developmental program based on our recent technical developments in using non-recombinant and recombinant attenuated Salmonella veterinary vaccines to prevent-reduce diarrheal diseases caused by bacterial enteropathogens. Our objectives include: (i) to further genetically modify a strain of Salmonella typhimurium that has been designed to minimize induction of immune responses to serotype-specific antigens and to maximize induction of cross protective immunity to common related antigens of S. enterica strains of diverse serotype and then fully evaluate this modified strain as a vaccine to reduce diarrheal diseases in humans caused by S. enterica serotypes and possibly by other bacterial enteric pathogens, especially Escherichia coli of the EPEC, ETEC and EHEC types and Shigella; (ii) to design, construct and fully evaluate an attenuated derivative of S. paratyphi A, with similar genetic attributes as the S. typhimurium vaccine designed for the same purpose, to induce cross protective immunity in humans to prevent enteric fever and to significantly reduce diarrheal diseases due to infection by diverse S. enterica serotypes and possibly by other bacterial enteric pathogens, especially E. coli of the EPEC, ETEC and EHEC types and Shigella; (iii) to further genetically modify the S. typhimurium and S. paratyphi A vaccines designed to induce cross protective immunity to also display biological containment so that they are less able to survive in the intestinal tract or in nature and/or die by lysis after approximately ten cell divisions following delivery to the immunized individual; and (iv) to design, construct and evaluate recombinant attenuated Salmonella vaccines, using optimal attributes for immunogenicity, biological containment and antigen delivery, to express antigens to further enhance induction of cross protective immunity
24
Campylobacter
to Salmonella-related bacterial enteropathogens or to confer protective immunity to one of the less Salmonella-related enteropathogens. We will also collaboratively work to develop our Master File, prepare and fully characterize candidate vaccine Master Seeds for stability and safety, prepare and submit protocols for IRB approvals, submit information necessary to obtain INDs, and perform any other work needed to arrange that the best candidate vaccines by clinically evaluated in human volunteers. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SECRETION MECHANISM OF A NOVEL C. RECTUS S-LAYER PROTEIN Principal Investigator & Institution: Kolodrubetz, David J.; Professor; Microbiology and Immunology; University of Texas Hlth Sci Ctr San Ant 7703 Floyd Curl Dr San Antonio, Tx 78229 Timing: Fiscal Year 2002; Project Start 01-APR-2000; Project End 31-MAR-2004 Summary: Periodontitis is associated with a dramatic shift in the subgingival microflora towards predominantly gram negative organisms. Campylobacter rectus is unique among the gram negative periodontal pathogens in its expression of a 150 kd surfacelayer (S-layer) protein. These abundant proteins form homogeneous arrays covering the surfaces of numerous bacteria and are required for bacterial pathogenesis. Thus , it is critical that S-layers are properly localized to the cell surface. There are only a few reports on the secretion mechanisms of S-layer proteins. Interestingly, unlike most other S-layer proteins, no amino acids are removed from the C. rectus S-layer protein (crsA) as it is transported to the cell surface. In addition, a homologue, crsD, to one of the three components of type I secretion systems is found in an operon upstream of the C. rectus crsA gene. This suggests that crsA is transported by a type I pathway. Most excitingly, the crsD operon contains another gene, crsC, whose protein has no known function. Analysis of the phenotype of a polar crsC mutant we constructed suggests that crsC is involved in crsA secretion, synthesis or degradation. We now propose to exploit the molecular genetic tools we have developed in order to determine the mechanisms used by C. rectus to transport its S-laver to the cell surface. It is our hypothesis that the crsA protein will be transported by a type l system. Importantly, we hypothesize that crsC will have a novel function in the type I secretion pathway perhaps as a chaperone. One goal of this proposal is to identify the C. rectus S-layer sequences that direct it to the cell surface using targeted mutagenesis and gene replacement technology. In addition, the genes required for crsA transport will be identified by cloning and sequencing the rest of the crsCD operon or by transposon mutagenesis. Importantly, the function of each putative transport gene will be characterized by making non-polar mutants. The resulting characterization of the crsC mutants will define, for the first time, the function of this novel protein in S-layer metabolism. Finally, the transport mutants will be examined for the possible mis-localization of non-S-layer proteins since there are two reports of type I transport pathways transporting more than one virulence protein. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: STUDY OF PERSISTENT INFECTION IN SSC SKIN AND VESSELS Principal Investigator & Institution: Mayes, Maureen D.; Professor; Internal Medicine; University of Texas Hlth Sci Ctr Houston Box 20036 Houston, Tx 77225 Timing: Fiscal Year 2002; Project Start 26-SEP-2001; Project End 31-MAY-2004 Summary: (provided by applicant): The overall objective of this proposal is to study the possibility that in some systemic sclerosis patients, a persistent bacterial infection
Studies
25
involving dermal microvascular endothelium or other cells that are resident in skin results in the obliterative microvasculopathy and/or the fibrosing features of this disease. As a first step in addressing this issue, we will test the following hypothesis: persistent bacterial infection of skin or microvasculature occurs more commonly in systemic sclerosis cases than in matched controls and participates in the disease process. Specific aims are: (1) to test skin biopsies from 60 systemic scleroderma patients and 30 matched normal controls for evidence of bacterial persistence by pan-bacterial and chlamydia-specific molecular screening; (2) to microdissect dermal vessels from these same cases and controls and test this tissue by panbacterial and chlamydia-specific molecular probes; (3) to prepare PBMC'S from these individuals and screen with these probes; and (4) depending on positive results, to perform immunohistochemistry studies for these organisms on skin biopsies/vessels from selected patients and appropriate controls. Scleroderma small vessel vasculopathy shares some key features with large vessel atherosclerosis, a condition also characterized by intimal proliferation and luminal narrowing among multiple other abnormalities. Inflammation may play an important role in the pathogenesis of atherosclerosis raising the possibility of infectious agents as mediators in this process. There are several examples of infection resulting in chronic inflammatory autoimmune diseases including Lyme disease (Borrelia burgdorferii), and reactive arthritis (ReA), an inflammatory joint disease associated with prior infection by a number of specific bacterial pathogens, including Chlamydia trachomatis and various species of the Genera Salmonella, Yersinia, Campylobacter, and others. This research team is comprised of individuals with expertise in clinical scleroderma, the vascular abnormalities of primary and secondary Raynaud's disease, and autoimmunity related to persistent bacterial infections with relevant pathogens. If positive results are obtained in at least a subset of scleroderma cases, intervention trials could be devised with therapy targeted to specific organisms. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRANSMISSION OF CAMPYLOBACTER JEJUNI & COLI IN INFANT COTTON TOP TAMARINS Principal Investigator & Institution: Johnson, Lorna D.; Harvard University (Medical School) Medical School Campus Boston, Ma 02115 Timing: Fiscal Year 2002 Summary: Infant primates were followed for varying periods from birth to one year of age with weekly stool cultures C coli and C jejuni were identified, and in a small sample, heterogeneity among C jejuni isolates was determined by polyacrilamide gel electrophoresis (PAGE) The epidemiology of infections was determined in a nursery where Campylobacter species were endemic, in an isolation nursery and in the main colony and an isolation unit Episodes of infection were correlated with cage location, calendar month, diet, clinical history of diarrhea, age, and species Computerized data is being analyzed using A Data Analysis Program (ADAPS) Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TRANSMISSION OF H. PYLORI INFECTION IN THE RHESUS MONKEY Principal Investigator & Institution: Solnick, Jay V.; Associate Professor of Medicine; Internal Medicine; University of California Davis Sponsored Programs, 118 Everson Hall Davis, Ca 956165200 Timing: Fiscal Year 2002; Project Start 12-SEP-2001; Project End 31-AUG-2006
26
Campylobacter
Summary: (provided by the applicant): Infection with Helicobacter pylori causes a histological gastritis that in some individuals is associated with the development of peptic ulcer disease or gastric malignancy. Although H. pylori may be the most common human bacterial infection, the mechanism by which it is transmitted remains unknown. Person to person transmission probably accounts for most infections. Yet one of the great paradoxes in the epidemiology of H. pylori is that when one examines the gastric lining, the bacterium is ubiquitous, but when fecal or oral secretions are studied it is often difficult to find. This may reflect the difficulty of studying in humans the role of acuity of infection, age of the host, and the possible effects of vomiting, diarrhea, and the CagA pathogenicity island on transmission. Rhesus monkeys are naturally infected with H. pylori that is very similar to strains that infect humans, and this animal model provides a unique opportunity to study experimentally the transmission of H. pylori in a naturally infected host. We hypothesize that acuity of infection, the presence of vomiting and diarrhea, and the CagA pathogenicity island are critical variables in transmission of H. pylori. Furthermore, we propose that there may be a cooperativity between transmission of H. pylori and transmission of bacterial enteric diseases. Diarrheal and vomiting diseases may increase H. pylori transmission by increasing the shedding H. pylori in feces and vomitus, and in turn, H. pylori infection may cause increased gastric pH and thereby promote infection with enteric bacteria by reducing the gastric bactericidal barrier. We propose to address four specific aims in this proposal: l) Determine how H. pylori is shed into the environment during acute and chronic infection; 2) Examine experimentally the effects of vomiting, diarrhea and the CagA pathogenicity island on the natural transmission of H. pylori; 3) Determine the effects of H. pylori infection on the acquisition of Campylobacter jejuni; and 4) Determine the effects of the CagA pathogenicity island on colonization and shedding. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “campylobacter” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for campylobacter in the PubMed Central database: •
3 4
"Campylobacter hyointestinalis" sp. nov.: a new species of Campylobacter found in the intestines of pigs and other animals. by Gebhart CJ, Edmonds P, Ward GE, Kurtz HJ, Brenner DJ.; 1985 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=271765
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies
27
•
30 years of campylobacters: biochemical characteristics and a biotyping proposal for Campylobacter jejuni. by Hebert GA, Hollis DG, Weaver RE, Lambert MA, Blaser MJ, Moss CW.; 1982 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=272255
•
A Campylobacter jejuni homolog of the LcrD/FlbF family of proteins is necessary for flagellar biogenesis. by Miller S, Pesci EC, Pickett CL.; 1993 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=280941
•
A Field-Suitable, Semisolid Aerobic Enrichment Medium for Isolation of Campylobacter jejuni in Small Numbers. by Jeffrey JS, Hunter A, Atwill ER.; 2000 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=86520
•
A genetic locus involved in iron utilization unique to some Campylobacter strains. by Guerry P, Perez-Casal J, Yao R, McVeigh A, Trust TJ.; 1997 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=179210
•
A molecular scheme based on 23S rRNA gene polymorphisms for rapid identification of Campylobacter and Arcobacter species. by Hurtado A, Owen RJ.; 1997 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=229976
•
A New Member of the S-Layer Protein Family: Characterization of the crs Gene from Campylobacter rectus. by Wang B, Kraig E, Kolodrubetz D.; 1998 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=108083
•
A Novel Campylobacter jejuni Two-Component Regulatory System Important for Temperature-Dependent Growth and Colonization. by Bras AM, Chatterjee S, Wren BW, Newell DG, Ketley JM.; 1999 May 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=93792
•
A Real-Time PCR Assay for the Detection of Campylobacter jejuni in Foods after Enrichment Culture. by Sails AD, Fox AJ, Bolton FJ, Wareing DR, Greenway DL.; 2003 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=150087
•
A Three-Year Study of Campylobacter jejuni Genotypes in Humans with Domestically Acquired Infections and in Chicken Samples from the Helsinki Area. by Hanninen ML, Perko-Makela P, Pitkala A, Rautelin H.; 2000 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=86651
•
Additional data on clinical isolates of Campylobacter mucosalis. by Lastovica AJ, Le Roux E, Warren R, Klump H.; 1994 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=264002
•
Adhesion to and invasion of HEp-2 cells by Campylobacter spp. by Konkel ME, Joens LA.; 1989 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=260759
•
Agilent 2100 Bioanalyzer for Restriction Fragment Length Polymorphism Analysis of the Campylobacter jejuni Flagellin Gene. by Nachamkin I, Panaro NJ, Li M, Ung H, Yuen PK, Kricka LJ, Wilding P.; 2001 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87813
28
Campylobacter
•
Allelic Diversity and Recombination in Campylobacter jejuni. by Suerbaum S, Lohrengel M, Sonnevend A, Ruberg F, Kist M.; 2001 Apr 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=95172
•
Amplified Fragment Length Polymorphism Analysis of Campylobacter jejuni Strains Isolated from Chickens and from Patients with Gastroenteritis or Guillain-Barre or Miller Fisher Syndrome. by Duim B, Ang CW, van Belkum A, Rigter A, van Leeuwen NW, Endtz HP, Wagenaar JA.; 2000 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92239
•
An Iron-Regulated Alkyl Hydroperoxide Reductase (AhpC) Confers Aerotolerance and Oxidative Stress Resistance to the Microaerophilic Pathogen Campylobacter jejuni. by Baillon ML, van Vliet AH, Ketley JM, Constantinidou C, Penn CW.; 1999 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=93964
•
An optimised recovery method for thermophilic Campylobacter from liver. by Moore JE.; 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=61043
•
Analysis of Campylobacter jejuni antigens with monoclonal antibodies. by Kosunen TU, Bang BE, Hurme M.; 1984 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=271001
•
Analysis of HL and O serotypes of Campylobacter strains by the flagellin gene typing system. by Nachamkin I, Ung H, Patton CM.; 1996 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=228782
•
Analysis of strains of Campylobacter fetus by pulsed-field gel electrophoresis. by Fujita M, Fujimoto S, Morooka T, Amako K.; 1995 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=228246
•
Antibiotic Resistance in Campylobacter Strains Isolated from Animals, Foods, and Humans in Spain in 1997 --1998. by Saenz Y, Zarazaga M, Lantero M, Gastanares MJ, Baquero F, Torres C.; 2000 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=89669
•
Antibody response to Campylobacter coli in children during intestinal infection and carriage. by Martin PM, Mathiot J, Ipero J, Georges AJ, Georges-Courbot MC.; 1988 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=266628
•
Antibody Responses to Campylobacter Infections Determined by an Enzyme-Linked Immunosorbent Assay: 2-Year Follow-Up Study of 210 Patients. by Strid MA, Engberg J, Larsen LB, Begtrup K, Molbak K, Krogfelt KA.; 2001 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=96055
•
Antigenic analysis of Campylobacter flagellar protein and other proteins. by Wenman WM, Chai J, Louie TJ, Goudreau C, Lior H, Newell DG, Pearson AD, Taylor DE.; 1985 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=271585
Studies
29
•
Antigenic variation of Campylobacter flagella. by Harris LA, Logan SM, Guerry P, Trust TJ.; 1987 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=213909
•
Antigenicity of Campylobacter jejuni flagella. by Blaser MJ, Hopkins JA, Perez-Perez GI, Cody HJ, Newell DG.; 1986 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=260073
•
Antimicrobial Resistance in Campylobacter jejuni and Campylobacter coli Strains Isolated in 1991 and 2001-2002 from Poultry and Humans in Berlin, Germany. by Luber P, Wagner J, Hahn H, Bartelt E.; 2003 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=296193
•
Antimicrobial resistance of Campylobacter jejuni and Campylobacter coli with special reference to plasmid profiles of Japanese clinical isolates. by Sagara H, Mochizuki A, Okamura N, Nakaya R.; 1987 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=174820
•
Antimicrobial Resistance of Campylobacter jejuni subsp. jejuni Strains Isolated from Humans in 1998 to 2001 in Montreal, Canada. by Gaudreau C, Gilbert H.; 2003 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=155825
•
Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli isolated in Sweden: a 10-year follow-up report. by Sjogren E, Kaijser B, Werner M.; 1992 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=245558
•
Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors. by Tajada P, Gomez-Graces JL, Alos JI, Balas D, Cogollos R.; 1996 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=163441
•
Antimicrobial Susceptibilities of Campylobacter Strains Isolated from Finnish Subjects Infected Domestically or from Those Infected Abroad. by Rautelin H, Vierikko A, Hanninen ML, Vaara M.; 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=148994
•
Antimicrobial Susceptibility Testing of 59 Strains of Campylobacter fetus subsp. fetus. by Tremblay C, Gaudreau C.; 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=105695
•
Antimicrobial-Resistant Campylobacter Species from Retail Raw Meats. by Ge B, White DG, McDermott PF, Girard W, Zhao S, Hubert S, Meng J.; 2003 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=154538
•
Application of different chromosomal DNA restriction digest fingerprints to specific and subspecific identification of Campylobacter isolates. by Owen RJ, Costas M, Dawson C.; 1989 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267020
30
Campylobacter
•
Application of Host-Specific Bacteriophages to the Surface of Chicken Skin Leads to a Reduction in Recovery of Campylobacter jejuni. by Atterbury RJ, Connerton PL, Dodd CE, Rees CE, Connerton IF.; 2003 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=201188
•
Application of Lior biotyping by use of genetically identified Campylobacter strains. by Nicholson MA, Patton CM.; 1993 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=266432
•
Application of serotyping and chromosomal restriction endonuclease digest analysis in investigating a laboratory-acquired case of Campylobacter jejuni enteritis. by Penner JL, Hennessy JN, Mills SD, Bradbury WC.; 1983 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=272922
•
Application of the 5[prime prime or minute]-Nuclease PCR Assay in Evaluation and Development of Methods for Quantitative Detection of Campylobacter jejuni. by Nogva HK, Bergh A, Holck A, Rudi K.; 2000 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92255
•
Association with HeLa cells of Campylobacter jejuni and Campylobacter coli isolated from human feces. by Fauchere JL, Rosenau A, Veron M, Moyen EN, Richard S, Pfister A.; 1986 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=260156
•
Associations between Heat-Stable (O) and Heat-Labile (HL) Serogroup Antigens of Campylobacter jejuni: Evidence for Interstrain Relationships within Three O/HL Serovars. by Jackson CJ, Fox AJ, Jones DM, Wareing DR, Hutchinson DN.; 1998 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=105019
•
Bacterial Genetic Fingerprint: a Reliable Factor in the Study of the Epidemiology of Human Campylobacter Enteritis? by Steinbrueckner B, Ruberg F, Kist M.; 2001 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88504
•
Bactericidal properties of Campylobacter jejuni-specific immunoglobulin M antibodies in commercial immunoglobulin preparations. by Autenrieth IB, Schwarzkopf A, Ewald JH, Karch H, Lissner R.; 1995 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=162864
•
Basis of the Superiority of Cefoperazone Amphotericin Teicoplanin for Isolating Campylobacter upsaliensis from Stools. by Byrne C, Doherty D, Mooney A, Byrne M, Woodward D, Johnson W, Rodgers F, Bourke B.; 2001 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88219
•
Biochemical and antigenic properties of the Campylobacter flagellar hook protein. by Power ME, Alm RA, Trust TJ.; 1992 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=206094
•
Biochemical and genetic characteristics of atypical Campylobacter fetus subsp. fetus strains isolated from humans in the United States. by Edmonds P, Patton CM, Barrett TJ, Morris GK, Steigerwalt AG, Brenner DJ.; 1985 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=271821
Studies
31
•
Biotype and serogroup distribution of Campylobacter isolates from children in Nigeria. by Alabi SA, Coker AO, Dosunmu-Ogunbi O, Odugbemi T.; 1986 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=269044
•
Biphasic culture system for rapid Campylobacter cultivation. by Rollins DM, Coolbaugh JC, Walker RI, Weiss E.; 1983 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=242266
•
Cadmium chloride susceptibility, a characteristic of Campylobacter spp. by Kazmi SU, Roberson BS, Stern NJ.; 1985 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=271763
•
Campylobacter pylori, the spiral bacterium associated with human gastritis, is not a true Campylobacter sp. by Romaniuk PJ, Zoltowska B, Trust TJ, Lane DJ, Olsen GJ, Pace NR, Stahl DA.; 1987 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=212113
•
Cellular fatty acid composition of Campylobacter fetus. by Blaser MJ, Moss CW, Weaver RE.; 1980 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=273429
•
Cellular fatty acid composition of Campylobacter pylori from primates and ferrets compared with those of other campylobacters. by Goodwin CS, McConnell W, McCulloch RK, McCullough C, Hill R, Bronsdon MA, Kasper G.; 1989 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267458
•
Changes in Campylobacter jejuni andCampylobacter coli Carriage Rates in the Zenica Canton of Bosnia and Herzegovina in the Pre- and Postwar Periods. by Uzunovic-Kamberovic S.; 2001 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88081
•
Changes in the Carriage of Campylobacter Strains by Poultry Carcasses during Processing in Abattoirs. by Newell DG, Shreeve JE, Toszeghy M, Domingue G, Bull S, Humphrey T, Mead G.; 2001 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92918
•
Characterization of erythromycin resistance in Campylobacter jejuni and Campylobacter coli. by Yan W, Taylor DE.; 1991 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=245313
•
Characterization of freshly isolated Campylobacter coli strains and suitability of selective media for their growth. by Ng LK, Taylor DE, Stiles ME.; 1988 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=266324
•
Characterization of high-level quinolone resistance in Campylobacter jejuni. by Gootz TD, Martin BA.; 1991 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=245117
32
Campylobacter
•
Characterization of tetracycline resistance plasmids from Campylobacter jejuni and Campylobacter coli. by Taylor DE, Garner RS, Allan BJ.; 1983 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=185410
•
Characterization of the Campylobacter jejuni Heptosyltransferase II Gene, waaF, Provides Genetic Evidence that Extracellular Polysaccharide Is Lipid A Core Independent. by Oldfield NJ, Moran AP, Millar LA, Prendergast MM, Ketley JM.; 2002 Apr 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=134946
•
Characterization of the Thermal Stress Response of Campylobacter jejuni. by Konkel ME, Kim BJ, Klena JD, Young CR, Ziprin R.; 1998 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=108400
•
Characterization of two plasmids from Campylobacter jejuni isolates that carry the aphA-7 kanamycin resistance determinant. by Tenover FC, Fennell CL, Lee L, LeBlanc DJ.; 1992 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=189362
•
Characterization of Urease-Positive Thermophilic Campylobacter Subspecies by Multilocus Enzyme Electrophoresis Typing. by Matsuda M, Kaneko A, Stanley T, Millar BC, Miyajima M, Murphy PG, Moore JE.; 2003 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=161486
•
Chronic Atrophic Gastritis in SCID Mice Experimentally Infected with Campylobacter fetus. by Young VB, Dangler CA, Fox JG, Schauer DB.; 2000 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=97392
•
Ciprofloxacin Resistance in Campylobacter jejuni Isolates: Detection of gyrA Resistance Mutations by Mismatch Amplification Mutation Assay PCR and DNA Sequence Analysis. by Zirnstein G, Li Y, Swaminathan B, Angulo F.; 1999 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=85547
•
Clinical isolates of Campylobacter mucosalis. by Lastovica A, Le Roux E, Warren R, Klump H.; 1993 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=266032
•
Clonal Complexes of Campylobacter jejuni Identified by Multilocus Sequence Typing Correlate with Strain Associations Identified by Multilocus Enzyme Electrophoresis. by Sails AD, Swaminathan B, Fields PI.; 2003 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=193858
•
Cloning and Expression of the dnaK Gene of Campylobacter jejuni and Antigenicity of Heat Shock Protein 70. by Thies FL, Karch H, Hartung HP, Giegerich G.; 1999 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=96446
•
Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations. by Wang Y, Huang WM, Taylor DE.; 1993 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=187693
Studies
33
•
Cloning and nucleotide sequence of the gyrA gene from Campylobacter fetus subsp. fetus ATCC 27374 and characterization of ciprofloxacin-resistant laboratory and clinical isolates. by Taylor DE, Chau AS.; 1997 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=163769
•
Cloning, characterization, and nucleotide sequence analysis of the argH gene from Campylobacter jejuni TGH9011 encoding argininosuccinate lyase. by Hani EK, Chan VL.; 1994 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=205288
•
Cloning, sequencing, and expression of a gene from Campylobacter jejuni encoding a protein (Omp18) with similarity to peptidoglycan-associated lipoproteins. by Konkel ME, Mead DJ, Cieplak W Jr.; 1996 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=174003
•
CmeABC Functions as a Multidrug Efflux System in Campylobacter jejuni. by Lin J, Overbye Michel L, Zhang Q.; 2002 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=127319
•
Coinfection of Enteric Helicobacter spp. and Campylobacter spp. in Cats. by Shen Z, Feng Y, Dewhirst FE, Fox JG.; 2001 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88106
•
Colony Multiplex PCR Assay for Identification and Differentiation of Campylobacter jejuni, C. coli, C. lari, C. upsaliensis, and C. fetus subsp. fetus. by Wang G, Clark CG, Taylor TM, Pucknell C, Barton C, Price L, Woodward DL, Rodgers FG.; 2002 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=154608
•
Common somatic O and heat-labile serotypes among Campylobacter strains from sporadic infections in the United States. by Patton CM, Nicholson MA, Ostroff SM, Ries AA, Wachsmuth IK, Tauxe RV.; 1993 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=265572
•
Comparative Fingerprinting Analysis of Campylobacter jejuni subsp. jejuni Strains by Amplified-Fragment Length Polymorphism Genotyping. by Lindstedt BA, Heir E, Vardund T, Melby KK, Kapperud G.; 2000 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87390
•
Comparative in vitro activities of twelve antimicrobial agents against Campylobacter species. by Fliegelman RM, Petrak RM, Goodman LJ, Segreti J, Trenholme GM, Kaplan RL.; 1985 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=176293
•
Comparative Study Using Amplified Fragment Length Polymorphism Fingerprinting, PCR Genotyping, and Phenotyping To Differentiate Campylobacter fetus Strains Isolated from Animals. by Wagenaar JA, van Bergen MA, Newell DG, GrogonoThomas R, Duim B.; 2001 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88125
34
Campylobacter
•
Comparative translocation of enteropathogenic Campylobacter spp. and Escherichia coli from the intestinal tract of gnotobiotic mice. by Youssef M, Corthier G, Goossens H, Tancrede C, Henry-Amar M, Andremont A.; 1987 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=260457
•
Comparison of antimicrobial susceptibility patterns of Campylobacter jejuni and Campylobacter coli. by Wang WL, Reller LB, Blaser MJ.; 1984 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=176168
•
Comparison of basal media for culturing Campylobacter jejuni and Campylobacter coli. by Ng LK, Stiles ME, Taylor DE.; 1985 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=271618
•
Comparison of broth enrichment and direct plating for the isolation of Campylobacter jejuni from dogs. by Monfort JD, Stills HF Jr, Bech-Nielsen S.; 1988 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=266868
•
Comparison of Broth Microdilution, E Test, and Agar Dilution Methods for Antibiotic Susceptibility Testing of Campylobacter jejuni and Campylobacter coli. by Luber P, Bartelt E, Genschow E, Wagner J, Hahn H.; 2003 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=150256
•
Comparison of CampyPak II with standard 5% oxygen and candle jars for growth of Campylobacter jejuni from human feces. by Wang WL, Luechtefeld NW, Blaser MJ, Reller LB.; 1982 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=272347
•
Comparison of four hippurate hydrolysis methods for identification of thermophilic Campylobacter spp. by Morris GK, el Sherbeeny MR, Patton CM, Kodaka H, Lombard GL, Edmonds P, Hollis DG, Brenner DJ.; 1985 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=268512
•
Comparison of gauze swabs and membrane filters for isolation of Campylobacter spp. from surface water. by el-Sherbeeny MR, Bopp C, Wells JG, Morris GK.; 1985 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=238677
•
Comparison of Genotypes and Serotypes of Campylobacter jejuni Isolated from Danish Wild Mammals and Birds and from Broiler Flocks and Humans. by Petersen L, Nielsen EM, Engberg J, On SL, Dietz HH.; 2001 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92989
•
Comparison of rapid urease tests, staining techniques, and growth on different solid media for detection of Campylobacter pylori. by Coudron PE, Kirby DF.; 1989 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267609
Studies
35
•
Comparison of selective media for primary isolation of Campylobacter fetus subsp. jejuni. by Patton CM, Mitchell SW, Potter ME, Kaufmann AF.; 1981 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=273785
•
Comparison of the Penner and Lior methods for serotyping Campylobacter spp. by Patton CM, Barrett TJ, Morris GK.; 1985 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=268467
•
Comparison of Two Methods for Serotyping Campylobacter spp. by McKay D, Fletcher J, Cooper P, Thomson-Carter FM.; 2001 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88048
•
Competitive Exclusion of Heterologous Campylobacter spp. in Chicks. by Chen HC, Stern NJ.; 2001 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92657
•
Comprehensive ribotyping scheme for heat-stable serotypes of Campylobacter jejuni. by Fitzgerald C, Owen RJ, Stanley J.; 1996 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=228780
•
Computer-Assisted Analysis and Epidemiological Value of Genotyping Methods for Campylobacter jejuni and Campylobacter coli. by de Boer P, Duim B, Rigter A, van der Plas J, Jacobs-Reitsma WF, Wagenaar JA.; 2000 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=86628
•
Confirmation of human Campylobacter concisus isolates misidentified as Campylobacter mucosalis and suggestions for improved differentiation between the two species. by On SL.; 1994 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=263990
•
Conformational analysis of the Campylobacter jejuni porin. by Bolla JM, Loret E, Zalewski M, Pages JM.; 1995 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=177172
•
Correlation between molecular size of the surface array protein and morphology and antigenicity of the Campylobacter fetus S layer. by Fujimoto S, Takade A, Amako K, Blaser MJ.; 1991 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=257959
•
Critical Role of Multidrug Efflux Pump CmeABC in Bile Resistance and In Vivo Colonization of Campylobacter jejuni. by Lin J, Sahin O, Overbye Michel L, Zhang Q.; 2003 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=165992
•
Cytolethal Distending Toxin Genes in Campylobacter jejuni and Campylobacter coli Isolates: Detection and Analysis by PCR. by Eyigor A, Dawson KA, Langlois BE, Pickett CL.; 1999 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=84865
36
Campylobacter
•
Cytotoxic and cytotonic factors produced by Campylobacter jejuni, Campylobacter coli, and Campylobacter laridis. by Johnson WM, Lior H.; 1986 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=268889
•
Cytotoxic and enterotoxic activities of Campylobacter jejuni are not specified by tetracycline resistance plasmids pMAK175 and pUA466. by Taylor DE, Johnson WM, Lior H.; 1987 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=265844
•
Demonstration of lipopolysaccharide with O-polysaccharide chains among different heat-stable serotypes of Campylobacter jejuni by silver staining of polyacrylamide gels. by Blake DC Jr, Russell RG.; 1993 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=281326
•
Demonstration of Polysaccharide Capsule in Campylobacter jejuni Using Electron Microscopy. by Karlyshev AV, McCrossan MV, Wren BW.; 2001 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=98714
•
Detection and Characterization of Autoagglutination Activity by Campylobacter jejuni. by Misawa N, Blaser MJ.; 2000 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=97695
•
Detection and Initial Characterization of Novel Capsular Polysaccharide among Diverse Campylobacter jejuni Strains Using Alcian Blue Dye. by Karlyshev AV, Wren BW.; 2001 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87715
•
Detection and Typing of Campylobacter jejuni and Campylobacter coli and Analysis of Indicator Organisms in Three Waterborne Outbreaks in Finland. by Hanninen ML, Haajanen H, Pummi T, Wermundsen K, Katila ML, Sarkkinen H, Miettinen I, Rautelin H.; 2003 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=150068
•
Detection of Campylobacter jejuni added to foods by using a combined selective enrichment and nucleic acid sequence-based amplification (NASBA). by Uyttendaele M, Schukkink R, van Gemen B, Debevere J.; 1995 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=167389
•
Detection of Campylobacter jejuni and Campylobacter coli in Environmental Waters by PCR Enzyme-Linked Immunosorbent Assay. by Sails AD, Bolton FJ, Fox AJ, Wareing DR, Greenway DL.; 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=123752
•
Detection of Cytolethal Distending Toxin Activity and cdt Genes in Campylobacter spp. Isolated from Chicken Carcasses. by Eyigor A, Dawson KA, Langlois BE, Pickett CL.; 1999 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91213
•
Detection of Heat-Stable Antigens of Campylobacter jejuni and C. coli by Direct Agglutination and Passive Hemagglutination. by Oza AN, Thwaites RT, Wareing DR, Bolton FJ, Frost JA.; 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=120255
Studies
37
•
Detection of pathogenic Campylobacter species in blood culture systems. by Wang WL, Blaser MJ.; 1986 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=362822
•
Detection of Small Numbers of Campylobacter jejuni and Campylobacter coli Cells in Environmental Water, Sewage, and Food Samples by a Seminested PCR Assay. by Waage AS, Vardund T, Lund V, Kapperud G.; 1999 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91231
•
Detection of two different kanamycin resistance genes in naturally occurring isolates of Campylobacter jejuni and Campylobacter coli. by Tenover FC, Elvrum PM.; 1988 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=172371
•
Detection on Surfaces and in Caco-2 Cells of Campylobacter jejuni Cells Transformed with New gfp, yfp, and cfp Marker Plasmids. by Miller WG, Bates AH, Horn ST, Brandl MT, Wachtel MR, Mandrell RE.; 2000 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92478
•
Detection, Isolation, and Molecular Subtyping of Escherichia coli O157:H7 and Campylobacter jejuni Associated with a Large Waterborne Outbreak. by Bopp DJ, Sauders BD, Waring AL, Ackelsberg J, Dumas N, Braun-Howland E, Dziewulski D, Wallace BJ, Kelly M, Halse T, Musser KA, Smith PF, Morse DL, Limberger RJ.; 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=149601
•
Development and Application of a New Scheme for Typing Campylobacter jejuni and Campylobacter coli by PCR-Based Restriction Fragment Length Polymorphism Analysis. by Shi F, Chen YY, Wassenaar TM, Woods WH, Coloe PJ, Fry BN.; 2002 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=130948
•
Development and characterization of recA mutants of Campylobacter jejuni for inclusion in attenuated vaccines. by Guerry P, Pope PM, Burr DH, Leifer J, Joseph SW, Bourgeois AL.; 1994 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=186125
•
Development of a rapid and specific colony-lift immunoassay for detection and enumeration of Campylobacter jejuni, C. coli, and C. lari. by Rice BE, Lamichhane C, Joseph SW, Rollins DM.; 1996 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=170429
•
Development of an Immunoassay for Rapid Detection of Ganglioside GM1 Mimicry in Campylobacter jejuni Strains. by Prendergast MM, Kosunen TU, Moran AP.; 2001 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87959
•
Development of species-specific DNA probes for Campylobacter jejuni, Campylobacter coli, and Campylobacter lari by polymerase chain reaction fingerprinting. by Giesendorf BA, van Belkum A, Koeken A, Stegeman H, Henkens MH, van der Plas J, Goossens H, Niesters HG, Quint WG.; 1993 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=265575
38
Campylobacter
•
Differential flagellin expression in a flaA flaB+ mutant of Campylobacter jejuni. by Wassenaar TM, Bleumink-Pluym NM, Newell DG, Nuijten PJ, van der Zeijst BA.; 1994 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=303046
•
Differentiation of Campylobacter and Campylobacter-like organisms by cellular fatty acid composition. by Lambert MA, Patton CM, Barrett TJ, Moss CW.; 1987 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=266064
•
Differentiation of Campylobacter Isolates on the Basis of Sensitivity to Boiling in Water as Measured by PCR-Detectable DNA. by Mohran ZS, Arthur RR, Oyofo BA, Peruski LF, Wasfy MO, Ismail TF, Murphy JR.; 1998 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=124720
•
Differentiation of Campylobacter jejuni and Campylobacter coli strains by using restriction endonuclease DNA profiles and DNA fragment polymorphisms. by Korolik V, Moorthy L, Coloe PJ.; 1995 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=228118
•
Differentiation of Campylobacter jejuni Serotype O19 Strains from Non-O19 Strains by PCR. by Misawa N, Allos BM, Blaser MJ.; 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=105241
•
Differentiation of Campylobacter species by protein banding patterns in polyacrylamide slab gels. by Ferguson DA Jr, Lambe DW Jr.; 1984 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=271349
•
Direct immunofluorescence microscopy for rapid screening of Campylobacter enteritis. by Hodge DS, Prescott JF, Shewen PE.; 1986 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=269047
•
Direct isolation of atypical thermophilic Campylobacter species from human feces on selective agar medium. by Walmsley SL, Karmali MA.; 1989 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267395
•
Direct polymerase chain reaction detection of Campylobacter jejuni and Campylobacter coli in raw milk and dairy products. by Wegmuller B, Luthy J, Candrian U.; 1993 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=182251
•
Discrimination among thermophilic Campylobacter species by polymerase chain reaction amplification of 23S rRNA gene fragments. by Eyers M, Chapelle S, Van Camp G, Goossens H, De Wachter R.; 1993 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=266428
Studies
39
•
Discrimination among thermophilic Campylobacter species by polymerase chain reaction amplification of 23S rRNA gene fragments. by Eyers M, Chapelle S, Van Camp G, Goossens H, De Wachter R.; 1994 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=264058
•
Discrimination of Campylobacter jejuni isolates by fla gene sequencing. by Meinersmann RJ, Helsel LO, Fields PI, Hiett KL.; 1997 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=230067
•
Dispersal in Campylobacter spp. of aphA-3, a kanamycin resistance determinant from gram-positive cocci. by Papadopoulou B, Courvalin P.; 1988 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=172315
•
Distinct genotypes of human and canine isolates of Campylobacter upsaliensis determined by 16S rRNA gene typing and plasmid profiling. by Stanley J, Jones C, Burnens A, Owen RJ.; 1994 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=263796
•
Distribution and polymorphism of the flagellin genes from isolates of Campylobacter coli and Campylobacter jejuni. by Alm RA, Guerry P, Trust TJ.; 1993 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=204625
•
Distribution and serotypes of Campylobacter jejuni and Campylobacter coli in enteric Campylobacter strains isolated from children in the Central African Republic. by Georges-Courbot MC, Baya C, Beraud AM, Meunier DM, Georges AJ.; 1986 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=268700
•
DNA fingerprinting and serotyping of Campylobacter jejuni isolates from epidemic outbreaks. by Lind L, Sjogren E, Melby K, Kaijser B.; 1996 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=228912
•
DNA probe culture confirmation assay for identification of thermophilic Campylobacter species. by Tenover FC, Carlson L, Barbagallo S, Nachamkin I.; 1990 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267920
•
DNA probes for identification of tetracycline resistance genes in Campylobacter species isolated from swine and cattle. by Ng LK, Stiles ME, Taylor DE.; 1987 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=175018
•
DNA relatedness among strains of Campylobacter jejuni and Campylobacter coli with divergent serogroup and hippurate reactions. by Hebert GA, Edmonds P, Brenner DJ.; 1984 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=271267
40
Campylobacter
•
DNA relatedness and biochemical features of Campylobacter spp. isolated in central and South Australia. by Steele TW, Sangster N, Lanser JA.; 1985 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=268324
•
DNA Sequence and Mutational Analyses of the pVir Plasmid of Campylobacter jejuni 81-176. by Bacon DJ, Alm RA, Hu L, Hickey TE, Ewing CP, Batchelor RA, Trust TJ, Guerry P.; 2002 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=130303
•
Double-Staining Method for Differentiation of Morphological Changes and Membrane Integrity of Campylobacter coli Cells. by Alonso JL, Mascellaro S, Moreno Y, Ferrus MA, Hernandez J.; 2002 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=126449
•
Effect of Incubation Temperature on Isolation of Campylobacter jejuni Genotypes from Foodstuffs Enriched in Preston Broth. by Scates P, Moran L, Madden RH.; 2003 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=169123
•
Effect of inoculum size on the phenotypic characterization of Campylobacter species. by On SL, Holmes B.; 1991 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=269909
•
Effect of Low Temperatures on Growth, Structure, and Metabolism of Campylobacter coli SP10. by Holler C, Witthuhn D, Janzen-Blunck B.; 1998 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106086
•
Effect of Low-Osmolality Nutrient Media on Growth and Culturability of Campylobacter Species. by Reezal A, McNeil B, Anderson JG.; 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=90903
•
Effect of moisture content of the medium on colony morphology of Campylobacter fetus subsp. jejuni. by Buck GE, Kelly MT.; 1981 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=273994
•
Effect of mutational alteration of Asn-128 in the putative GTP-binding domain of tetracycline resistance determinant Tet(O) from Campylobacter jejuni. by Grewal J, Manavathu EK, Taylor DE.; 1993 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=192766
•
Effects of diet formulations containing proteins from different sources on intestinal colonization by Campylobacter jejuni in broiler chickens. by Udayamputhoor RS, Hariharan H, Van Lunen TA, Lewis PJ, Heaney S, Price L, Woodward D.; 2003 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=227054
•
Effects of erythromycin and ciprofloxacin on chronic fecal excretion of Campylobacter species in marmosets. by Goodman LJ, Kaplan RL, Petrak RM, Fliegelman RM, Taff D, Walton F, Penner JL, Trenholme GM.; 1986 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=176374
Studies
41
•
Efficacy of filter types for detecting Campylobacter jejuni and Campylobacter coli in environmental water samples by polymerase chain reaction. by Oyofo BA, Rollins DM.; 1993 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=195871
•
Efficacy of media and methods for detecting and enumerating Campylobacter jejuni in refrigerated chicken meat. by Beuchat LR.; 1985 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=291772
•
Efficient Isolation of Campylobacter upsaliensis from Stools. by Lastovica AJ, Le Roux E.; 2001 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88526
•
Emergence of fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli in subjects from Finland. by Rautelin H, Renkonen OV, Kosunen TU.; 1991 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=245327
•
Enrichment medium for isolation of Campylobacter jejuni-Campylobacter coli. by Rogol M, Shpak B, Rothman D, Sechter I.; 1985 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=238583
•
Enterotoxin production and serogroups of Campylobacter jejuni and Campylobacter coli from patients with diarrhea and from healthy laying hens. by Lindblom GB, Kaijser B, Sjogren E.; 1989 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267540
•
Enzyme-linked immunosorbent assays for virulence properties of Campylobacter jejuni clinical isolates. by Klipstein FA, Engert RF, Short HB.; 1986 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=268788
•
Epidemiological Typing of Campylobacter Isolates from Meat Processing Plants by Pulsed-Field Gel Electrophoresis, Fatty Acid Profile Typing, Serotyping, and Biotyping. by Steele M, McNab B, Fruhner L, DeGrandis S, Woodward D, Odumeru JA.; 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106393
•
Epidemiology and Antimicrobial Susceptibilities of 111 Campylobacter fetus subsp. fetus Strains Isolated in Quebec, Canada, from 1983 to 2000. by Tremblay C, Gaudreau C, Lorange M.; 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=149556
•
Erythromycin-resistant Campylobacter infections in Thailand. by Taylor DN, Blaser MJ, Echeverria P, Pitarangsi C, Bodhidatta L, Wang WL.; 1987 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=174747
42
Campylobacter
•
Evaluation of 10 methods to distinguish epidemic-associated Campylobacter strains. by Patton CM, Wachsmuth IK, Evins GM, Kiehlbauch JA, Plikaytis BD, Troup N, Tompkins L, Lior H.; 1991 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=269853
•
Evaluation of 11 PCR Assays for Species-Level Identification of Campylobacter jejuni and Campylobacter coli. by On SL, Jordan PJ.; 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=149560
•
Evaluation of a blood-free, charcoal-based, selective medium for the isolation of Campylobacter organisms from feces. by Karmali MA, Simor AE, Roscoe M, Fleming PC, Smith SS, Lane J.; 1986 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=268673
•
Evaluation of a disk method for detection of hippurate hydrolysis by Campylobacter spp. by Cacho JB, Aguirre PM, Hernanz A, Velasco AC.; 1989 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267313
•
Evaluation of a PCR/DNA Probe Colorimetric Membrane Assay for Identification of Campylobacter spp. in Human Stool Specimens. by Collins E, Glennon M, Hanley S, Murray AM, Cormican M, Smith T, Maher M.; 2001 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88506
•
Evaluation of a simplified procedure for serotyping Campylobacter jejuni and Campylobacter coli which is based on the O antigen. by Mills SD, Congi RV, Hennessy JN, Penner JL.; 1991 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=270279
•
Evaluation of a Truncated Recombinant Flagellin Subunit Vaccine against Campylobacter jejuni. by Lee LH, Burg E III, Baqar S, Bourgeois AL, Burr DH, Ewing CP, Trust TJ, Guerry P.; 1999 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=96957
•
Evaluation of commercial antisera for serotyping heat-labile antigens of Campylobacter jejuni and Campylobacter coli. by Nicholson MA, Patton CM.; 1993 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=263584
•
Evaluation of Culture Methods and a DNA Probe-Based PCR Assay for Detection of Campylobacter Species in Clinical Specimens of Feces. by Maher M, Finnegan C, Collins E, Ward B, Carroll C, Cormican M.; 2003 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=165355
•
Evaluation of disk method for hippurate hydrolysis by Campylobacter species. by Nicholson MA, Patton CM.; 1995 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=228159
•
Evaluation of media for isolation of Campylobacter fetus subsp. jejuni from fecal specimens. by Gilchrist MJ, Grewell CM, Washington JA 2nd.; 1981 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=271990
Studies
43
•
Evaluation of Methods for Subtyping Campylobacter jejuni during an Outbreak Involving a Food Handler. by Fitzgerald C, Helsel LO, Nicholson MA, Olsen SJ, Swerdlow DL, Flahart R, Sexton J, Fields PI.; 2001 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88159
•
Evaluation of Phenotypic and Genotypic Methods for Subtyping Campylobacter jejuni Isolates from Humans, Poultry, and Cattle. by Nielsen EM, Engberg J, Fussing V, Petersen L, Brogren CH, On SL.; 2000 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87479
•
Evaluation of the Alexon-Trend ProSpecT Campylobacter Microplate Assay. by Tolcin R, LaSalvia MM, Kirkley BA, Vetter EA, Cockerill FR III, Procop GW.; 2000 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87492
•
Evaluation of the campyslide agglutination test for confirmatory identification of selected Campylobacter species. by Hodinka RL, Gilligan PH.; 1988 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=266180
•
Evaluation of transport and storage techniques for isolation of Campylobacter fetus subsp. jejuni from turkey cecal specimens. by Luechtefeld NW, Wang WL, Blaser MJ, Reller LB.; 1981 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=273810
•
Evidence for a Genetically Stable Strain of Campylobacter jejuni. by Manning G, Duim B, Wassenaar T, Wagenaar JA, Ridley A, Newell DG.; 2001 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92712
•
Evidence for an efflux pump in multidrug-resistant Campylobacter jejuni. by Charvalos E, Tselentis Y, Hamzehpour MM, Kohler T, Pechere JC.; 1995 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=162874
•
Evidence for recombination in the flagellin locus of Campylobacter jejuni: implications for the flagellin gene typing scheme. by Harrington CS, Thomson-Carter FM, Carter PE.; 1997 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=229973
•
Evidence for the occurrence of the same strain of Campylobacter pylori in the stomach and dental plaque. by Shames B, Krajden S, Fuksa M, Babida C, Penner JL.; 1989 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267140
•
Evidence of reinfection with multiple strains of Campylobacter jejuni and Campylobacter coli in Macaca nemestrina housed under hyperendemic conditions. by Russell RG, Sarmiento JI, Fox J, Panigrahi P.; 1990 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=258790
•
Evidence that Certain Clones of Campylobacter jejuni Persist during Successive Broiler Flock Rotations. by Petersen L, Wedderkopp A.; 2001 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92933
44
Campylobacter
•
Evidence that the Campylobacter fetus sap Locus Is an Ancient Genomic Constituent with Origins before Mammals and Reptiles Diverged. by Tu ZC, Dewhirst FE, Blaser MJ.; 2001 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=98151
•
Experimental Campylobacter jejuni Infection of Adult Mice. by Blaser MJ, Duncan DJ, Warren GH, Wang WL.; 1983 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=348033
•
Expression and characterization of Campylobacter jejuni benzoylglycine amidohydrolase (Hippuricase) gene in Escherichia coli. by Hani EK, Chan VL.; 1995 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=176897
•
Extended Survival and Persistence of Campylobacter spp. in Water and Aquatic Biofilms and Their Detection by Immunofluorescent-Antibody and -rRNA Staining. by Buswell CM, Herlihy YM, Lawrence LM, McGuiggan JT, Marsh PD, Keevil CW, Leach SA.; 1998 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106109
•
Fecal Shedding of Campylobacter and Arcobacter spp. in Dairy Cattle. by Wesley IV, Wells SJ, Harmon KM, Green A, Schroeder-Tucker L, Glover M, Siddique I.; 2000 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=101445
•
Fibronectin-Facilitated Invasion of T84 Eukaryotic Cells by Campylobacter jejuni Occurs Preferentially at the Basolateral Cell Surface. by Monteville MR, Konkel ME.; 2002 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=133038
•
Flagella as a Potential Marker for Campylobacter jejuni Strains Associated with Guillain-Barre Syndrome. by Tsang RS, Figueroa G, Bryden L, Ng LK.; 2001 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87815
•
Flagellin gene typing of Campylobacter jejuni by restriction fragment length polymorphism analysis. by Nachamkin I, Bohachick K, Patton CM.; 1993 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=265573
•
Gene disruption and replacement as a feasible approach for mutagenesis of Campylobacter jejuni. by Labigne-Roussel A, Courcoux P, Tompkins L.; 1988 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=211020
•
Gene Expression Profile of Campylobacter jejuni in Response to Growth Temperature Variation. by Stintzi A.; 2003 Mar 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=150132
•
Gene transfer from Escherichia coli to Campylobacter species: development of shuttle vectors for genetic analysis of Campylobacter jejuni. by Labigne-Roussel A, Harel J, Tompkins L.; 1987 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=213946
Studies
45
•
Generation of a Superoxide Dismutase (SOD)-Deficient Mutant of Campylobacter coli: Evidence for the Significance of SOD in Campylobacter Survival and Colonization. by Purdy D, Cawthraw S, Dickinson JH, Newell DG, Park SF.; 1999 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91375
•
Genetic Characterization of Campylobacter jejuni O:41 Isolates in Relation with Guillain-Barre Syndrome. by Wassenaar TM, Fry BN, Lastovica AJ, Wagenaar JA, Coloe PJ, Duim B.; 2000 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=86231
•
Genetic, enzymatic, and pathogenic studies of the iron superoxide dismutase of Campylobacter jejuni. by Pesci EC, Cottle DL, Pickett CL.; 1994 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=302869
•
Genome Sequence-Based Fluorescent Amplified Fragment Length Polymorphism of Campylobacter jejuni, Its Relationship to Serotyping, and Its Implications for Epidemiological Analysis. by Desai M, Logan JM, Frost JA, Stanley J.; 2001 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88450
•
Genomic Heterogeneity and O-Antigenic Diversity of Campylobacter upsaliensis and Campylobacter helveticus Strains Isolated from Dogs and Cats in Germany. by Moser I, Rieksneuwohner B, Lentzsch P, Schwerk P, Wieler LH.; 2001 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88183
•
Genomic Relatedness within Five Common Finnish Campylobacter jejuni PulsedField Gel Electrophoresis Genotypes Studied by Amplified Fragment Length Polymorphism Analysis, Ribotyping, and Serotyping. by Hanninen ML, Perko-Makela P, Rautelin H, Duim B, Wagenaar JA.; 2001 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92772
•
Genotypic Identification of Erythromycin-Resistant Campylobacter Isolates as Helicobacter Species and Analysis of Resistance Mechanism. by Kuijper EJ, Stevens S, Imamura T, de Wever B, Claas EC.; 2003 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=179794
•
Genotyping of Campylobacter spp. by Wassenaar TM, Newell DG.; 2000 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91777
•
Growth of Campylobacter jejuni Supported by Respiration of Fumarate, Nitrate, Nitrite, Trimethylamine-N-Oxide, or Dimethyl Sulfoxide Requires Oxygen. by Sellars MJ, Hall SJ, Kelly DJ.; 2002 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=135223
•
Guillain-Barre Syndrome- and Miller Fisher Syndrome-Associated Campylobacter jejuni Lipopolysaccharides Induce Anti-GM1 and Anti-GQ1b Antibodies in Rabbits. by Ang CW, De Klerk MA, Endtz HP, Jacobs BC, Laman JD, van der Meche FG, van Doorn PA.; 2001 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=98180
•
Healthy puppies and kittens as carriers of Campylobacter spp., with special reference to Campylobacter upsaliensis. by Hald B, Madsen M.; 1997 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=230185
•
Heat injury and repair in Campylobacter jejuni. by Palumbo SA.; 1984 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=241551
46
Campylobacter
•
Heat-Labile Serotyping of Two Campylobacter jejuni Strains Isolated from Patients with Guillain-Barre Syndrome and Belonging to Serotype O19 (Penner). by Tsang RS, Frosk P, Johnson WM.; 2000 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=86658
•
Hexagonal surface layer of Campylobacter fetus isolated from humans. by Fujimoto S, Umeda A, Takade A, Murata K, Amako K.; 1989 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=313487
•
High-Level Resistance to Trimethoprim in Clinical Isolates of Campylobacter jejuni by Acquisition of Foreign Genes (dfr1 and dfr9) Expressing Drug-Insensitive Dihydrofolate Reductases. by Gibreel A, Skold O.; 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=105999
•
High-Resolution Genotyping of Campylobacter Strains Isolated from Poultry and Humans with Amplified Fragment Length Polymorphism Fingerprinting. by Duim B, Wassenaar TM, Rigter A, Wagenaar J.; 1999 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91350
•
Hippurate hydrolysis by and triphenyltetrazolium tolerance of Campylobacter fetus. by Luechtefeld NW, Wang WL.; 1982 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=272038
•
Hippurate hydrolysis by Campylobacter fetus. by Harvey SM.; 1980 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=273421
•
House flies (Musca domestica) as possible vectors of Campylobacter fetus subsp. jejuni. by Rosef O, Kapperud G.; 1983 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=242296
•
Human disease associated with "Campylobacter upsaliensis" (catalase-negative or weakly positive Campylobacter species) in the United States. by Patton CM, Shaffer N, Edmonds P, Barrett TJ, Lambert MA, Baker C, Perlman DM, Brenner DJ.; 1989 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267234
•
Hydrolysis of indoxyl acetate by Campylobacter species. by Mills CK, Gherna RL.; 1987 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=269272
•
Identification and characterization of an immunogenic outer membrane protein of Campylobacter jejuni. by Burnens A, Stucki U, Nicolet J, Frey J.; 1995 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=228588
•
Identification and characterization of Campylobacter jejuni outer membrane proteins. by Blaser MJ, Hopkins JA, Berka RM, Vasil ML, Wang WL.; 1983 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=264555
Studies
47
•
Identification and classification of Campylobacter strains by using nonradioactive DNA probes. by Chevrier D, Larzul D, Megraud F, Guesdon JL.; 1989 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267300
•
Identification of Campylobacter cinaedi isolated from blood and feces of children and adult females. by Vandamme P, Falsen E, Pot B, Kersters K, De Ley J.; 1990 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267856
•
Identification of Campylobacter fetus by PCR-DNA probe method. by Blom K, Patton CM, Nicholson MA, Swaminathan B.; 1995 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=228165
•
Identification of Campylobacter Heat-Stable and Heat-Labile Antigens by Combining the Penner and Lior Serotyping Schemes. by Woodward DL, Rodgers FG.; 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=120291
•
Identification of Campylobacter jejuni and C. coli by gel electrophoresis of the outer membrane proteins. by Derclaye I, Delor I, Van Bouchaute M, Moureau P, Wauters G, Cornelis GR.; 1989 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267485
•
Identification of Campylobacter jejuni and Campylobacter coli antigens with mucosal and systemic antibodies. by Wu SJ, Pacheco ND, Oprandy JJ, Rollwagen FM.; 1991 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=258055
•
Identification of Campylobacter jejuni on the basis of a species-specific gene that encodes a membrane protein. by Stucki U, Frey J, Nicolet J, Burnens AP.; 1995 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=228055
•
Identification of Campylobacter jejuni, C. coli, C. lari, C. upsaliensis, Arcobacter butzleri, and A. butzleri-Like Species Based on the glyA Gene. by Al Rashid ST, Dakuna I, Louie H, Ng D, Vandamme P, Johnson W, Chan VL.; 2000 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=86472
•
Identification of Campylobacter pyloridis isolates by restriction endonuclease DNA analysis. by Langenberg W, Rauws EA, Widjojokusumo A, Tytgat GN, Zanen HC.; 1986 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=268925
•
Identification of Ciprofloxacin-Resistant Campylobacter jejuni by Use of a Fluorogenic PCR Assay. by Wilson DL, Abner SR, Newman TC, Mansfield LS, Linz JE.; 2000 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87527
48
Campylobacter
•
Identification of EF group 22 campylobacters from gastroenteritis cases as Campylobacter concisus. by Vandamme P, Falsen E, Pot B, Hoste B, Kersters K, De Ley J.; 1989 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267670
•
Identification of Motility and Autoagglutination Campylobacter jejuni Mutants by Random Transposon Mutagenesis. by Golden NJ, Acheson DW.; 2002 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=127829
•
Identification of the Enteropathogens Campylobacter jejuni and Campylobacter coli Based on the cadF Virulence Gene and Its Product. by Konkel ME, Gray SA, Kim BJ, Garvis SG, Yoon J.; 1999 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=84446
•
Identification, Characterization, and Variation in Expression of Two Serologically Distinct O-Antigen Epitopes in Lipopolysaccharides of Campylobacter fetus Serotype A Strains. by Brooks BW, Robertson RH, Lutze-Wallace CL, Pfahler W.; 2001 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=98852
•
Immune response of athymic and euthymic germfree mice to Campylobacter spp. by Yrios JW, Balish E.; 1986 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=260166
•
Impact of Transport Crate Reuse and of Catching and Processing on Campylobacter and Salmonella Contamination of Broiler Chickens. by Slader J, Domingue G, Jorgensen F, McAlpine K, Owen RJ, Bolton FJ, Humphrey TJ.; 2002 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=126660
•
Improved biotyping schemes for Campylobacter jejuni and Campylobacter coli. by Roop RM 2nd, Smibert RM, Krieg NR.; 1984 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=271491
•
In Vitro Activities of New Fluoroquinolones against Campylobacter jejuni and Campylobacter coli Isolates Obtained from Humans in 1980 to 1982 and 1997 to 2001. by Krausse R, Ullmann U.; 2003 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=182638
•
In vitro antimicrobial susceptibility, plasmid analysis, and serotyping of epidemicassociated Campylobacter jejuni. by Bopp CA, Birkness KA, Wachsmuth IK, Barrett TJ.; 1985 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=271568
•
In vitro susceptibilities of aerotolerant Campylobacter isolates to 22 antimicrobial agents. by Kiehlbauch JA, Baker CN, Wachsmuth IK.; 1992 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=189365
•
In vitro susceptibilities of Campylobacter jejuni and Campylobacter coli to azithromycin and erythromycin. by Taylor DE, Chang N.; 1991 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=245292
Studies
49
•
In Vivo Selection of Campylobacter Isolates with High Levels of Fluoroquinolone Resistance Associated with gyrA Mutations and the Function of the CmeABC Efflux Pump. by Luo N, Sahin O, Lin J, Michel LO, Zhang Q.; 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=148968
•
In Vivo Tracking of Campylobacter jejuni by Using a Novel Recombinant Expressing Green Fluorescent Protein. by Mixter PF, Klena JD, Flom GA, Siegesmund AM, Konkel ME.; 2003 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=154531
•
Inactivation of Campylobacter jejuni by chlorine and monochloramine. by Blaser MJ, Smith PF, Wang WL, Hoff JC.; 1986 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=238864
•
Incidence of toxigenic Campylobacter strains in South Africa. by Bok HE, Greeff AS, Crewe-Brown HH.; 1991 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=271974
•
Indwelling device-related bacteremia caused by serum-susceptible Campylobacter coli. by Hsueh PR, Teng LJ, Yang PC, Ho SW, Luh KT.; 1997 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=229932
•
Influence of strain characteristics and immunity on the epidemiology of Campylobacter infections in Thailand. by Taylor DN, Echeverria P, Pitarangsi C, Seriwatana J, Bodhidatta L, Blaser MJ.; 1988 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=266475
•
Inhibition of Campylobacter coli and Campylobacter jejuni by antibiotics used in selective growth media. by Ng LK, Stiles ME, Taylor DE.; 1985 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=268456
•
Interaction of Campylobacter jejuni and Campylobacter coli with lectins and blood group antibodies. by Wong KH, Skelton SK, Feeley JC.; 1985 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=268339
•
Interactions of Campylobacter jejuni Cytolethal Distending Toxin Subunits CdtA and CdtC with HeLa Cells. by Lee RB, Hassane DC, Cottle DL, Pickett CL.; 2003 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=187314
•
Intestinal colonization of neonatal animals by Campylobacter fetus subsp. jejuni. by Field LH, Underwood JL, Pope LM, Berry LJ.; 1981 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=350794
•
Investigation of a Campylobacter jejuni outbreak by serotyping and chromosomal restriction endonuclease analysis. by Bradbury WC, Pearson AD, Marko MA, Congi RV, Penner JL.; 1984 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=271061
50
Campylobacter
•
Involvement of a Plasmid in Virulence of Campylobacter jejuni 81-176. by Bacon DJ, Alm RA, Burr DH, Hu L, Kopecko DJ, Ewing CP, Trust TJ, Guerry P.; 2000 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=98329
•
Isoelectric focusing of ureases from Campylobacter pylori and related organisms. by Tompkins DS, Millar MR, West AP.; 1988 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=266974
•
Isolation and Characterization of Campylobacter jejuni subsp. jejuni from Macaroni Penguins (Eudyptes chrysolophus) in the Subantarctic Region. by Broman T, Bergstrom S, On SL, Palmgren H, McCafferty DJ, Sellin M, Olsen B.; 2000 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91847
•
Isolation and characterization of catalase-negative and catalase-weak strains of Campylobacter species, including "Campylobacter upsaliensis," from humans with gastroenteritis. by Taylor DE, Hiratsuka K, Mueller L.; 1989 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267734
•
Isolation and characterization of cephalothin-susceptible Campylobacter coli from slaughter cattle. by Brooks BW, Garcia MM, Fraser DE, Lior H, Stewart RB, Lammerding AM.; 1986 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=268977
•
Isolation of Campylobacter concisus from feces of children with and without diarrhea. by Van Etterijck R, Breynaert J, Revets H, Devreker T, Vandenplas Y, Vandamme P, Lauwers S.; 1996 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=229239
•
Isolation of Campylobacter fetus subsp. fetus from a Patient with Cellulitis. by Briedis DJ, Khamessan A, McLaughlin RW, Vali H, Panaritou M, Chan EC.; 2002 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=154594
•
Isolation of Campylobacter fetus subsp. jejuni from Human Fecal Specimens by Incubation at 35 and 42[deg]C. by Janssen D, Helstad AG.; 1982 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=272369
•
Isolation of Campylobacter jejuni from retail mushrooms. by Doyle MP, Schoeni JL.; 1986 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=238894
•
Isolation of Campylobacter spp. from pigeon feces by a combined enrichmentfiltration technique. by Megraud F.; 1987 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=203878
•
Isolation of nonchemotactic mutants of Campylobacter jejuni and their colonization of the mouse intestinal tract. by Takata T, Fujimoto S, Amako K.; 1992 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=257366
Studies
51
•
Isolation of Plasmids Encoding Tetracycline Resistance from Campylobacter jejuni Strains Isolated from Simians. by Tenover FC, Bronsdon MA, Gordon KP, Plorde JJ.; 1983 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=186045
•
Isolation, characterization, and serotyping of Campylobacter jejuni and Campylobacter coli from slaughter cattle. by Garcia MM, Lior H, Stewart RB, Ruckerbauer GM, Trudel JR, Skljarevski A.; 1985 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=373568
•
Isoprenoid quinone content and cellular fatty acid composition of Campylobacter species. by Moss CW, Kai A, Lambert MA, Patton C.; 1984 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=271183
•
Isoprenoid quinones of Campylobacter cryaerophila, C. cinaedi, C. fennelliae, C. hyointestinalis, C. pylori, and "C. upsaliensis". by Moss CW, Lambert-Fair MA, Nicholson MA, Guerrant GO.; 1990 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=269621
•
Laboratory and clinical evaluation of isolation media for Campylobacter jejuni. by Gun-Munro J, Rennie RP, Thornley JH, Richardson HL, Hodge D, Lynch J.; 1987 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=269469
•
Large-Scale Survey of Campylobacter Species in Human Gastroenteritis by PCR and PCR --Enzyme-Linked Immunosorbent Assay. by Lawson AJ, Logan JM, O'neill GL, Desai M, Stanley J.; 1999 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=85830
•
Lectin Typing of Campylobacter concisus. by Aabenhus R, Hynes SO, Permin H, Moran AP, Andersen LP.; 2002 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=153386
•
Lipopolysaccharide structures in Enterobacteriaceae, Pseudomonas aeruginosa, and Vibrio cholerae are immunologically related to Campylobacter spp. by Perez-Perez GI, Hopkins JA, Blaser MJ.; 1986 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=261087
•
Lipopolysaccharide structures of Campylobacter fetus are related to heat-stable serogroups. by Perez-Perez GI, Blaser MJ, Bryner JH.; 1986 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=261088
•
Lipopolysaccharides from Campylobacter jejuni O:41 Strains Associated with Guillain-Barre Syndrome Exhibit Mimicry of GM1 Ganglioside. by Prendergast MM, Lastovica AJ, Moran AP.; 1998 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=108398
•
Local immune responses to the Campylobacter flagellin in acute Campylobacter gastrointestinal infection. by Nachamkin I, Yang XH.; 1992 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=265089
52
Campylobacter
•
Location of epitopes on Campylobacter jejuni flagella. by Logan SM, Trust TJ.; 1986 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=213544
•
Lysyl-tRNA synthetase gene of Campylobacter jejuni. by Chan VL, Bingham HL.; 1992 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=206145
•
Major outer membrane protein of Campylobacter fetus: physical and immunological characterization. by McCoy EC, Wiltberger HA, Winter J.; 1976 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=420747
•
Mechanisms of antibiotic resistance in Campylobacter species. by Taylor DE, Courvalin P.; 1988 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=172360
•
Microarray-Based Identification of Thermophilic Campylobacter jejuni, C. coli, C. lari, and C. upsaliensis. by Volokhov D, Chizhikov V, Chumakov K, Rasooly A.; 2003 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=193862
•
Microtiter Assay for Detecting Campylobacter spp. and Helicobacter pylori with Surface Gangliosides Which Bind Cholera Toxin. by Sack DA, Lastovica AJ, Chang SH, Pazzaglia G.; 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104975
•
Miller-Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that mimic human ganglioside GD3. by Salloway S, Mermel LA, Seamans M, Aspinall GO, Nam Shin JE, Kurjanczyk LA, Penner JL.; 1996 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=174172
•
Modified ammonia electrode method to investigate D-asparagine breakdown by Campylobacter strains. by Karmali MA, Roscoe M, Fleming PC.; 1986 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=362828
•
Modified selective medium for isolation of Campylobacter spp. from feces: comparison with Preston medium, a blood-free medium, and a filtration system. by Goossens H, De Boeck M, Coignau H, Vlaes L, Van den Borre C, Butzler JP.; 1986 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=269038
•
Molecular characterization of a Campylobacter jejuni 29-kilodalton periplasmic binding protein. by Garvis SG, Puzon GJ, Konkel ME.; 1996 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=174260
•
Molecular characterization of a Campylobacter jejuni lipoprotein with homology to periplasmic siderophore-binding proteins. by Park SF, Richardson PT.; 1995 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=176878
Studies
53
•
Molecular Characterization of Campylobacter jejuni from Patients with GuillainBarre and Miller Fisher Syndromes. by Endtz HP, Ang CW, van den Braak N, Duim B, Rigter A, Price LJ, Woodward DL, Rodgers FG, Johnson WM, Wagenaar JA, Jacobs BC, Verbrugh HA, van Belkum A.; 2000 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=86786
•
Molecular Characterization of Invasive and Noninvasive Campylobacter jejuni and Campylobacter coli Isolates. by Carvalho AC, Ruiz-Palacios GM, Ramos-Cervantes P, Cervantes LE, Jiang X, Pickering LK.; 2001 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87939
•
Molecular cloning and expression of Campylobacter pylori species-specific antigens in Escherichia coli K-12. by Clayton CL, Wren BW, Mullany P, Topping A, Tabaqchali S.; 1989 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=313142
•
Molecular cloning and site-specific mutagenesis of a gene involved in arylsulfatase production in Campylobacter jejuni. by Yao R, Guerry P.; 1996 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=178088
•
Molecular Epidemiology of Campylobacter jejuni in Broiler Flocks Using Randomly Amplified Polymorphic DNA-PCR and 23S rRNA-PCR and Role of Litter in Its Transmission. by Payne RE, Lee MD, Dreesen DW, Barnhart HM.; 1999 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91010
•
Molecular Evidence for Dissemination of Unique Campylobacter jejuni Clones in Curacao, Netherlands Antilles. by Duim B, Godschalk PC, van den Braak N, Dingle KE, Dijkstra JR, Leyde E, van der Plas J, Colles FM, Endtz HP, Wagenaar JA, Maiden MC, van Belkum A.; 2003 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=309031
•
Molecular Identification of Campylobacter concisus. by Matsheka MI, Lastovica AJ, Elisha BG.; 2001 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88407
•
Molecular Subtype Analyses of Campylobacter spp. from Arkansas and California Poultry Operations. by Hiett KL, Stern NJ, Fedorka-Cray P, Cox NA, Musgrove MT, Ladely S.; 2002 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=134383
•
Molecular subtyping scheme for serotypes HS1 and HS4 of Campylobacter jejuni. by Owen RJ, Sutherland K, Fitzgerald C, Gibson J, Borman P, Stanley J.; 1995 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=228058
•
Molecular Typing of Campylobacter jejuni and Campylobacter coli. by Lastovica AJ.; 2003 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=150320
•
Molecular Typing of Campylobacter jejuni Isolates Involved in a Neonatal Outbreak Indicates Nosocomial Transmission. by Llovo J, Mateo E, Munoz A, Urquijo M, On SL, Fernandez-Astorga A.; 2003 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=179862
54
Campylobacter
•
Multilocus Sequence Typing for Comparison of Veterinary and Human Isolates of Campylobacter jejuni. by Manning G, Dowson CG, Bagnall MC, Ahmed IH, West M, Newell DG.; 2003 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=262249
•
Multilocus Sequence Typing System for Campylobacter jejuni. by Dingle KE, Colles FM, Wareing DR, Ure R, Fox AJ, Bolton FE, Bootsma HJ, Willems RJ, Urwin R, Maiden MC.; 2001 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87672
•
Mutation in the peb1A Locus of Campylobacter jejuni Reduces Interactions with Epithelial Cells and Intestinal Colonization of Mice. by Pei Z, Burucoa C, Grignon B, Baqar S, Huang XZ, Kopecko DJ, Bourgeois AL, Fauchere JL, Blaser MJ.; 1998 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=107999
•
Natural transformation in Campylobacter species. by Wang Y, Taylor DE.; 1990 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=208523
•
Natural Transformation of Campylobacter jejuni Requires Components of a Type II Secretion System. by Wiesner RS, Hendrixson DR, DiRita VJ.; 2003 Sep 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=193740
•
Naturally occurring auxotrophs of Campylobacter jejuni and Campylobacter coli. by Tenover FC, Patton CM.; 1987 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=269302
•
Nested DNA inversion of Campylobacter fetus S-layer genes is recA dependent. by Dworkin J, Shedd OL, Blaser MJ.; 1997 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=179705
•
New, extended biotyping scheme for Campylobacter jejuni, Campylobacter coli, and "Campylobacter laridis". by Lior H.; 1984 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=271400
•
Occurrence of plasmid DNA in serologically defined strains of Campylobacter jejuni and Campylobacter coli. by Bradbury WC, Marko MA, Hennessy JN, Penner JL.; 1983 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=264877
•
Occurrence of plasmids and antibiotic resistance among Campylobacter jejuni and Campylobacter coli isolated from healthy and diarrheic animals. by Bradbury WC, Munroe DL.; 1985 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=268406
•
Oligodeoxynucleotide probes for Campylobacter fetus and Campylobacter hyointestinalis based on 16S rRNA sequences. by Wesley IV, Wesley RD, Cardella M, Dewhirst FE, Paster BJ.; 1991 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=270216
Studies
55
•
Oligonucleotide probe for detection and identification of Campylobacter pylori. by Morotomi M, Hoshina S, Green P, Neu HC, LoGerfo P, Watanabe I, Mutai M, Weinstein IB.; 1989 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267102
•
Outer membrane characteristics of Campylobacter jejuni. by Logan SM, Trust TJ.; 1982 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=347834
•
Pathophysiology of Campylobacter enteritis. by Walker RI, Caldwell MB, Lee EC, Guerry P, Trust TJ, Ruiz-Palacios GM.; 1986 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=373055
•
PCR detection, identification to species level, and fingerprinting of Campylobacter jejuni and Campylobacter coli direct from diarrheic samples. by Linton D, Lawson AJ, Owen RJ, Stanley J.; 1997 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=230012
•
PCR --Enzyme-Linked Immunosorbent Assay for Detection and Identification of Campylobacter Species: Application to Isolates and Stool Samples. by Metherell LA, Logan JM, Stanley J.; 1999 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=84331
•
PCR-Restriction Fragment Length Polymorphism Analysis for Detection of Point Mutations Associated with Macrolide Resistance in Campylobacter spp. by Vacher S, Menard A, Bernard E, Megraud F.; 2003 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=149329
•
Phagocytosis of Campylobacter jejuni and its intracellular survival in mononuclear phagocytes. by Kiehlbauch JA, Albach RA, Baum LL, Chang KP.; 1985 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=261341
•
Phenotyping of Campylobacter jejuni and Campylobacter coli by a quantitative antibiogram [MIC] typing scheme using Euclidean distances [QATED]. by Moore JE, Goldsmith CE.; 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=45583
•
Phylogenetic and molecular characterization of a 23S rRNA gene positions the genus Campylobacter in the epsilon subdivision of the Proteobacteria and shows that the presence of transcribed spacers is common in Campylobacter spp. by Trust TJ, Logan SM, Gustafson CE, Romaniuk PJ, Kim NW, Chan VL, Ragan MA, Guerry P, Gutell RR.; 1994 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=196280
•
Physiological Activity of Campylobacter jejuni Far below the Minimal Growth Temperature. by Hazeleger WC, Wouters JA, Rombouts FM, Abee T.; 1998 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106578
•
Physiological Characterization of Viable-but-Nonculturable Campylobacter jejuni Cells. by Tholozan JL, Cappelier JM, Tissier JP, Delattre G, Federighi M.; 1999 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91151
56
Campylobacter
•
Polynucleotide sequence relationships among flagellin genes of Campylobacter jejuni and Campylobacter coli. by Thornton SA, Logan SM, Trust TJ, Guerry P.; 1990 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=258875
•
Population genetics of human and animal enteric Campylobacter strains. by Aeschbacher M, Piffaretti JC.; 1989 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=313295
•
Prevalence and characterization of hippurate-negative Campylobacter jejuni in King County, Washington. by Totten PA, Patton CM, Tenover FC, Barrett TJ, Stamm WE, Steigerwalt AG, Lin JY, Holmes KK, Brenner DJ.; 1987 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=269320
•
Prevalence of Campylobacter jejuni, Campylobacter lari, and Campylobacter coli in Different Ecological Guilds and Taxa of Migrating Birds. by Waldenstrom J, Broman T, Carlsson I, Hasselquist D, Achterberg RP, Wagenaar JA, Olsen B.; 2002 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=134389
•
Prevalence of Campylobacter spp., Escherichia coli, and Salmonella Serovars in Retail Chicken, Turkey, Pork, and Beef from the Greater Washington, D.C., Area. by Zhao C, Ge B, De Villena J, Sudler R, Yeh E, Zhao S, White DG, Wagner D, Meng J.; 2001 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=93326
•
Problems in identification of Campylobacter jejuni associated with acquisition of resistance to nalidixic acid. by Altwegg M, Burnens A, Zollinger-Iten J, Penner JL.; 1987 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=269340
•
Prospective study of enteric Campylobacter infections in children from birth to 6 months in the Central African Republic. by Georges-Courbot MC, Beraud-Cassel AM, Gouandjika I, Georges AJ.; 1987 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=266099
•
Prosthetic hip joint infection due to Campylobacter fetus. by Yao JD, Ng HM, Campbell I.; 1993 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=266419
•
Protein shift and antigenic variation in the S-layer of Campylobacter fetus subsp. venerealis during bovine infection accompanied by genomic rearrangement of sapA homologs. by Garcia MM, Lutze-Wallace CL, Denes AS, Eaglesome MD, Holst E, Blaser MJ.; 1995 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=176838
•
Pulsed-field gel electrophoresis for epidemiologic studies of Campylobacter hyointestinalis isolates. by Salama SM, Tabor H, Richter M, Taylor DE.; 1992 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=265427
Studies
57
•
Purification and characterization of Campylobacter rectus surface layer proteins. by Nitta H, Holt SC, Ebersole JL.; 1997 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=176083
•
Quality Control Strains Used in Susceptibility Testing of Campylobacter spp. by Hakanen A, Huovinen P.; 2002 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=120564
•
Quantitative Immunocapture PCR Assay for Detection of Campylobacter jejuni in Foods. by Waller DF, Ogata SA.; 2000 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92267
•
Rapid and improved gas-liquid chromatography technique for detection of hippurate hydrolysis by Campylobacter jejuni and Campylobacter coli. by Bar W, Fricke G.; 1987 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=269328
•
Rapid and sensitive detection of Campylobacter spp. in chicken products by using the polymerase chain reaction. by Giesendorf BA, Quint WG, Henkens MH, Stegeman H, Huf FA, Niesters HG.; 1992 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=183185
•
Rapid Detection of Campylobacter coli, C. jejuni, and Salmonella enterica on Poultry Carcasses by Using PCR-Enzyme-Linked Immunosorbent Assay. by Hong Y, Berrang ME, Liu T, Hofacre CL, Sanchez S, Wang L, Maurer JJ.; 2003 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=161512
•
Rapid Detection of Campylobacter jejuni in Stool Specimens by an Enzyme Immunoassay and Surveillance for Campylobacter upsaliensis in the Greater Salt Lake City Area. by Hindiyeh M, Jense S, Hohmann S, Benett H, Edwards C, Aldeen W, Croft A, Daly J, Mottice S, Carroll KC.; 2000 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87189
•
Rapid Emergence of High-Level Resistance to Quinolones in Campylobacter jejuni Associated with Mutational Changes in gyrA and parC. by Gibreel A, Sjogren E, Kaijser B, Wretlind B, Skold O.; 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106034
•
Rapid identification of Campylobacter pylori (C. pyloridis) by preformed enzymes. by McNulty CA, Dent JC.; 1987 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=269307
•
Rapid identification of Campylobacter species by restriction fragment length polymorphism analysis of a PCR-amplified fragment of the gene coding for 16S rRNA. by Cardarelli-Leite P, Blom K, Patton CM, Nicholson MA, Steigerwalt AG, Hunter SB, Brenner DJ, Barrett TJ, Swaminathan B.; 1996 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=228731
•
Rapid Identification of Campylobacter spp. by Melting Peak Analysis of Biprobes in Real-Time PCR. by Logan JM, Edwards KJ, Saunders NA, Stanley J.; 2001 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88115
58
Campylobacter
•
Rapid Identification of Thermotolerant Campylobacter jejuni, Campylobacter coli, Campylobacter lari, and Campylobacter upsaliensis from Various Geographic Locations by a GTPase-Based PCR-Reverse Hybridization Assay. by van Doorn LJ, Verschuuren-van Haperen A, Burnens A, Huysmans M, Vandamme P, Giesendorf BA, Blaser MJ, Quint WG.; 1999 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=84952
•
Rapid Pulsed-Field Gel Electrophoresis Protocol for Subtyping of Campylobacter jejuni. by Ribot EM, Fitzgerald C, Kubota K, Swaminathan B, Barrett TJ.; 2001 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88044
•
Rate of Campylobacter spp. isolation in three regions of Ontario, Canada, from 1978 to 1985. by Thompson JS, Cahoon FE, Hodge DS.; 1986 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=269051
•
Reattachment of surface array proteins to Campylobacter fetus cells. by Yang LY, Pei ZH, Fujimoto S, Blaser MJ.; 1992 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=206419
•
Recovery in Embryonated Eggs of Viable but Nonculturable Campylobacter jejuni Cells and Maintenance of Ability To Adhere to HeLa Cells after Resuscitation. by Cappelier JM, Minet J, Magras C, Colwell RR, Federighi M.; 1999 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91695
•
Recovery of Campylobacter jejuni and Campylobacter coli from inoculated foods by selective enrichment. by Doyle MP, Roman DJ.; 1982 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=244238
•
Recovery of injured Campylobacter jejuni cells after animal passage. by Saha SK, Saha S, Sanyal SC.; 1991 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=183978
•
Restriction Fragment Length Polymorphism Analysis Using Random Chromosomal Gene Probes for Epidemiological Analysis of Campylobacter jejuni Infections. by Fujimoto S, Umene K, Saito M, Horikawa K, Blaser MJ.; 2000 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=86518
•
Restriction fragment length polymorphism of flagellin genes of Campylobacter jejuni and/or C. coli isolates from Egypt. by Mohran ZS, Guerry P, Lior H, Murphy JR, elGendy AM, Mikhail MM, Oyofo BA.; 1996 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=228984
•
Risk Factors Associated with Campylobacter jejuni Infections in Curacao, Netherlands Antilles. by Endtz HP, van West H, Godschalk PC, de Haan L, Halabi Y, van den Braak N, Kesztyus BI, Leyde E, Ott A, Verkooyen R, Price LJ, Woodward DL, Rodgers FG, Ang CW, van Koningsveld R, van Belkum A, Gerstenbluth I.; 2003 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=309032
•
Risk factors for antibiotic resistance in Campylobacter spp. isolated from raw poultry meat in Switzerland. by Ledergerber U, Regula G, Stephan R, Danuser J, Bissig B, Stark KD.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=317320
Studies
59
•
Role of Campylobacter jejuni flagella as colonization factors for three-day-old chicks: analysis with flagellar mutants. by Nachamkin I, Yang XH, Stern NJ.; 1993 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=182076
•
Role of Catalase in Campylobacter jejuni Intracellular Survival. by Day WA Jr, Sajecki JL, Pitts TM, Joens LA.; 2000 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=97717
•
Role of two flagellin genes in Campylobacter motility. by Guerry P, Alm RA, Power ME, Logan SM, Trust TJ.; 1991 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=208154
•
Roles of Fe Superoxide Dismutase and Catalase in Resistance of Campylobacter coli to Freeze-Thaw Stress. by Stead D, Park SF.; 2000 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92120
•
Roles of rpoN, fliA, and flgR in Expression of Flagella in Campylobacter jejuni. by Jagannathan A, Constantinidou C, Penn CW.; 2001 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=99512
•
Roles of the Surface Layer Proteins of Campylobacter fetus subsp. fetus in Ovine Abortion. by Grogono-Thomas R, Dworkin J, Blaser MJ, Newell DG.; 2000 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=97330
•
Seasonal occurrence of Campylobacter spp. in surface waters and their correlation with standard indicator bacteria. by Carter AM, Pacha RE, Clark GW, Williams EA.; 1987 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=203700
•
Sequence Polymorphism, Predicted Secondary Structures, and Surface-Exposed Conformational Epitopes of Campylobacter Major Outer Membrane Protein. by Zhang Q, Meitzler JC, Huang S, Morishita T.; 2000 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=101523
•
Sequence Typing Confirms that Campylobacter jejuni Strains Associated with Guillain-Barre and Miller-Fisher Syndromes Are of Diverse Genetic Lineage, Serotype, and Flagella Type. by Dingle KE, Van Den Braak N, Colles FM, Price LJ, Woodward DL, Rodgers FG, Endtz HP, Van Belkum A, Maiden MC.; 2001 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88342
•
Serogroups of Campylobacter jejuni, Campylobacter coli, and Campylobacter fetus defined by direct immunofluorescence. by Hebert GA, Hollis DG, Weaver RE, Steigerwalt AG, McKinney RM, Brenner DJ.; 1983 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=272680
•
Serotype distribution of Campylobacter jejuni and Campylobacter coli isolated from hospitalized patients with diarrhea in central Australia. by Albert MJ, Leach A, Asche V, Hennessy J, Penner JL.; 1992 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=265021
60
Campylobacter
•
Serotyping of Campylobacter jejuni, Campylobacter coli, and Campylobacter laridis from domestic and wild animals. by Rosef O, Kapperud G, Lauwers S, Gondrosen B.; 1985 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=241755
•
Serotyping Scheme for Campylobacter jejuni and Campylobacter coli Based on Direct Agglutination of Heat-Stable Antigens. by Frost JA, Oza AN, Thwaites RT, Rowe B.; 1998 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104538
•
Shift in S-layer protein expression responsible for antigenic variation in Campylobacter fetus. by Wang E, Garcia MM, Blake MS, Pei Z, Blaser MJ.; 1993 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=204962
•
Sialylation of Lipooligosaccharide Cores Affects Immunogenicity and Serum Resistance of Campylobacter jejuni. by Guerry P, Ewing CP, Hickey TE, Prendergast MM, Moran AP.; 2000 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=97763
•
Significance of flagella in colonization resistance of rabbits immunized with Campylobacter spp. by Pavlovskis OR, Rollins DM, Haberberger RL Jr, Green AE, Habash L, Strocko S, Walker RI.; 1991 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=258004
•
Species-specific cloned DNA probes for the identification of Campylobacter hyointestinalis. by Gebhart CJ, Ward GE, Murtaugh MP.; 1989 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267116
•
Specific detection and confirmation of Campylobacter jejuni by DNA hybridization and PCR. by Ng LK, Kingombe CI, Yan W, Taylor DE, Hiratsuka K, Malik N, Garcia MM.; 1997 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=168775
•
Specific Detection of Arcobacter and Campylobacter Strains in Water and Sewage by PCR and Fluorescent In Situ Hybridization. by Moreno Y, Botella S, Alonso JL, Ferrus MA, Hernandez M, Hernandez J.; 2003 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=143587
•
Specific detection of Campylobacter jejuni and Campylobacter coli by using polymerase chain reaction. by Oyofo BA, Thornton SA, Burr DH, Trust TJ, Pavlovskis OR, Guerry P.; 1992 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=270487
•
Specific identification of the enteropathogens Campylobacter jejuni and Campylobacter coli by using a PCR test based on the ceuE gene encoding a putative virulence determinant. by Gonzalez I, Grant KA, Richardson PT, Park SF, Collins MD.; 1997 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=229667
Studies
61
•
Specific PCR Identification and Differentiation of the Thermophilic Campylobacters, Campylobacter jejuni, C. coli, C. lari, and C. upsaliensis. by Fermer C, Engvall EO.; 1999 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=85572
•
Stability of Related Human and Chicken Campylobacter jejuni Genotypes after Passage through Chick Intestine Studied by Pulsed-Field Gel Electrophoresis. by Hanninen ML, Hakkinen M, Rautelin H.; 1999 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91334
•
Standardizing Antimicrobial Susceptibility Testing of Campylobacter Species. by McDermott PF, Walker RD.; 2003 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=153937
•
Strain characterization and grouping of Campylobacter jejuni and Campylobacter coli by interaction with lectins. by Wong KH, Skelton SK, Feeley JC.; 1986 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=268663
•
Structural and antigenic characteristics of Campylobacter coli FlaA flagellin. by Power ME, Guerry P, McCubbin WD, Kay CM, Trust TJ.; 1994 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=205501
•
Structural and antigenic heterogeneity of lipopolysaccharides of Campylobacter jejuni and Campylobacter coli. by Logan SM, Trust TJ.; 1984 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=263302
•
Structural and biochemical analyses of a surface array protein of Campylobacter fetus. by Dubreuil JD, Logan SM, Cubbage S, Eidhin DN, McCubbin WD, Kay CM, Beveridge TJ, Ferris FG, Trust TJ.; 1988 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=211424
•
Structure of Campylobacter jejuni Lipopolysaccharides Determines Antiganglioside Specificity and Clinical Features of Guillain-Barre and Miller Fisher Patients. by Ang CW, Laman JD, Willison HJ, Wagner ER, Endtz HP, De Klerk MA, Tio-Gillen AP, Van den Braak N, Jacobs BC, Doorn PA.; 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=127781
•
Study of the Infectivity of Saline-Stored Campylobacter jejuni for Day-Old Chicks. by Hald B, Knudsen K, Lind P, Madsen M.; 2001 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92885
•
Study on the epidemiology and control of Campylobacter jejuni in poultry broiler flocks. by van de Giessen A, Mazurier SI, Jacobs-Reitsma W, Jansen W, Berkers P, Ritmeester W, Wernars K.; 1992 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=195703
•
Substrate utilization by Campylobacter jejuni and Campylobacter coli. by Westfall HN, Rollins DM, Weiss E.; 1986 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=239100
62
Campylobacter
•
Sulfonamide Resistance in Clinical Isolates of Campylobacter jejuni: Mutational Changes in the Chromosomal Dihydropteroate Synthase. by Gibreel A, Skold O.; 1999 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=89439
•
Surface array proteins of Campylobacter fetus block lectin-mediated binding to type A lipopolysaccharide. by Fogg GC, Yang LY, Wang E, Blaser MJ.; 1990 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=313561
•
Survey of plasmids and resistance factors in Campylobacter jejuni and Campylobacter coli. by Tenover FC, Williams S, Gordon KP, Nolan C, Plorde JJ.; 1985 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=176201
•
Survival and growth of Campylobacter fetus subsp. jejuni on meat and in cooked foods. by Gill CO, Harris LM.; 1982 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=242004
•
Survival and Resuscitation of Ten Strains of Campylobacter jejuni and Campylobacter coli under Acid Conditions. by Chaveerach P, ter Huurne AA, Lipman LJ, van Knapen F.; 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=152468
•
Survival of Campylobacter jejuni during Stationary Phase: Evidence for the Absence of a Phenotypic Stationary-Phase Response. by Kelly AF, Park SF, Bovill R, Mackey BM.; 2001 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92863
•
Survival of Clinical and Poultry-Derived Isolates of Campylobacter jejuni at a Low Temperature (4[deg]C). by Chan KF, Le Tran H, Kanenaka RY, Kathariou S.; 2001 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=93146
•
Susceptibility of Campylobacter species to nalidixic acid, enoxacin, and other DNA gyrase inhibitors. by Taylor DE, Ng LK, Lior H.; 1985 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=176366
•
Susceptibility testing of Campylobacter fetus subsp. jejuni, using broth microdilution panels. by Buck GE, Kelly MT.; 1982 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=181872
•
Temperature-dependent membrane fatty acid and cell physiology changes in coccoid forms of Campylobacter jejuni. by Hazeleger WC, Janse JD, Koenraad PM, Beumer RR, Rombouts FM, Abee T.; 1995 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=167543
•
Temporal and Geographical Distribution and Overlap of Penner Heat-Stable Serotypes and Pulsed-Field Gel Electrophoresis Genotypes of Campylobacter jejuni Isolates Collected from Humans and Chickens in Finland during a Seasonal Peak. by Karenlampi R, Rautelin H, Hakkinen M, Hanninen ML.; 2003 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=254332
Studies
63
•
The Campylobacter sigma 54 flaB flagellin promoter is subject to environmental regulation. by Alm RA, Guerry P, Trust TJ.; 1993 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=204885
•
The Central, Surface-Exposed Region of the Flagellar Hook Protein FlgE of Campylobacter jejuni Shows Hypervariability among Strains. by Luneberg E, GlennCalvo E, Hartmann M, Bar W, Frosch M.; 1998 Jul 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=107344
•
The galE Gene of Campylobacter jejuni Is Involved in Lipopolysaccharide Synthesis and Virulence. by Fry BN, Feng S, Chen YY, Newell DG, Coloe PJ, Korolik V.; 2000 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=97464
•
The Iron-Binding Protein Dps Confers Hydrogen Peroxide Stress Resistance to Campylobacter jejuni. by Ishikawa T, Mizunoe Y, Kawabata SI, Takade A, Harada M, Wai SN, Yoshida SI.; 2003 Feb 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=142835
•
Three supplementary diagnostic tests for Campylobacter species and related organisms. by Burnens AP, Nicolet J.; 1993 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=262849
•
Tolerance to Self Gangliosides Is the Major Factor Restricting the Antibody Response to Lipopolysaccharide Core Oligosaccharides in Campylobacter jejuni Strains Associated with Guillain-Barre Syndrome. by Bowes T, Wagner ER, Boffey J, Nicholl D, Cochrane L, Benboubetra M, Conner J, Furukawa K, Furukawa K, Willison HJ.; 2002 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=128228
•
Toxin production by Campylobacter spp. by Wassenaar TM.; 1997 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=172930
•
Transmissible plasmids from Campylobacter jejuni. by Taylor DE, De Grandis SA, Karmali MA, Fleming PC.; 1981 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=181531
•
Transmission of Campylobacter hyointestinalis from a Pig to a Human. by Gorkiewicz G, Feierl G, Zechner R, Zechner EL.; 2002 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=120582
•
Trimethoprim activity in media selective for Campylobacter jejuni. by Bopp CA, Wells JG, Barrett TJ.; 1982 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=272481
•
Typing of Campylobacter pylori by bacterial DNA restriction endonuclease analysis and determination of plasmid profile. by Simor AE, Shames B, Drumm B, Sherman P, Low DE, Penner JL.; 1990 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=269541
64
Campylobacter
•
Typing of heat-stable and heat-labile antigens of Campylobacter jejuni and Campylobacter coli by coagglutination. by Wong KH, Skelton SK, Patton CM, Feeley JC, Morris G.; 1985 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=271762
•
Typing of Human Campylobacter jejuni Isolates in Finland by Pulsed-Field Gel Electrophoresis. by Hanninen ML, Pajarre S, Klossner ML, Rautelin H.; 1998 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104923
•
Ultrastructure and chemical analysis of Campylobacter pylori flagella. by Geis G, Leying H, Suerbaum S, Mai U, Opferkuch W.; 1989 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267336
•
Uncommon Campylobacter species in infant Macaca nemestrina monkeys housed in a nursery. by Russell RG, Kiehlbauch JA, Gebhart CJ, DeTolla LJ.; 1992 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=270576
•
Unusual Microtuble-Dependent Endocytosis Mechanisms Triggered by Campylobacter jejuni and Citrobacter freundii. by Oelschlaeger TA, Guerry P, Kopecko DJ.; 1993 Jul 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=47037
•
Urease-positive thermophilic Campylobacter (Campylobacter laridis variant) isolated from an appendix and from human feces. by Megraud F, Chevrier D, Desplaces N, Sedallian A, Guesdon JL.; 1988 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=266518
•
Use of an alkaline phosphatase-labeled synthetic oligonucleotide probe for detection of Campylobacter jejuni and Campylobacter coli. by Olive DM, Johny M, Sethi SK.; 1990 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=267989
•
Use of an arbitrarily primed PCR product in the development of a Campylobacter jejuni-specific PCR. by Day WA Jr, Pepper IL, Joens LA.; 1997 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=168393
•
Use of auxotyping for epidemiological studies of Campylobacter jejuni and Campylobacter coli infections. by Tenover FC, Knapp JS, Patton C, Plorde JJ.; 1985 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=261318
•
Use of PCR for Direct Detection of Campylobacter Species in Bovine Feces. by Inglis GD, Kalischuk LD.; 2003 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=161499
Studies
65
•
Use of pulsed-field agarose gel electrophoresis to size genomes of Campylobacter species and to construct a SalI map of Campylobacter jejuni UA580. by Chang N, Taylor DE.; 1990 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=213182
•
Use of Pulsed-Field Gel Electrophoresis and Flagellin Gene Typing in Identifying Clonal Groups of Campylobacter jejuni and Campylobacter coli in Farm and Clinical Environments. by Fitzgerald C, Stanley K, Andrew S, Jones K.; 2001 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=92751
•
Use of tri-gas incubator for routine culture of Campylobacter species from fecal specimens. by Thompson JS, Hodge DS, Smith DE, Yong YA.; 1990 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=268277
•
Utility of Multilocus Sequence Typing as an Epidemiological Tool for Investigation of Outbreaks of Gastroenteritis Caused by Campylobacter jejuni. by Sails AD, Swaminathan B, Fields PI.; 2003 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=254344
•
Utilization of exogenous siderophores by Campylobacter species. by Baig BH, Wachsmuth IK, Morris GK.; 1986 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=268668
•
Variation in antigenicity and molecular weight of Campylobacter coli VC167 flagellin in different genetic backgrounds. by Alm RA, Guerry P, Power ME, Trust TJ.; 1992 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=206204
•
Viability and DNA Maintenance in Nonculturable Spiral Campylobacter jejuni Cells after Long-Term Exposure to Low Temperatures. by Lazaro B, Carcamo J, Audicana A, Perales I, Fernandez-Astorga A.; 1999 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=91624
•
Viable but nonculturable stage of Campylobacter jejuni and its role in survival in the natural aquatic environment. by Rollins DM, Colwell RR.; 1986 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=203568
•
Virulence of Campylobacter jejuni for chicken embryos is associated with decreased bloodstream clearance and resistance to phagocytosis. by Field LH, Underwood JL, Payne SM, Berry LJ.; 1991 Apr; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=257862
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 6
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text
66
Campylobacter
The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with campylobacter, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “campylobacter” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for campylobacter (hyperlinks lead to article summaries): •
A 16S rDNA-based nested PCR protocol to detect Campylobacter gracilis in oral infections. Author(s): Siqueira Junior JF, Rocas IN. Source: Pesquisa Odontologica Brasileira = Brazilian Oral Research. 2003 April-June; 17(2): 142-6. Epub 2003 October 10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14569356
•
A case-control study of risk factors for sporadic campylobacter infections in Denmark. Author(s): Neimann J, Engberg J, Molbak K, Wegener HC. Source: Epidemiology and Infection. 2003 June; 130(3): 353-66. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12825719
•
A comparison of Campylobacter jejuni enteritis incidence rates in high- and lowpoultry-density counties: Michigan 1992-1999. Author(s): Potter RC, Kaneene JB, Gardiner J. Source: Vector Borne and Zoonotic Diseases (Larchmont, N.Y.). 2002 Fall; 2(3): 137-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12737543
•
A deep-rough mutant of Campylobacter jejuni 81-176 is noninvasive for intestinal epithelial cells. Author(s): Kanipes MI, Holder LC, Corcoran AT, Moran AP, Guerry P. Source: Infection and Immunity. 2004 April; 72(4): 2452-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15039381
•
A descriptive study of Guillain-Barre syndrome in high and low Campylobacter jejuni incidence regions of Michigan: 1992-1999. Author(s): Church Potter R, Kaneene JB. Source: Neuroepidemiology. 2003 July-August; 22(4): 245-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12792145
journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
Studies
67
•
A family with Campylobacter enteritis: anti-GD1a antibody with/without GuillainBarre syndrome. Author(s): Hirano M, Kusunoki S, Asai H, Tonomura Y, Morita D, Ueno S. Source: Neurology. 2003 May 27; 60(10): 1719-20. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12771281
•
A phenylalanine-arginine beta-naphthylamide sensitive multidrug efflux pump involved in intrinsic and acquired resistance of Campylobacter to macrolides. Author(s): Mamelli L, Amoros JP, Pages JM, Bolla JM. Source: International Journal of Antimicrobial Agents. 2003 September; 22(3): 237-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=13678827
•
Acute anterior uveitis in association with an outbreak of Campylobacter jejuni infection. Author(s): Hannu T, Sihto-Kauppi K, Kotaniemi K, Kauppi M. Source: Scandinavian Journal of Rheumatology. 2004; 33(1): 55-7. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15124945
•
Acute disseminated encephalomyelitis temporally associated with Campylobacter gastroenteritis. Author(s): Orr D, McKendrick MW, Sharrack B. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2004 May; 75(5): 792-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15090589
•
An outbreak of Campylobacter jejuni infection among conference delegates. Author(s): Raupach JC, Hundy RL. Source: Commun Dis Intell. 2003; 27(3): 380-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14510066
•
Antibiotic resistance among Campylobacter jejuni/coli strains acquired in Sweden and abroad: a longitudinal study. Author(s): Osterlund A, Hermann M, Kahlmeter G. Source: Scandinavian Journal of Infectious Diseases. 2003; 35(8): 478-81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14514147
•
Antibiotic resistance in Campylobacter jejuni isolated from humans in the Hunter Region, New South Wales. Author(s): Sharma H, Unicomb L, Forbes W, Djordjevic S, Valcanis M, Dalton C, Ferguson J. Source: Commun Dis Intell. 2003; 27 Suppl: S80-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12807280
68
Campylobacter
•
Anti-GM1b IgG antibody is associated with acute motor axonal neuropathy and Campylobacter jejuni infection. Author(s): Ogawara K, Kuwabara S, Koga M, Mori M, Yuki N, Hattori T. Source: Journal of the Neurological Sciences. 2003 June 15; 210(1-2): 41-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12736086
•
Antimicrobial resistance in Campylobacter jejuni and Campylobacter coli strains isolated in 1991 and 2001-2002 from poultry and humans in Berlin, Germany. Author(s): Luber P, Wagner J, Hahn H, Bartelt E. Source: Antimicrobial Agents and Chemotherapy. 2003 December; 47(12): 3825-30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14638490
•
Antimicrobial resistance of Campylobacter jejuni subsp. jejuni strains isolated from humans in 1998 to 2001 in Montreal, Canada. Author(s): Gaudreau C, Gilbert H. Source: Antimicrobial Agents and Chemotherapy. 2003 June; 47(6): 2027-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12760892
•
Antimicrobial susceptibility trends in Campylobacter jejuni and Campylobacter coli isolated from a rural Egyptian pediatric population with diarrhea. Author(s): Putnam SD, Frenck RW, Riddle MS, El-Gendy A, Taha NN, Pittner BT, AbuElyazeed R, Wierzba TF, Rao MR, Savarino SJ, Clemens JD. Source: Diagnostic Microbiology and Infectious Disease. 2003 December; 47(4): 601-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14711482
•
Antimicrobial-resistant Campylobacter species from retail raw meats. Author(s): Ge B, White DG, McDermott PF, Girard W, Zhao S, Hubert S, Meng J. Source: Applied and Environmental Microbiology. 2003 May; 69(5): 3005-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12732579
•
Association between environmental risk factors and campylobacter infections in Sweden. Author(s): Nygard K, Andersson Y, Rottingen JA, Svensson A, Lindback J, Kistemann T, Giesecke J. Source: Epidemiology and Infection. 2004 April; 132(2): 317-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15061507
•
Association of anti-GM1 antibodies but not of anti-cytomegalovirus, Campylobacter jejuni and Helicobacter pylori IgG, with a poor outcome in Guillain-Barre syndrome. Author(s): Annunziata P, Figura N, Galli R, Mugnaini F, Lenzi C. Source: Journal of the Neurological Sciences. 2003 September 15; 213(1-2): 55-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12873755
Studies
69
•
Bacteraemia caused by Campylobacter spp. Author(s): Armstrong C, Murphy PG. Source: Journal of Clinical Pathology. 1995 June; 48(6): 596. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7665714
•
Bacteraemia caused by Campylobacter spp. Author(s): Ladron de Guevara C, Gonzalez J, Pena P. Source: Journal of Clinical Pathology. 1994 February; 47(2): 174-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8132835
•
Bacteremia due to Campylobacter species: clinical findings and antimicrobial susceptibility patterns. Author(s): Pigrau C, Bartolome R, Almirante B, Planes AM, Gavalda J, Pahissa A. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 1997 December; 25(6): 1414-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9431389
•
Bacteremia due to Campylobacter species: high rate of resistance to macrolide and quinolone antibiotics. Author(s): Lu PL, Hsueh PR, Hung CC, Chang SC, Luh KT, Lee CY. Source: J Formos Med Assoc. 2000 August; 99(8): 612-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10969503
•
Bacteremia due to Campylobacter sputorum Biovar sputorum. Author(s): Tee W, Luppino M, Rambaldo S. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 1998 December; 27(6): 1544-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9868686
•
Bacterial enteric pathogens in children with acute dysentery in Thailand: increasing importance of quinolone-resistant Campylobacter. Author(s): Bodhidatta L, Vithayasai N, Eimpokalarp B, Pitarangsi C, Serichantalergs O, Isenbarger DW. Source: Southeast Asian J Trop Med Public Health. 2002 December; 33(4): 752-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12757222
•
Bacterial genetic fingerprint: a reliable factor in the study of the epidemiology of human campylobacter enteritis? Author(s): Steinbrueckner B, Ruberg F, Kist M. Source: Journal of Clinical Microbiology. 2001 November; 39(11): 4155-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11682547
70
Campylobacter
•
Bacterial secreted proteins are required for the internaliztion of Campylobacter jejuni into cultured mammalian cells. Author(s): Konkel ME, Kim BJ, Rivera-Amill V, Garvis SG. Source: Molecular Microbiology. 1999 May; 32(4): 691-701. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10361274
•
Bactericidal properties of Campylobacter jejuni-specific immunoglobulin M antibodies in commercial immunoglobulin preparations. Author(s): Autenrieth IB, Schwarzkopf A, Ewald JH, Karch H, Lissner R. Source: Antimicrobial Agents and Chemotherapy. 1995 September; 39(9): 1965-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8540699
•
Barbecued chicken causing a multi-state outbreak of Campylobacter jejuni enteritis. Author(s): Allerberger F, Al-Jazrawi N, Kreidl P, Dierich MP, Feierl G, Hein I, Wagner M. Source: Infection. 2003 January; 31(1): 19-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12590328
•
Basis of the superiority of cefoperazone amphotericin teicoplanin for isolating Campylobacter upsaliensis from stools. Author(s): Byrne C, Doherty D, Mooney A, Byrne M, Woodward D, Johnson W, Rodgers F, Bourke B. Source: Journal of Clinical Microbiology. 2001 July; 39(7): 2713-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11427603
•
Beta-lactamase production in human and animal isolates of Campylobacter jejuni in Turkey. Author(s): Diker KS, Akan M, Hascelik G, Emekdas G. Source: The Journal of Antimicrobial Chemotherapy. 1991 May; 27(5): 693-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1885429
•
Bias of phenotypic techniques for identification of Campylobacter isolates. Author(s): Matsiota-Bernard P, Chevrier D, Nauciel C, Guesdor J. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 1995 February; 14(2): 1535. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7758488
•
Bickerstaff's brainstem encephalitis subsequent to Campylobacter jejuni enteritis. Author(s): Yuki N, Odaka M, Hirata K. Source: Journal of Neurology, Neurosurgery, and Psychiatry. 2000 May; 68(5): 680-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10836867
Studies
71
•
Bilateral ptosis, tonic pupils and abducens palsies following Campylobacter jejuni enteritis. Author(s): Roberts BN, Mills PV, Hawksworth NJ. Source: Eye (London, England). 1995; 9 ( Pt 5): 657-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8543096
•
Binding of outer membrane preparations of Campylobacter jejuni to INT 457 cell membranes and extracellular matrix proteins. Author(s): Moser I, Schroder W. Source: Medical Microbiology and Immunology. 1995 October; 184(3): 147-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8577316
•
Biochemical characteristics, serogroup distribution, antibiotic susceptibility and agerelated significance of Campylobacter strains causing diarrhoea in humans in Hungary. Author(s): Varga J, Fodor L. Source: Zentralbl Bakteriol. 1998 July; 288(1): 67-73. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9728406
•
Biotyping of Campylobacter jejuni and Campylobacter coli infections in Spain. Author(s): Jimenez A, Velaquez JB, Rodriguez J, Chomon B, Villa TG. Source: The Journal of Infection. 1994 November; 29(3): 305-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7884224
•
Biotyping of Campylobacter strains isolated in Lagos, Nigeria using the modified Preston biotype. Author(s): Smith SI, Coker AO, Olukoya DK. Source: Z Naturforsch [c]. 1997 March-April; 52(3-4): 259-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9167277
•
Bird attacks on milk bottles and campylobacter infection. Author(s): Phillips CA. Source: Lancet. 1995 August 5; 346(8971): 386. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7623562
•
Campylobacter bacteraemia--can we improve our recognition of this clinical entity? Author(s): Jenks PJ, Bailey D, Wilson P. Source: The Journal of Infection. 1997 November; 35(3): 326-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9459423
72
Campylobacter
•
Campylobacter enteritis in children in an urban community. Author(s): Simango C, Nyahanana M. Source: Cent Afr J Med. 1997 June; 43(6): 172-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9431745
•
Campylobacter fetus septic arthritis revealing a malignancy. Author(s): Rollot K, Albert JD, Werner S, Tattevin P, Cozic I, Perdriger A, Chales G, Guggenbuhl P. Source: Joint, Bone, Spine : Revue Du Rhumatisme. 2004 January; 71(1): 63-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14769524
•
Campylobacter in ready-to-eat foods: the result of a 15-month survey. Author(s): Meldrum RJ, Ribeiro CD. Source: J Food Prot. 2003 November; 66(11): 2135-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14627294
•
Campylobacter jejuni 72Dz/92 cjaC gene coding 28 kDa immunopositive protein, a homologue of the solute-binding components of the ABC transport system. Author(s): Pawelec D, Jakubowska-Mroz J, Jagusztyn-Krynicka EK. Source: Letters in Applied Microbiology. 1998 January; 26(1): 69-76. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9489038
•
Campylobacter jejuni bacteremia in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients: comparison of clinical features and review. Author(s): Tee W, Mijch A. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 1998 January; 26(1): 91-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9455515
•
Campylobacter jejuni enterocolitis presenting as inflammatory bowel disease. Author(s): Quondamcarlo C, Valentini G, Ruggeri M, Forlini G, Fenderico P, Rossi Z. Source: Techniques in Coloproctology. 2003 October; 7(3): 173-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14628162
•
Campylobacter jejuni infection as a cause of the Guillain-Barre syndrome. Author(s): Allos BM. Source: Infectious Disease Clinics of North America. 1998 March; 12(1): 173-84. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9494837
Studies
73
•
Campylobacter jejuni infection of differentiated THP-1 macrophages results in interleukin 1 beta release and caspase-1-independent apoptosis. Author(s): Siegesmund AM, Konkel ME, Klena JD, Mixter PF. Source: Microbiology (Reading, England). 2004 March; 150(Pt 3): 561-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14993305
•
Campylobacter jejuni: unusual cause of cholecystitis with lithiasis. Case report and literature review. Author(s): Dakdouki GK, Araj GF, Hussein M. Source: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2003 September; 9(9): 970-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14616689
•
Campylobacter spp., Giardia spp., Cryptosporidium spp., noroviruses, and indicator organisms in surface water in southwestern Finland, 2000-2001. Author(s): Horman A, Rimhanen-Finne R, Maunula L, von Bonsdorff CH, Torvela N, Heikinheimo A, Hanninen ML. Source: Applied and Environmental Microbiology. 2004 January; 70(1): 87-95. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14711629
•
Characterization of Campylobacter isolates recovered from clinically healthy pigs and from sporadic cases of campylobacteriosis in humans. Author(s): Guevremont E, Higgins R, Quessy S. Source: J Food Prot. 2004 February; 67(2): 228-34. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14968951
•
Characterization of Campylobacter jejuni isolates from patients with Guillain-Barre syndrome. Author(s): Nishimura M, Nukina M, Kuroki S, Obayashi H, Ohta M, Ma JJ, Saida T, Uchiyama T. Source: Journal of the Neurological Sciences. 1997 December 9; 153(1): 91-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9455985
•
Characterization of waterborne outbreak-associated Campylobacter jejuni, Walkerton, Ontario. Author(s): Clark CG, Price L, Ahmed R, Woodward DL, Melito PL, Rodgers FG, Jamieson F, Ciebin B, Li A, Ellis A. Source: Emerging Infectious Diseases. 2003 October; 9(10): 1232-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14609457
74
Campylobacter
•
Comparison of a novel microaerobic system with three other gas-generating systems for the recovery of Campylobacter species from human faecal samples. Author(s): Bolton FJ, Wareing DR, Sails AD. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 1997 November; 16(11): 839-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9447907
•
Comparison of Campylobacter jejuni isolates implicated in Guillain-Barre syndrome and strains that cause enteritis by a DNA microarray. Author(s): Leonard EE 2nd, Tompkins LS, Falkow S, Nachamkin I. Source: Infection and Immunity. 2004 February; 72(2): 1199-203. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14742576
•
Comparison of survival of Campylobacter jejuni in the phyllosphere with that in the rhizosphere of spinach and radish plants. Author(s): Brandl MT, Haxo AF, Bates AH, Mandrell RE. Source: Applied and Environmental Microbiology. 2004 February; 70(2): 1182-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14766604
•
Comparison of three methods for epidemiological typing of Campylobacter jejuni and C. coli. Author(s): Ono K, Kurazono T, Niwa H, Itoh K. Source: Current Microbiology. 2003 November; 47(5): 364-71. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14669910
•
Conservation and diversity of sap homologues and their organization among Campylobacter fetus isolates. Author(s): Tu ZC, Hui J, Blaser MJ. Source: Infection and Immunity. 2004 March; 72(3): 1715-24. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14977980
•
Consumption of foods by young children with diagnosed campylobacter infection - a pilot case-control study. Author(s): Cameron S, Ried K, Worsley A, Topping D. Source: Public Health Nutrition. 2004 February; 7(1): 85-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14972076
•
Deciphering Campylobacter jejuni cell surface interactions from the genome sequence. Author(s): Linton D, Karlyshev AV, Wren BW. Source: Current Opinion in Microbiology. 2001 February; 4(1): 35-40. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11173031
Studies
75
•
Demonstration of polysaccharide capsule in Campylobacter jejuni using electron microscopy. Author(s): Karlyshev AV, McCrossan MV, Wren BW. Source: Infection and Immunity. 2001 September; 69(9): 5921-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11500474
•
Detection and initial characterization of novel capsular polysaccharide among diverse Campylobacter jejuni strains using alcian blue dye. Author(s): Karlyshev AV, Wren BW. Source: Journal of Clinical Microbiology. 2001 January; 39(1): 279-84. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11136784
•
Detection and typing of Campylobacter jejuni and Campylobacter coli and analysis of indicator organisms in three waterborne outbreaks in Finland. Author(s): Hanninen ML, Haajanen H, Pummi T, Wermundsen K, Katila ML, Sarkkinen H, Miettinen I, Rautelin H. Source: Applied and Environmental Microbiology. 2003 March; 69(3): 1391-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12620821
•
Detection of Campylobacter jejuni in poultry samples using an enzyme-linked immunoassay coupled with an enzyme electrode. Author(s): Che Y, Li Y, Slavik M. Source: Biosensors & Bioelectronics. 2001 December; 16(9-12): 791-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11679257
•
Detection of Campylobacter rectus in periodontitis sites by monoclonal antibodies. Author(s): Ihara H, Miura T, Kato T, Ishihara K, Nakagawa T, Yamada S, Okuda K. Source: Journal of Periodontal Research. 2003 February; 38(1): 64-72. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12558939
•
Detection of campylobacter species: a comparison of culture and polymerase chain reaction based methods. Author(s): Kulkarni SP, Lever S, Logan JM, Lawson AJ, Stanley J, Shafi MS. Source: Journal of Clinical Pathology. 2002 October; 55(10): 749-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12354800
76
Campylobacter
•
Detection, isolation, and molecular subtyping of Escherichia coli O157:H7 and Campylobacter jejuni associated with a large waterborne outbreak. Author(s): Bopp DJ, Sauders BD, Waring AL, Ackelsberg J, Dumas N, Braun-Howland E, Dziewulski D, Wallace BJ, Kelly M, Halse T, Musser KA, Smith PF, Morse DL, Limberger RJ. Source: Journal of Clinical Microbiology. 2003 January; 41(1): 174-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12517844
•
Development of a ceuE-based multiplex polymerase chain reaction (PCR) assay for direct detection and differentiation of Campylobacter jejuni and Campylobacter coli in Thailand. Author(s): Houng HS, Sethabutr O, Nirdnoy W, Katz DE, Pang LW. Source: Diagnostic Microbiology and Infectious Disease. 2001 May-June; 40(1-2): 11-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11448558
•
Development of a combined filtration-enrichment culture followed by a one-step duplex PCR technique for the rapid detection of Campylobacter jejuni and C. coli in human faecal samples. Author(s): Misawa N, Kawashima K, Kawamoto H, Kondo F. Source: Journal of Medical Microbiology. 2002 January; 51(1): 86-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11800478
•
Development of a PCR ELISA assay for the identification of Campylobacter jejuni and Campylobacter coli. Author(s): Sails AD, Fox AJ, Bolton FJ, Wareing DR, Greenway DL, Borrow R. Source: Molecular and Cellular Probes. 2001 October; 15(5): 291-300. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11735301
•
Development of a sensitive DNA microarray suitable for rapid detection of Campylobacter spp. Author(s): Keramas G, Bang DD, Lund M, Madsen M, Rasmussen SE, Bunkenborg H, Telleman P, Christensen CB. Source: Molecular and Cellular Probes. 2003 August; 17(4): 187-96. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12944122
•
Development of an immunoassay for rapid detection of ganglioside GM(1) mimicry in Campylobacter jejuni strains. Author(s): Prendergast MM, Kosunen TU, Moran AP. Source: Journal of Clinical Microbiology. 2001 April; 39(4): 1494-500. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11283076
Studies
77
•
Diarrhea incidence and farm-related risk factors for Escherichia coli O157:H7 and Campylobacter jejuni antibodies among rural children. Author(s): Belongia EA, Chyou PH, Greenlee RT, Perez-Perez G, Bibb WF, DeVries EO. Source: The Journal of Infectious Diseases. 2003 May 1; 187(9): 1460-8. Epub 2003 April 09. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12717628
•
Differentiation of Campylobacter species by AFLP fingerprinting. Author(s): Duim B, Vandamme PA, Rigter A, Laevens S, Dijkstra JR, Wagenaar JA. Source: Microbiology (Reading, England). 2001 October; 147(Pt 10): 2729-37. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11577152
•
Disinfectant susceptibility testing of avian and swine Campylobacter isolates by a filtration method. Author(s): Avrain L, Allain L, Vernozy-Rozand C, Kempf I. Source: Veterinary Microbiology. 2003 October 8; 96(1): 35-40. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14516706
•
Diversity of Campylobacter isolates from retail poultry carcasses and from humans as demonstrated by pulsed-field gel electrophoresis. Author(s): Dickins MA, Franklin S, Stefanova R, Schutze GE, Eisenach KD, Wesley I, Cave MD. Source: J Food Prot. 2002 June; 65(6): 957-62. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12092728
•
DNA sequence and mutational analyses of the pVir plasmid of Campylobacter jejuni 81-176. Author(s): Bacon DJ, Alm RA, Hu L, Hickey TE, Ewing CP, Batchelor RA, Trust TJ, Guerry P. Source: Infection and Immunity. 2002 November; 70(11): 6242-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12379703
•
Domestically acquired Campylobacter infections in Finland. Author(s): Vierikko A, Hanninen ML, Siitonen A, Ruutu P, Rautelin H. Source: Emerging Infectious Diseases. 2004 January; 10(1): 127-30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15078608
•
Effect of environmental and chemotactic stimuli on the activity of the Campylobacter jejuni flaA sigma(28) promoter. Author(s): Allen KJ, Griffiths MW. Source: Fems Microbiology Letters. 2001 November 27; 205(1): 43-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11728714
78
Campylobacter
•
Effect of incubation temperature on the isolation of thermophilic species of Campylobacter from faeces. Author(s): Gee B, Nye KJ, Fallon D, Messer S, Howe S, Warren RE, Andrews N; Public Health Laboratory Service (Midlands) Bacterial Methods Evaluation Group. Source: Commun Dis Public Health. 2002 December; 5(4): 282-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12564241
•
Effects of quorum sensing on flaA transcription and autoagglutination in Campylobacter jejuni. Author(s): Jeon B, Itoh K, Misawa N, Ryu S. Source: Microbiology and Immunology. 2003; 47(11): 833-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14638994
•
Efficient isolation of Campylobacter upsaliensis from stools. Author(s): Lastovica AJ, Le Roux E. Source: Journal of Clinical Microbiology. 2001 November; 39(11): 4222-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11712518
•
Elucidation of potential transmission routes of Campylobacter in New Zealand. Author(s): Savill M, Hudson A, Devane M, Garrett N, Gilpin B, Ball A. Source: Water Science and Technology : a Journal of the International Association on Water Pollution Research. 2003; 47(3): 33-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12639002
•
Enhanced surveillance of campylobacter infection in the North West of England 19971999. Author(s): Sopwith W, Ashton M, Frost JA, Tocque K, O'Brien S, Regan M, Syed Q. Source: The Journal of Infection. 2003 January; 46(1): 35-45. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12504607
•
Epidemiology and antimicrobial susceptibilities of 111 Campylobacter fetus subsp. fetus strains isolated in Quebec, Canada, from 1983 to 2000. Author(s): Tremblay C, Gaudreau C, Lorange M. Source: Journal of Clinical Microbiology. 2003 January; 41(1): 463-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12517895
Studies
79
•
Epidemiology of sporadic Campylobacter infection in the United States and declining trend in incidence, FoodNet 1996-1999. Author(s): Samuel MC, Vugia DJ, Shallow S, Marcus R, Segler S, McGivern T, Kassenborg H, Reilly K, Kennedy M, Angulo F, Tauxe RV; Emerging Infections Program FoodNet Working Group. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2004 April 15; 38 Suppl 3: S165-74. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15095186
•
Ethnic inequalities in campylobacter infection in Birmingham, UK: descriptive study of notified cases. Author(s): Manaseki S, Hawker J, Ali S. Source: Journal of Epidemiology and Community Health. 2004 April; 58(4): 278-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15026435
•
Ethnicity and Campylobacter infection: a population-based questionnaire survey. Author(s): Campylobacter sentinel surveillance schemecollaborators. Source: The Journal of Infection. 2003 October; 47(3): 210-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12963382
•
European survey on Campylobacter surveillance and diagnosis 2001. Author(s): Takkinen J, Ammon A, Robstad O, Breuer T; Campylobacter Working Group. Source: Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin. 2003 November; 8(11): 207-13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14684880
•
Evaluation of 11 PCR assays for species-level identification of Campylobacter jejuni and Campylobacter coli. Author(s): On SL, Jordan PJ. Source: Journal of Clinical Microbiology. 2003 January; 41(1): 330-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12517869
•
Evaluation of a PCR/DNA probe colorimetric membrane assay for identification of Campylobacter spp. in human stool specimens. Author(s): Collins E, Glennon M, Hanley S, Murray AM, Cormican M, Smith T, Maher M. Source: Journal of Clinical Microbiology. 2001 November; 39(11): 4163-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11682549
80
Campylobacter
•
Evaluation of culture methods and a DNA probe-based PCR assay for detection of Campylobacter species in clinical specimens of feces. Author(s): Maher M, Finnegan C, Collins E, Ward B, Carroll C, Cormican M. Source: Journal of Clinical Microbiology. 2003 July; 41(7): 2980-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12843030
•
Evaluation of methods for subtyping Campylobacter jejuni during an outbreak involving a food handler. Author(s): Fitzgerald C, Helsel LO, Nicholson MA, Olsen SJ, Swerdlow DL, Flahart R, Sexton J, Fields PI. Source: Journal of Clinical Microbiology. 2001 July; 39(7): 2386-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11427543
•
Evaluation of the ProSpecT Microplate Assay for detection of Campylobacter: a routine laboratory perspective. Author(s): Dediste A, Vandenberg O, Vlaes L, Ebraert A, Douat N, Bahwere P, Butzler JP. Source: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2003 November; 9(11): 1085-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14616724
•
Evidence for a genetically stable strain of Campylobacter jejuni. Author(s): Manning G, Duim B, Wassenaar T, Wagenaar JA, Ridley A, Newell DG. Source: Applied and Environmental Microbiology. 2001 March; 67(3): 1185-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11229909
•
Evidence for acquisition of the lipooligosaccharide biosynthesis locus in Campylobacter jejuni GB11, a strain isolated from a patient with Guillain-Barre syndrome, by horizontal exchange. Author(s): Gilbert M, Godschalk PC, Karwaski MF, Ang CW, van Belkum A, Li J, Wakarchuk WW, Endtz HP. Source: Infection and Immunity. 2004 February; 72(2): 1162-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14742567
•
Expansion of human gammadelta T cells after in vitro stimulation with Campylobacter jejuni. Author(s): Van Rhijn I, Van den Berg LH, Ang CW, Admiraal J, Logtenberg T. Source: International Immunology. 2003 March; 15(3): 373-82. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12618481
Studies
81
•
Extended survival and persistence of Campylobacter spp. in water and aquatic biofilms and their detection by immunofluorescent-antibody and -rRNA staining. Author(s): Buswell CM, Herlihy YM, Lawrence LM, McGuiggan JT, Marsh PD, Keevil CW, Leach SA. Source: Applied and Environmental Microbiology. 1998 February; 64(2): 733-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9464415
•
Factors associated with increased and decreased risk of Campylobacter infection: a prospective case-control study in Norway. Author(s): Kapperud G, Espeland G, Wahl E, Walde A, Herikstad H, Gustavsen S, Tveit I, Natas O, Bevanger L, Digranes A. Source: American Journal of Epidemiology. 2003 August 1; 158(3): 234-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12882945
•
Family clusters of campylobacter infection. Author(s): Ribeiro CD, Frost JA. Source: Commun Dis Public Health. 2000 December; 3(4): 274-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11280258
•
Fatal Campylobacter jejuni bacteraemia in patients with AIDS. Author(s): Manfredi R, Nanetti A, Ferri M, Chiodo F. Source: Journal of Medical Microbiology. 1999 June; 48(6): 601-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10359311
•
Fatal prosthetic valve endocarditis due to Campylobacter fetus. Author(s): Peetermans WE, De Man F, Moerman P, van de Werf F. Source: The Journal of Infection. 2000 September; 41(2): 180-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11023767
•
Fibronectin-facilitated invasion of T84 eukaryotic cells by Campylobacter jejuni occurs preferentially at the basolateral cell surface. Author(s): Monteville MR, Konkel ME. Source: Infection and Immunity. 2002 December; 70(12): 6665-71. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12438340
•
Flagella as a potential marker for Campylobacter jejuni strains associated with Guillain-Barre syndrome. Author(s): Tsang RS, Figueroa G, Bryden L, Ng L. Source: Journal of Clinical Microbiology. 2001 February; 39(2): 762-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11158146
82
Campylobacter
•
Flagellin gene polymorphism analysis of Campylobacter compared with antigen serotyping. Author(s): Smith SI, Olukoya DK, Fox AJ, Coker AO. Source: Z Naturforsch [c]. 1999 November; 54(11): 946-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10627993
•
Florid computed tomographic appearance of acute Campylobacter enterocolitis. Author(s): Brown G, Bui A, Vrazas J. Source: Australasian Radiology. 2000 May; 44(2): 204-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10849986
•
Fluorescent amplified fragment length polymorphism genotyping of Campylobacter jejuni and Campylobacter coli strains and its relationship with host specificity, serotyping, and phage typing. Author(s): Hopkins KL, Desai M, Frost JA, Stanley J, Logan JM. Source: Journal of Clinical Microbiology. 2004 January; 42(1): 229-35. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14715757
•
Fluoroquinolone resistance in Campylobacter absent from isolates, Australia. Author(s): Unicomb L, Ferguson J, Riley TV, Collignon P. Source: Emerging Infectious Diseases. 2003 November; 9(11): 1482-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14718099
•
Fluoroquinolone resistance in Campylobacter jejuni isolates in travelers returning to Finland: association of ciprofloxacin resistance to travel destination. Author(s): Hakanen A, Jousimies-Somer H, Siitonen A, Huovinen P, Kotilainen P. Source: Emerging Infectious Diseases. 2003 February; 9(2): 267-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12604004
•
Fluoroquinolone resistance in Campylobacter species from man and animals: detection of mutations in topoisomerase genes. Author(s): Piddock LJ, Ricci V, Pumbwe L, Everett MJ, Griggs DJ. Source: The Journal of Antimicrobial Chemotherapy. 2003 January; 51(1): 19-26. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12493783
•
Fluoroquinolone-resistant Campylobacter infections: eating poultry outside of the home and foreign travel are risk factors. Author(s): Kassenborg HD, Smith KE, Vugia DJ, Rabatsky-Ehr T, Bates MR, Carter MA, Dumas NB, Cassidy MP, Marano N, Tauxe RV, Angulo FJ; Emerging Infections Program FoodNet Working Group. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2004 April 15; 38 Suppl 3: S279-84. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15095200
Studies
83
•
Focal myositis due to Campylobacter infection. Author(s): Dawson JK, Davidson JE. Source: Rheumatology (Oxford, England). 2001 June; 40(6): 704-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11426033
•
Foreign and domestic travel and the risk of Campylobacter infection: results from a population-based sentinel surveillance scheme. Author(s): Campylobacter Sentinel Surveillance Scheme Collaborators. Source: Journal of Travel Medicine : Official Publication of the International Society of Travel Medicine and the Asia Pacific Travel Health Association. 2003 March-April; 10(2): 136-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12650661
•
Formation of cytotoxins by enteric Campylobacter in humans and animals. Author(s): Schulze F, Hanel I, Borrmann E. Source: Zentralbl Bakteriol. 1998 October; 288(2): 225-36. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9809404
•
Frequent molecular identification of Campylobacter but not Helicobacter genus in bile and biliary epithelium in hepatolithiasis. Author(s): Harada K, Ozaki S, Kono N, Tsuneyama K, Katayanagi K, Hiramatsu K, Nakanuma Y. Source: The Journal of Pathology. 2001 February; 193(2): 218-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11180169
•
Fulminant Guillain-Barre syndrome after Campylobacter jejuni enteritis and antiganglioside antibody. Author(s): Saito T. Source: Intern Med. 2002 October; 41(10): 760-1. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12412991
•
Fulminant Guillain-Barre syndrome after Campylobacter jejuni enteritis and monospecific anti-GT1a IgG antibody. Author(s): Okuda B, Koga M, Katsuta T, Okamoto K, Yuki N. Source: Intern Med. 2002 October; 41(10): 889-91. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12413017
•
Gammadelta T cell non-responsiveness in Campylobacter jejuni-associated GuillainBarre syndrome patients. Author(s): Van Rhijn I, Logtenberg T, Ang CW, Van den Berg LH. Source: Neurology. 2003 October 14; 61(7): 994-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14557578
84
Campylobacter
•
Ganglioside mimicry of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity in rabbits. Author(s): Ang CW, Noordzij PG, de Klerk MA, Endtz HP, van Doorn PA, Laman JD. Source: Infection and Immunity. 2002 September; 70(9): 5081-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12183556
•
Ganglioside-induced antiganglioside antibodies from a neuropathy patient crossreact with lipopolysaccharides of Campylobacter jejuni associated with GuillainBarre syndrome. Author(s): Neisser A, Schwerer B, Bernheimer H, Moran AP. Source: Journal of Neuroimmunology. 2000 January 3; 102(1): 85-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10626671
•
Genetic characterization and antibiotic resistance of Campylobacter jejuni isolated from meats, water, and humans in Sweden. Author(s): Lindmark H, Harbom B, Thebo L, Andersson L, Hedin G, Osterman B, Lindberg T, Andersson Y, Westoo A, Olsson Engvall E. Source: Journal of Clinical Microbiology. 2004 February; 42(2): 700-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14766839
•
Genetic characterization of Campylobacter jejuni O:41 isolates in relation with Guillain-Barre syndrome. Author(s): Wassenaar TM, Fry BN, Lastovica AJ, Wagenaar JA, Coloe PJ, Duim B. Source: Journal of Clinical Microbiology. 2000 February; 38(2): 874-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10655404
•
Genetic diversity of Campylobacter jejuni isolates from farm animals and the farm environment. Author(s): Colles FM, Jones K, Harding RM, Maiden MC. Source: Applied and Environmental Microbiology. 2003 December; 69(12): 7409-13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14660392
•
Genetic diversity of the Campylobacter genes coding immunodominant proteins. Author(s): Pawelec DP, Korsak D, Wyszynska AK, Rozynek E, Popowski J, JagusztynKrynicka EK. Source: Fems Microbiology Letters. 2000 April 1; 185(1): 43-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10731605
Studies
85
•
Genome sequence-based fluorescent amplified fragment length polymorphism of Campylobacter jejuni, its relationship to serotyping, and its implications for epidemiological analysis. Author(s): Desai M, Logan JM, Frost JA, Stanley J. Source: Journal of Clinical Microbiology. 2001 November; 39(11): 3823-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11682493
•
Genome-wide expression analyses of Campylobacter jejuni NCTC11168 reveals coordinate regulation of motility and virulence by flhA. Author(s): Carrillo CD, Taboada E, Nash JH, Lanthier P, Kelly J, Lau PC, Verhulp R, Mykytczuk O, Sy J, Findlay WA, Amoako K, Gomis S, Willson P, Austin JW, Potter A, Babiuk L, Allan B, Szymanski CM. Source: The Journal of Biological Chemistry. 2004 May 7; 279(19): 20327-38. Epub 2004 February 25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14985343
•
Genomic relatedness within five common Finnish Campylobacter jejuni pulsed-field gel electrophoresis genotypes studied by amplified fragment length polymorphism analysis, ribotyping, and serotyping. Author(s): Hanninen ML, Perko-Makela P, Rautelin H, Duim B, Wagenaar JA. Source: Applied and Environmental Microbiology. 2001 April; 67(4): 1581-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11282608
•
Genotypic and antibiotic susceptibility characteristics of a Campylobacter coli population isolated from dairy farmland in the United Kingdom. Author(s): Leatherbarrow AJ, Hart CA, Kemp R, Williams NJ, Ridley A, Sharma M, Diggle PJ, Wright EJ, Sutherst J, French NP. Source: Applied and Environmental Microbiology. 2004 February; 70(2): 822-30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14766560
•
Genotypic and serotypic stability of Campylobacter jejuni strains during in vitro and in vivo passage. Author(s): Nielsen EM, Engberg J, Fussing V. Source: International Journal of Medical Microbiology : Ijmm. 2001 November; 291(5): 379-85. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11727822
•
Genotypic identification of erythromycin-resistant campylobacter isolates as helicobacter species and analysis of resistance mechanism. Author(s): Kuijper EJ, Stevens S, Imamura T, De Wever B, Claas EC. Source: Journal of Clinical Microbiology. 2003 August; 41(8): 3732-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12904383
86
Campylobacter
•
Genotyping of Campylobacter spp. Author(s): Wassenaar TM, Newell DG. Source: Applied and Environmental Microbiology. 2000 January; 66(1): 1-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10618195
•
Genotyping of clinical and chicken isolates of Campylobacter jejuni and Campylobacter coli. Author(s): Smith SI, Olukoya DK, Fox AJ, Coker AO. Source: Cytobios. 2000; 103(403): 91-101. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11077971
•
Guillain-Barre syndrome and Campylobacter infection. Author(s): Isaacson M. Source: Journal of Travel Medicine : Official Publication of the International Society of Travel Medicine and the Asia Pacific Travel Health Association. 1998 September; 5(3): 160. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9882164
•
Guillain--Barre syndrome and Campylobacter jejuni infection. Author(s): Hadden RD, Gregson NA. Source: Symp Ser Soc Appl Microbiol. 2001; (30): 145S-54S. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11422570
•
Guillain-Barre syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits. Author(s): Ang CW, De Klerk MA, Endtz HP, Jacobs BC, Laman JD, van der Meche FG, van Doorn PA. Source: Infection and Immunity. 2001 April; 69(4): 2462-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11254608
•
Guillain-Barre syndrome associated with Campylobacter jejuni infection in England, 2000-2001. Author(s): Tam CC, Rodrigues LC, O'Brien SJ. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 July 15; 37(2): 307-10. Epub 2003 Jul 09. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12856224
•
Guillain-Barre syndrome serum and anti-Campylobacter antibody do not exacerbate experimental autoimmune neuritis. Author(s): Hadden RD, Gregson NA, Gold R, Willison HJ, Hughes RA. Source: Journal of Neuroimmunology. 2001 October 1; 119(2): 306-16. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11585634
Studies
87
•
Hazards of healthy living: bottled water and salad vegetables as risk factors for Campylobacter infection. Author(s): Evans MR, Ribeiro CD, Salmon RL. Source: Emerging Infectious Diseases. 2003 October; 9(10): 1219-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14609455
•
Health burden in the Netherlands due to infection with thermophilic Campylobacter spp. Author(s): Havelaar AH, de Wit MA, van Koningsveld R, van Kempen E. Source: Epidemiology and Infection. 2000 December; 125(3): 505-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11218201
•
Health problems following Campylobacter jejuni enteritis in a Lancashire population. Author(s): Zia S, Wareing D, Sutton C, Bolton E, Mitchell D, Goodacre JA. Source: Rheumatology (Oxford, England). 2003 September; 42(9): 1083-8. Epub 2003 April 16. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12730525
•
Heat-labile serotyping of two Campylobacter jejuni strains isolated from patients with Guillain-Barre syndrome and belonging to serotype O19 (Penner) Author(s): Tsang RS, Frosk P, Johnson WM. Source: Journal of Clinical Microbiology. 2000 May; 38(5): 2021-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10866545
•
Heat-stable antigen serotyping of Campylobacter jejuni strains isolated from hospitalized children in Athens, Greece. Author(s): Chatzipanagiotou S, Papavasileiou E, Lakumenta A, Makri A, Nicolaou C, Chantzis K, Manganas S, Legakis N. Source: European Journal of Epidemiology. 2003; 18(11): 1097-100. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14620946
•
Helicobacter pylori and Campylobacter rectus share a common antigen. Author(s): Tanabe S, Hinode D, Yokoyama M, Fukui M, Nakamura R, Yoshioka M, Grenier D, Mayrand D. Source: Oral Microbiology and Immunology. 2003 April; 18(2): 79-87. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12654095
88
Campylobacter
•
Hemolytic-uremic syndrome associated with acute Campylobacter upsaliensis gastroenteritis. Author(s): Carter JE, Cimolai N. Source: Nephron. 1996; 74(2): 489. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8893206
•
Henoch-Schonlein purpura associated with Campylobacter enterocolitis. Author(s): Apostolopoulos P, Vafiadis-Zouboulis E, Delladetsima I, Charalambopoulos D, Archimandritis A, Katsilambros N. Source: Journal of Clinical Gastroenterology. 1999 December; 29(4): 346-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10599641
•
Henoch-Schonlein purpura associated with Campylobacter jejuni enteritis. Case report. Author(s): Lind KM, Gaub J, Pedersen RS. Source: Scandinavian Journal of Urology and Nephrology. 1994 June; 28(2): 179-81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7939469
•
High frequency of metronidazole resistance among strains of Campylobacter jejuni isolated from birds. Author(s): Stanley KN, Jones K. Source: Letters in Applied Microbiology. 1998 November; 27(5): 247-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9830138
•
High rates of phase variation in Campylobacter jejuni? Author(s): Saunders NJ, Jeffries AC, Hood DW, Moxon ER. Source: Molecular Microbiology. 2000 June; 36(6): 1504. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10931299
•
High resolution genotyping of Campylobacter jejuni strains by macrorestriction analysis with XhoI and polymerase chain reaction targeting enterobacterial repetitive intergenic consensus sequences: can we predict the zoonotic potential of strains? Author(s): Moser I, Lentzsch P, Rieksneuwoehner B, Schwerk P, Wieler LH. Source: Epidemiology and Infection. 2002 December; 129(3): 435-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12558325
•
High-level resistance to trimethoprim in clinical isolates of Campylobacter jejuni by acquisition of foreign genes (dfr1 and dfr9) expressing drug-insensitive dihydrofolate reductases. Author(s): Gibreel A, Skold O. Source: Antimicrobial Agents and Chemotherapy. 1998 December; 42(12): 3059-64. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9835491
Studies
89
•
High-resolution genotyping of Campylobacter coli identifies clones of epidemiologic and evolutionary significance. Author(s): Stanley J, Linton D, Sutherland K, Jones C, Owen RJ. Source: The Journal of Infectious Diseases. 1995 October; 172(4): 1130-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7561196
•
HLA-class II alleles in Guillain-Barre syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection. Author(s): Rees JH, Vaughan RW, Kondeatis E, Hughes RA. Source: Journal of Neuroimmunology. 1995 October; 62(1): 53-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7499492
•
Human campylobacter infections: epidemiology and control. Author(s): Humphrey TJ. Source: Sci Prog. 1995; 78 ( Pt 2): 135-46. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7644910
•
Human IgM paraproteins demonstrate shared reactivity between Campylobacter jejuni lipopolysaccharides and human peripheral nerve disialylated gangliosides. Author(s): Jacobs BC, O'Hanlon GM, Breedland EG, Veitch J, van Doorn PA, Willison HJ. Source: Journal of Neuroimmunology. 1997 December; 80(1-2): 23-30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9413256
•
Human monoclonal immunoglobulin M antibodies to ganglioside GM1 show diverse cross-reactivities with lipopolysaccharides of Campylobacter jejuni strains associated with Guillain-Barre syndrome. Author(s): Prendergast MM, Willison HJ, Moran AP. Source: Infection and Immunity. 1999 July; 67(7): 3698-701. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10377164
•
Humoral immune response against Campylobacter jejuni lipopolysaccharides in Guillain-Barre and Miller Fisher syndrome. Author(s): Jacobs BC, Endtz HP, van der Meche FG, Hazenberg MP, de Klerk MA, van Doorn PA. Source: Journal of Neuroimmunology. 1997 October; 79(1): 62-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9357448
•
Hydrophobic characterization of thermophilic Campylobacter species and adhesion to INT 407 cell membranes and fibronectin. Author(s): Moser I, Schroder W. Source: Microbial Pathogenesis. 1997 March; 22(3): 155-64. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9075218
90
Campylobacter
•
Identification of a new source of Campylobacter contamination in poultry: transmission from breeder hens to broiler chickens. Author(s): Cox NA, Stern NJ, Hiett KL, Berrang ME. Source: Avian Dis. 2002 July-September; 46(3): 535-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12243515
•
Identification of distinct Campylobacter lari genogroups by amplified fragment length polymorphism and protein electrophoretic profiles. Author(s): Duim B, Wagenaar JA, Dijkstra JR, Goris J, Endtz HP, Vandamme PA. Source: Applied and Environmental Microbiology. 2004 January; 70(1): 18-24. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14711621
•
Identification of thermophilic Campylobacter spp. by phenotypic and molecular methods. Author(s): Steinhauserova I, Ceskova J, Fojtikova K, Obrovska I. Source: Journal of Applied Microbiology. 2001 March; 90(3): 470-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11298244
•
Immunoproliferative small intestinal disease associated with Campylobacter jejuni. Author(s): Peterson MC. Source: The New England Journal of Medicine. 2004 April 15; 350(16): 1685-6; Author Reply 1685-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15084705
•
Immunoproliferative small intestinal disease associated with Campylobacter jejuni. Author(s): Lecuit M, Abachin E, Martin A, Poyart C, Pochart P, Suarez F, Bengoufa D, Feuillard J, Lavergne A, Gordon JI, Berche P, Guillevin L, Lortholary O. Source: The New England Journal of Medicine. 2004 January 15; 350(3): 239-48. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14724303
•
In vitro activities of new fluoroquinolones against Campylobacter jejuni and Campylobacter coli isolates obtained from humans in 1980 to 1982 and 1997 to 2001. Author(s): Krausse R, Ullmann U. Source: Antimicrobial Agents and Chemotherapy. 2003 September; 47(9): 2946-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12936999
•
In vivo phase variation and serologic response to lipooligosaccharide of Campylobacter jejuni in experimental human infection. Author(s): Prendergast MM, Tribble DR, Baqar S, Scott DA, Ferris JA, Walker RI, Moran AP. Source: Infection and Immunity. 2004 February; 72(2): 916-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14742536
Studies
91
•
In vivo tracking of Campylobacter jejuni by using a novel recombinant expressing green fluorescent protein. Author(s): Mixter PF, Klena JD, Flom GA, Siegesmund AM, Konkel ME. Source: Applied and Environmental Microbiology. 2003 May; 69(5): 2864-74. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12732559
•
Increasing fluoroquinolone resistance in Campylobacter jejuni, Pennsylvania, USA,1982-2001. Author(s): Nachamkin I, Ung H, Li M. Source: Emerging Infectious Diseases. 2002 December; 8(12): 1501-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12498672
•
Induction of alpha and beta chemokines by intestinal epithelial cells stimulated with Campylobacter jejuni. Author(s): Bakhiet M, Al-Salloom FS, Qareiballa A, Bindayna K, Farid I, Botta GA. Source: The Journal of Infection. 2004 April; 48(3): 236-44. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15001302
•
Induction of human IgM and IgG anti-GM1 antibodies in transgenic mice in response to lipopolysaccharides from Campylobacter jejuni. Author(s): Lee G, Jeong Y, Wirguin I, Hays AP, Willison HJ, Latov N. Source: Journal of Neuroimmunology. 2004 January; 146(1-2): 63-75. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14698848
•
Induction of proinflammatory responses in the human monocytic cell line THP-1 by Campylobacter jejuni. Author(s): Jones MA, Totemeyer S, Maskell DJ, Bryant CE, Barrow PA. Source: Infection and Immunity. 2003 May; 71(5): 2626-33. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12704137
•
Interactions of Campylobacter jejuni cytolethal distending toxin subunits CdtA and CdtC with HeLa cells. Author(s): Lee RB, Hassane DC, Cottle DL, Pickett CL. Source: Infection and Immunity. 2003 September; 71(9): 4883-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12933829
•
Inter-laboratory evaluation of three flagellin PCR/RFLP methods for typing Campylobacter jejuni and C. coli: the CAMPYNET experience. Author(s): Harrington CS, Moran L, Ridley AM, Newell DG, Madden RH. Source: Journal of Applied Microbiology. 2003; 95(6): 1321-33. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14633007
92
Campylobacter
•
Intravenous immunoglobulin for cranial polyneuropathy associated with Campylobacter jejuni infection. Author(s): Wakamoto H, Ohta M, Nakano N, Tagawa M, Shiraishi T. Source: Pediatric Neurology. 2001 October; 25(4): 325-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11704403
•
Investigation of infection with Campylobacter jejuni in a man with hypogammaglobulinaemia using PCR-single-stranded conformational polymorphism (PCR-SSCP) typing. Author(s): Moore J, Curran M, Wareing D, Fox A, Boyd N, Glynn G, Millar B, Daly G, Murphy P. Source: International Journal of Medical Microbiology : Ijmm. 2001 April; 291(1): 21-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11403407
•
Isolation and identification of Campylobacter species by use of selective enrichment, nucleic acid amplification methods, and gene probes. Author(s): van Belkum A, van den Braak N, van Doorn LJ, Endtz H. Source: Methods in Molecular Biology (Clifton, N.J.). 2002; 179: 101-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11692855
•
Isolation of Campylobacter and identification by PCR. Author(s): Englen MD, Ladely SR, Fedorka-Cray PJ. Source: Methods in Molecular Biology (Clifton, N.J.). 2003; 216: 109-21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12512359
•
Isolation of Campylobacter fetus subsp. fetus from a patient with cellulitis. Author(s): Briedis DJ, Khamessan A, McLaughlin RW, Vali H, Panaritou M, Chan EC. Source: Journal of Clinical Microbiology. 2002 December; 40(12): 4792-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12454199
•
Jackdaws and magpies as vectors of milkborne human Campylobacter infection. Author(s): Hudson SJ, Lightfoot NF, Coulson JC, Russell K, Sisson PR, Sobo AO. Source: Epidemiology and Infection. 1991 October; 107(2): 363-72. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1936158
•
Jackdaws as potential source of milk-borne Campylobacter jejuni infection. Author(s): Hudson SJ, Sobo AO, Russel K, Lightfoot NF. Source: Lancet. 1990 May 12; 335(8698): 1160. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1971891
Studies
93
•
JlpA of Campylobacter jejuni interacts with surface-exposed heat shock protein 90alpha and triggers signalling pathways leading to the activation of NF-kappaB and p38 MAP kinase in epithelial cells. Author(s): Jin S, Song YC, Emili A, Sherman PM, Chan VL. Source: Cellular Microbiology. 2003 March; 5(3): 165-74. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12614460
•
JlpA, a novel surface-exposed lipoprotein specific to Campylobacter jejuni, mediates adherence to host epithelial cells. Author(s): Jin S, Joe A, Lynett J, Hani EK, Sherman P, Chan VL. Source: Molecular Microbiology. 2001 March; 39(5): 1225-36. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11251839
•
Kinetic and antigenic characterization of altered protein synthesis by Campylobacter jejuni during cultivation with human epithelial cells. Author(s): Konkel ME, Mead DJ, Cieplak W Jr. Source: The Journal of Infectious Diseases. 1993 October; 168(4): 948-54. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8376841
•
Large-scale survey of Campylobacter species in human gastroenteritis by PCR and PCR-enzyme-linked immunosorbent assay. Author(s): Lawson AJ, Logan JM, O'neill GL, Desai M, Stanley J. Source: Journal of Clinical Microbiology. 1999 December; 37(12): 3860-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10565897
•
Lectin typing of Campylobacter concisus. Author(s): Aabenhus R, Hynes SO, Permin H, Moran AP, Andersen LP. Source: Journal of Clinical Microbiology. 2002 February; 40(2): 715-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11826005
•
Lethal maternal sepsis caused by Campylobacter jejuni: pathogen preserved in placenta and identified by molecular methods. Author(s): Meyer A, Stallmach T, Goldenberger D, Altwegg M. Source: Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc. 1997 December; 10(12): 1253-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9436972
•
Limitations of pulsed-field gel electrophoresis for the routine surveillance of Campylobacter infections. Author(s): Hedberg CW, Smith KE, Besser JM, Boxrud DJ, Hennessy TW, Bender JB, Anderson FA, Osterholm MT. Source: The Journal of Infectious Diseases. 2001 July 15; 184(2): 242-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11424025
94
Campylobacter
•
Lineages within Campylobacter jejuni defined by numerical analysis of pulsed-field gel electrophoretic DNA profiles. Author(s): Gibson J, Lorenz E, Owen RJ. Source: Journal of Medical Microbiology. 1997 February; 46(2): 157-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9060876
•
Lipo-oligosaccharides of Campylobacter jejuni serotype O:10. Structures of core oligosaccharide regions from a bacterial isolate from a patient with the Miller-Fisher syndrome and from the serotype reference strain. Author(s): Shin JE, Ackloo S, Mainkar AS, Monteiro MA, Pang H, Penner JL, Aspinall GO. Source: Carbohydrate Research. 1997 December; 305(2): 223-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9581276
•
Lipopolysaccharides from Campylobacter jejuni associated with Guillain-Barre syndrome patients mimic human gangliosides in structure. Author(s): Aspinall GO, Fujimoto S, McDonald AG, Pang H, Kurjanczyk LA, Penner JL. Source: Infection and Immunity. 1994 May; 62(5): 2122-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8168981
•
Lipopolysaccharides from Campylobacter jejuni O:41 strains associated with Guillain-Barre syndrome exhibit mimicry of GM1 ganglioside. Author(s): Prendergast MM, Lastovica AJ, Moran AP. Source: Infection and Immunity. 1998 August; 66(8): 3649-55. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9673245
•
Lipopolysaccharides of a Campylobacter coli isolate from a patient with GuillainBarre syndrome display ganglioside mimicry. Author(s): Bersudsky M, Rosenberg P, Rudensky B, Wirguin I. Source: Neuromuscular Disorders : Nmd. 2000 March; 10(3): 182-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10734265
•
Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barre syndrome. Author(s): Aspinall GO, McDonald AG, Pang H, Kurjanczyk LA, Penner JL. Source: Biochemistry. 1994 January 11; 33(1): 241-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8286348
Studies
95
•
Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of O antigen chains from the serostrain and two bacterial isolates from patients with the GuillainBarre syndrome. Author(s): Aspinall GO, McDonald AG, Pang H. Source: Biochemistry. 1994 January 11; 33(1): 250-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7506928
•
Longitudinal changes of anti-ganglioside antibodies before and after Guillain-Barre syndrome onset subsequent to Campylobacter jejuni enteritis. Author(s): Odaka M, Koga M, Yuki N, Susuki K, Hirata K. Source: Journal of the Neurological Sciences. 2003 June 15; 210(1-2): 99-103. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12736097
•
Longitudinal study of serum and cerebrospinal fluid (CSF) class-specific antibodies against Campylobacter jejuni and GM1 ganglioside in Guillain-Barre syndrome. Author(s): Kimura F, Ito T, Yuki N, Nakajima H, Tanaka T, Shinoda K, Ohsawa N. Source: Intern Med. 1995 October; 34(10): 1009-14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8563080
•
Long-term antibody responses following human infection with Campylobacter jejuni. Author(s): Cawthraw SA, Feldman RA, Sayers AR, Newell DG. Source: Clinical and Experimental Immunology. 2002 October; 130(1): 101-6. Erratum In: Clin Exp Immunol 2002 December; 130(3): 564. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12296859
•
Long-term preservation of thermophilic Campylobacter species: a simple method. Author(s): Stanley T, Moore JE. Source: British Journal of Biomedical Science. 2000; 57(3): 214-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11050772
•
Low frequency of enteric infections by Salmonella, Shigella, Yersinia and Campylobacter in patients with acute leukemia. Author(s): Gorschluter M, Hahn C, Ziske C, Mey U, Schottker B, Molitor E, Becker S, Marklein G, Sauerbruch T, Schmidt-Wolf IG, Glasmacher A. Source: Infection. 2002 January; 30(1): 22-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11878289
96
Campylobacter
•
Lowered gastrin and gastric acidity after eradication of Campylobacter pylori in duodenal ulcer. Author(s): McColl KE, Fullarton GM, el Nujumi AM, Macdonald AM, Brown IL, Hilditch TE. Source: Lancet. 1989 August 26; 2(8661): 499-500. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2570202
•
Maximal adherence and invasion of INT 407 cells by Campylobacter jejuni requires the CadF outer-membrane protein and microfilament reorganization. Author(s): Monteville MR, Yoon JE, Konkel ME. Source: Microbiology (Reading, England). 2003 January; 149(Pt 1): 153-65. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12576589
•
Molecular characterization of Campylobacter jejuni clones: a basis for epidemiologic investigation. Author(s): Dingle KE, Colles FM, Ure R, Wagenaar JA, Duim B, Bolton FJ, Fox AJ, Wareing DR, Maiden MC. Source: Emerging Infectious Diseases. 2002 September; 8(9): 949-55. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12194772
•
Molecular epidemiology of nalidixic acid-resistant campylobacter isolates from humans and poultry by pulsed-field gel electrophoresis and flagellin gene analysis. Author(s): Wu TL, Su LH, Chia JH, Kao TM, Chiu CH, Kuo AJ, Sun CF. Source: Epidemiology and Infection. 2002 August; 129(1): 227-31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12211592
•
Molecular evidence for dissemination of unique Campylobacter jejuni clones in Curacao, Netherlands Antilles. Author(s): Duim B, Godschalk PC, van den Braak N, Dingle KE, Dijkstra JR, Leyde E, van der Plas J, Colles FM, Endtz HP, Wagenaar JA, Maiden MC, van Belkum A. Source: Journal of Clinical Microbiology. 2003 December; 41(12): 5593-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14662946
•
Molecular microbiology and pathogenesis of Helicobacter and Campylobacter updated: a meeting report of the 11th conference on Campylobacter, Helicobacter and related organisms. Author(s): Bereswill S, Kist M. Source: Molecular Microbiology. 2002 July; 45(1): 255-62. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12100564
Studies
97
•
Molecular typing of Campylobacter jejuni and Campylobacter coli. Author(s): Lastovica AJ. Source: Journal of Clinical Microbiology. 2003 March; 41(3): 1349; Author Reply 1349-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12624086
•
Molecular typing of Campylobacter jejuni isolates involved in a neonatal outbreak indicates nosocomial transmission. Author(s): Llovo J, Mateo E, Munoz A, Urquijo M, On SL, Fernandez-Astorga A. Source: Journal of Clinical Microbiology. 2003 August; 41(8): 3926-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12904420
•
Multifocal motor neuropathy and Campylobacter jejuni reactivity. Author(s): Terenghi F, Allaria S, Scarlato G, Nobile-Orazio E. Source: Neurology. 2002 July 23; 59(2): 282-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12136073
•
Multilocus sequence typing for comparison of veterinary and human isolates of Campylobacter jejuni. Author(s): Manning G, Dowson CG, Bagnall MC, Ahmed IH, West M, Newell DG. Source: Applied and Environmental Microbiology. 2003 November; 69(11): 6370-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14602588
•
Mutation in the peb1A locus of Campylobacter jejuni reduces interactions with epithelial cells and intestinal colonization of mice. Author(s): Pei Z, Burucoa C, Grignon B, Baqar S, Huang XZ, Kopecko DJ, Bourgeois AL, Fauchere JL, Blaser MJ. Source: Infection and Immunity. 1998 March; 66(3): 938-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9488379
•
Natural bactericidal activity of human serum against strains of Campylobacter jejuni isolated in Lagos, Nigeria. Author(s): Obi CL, Coker AO. Source: Cent Afr J Med. 1989 August; 35(8): 444-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2805054
•
Natural competence for genetic transformation in Campylobacter pylori. Author(s): Nedenskov-Sorensen P, Bukholm G, Bovre K. Source: The Journal of Infectious Diseases. 1990 February; 161(2): 365-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2299221
98
Campylobacter
•
Neck stiffness in two children with Guillain-Barre syndrome after Campylobacter jejuni infection. Author(s): Nishimoto Y, Koga M, Yuki N. Source: Journal of Neurology. 2001 December; 248(12): 1104-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12013593
•
Neonatal Campylobacter fetus meningitis: a report of an unusual case. Author(s): Bingham WT, Chan A, Rennie R, Williams KE, Sankarna K. Source: Clinical Pediatrics. 1992 April; 31(4): 255-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1563204
•
Neonatal sepsis by Campylobacter jejuni: genetically proven transmission from a household puppy. Author(s): Wolfs TF, Duim B, Geelen SP, Rigter A, Thomson-Carter F, Fleer A, Wagenaar JA. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2001 March 1; 32(5): E97-9. Epub 2001 February 23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11229867
•
No signs of Campylobacter jejuni/coli-related antibodies in patients with active ankylosing spondylitis. Author(s): Andreasen JJ, Ringsdal VS, Helin P. Source: Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. 1991 August; 99(8): 735-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1677583
•
Norfloxacin resistance in Campylobacter jejuni and Campylobacter coli isolates from Swedish patients. Author(s): Sjogren E, Lindblom GB, Kaijser B. Source: The Journal of Antimicrobial Chemotherapy. 1997 August; 40(2): 257-61. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9301992
•
Nosocomial meningitis due to Campylobacter fetus subspecies fetus in a neonatal intensive care unit. Author(s): Morooka T, Takeo H, Yasumoto S, Mimatsu T, Yukitake K, Oda T. Source: Acta Paediatr Jpn. 1992 October; 34(5): 530-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1442025
•
Novel Campylobacter-like organism resembling Helicobacter fennelliae isolated from a boy with gastroenteritis and from dogs. Author(s): Burnens AP, Stanley J, Schaad UB, Nicolet J. Source: Journal of Clinical Microbiology. 1993 July; 31(7): 1916-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8349774
Studies
99
•
Novel employment of lactate dehydrogenase release from porcine aortic endothelial cells (PAEC) as a quantitative marker of cytotoxic activity in thermophilic Campylobacter spp. from human faecal isolates, poultry and environmental sources. Author(s): Millar BC, McCarron M, Murphy PG, Moore JE. Source: Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public Health. 2003 August; 50(6): 275-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14628998
•
Occurrence and resistance to antibiotics of Campylobacter jejuni and Campylobacter coli in animals and meat in northeastern Italy. Author(s): Pezzotti G, Serafin A, Luzzi I, Mioni R, Milan M, Perin R. Source: International Journal of Food Microbiology. 2003 May 15; 82(3): 281-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12593931
•
Occurrence of Campylobacter jejuni in pets living with human patients infected with C. jejuni. Author(s): Damborg P, Olsen KE, Moller Nielsen E, Guardabassi L. Source: Journal of Clinical Microbiology. 2004 March; 42(3): 1363-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15004120
•
Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. Author(s): Neal KR, Scott HM, Slack RC, Logan RF. Source: Bmj (Clinical Research Ed.). 1996 February 17; 312(7028): 414-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8601113
•
Optimal detection of Campylobacter spp in stools. Author(s): Lastovica AJ, Le Roux E. Source: Journal of Clinical Pathology. 2003 June; 56(6): 480. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12783980
•
Outbreak of campylobacter enteritis in a residential school associated with bird pecked bottle tops. Author(s): Stuart J, Sufi F, McNulty C, Park P. Source: Commun Dis Rep Cdr Rev. 1997 March 7; 7(3): R38-40. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9080727
•
Outbreak of Campylobacter food-poisoning in Northern Ireland. Author(s): Moore JE, Stanley T, Smithson R, O'Malley H, Murphy PG. Source: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2000 July; 6(7): 399-400. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11168160
100
Campylobacter
•
Outbreak of Campylobacter infection in a subartic community. Author(s): Melby KK, Svendby JG, Eggebo T, Holmen LA, Andersen BM, Lind L, Sjogren E, Kaijser B. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2000 July; 19(7): 542-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10968326
•
Outbreaks of campylobacter infection: rare events for a common pathogen. Author(s): Pebody RG, Ryan MJ, Wall PG. Source: Commun Dis Rep Cdr Rev. 1997 March 7; 7(3): R33-7. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9080726
•
Outbreaks of food poisoning in adults due to Escherichia coli O111 and campylobacter associated with coach trips to northern France. Author(s): Wight JP, Rhodes P, Chapman PA, Lee SM, Finner P. Source: Epidemiology and Infection. 1997 August; 119(1): 9-14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9287937
•
PCR-restriction fragment length polymorphism analysis for detection of point mutations associated with macrolide resistance in Campylobacter spp. Author(s): Vacher S, Menard A, Bernard E, Megraud F. Source: Antimicrobial Agents and Chemotherapy. 2003 March; 47(3): 1125-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12604552
•
Phenotypic and genotypic relationship between Campylobacter spp isolated from humans and chickens in Northern Ireland--a comparison of three phenotyping and two genotyping schemes. Author(s): Moore JE, O'Riordan L, Wareing DR, Doyle R, Lanser J, Stanley T, Matsuda M, Matsui T, Murphy PG. Source: International Journal of Hygiene and Environmental Health. 2003 June; 206(3): 211-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12872530
•
Phenotypic diversity of campylobacter isolates from sporadic cases of human enteritis in Northern Ireland. Author(s): Moore JE, Wareing DR. Source: British Journal of Biomedical Science. 2003; 60(1): 28-30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12680629
Studies
101
•
Point source outbreaks of Campylobacter jejuni infection--are they more common than we think and what might cause them? Author(s): Gillespie IA, O'Brien SJ, Adak GK, Tam CC, Frost JA, Bolton FJ, Tompkins DS; Campylobacter Sentinel Surveillance Scheme Collaborators. Source: Epidemiology and Infection. 2003 June; 130(3): 367-75. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12825720
•
Possible Campylobacter jejuni osteomyelitis in a 14-month-old child. Author(s): Vandenberg O, Klein A, Souayah H, Devaster JM, Levy J, Butzler JP. Source: International Journal of Infectious Diseases : Ijid : Official Publication of the International Society for Infectious Diseases. 2003 June; 7(2): 164-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12839722
•
Poultry farm study probes sources of Campylobacter. Author(s): James W. Source: J Am Vet Med Assoc. 1998 January 15; 212(2): 164. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9448816
•
Prevalence of 11 pathogenic genes of Campylobacter jejuni by PCR in strains isolated from humans, poultry meat and broiler and bovine faeces. Author(s): Datta S, Niwa H, Itoh K. Source: Journal of Medical Microbiology. 2003 April; 52(Pt 4): 345-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12676874
•
Prevalence of Campylobacter species among HIV/AIDS patients in Nigeria. Author(s): Smith SI, Otuonye MN, Omonigbehin EA, Nkoth A, Okany CC, Ariyo F, Badaru OS, Ajayi A, Coker AO. Source: British Journal of Biomedical Science. 2002; 59(3): 162-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12371060
•
Prevalence of multiple antibiotic resistance in 443 Campylobacter spp. isolated from humans and animals. Author(s): Randall LP, Ridley AM, Cooles SW, Sharma M, Sayers AR, Pumbwe L, Newell DG, Piddock LJ, Woodward MJ. Source: The Journal of Antimicrobial Chemotherapy. 2003 September; 52(3): 507-10. Epub 2003 August 13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12917241
•
Prevalence of thermophilic Campylobacter spp. in ready-to-eat foods and raw poultry in Northern Ireland. Author(s): Moore JE, Wilson TS, Wareing DR, Humphrey TJ, Murphy PG. Source: J Food Prot. 2002 August; 65(8): 1326-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12182488
102
Campylobacter
•
Quality control strains used in susceptibility testing of Campylobacter spp. Author(s): Hakanen A, Huovinen P, Kotilainen P, Siitonen A, Jousimies-Somer H. Source: Journal of Clinical Microbiology. 2002 July; 40(7): 2705-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12089316
•
Quantitative immunocapture PCR assay for detection of Campylobacter jejuni in foods. Author(s): Waller DF, Ogata SA. Source: Applied and Environmental Microbiology. 2000 September; 66(9): 4115-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10966437
•
Quantitative risk assessment of human campylobacteriosis associated with thermophilic Campylobacter species in chickens. Author(s): Rosenquist H, Nielsen NL, Sommer HM, Norrung B, Christensen BB. Source: International Journal of Food Microbiology. 2003 May 25; 83(1): 87-103. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12672595
•
Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Author(s): Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P, Nachamkin I. Source: Emerging Infectious Diseases. 2001 January-February; 7(1): 24-34. Erratum In: Emerg Infect Dis 2001 May-June; 7(3): 491. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11266291
•
Quinolone resistance and Campylobacter species. Author(s): Bowler IC, Connor M, Lessing MP, Day D. Source: The Journal of Antimicrobial Chemotherapy. 1996 August; 38(2): 315. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8877548
•
Quinolone resistance and Campylobacter spp. Author(s): Piddock LJ. Source: The Journal of Antimicrobial Chemotherapy. 1995 December; 36(6): 891-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8821589
•
Quinolone resistance in Campylobacter. Author(s): Greig JR. Source: The Journal of Antimicrobial Chemotherapy. 2003 March; 51(3): 740-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12615883
Studies
103
•
Quinolone resistance in clinical strains of Campylobacter jejuni and Campylobacter coli. Author(s): Harnett N, McLeod S, Yong YA, Hewitt C, Vearncombe M, Krishnan C. Source: The Journal of Antimicrobial Chemotherapy. 1995 July; 36(1): 269-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8537280
•
Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team. Author(s): Smith KE, Besser JM, Hedberg CW, Leano FT, Bender JB, Wicklund JH, Johnson BP, Moore KA, Osterholm MT. Source: The New England Journal of Medicine. 1999 May 20; 340(20): 1525-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10332013
•
Quorum sensing in Campylobacter jejuni: detection of a luxS encoded signalling molecule. Author(s): Elvers KT, Park SF. Source: Microbiology (Reading, England). 2002 May; 148(Pt 5): 1475-81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11988522
•
Recent developments in Campylobacter pathogenesis. Author(s): Bereswill S, Kist M. Source: Current Opinion in Infectious Diseases. 2003 October; 16(5): 487-91. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14502003
•
Resistotyping of Campylobacter jejuni. Author(s): Adesida SA, Coker AO, Smith SI. Source: Niger Postgrad Med J. 2003 December; 10(4): 211-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15045011
•
Ribotyping characterisation of campylobacter isolates randomly collected from different sources in Italy. Author(s): Manfreda G, De Cesare A, Bondioli V, Franchini A. Source: Diagnostic Microbiology and Infectious Disease. 2003 October; 47(2): 385-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14522511
•
Risk factors associated with Campylobacter jejuni infections in Curacao, Netherlands Antilles. Author(s): Endtz HP, van West H, Godschalk PC, de Haan L, Halabi Y, van den Braak N, Kesztyus BI, Leyde E, Ott A, Verkooyen R, Price LJ, Woodward DL, Rodgers FG, Ang CW, van Koningsveld R, van Belkum A, Gerstenbluth I. Source: Journal of Clinical Microbiology. 2003 December; 41(12): 5588-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14662945
104
Campylobacter
•
Risk factors for antibiotic resistance in Campylobacter spp. isolated from raw poultry meat in Switzerland. Author(s): Ledergerber U, Regula G, Stephan R, Danuser J, Bissig B, Stark KD. Source: Bmc Public Health [electronic Resource]. 2003 December 09; 3(1): 39. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14662013
•
Risk factors for sporadic Campylobacter infection in the United States: A case-control study in FoodNet sites. Author(s): Friedman CR, Hoekstra RM, Samuel M, Marcus R, Bender J, Shiferaw B, Reddy S, Ahuja SD, Helfrick DL, Hardnett F, Carter M, Anderson B, Tauxe RV; Emerging Infections Program FoodNet Working Group. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2004 April 15; 38 Suppl 3: S285-96. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15095201
•
Risk factors for sporadic Campylobacter jejuni infections in rural michigan: a prospective case-control study. Author(s): Potter RC, Kaneene JB, Hall WN. Source: American Journal of Public Health. 2003 December; 93(12): 2118-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14652344
•
Role for the S-layer of Campylobacter rectus ATCC33238 in complement mediated killing and phagocytic killing by leukocytes from guinea pig and human peripheral blood. Author(s): Okuda K, Kigure T, Yamada S, Kaneko T, Ishihara K, Miura T, Kato T, Takazoe I. Source: Oral Diseases. 1997 June; 3(2): 113-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9467352
•
Role of microfilaments and microtubules in the invasion of INT-407 cells by Campylobacter jejuni. Author(s): Biswas D, Itoh K, Sasakawa C. Source: Microbiology and Immunology. 2003; 47(6): 469-73. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12906108
•
Severe myelitis following infection with Campylobacter enteritis. Author(s): Aberle J, Kluwe J, Pawlas F, Stellbrink HJ, Greten H. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2004 February; 23(2): 1345. Epub 2004 January 15. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14727151
Studies
105
•
Some epidemiologic features of Campylobacter jejuni/coli infections in Bosnia and Herzegovina after the war. Author(s): Uzunovic-Kamberovic S. Source: Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2003 May; 9(5): 458-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12848765
•
Sources of Campylobacter colonization in broiler chickens. Author(s): Newell DG, Fearnley C. Source: Applied and Environmental Microbiology. 2003 August; 69(8): 4343-51. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12902214
•
Spatial and temporal patterns of Campylobacter contamination underlying public health risk in the Taieri River, New Zealand. Author(s): Eyles R, Niyogi D, Townsend C, Benwell G, Weinstein P. Source: J Environ Qual. 2003 September-October; 32(5): 1820-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14535325
•
Specific identification of Campylobacter fetus by PCR targeting variable regions of the 16S rDNA. Author(s): Oyarzabal OA, Wesley IV, Harmon KM, Schroeder-Tucker L, Barbaree JM, Lauerman LH, Backert S, Conner DE. Source: Veterinary Microbiology. 1997 October 31; 58(1): 61-71. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9451462
•
Strategies to control Salmonella and Campylobacter in raw poultry products. Author(s): White PL, Baker AR, James WO. Source: Rev Sci Tech. 1997 August; 16(2): 525-41. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9501366
•
Subtypes of Campylobacter jejuni from sporadic cases of diarrhoeal disease at different locations in England are highly diverse. Author(s): Owen RJ, Slater E, Telford D, Donovan T, Barnham M. Source: European Journal of Epidemiology. 1997 October; 13(7): 837-40. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9384275
•
Surveillance of human Campylobacter infections in France--part 1--which data? A study of microbiological laboratories, 2000. Author(s): Gallay A, Simon F, Megraud F. Source: Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin. 2003 November; 8(11): 213-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14684881
106
Campylobacter
•
Surveillance of human Campylobacter infections in France--part 2--implementation of national surveillance. Author(s): Gallay A, Simon F, Megraud F. Source: Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin. 2003 November; 8(11): 218. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14684882
•
Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline. Author(s): Wagner J, Jabbusch M, Eisenblatter M, Hahn H, Wendt C, Ignatius R. Source: Antimicrobial Agents and Chemotherapy. 2003 July; 47(7): 2358-61. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12821499
•
Temporal and geographical distribution and overlap of Penner heat-stable serotypes and pulsed-field gel electrophoresis genotypes of Campylobacter jejuni isolates collected from humans and chickens in Finland during a seasonal peak. Author(s): Karenlampi R, Rautelin H, Hakkinen M, Hanninen ML. Source: Journal of Clinical Microbiology. 2003 October; 41(10): 4870-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14532246
•
The 11th international workshop on Campylobacter, Helicobacter and related Organisms (CHRO), 2001. Author(s): Takkinen J, Ammon A. Source: Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin. 2003 November; 8(11): 219-22. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14684883
•
The genome-sequenced variant of Campylobacter jejuni NCTC 11168 and the original clonal clinical isolate differ markedly in colonization, gene expression, and virulenceassociated phenotypes. Author(s): Gaynor EC, Cawthraw S, Manning G, MacKichan JK, Falkow S, Newell DG. Source: Journal of Bacteriology. 2004 January; 186(2): 503-17. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14702320
•
The impact of sporadic campylobacter and salmonella infection on health and health related behaviour: a case control study. Author(s): Smith GE, Lewis M, Paterson S, Gray J, Gunn K, Farrington F, Croft P. Source: Epidemiology and Infection. 2002 June; 128(3): 529-31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12113499
Studies
107
•
The seasonal distribution of campylobacter infection in nine European countries and New Zealand. Author(s): Nylen G, Dunstan F, Palmer SR, Andersson Y, Bager F, Cowden J, Feierl G, Galloway Y, Kapperud G, Megraud F, Molbak K, Petersen LR, Ruutu P. Source: Epidemiology and Infection. 2002 June; 128(3): 383-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12113481
•
The study of infectious intestinal disease in England: risk factors for cases of infectious intestinal disease with Campylobacter jejuni infection. Author(s): Rodrigues LC, Cowden JM, Wheeler JG, Sethi D, Wall PG, Cumberland P, Tompkins DS, Hudson MJ, Roberts JA, Roderick PJ. Source: Epidemiology and Infection. 2001 October; 127(2): 185-93. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11693495
•
Thermo-tolerant Campylobacter fetus bacteraemia identified by 16S ribosomal RNA gene sequencing: an emerging pathogen in immunocompromised patients. Author(s): Woo PC, Leung KW, Tsoi HW, Wong SS, Teng JL, Yuen KY. Source: Journal of Medical Microbiology. 2002 September; 51(9): 740-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12358064
•
Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barre syndrome. Author(s): Bowes T, Wagner ER, Boffey J, Nicholl D, Cochrane L, Benboubetra M, Conner J, Furukawa K, Furukawa K, Willison HJ. Source: Infection and Immunity. 2002 September; 70(9): 5008-18. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12183547
•
Transient increases in colony counts observed in declining populations of Campylobacter jejuni held at low temperature. Author(s): Ekweozor CC, Nwoguh CE, Barer MR. Source: Fems Microbiology Letters. 1998 January 15; 158(2): 267-72. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9465398
•
Trends in antimicrobial susceptibility among isolates of Campylobacter species in Ireland and the emergence of resistance to ciprofloxacin. Author(s): Lucey B, Cryan B, O'Halloran F, Wall PG, Buckley T, Fanning S. Source: The Veterinary Record. 2002 September 14; 151(11): 317-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12356234
108
Campylobacter
•
Ultrastructural characterization of Anaerobiospirillum succiniciproducens and its differentiation from Campylobacter species. Author(s): Wecke J, Horbach I. Source: Fems Microbiology Letters. 1999 January 1; 170(1): 83-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9919655
•
Uptake pathways of clinical and healthy animal isolates of Campylobacter jejuni into INT-407 cells. Author(s): Biswas D, Itoh K, Sasakawa C. Source: Fems Immunology and Medical Microbiology. 2000 November; 29(3): 203-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11064267
•
Urease production by Helicobacter (Campylobacter) pylori. Author(s): Vogt K, Hahn H. Source: Zentralbl Bakteriol. 1991 April; 275(1): 63-72. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1930566
•
Use of a LightCycler gyrA mutation assay for identification of ciprofloxacin-resistant Campylobacter coli. Author(s): Carattoli A, Dionisi A, Luzzi I. Source: Fems Microbiology Letters. 2002 August 27; 214(1): 87-93. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12204377
•
Use of a multiplex PCR-based assay to differentiate Campylobacter jejuni and Campylobacter coli strains isolated from human and animal sources. Author(s): Aquino MH, Regua Mangia AH, Filgueiras AL, Teixeira LM, Ferreira MC, Tibana A. Source: Veterinary Journal (London, England : 1997). 2002 January; 163(1): 102-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11749144
•
Use of a selective medium and a membrane filter method for isolation of Campylobacter species from Spanish paediatric patients. Author(s): Lopez L, Castillo FJ, Clavel A, Rubio MC. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 1998 July; 17(7): 489-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9764551
•
Use of an open-reading frame-specific Campylobacter jejuni DNA microarray as a new genotyping tool for studying epidemiologically related isolates. Author(s): Leonard EE 2nd, Takata T, Blaser MJ, Falkow S, Tompkins LS, Gaynor EC. Source: The Journal of Infectious Diseases. 2003 February 15; 187(4): 691-4. Epub 2003 January 29. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12599089
Studies
109
•
Use of defined mutants to assess the role of the Campylobacter rectus S-layer in bacterium-epithelial cell interactions. Author(s): Wang B, Kraig E, Kolodrubetz D. Source: Infection and Immunity. 2000 March; 68(3): 1465-73. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10678961
•
Use of pulsed-field gel electrophoresis and flagellin gene typing in identifying clonal groups of Campylobacter jejuni and Campylobacter coli in farm and clinical environments. Author(s): Fitzgerald C, Stanley K, Andrew S, Jones K. Source: Applied and Environmental Microbiology. 2001 April; 67(4): 1429-36. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11282587
•
Utility of multilocus sequence typing as an epidemiological tool for investigation of outbreaks of gastroenteritis caused by Campylobacter jejuni. Author(s): Sails AD, Swaminathan B, Fields PI. Source: Journal of Clinical Microbiology. 2003 October; 41(10): 4733-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14532212
•
Vaccines against Campylobacter jejuni. Author(s): Scott DA. Source: The Journal of Infectious Diseases. 1997 December; 176 Suppl 2: S183-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9396708
•
Validity of SmaI-defined genotypes of Campylobacter jejuni examined by SalI, KpnI, and BamHI polymorphisms: evidence of identical clones infecting humans, poultry, and cattle. Author(s): On SL, Nielsen EM, Engberg J, Madsen M. Source: Epidemiology and Infection. 1998 June; 120(3): 231-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9692600
•
Variation of the O antigen of Campylobacter jejuni in vivo. Author(s): Mills SD, Kuzniar B, Shames B, Kurjanczyk LA, Penner JL. Source: Journal of Medical Microbiology. 1992 March; 36(3): 215-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1372364
•
Very long term diarrhoea due to Campylobacter jejuni. Author(s): Paulet P, Coffernils M. Source: Postgraduate Medical Journal. 1990 May; 66(775): 410-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2371198
110
Campylobacter
•
Waterborne Campylobacter jejuni epidemic in a Finnish hospital for rheumatic diseases. Author(s): Rautelin H, Koota K, von Essen R, Jahkola M, Siitonen A, Kosunen TU. Source: Scandinavian Journal of Infectious Diseases. 1990; 22(3): 321-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2371546
•
Waterborne outbreak of Campylobacter enteritis after outdoors infantry drill in Utti, Finland. Author(s): Aho M, Kurki M, Rautelin H, Kosunen TU. Source: Epidemiology and Infection. 1989 August; 103(1): 133-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2776848
•
Waterborne outbreak of Campylobacter jejuni in Christchurch: the importance of a combined epidemiologic and microbiologic investigation. Author(s): Stehr-Green JK, Nicholls C, McEwan S, Payne A, Mitchell P. Source: N Z Med J. 1991 August 28; 104(918): 356-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1891134
•
Whole genome comparison of Campylobacter jejuni human isolates using a low-cost microarray reveals extensive genetic diversity. Author(s): Dorrell N, Mangan JA, Laing KG, Hinds J, Linton D, Al-Ghusein H, Barrell BG, Parkhill J, Stoker NG, Karlyshev AV, Butcher PD, Wren BW. Source: Genome Research. 2001 October; 11(10): 1706-15. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11591647
•
Workshop summary and recommendations regarding the development of GuillainBarre syndrome following Campylobacter infection. Author(s): Lang DR, Allos BM, Blaser MJ. Source: The Journal of Infectious Diseases. 1997 December; 176 Suppl 2: S198-200. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9396711
111
CHAPTER 2. NUTRITION AND CAMPYLOBACTER Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and campylobacter.
Finding Nutrition Studies on Campylobacter The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “campylobacter” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7
Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
112
Campylobacter
The following information is typical of that found when using the “Full IBIDS Database” to search for “campylobacter” (or a synonym): •
Antibacterial activity of Piper chaba Hunter (Chui) [in Bangladesh]. Author(s): Dhaka Univ. (Bangladesh). Dept. of Pharmacy Source: Sarker, S.D. Muniruzzaman, S. Khan, S.I. Chowdhury, A.K.A. BangladeshJournal-of-Botany (Bangladesh). (1991). volume 20(2) page 179-182.
•
Enteropathogenic bacteria in faecal swabs of young children fed on lactic acidfermented cereal gruels. Author(s): Department of Food Science and Nutrition, Tanzania Food and Nutrition Centre, Dar-es-Salaam (Tanzania) Source: Kingamkono, R. Sjogren, E. Svanberg, U. Epidemiology-and-Infection (United Kingdom). (1999). volume 122(1) page 23-32.
Additional physician-oriented references include: •
A mixed foodborne outbreak with Salmonella heidelberg and Campylobacter jejuni in a nursing home. Author(s): Bureau of Communicable Disease, New York City Department of Health, NY 10013, USA. Source: Layton, M C Calliste, S G Gomez, T M Patton, C Brooks, S Infect-Control-HospEpidemiol. 1997 February; 18(2): 115-21 0899-823X
•
A novel Campylobacter jejuni two-component regulatory system important for temperature-dependent growth and colonization. Source: Bras, A.M. Chatterjee, S. Wren, B.W. Newell, D.G. Ketley, J.M. J-bacteriol. Washington, D.C. : American Society for Microbiology. May 1999. volume 181 (10) page 3298-3302. 0021-9193
•
Adherence to lipids and intestinal mucin by a recently recognized human pathogen, Campylobacter upsaliensis. Source: Sylvester, F.A. Philpott, D. Gold, D. Lastovica, A. Forstner, J.F. Infect-immun. Washington, D.C., American Society for Microbiology. October 1996. volume 64 (10) page 4060-4066. 0019-9567
•
Bactericidal activities of plant essential oils and some of their isolated constituents against Campylobacter jejuni, Escherichia coli, Listeria monocytogenes, and Salmonella enterica. Author(s): Western Regional Research Center, Agricultural Research Service, U.S. Department of Agriculture, Albany, California 94710, USA.
[email protected] Source: Friedman, M Henika, P R Mandrell, R E J-Food-Prot. 2002 October; 65(10): 154560 0362-028X
•
Biochemical characterization of Campylobacter fetus lipopolysaccharides. Source: Moran, A.P. O'Malley, D.T. Kosunen, T.U. Helander, I.M. Infect-immun. Washington, D.C., American Society for Microbiology. Sept 1994. volume 62 (9) page 3922-3929. 0019-9567
•
Biological characterization of Campylobacter fetus lipopolysaccharides. Source: Moran, A.P. O'Malley, D.T. Vuopio Varkila, J. Varkila, K. Pyhala, L. Saxen, H. Helander, I.M. FEMS-immunol-med-microbiol. Amsterdam : Elsevier Science Publishers, B.V. on behalf of the Federation of European Microbiological Societies, 1993-. August 1996. volume 15 (1) page 43-50. 0928-8244
Nutrition
113
•
Bismuth subsalicylate in the prevention of colonization of infant mice with Campylobacter jejuni. Author(s): College of Veterinary Medicine, Department of Food and Environmental Hygiene, Helsinki, Finland. Source: Hanninen, M L Epidemiol-Infect. 1990 June; 104(3): 397-404 0950-2688
•
Carbohydrate-based cocktails that decrease the population of Salmonella and Campylobacter in the crop of broiler chickens subjected to feed withdrawal. Author(s): Poultry Processing and Meat Quality Unit, Agricultural Research Service, United States Department of Agriculture, Russell Research Center, Athens, Georgia 30604, USA.
[email protected] Source: Hinton, A Jr Buhr, R J Ingram, K D Poult-Sci. 2002 June; 81(6): 780-4 0032-5791
•
Characterization of Campylobacter upsaliensis fur and its localization in a highly conserved region of the Campylobacter genome. Source: Bourke, B. Al Rashid, S.T. Bingham, H.L. Chan, V.L. Gene. Amsterdam : Elsevier Science. December 12, 1996. volume 183 (1/2) page 219-224. 0378-1119
•
Clinical experience with Campylobacter pylori in western Kentucky. Source: Kraus, J W Morello, P J J-Ky-Med-Assoc. 1989 September; 87(9): 448-50 00230294
•
Concerns regarding the occurrence of Listeria monocytogenes, Campylobacter jejuni, and Escherichia coli O157:H7 in foods regulated by the U.S. Food and Drug Administration. Source: Madden, J.M. Dairy-food-environ-sanit. Des Moines, Iowa : International Association of Milk, Food and Environmental Sanitarians, Inc. May 1994. volume 14 (5) page 262-267. 1043-3546
•
Cross-contamination with Campylobacter jejuni and Salmonella spp. from raw chicken products during food preparation. Source: Boer, E. de Hahne, M. J-Food-Prot. Des Moines, Iowa : International Association of Milk, Food, and Environmental Sanitarians. December 1990. volume 53 (12) page 1067-1068. 0362-028X
•
Dairy products, produce and other non-meat foods as possible sources of Campylobacter jejuni and Campylobacter coli enteritis. Source: Harris, N.V. Kimball, T. Weiss, N.S. Nolan, C. J-Food-Prot. Ames, Iowa : International Association of Milk, Food, and Environmental Sanitarians. May 1986. volume 49 (5) page 347-351. charts. 0362-028X
•
Determinants that may be involved in virulence and disease in Campylobacter jejuni. Source: Smith, J.L. J-food-saf. Trumbull, Conn. : Food & Nutrition Press. July 1996. volume 16 (2) page 105-139. 0149-6085
•
Development of a selective differential agar for isolation and enumeration of Campylobacter spp. Author(s): US Department of Agriculture, Russell Research Center, Athens, Georgia 30677, USA.
[email protected] Source: Line, J E J-Food-Prot. 2001 November; 64(11): 1711-5 0362-028X
•
Discrimination of Helicobacter pullorum and Campylobacter lari by analysis of whole cell fatty acid extracts. Source: Steinbrueckner, B. Haerter, G. Pelz, K. Burnens, A. Kist, M. FEMS-micro-biollett. Amsterdam, The Netherlands : Elsevier Science B.V. November 15, 1998. volume 168 (2) page 209-212. 0378-1097
114
Campylobacter
•
Effect of bismuth subcarbonate against Campylobacter pylori: do citrate ions improve antibacterial activity? Author(s): Institut fur Medizinische Mikrobiologie, Freien Universitat Berlin. Source: Vogt, K Warrelmann, M Hahn, H Zentralbl-Bakteriol. 1990 May; 273(1): 33-5 0934-8840
•
Effect of iron-dextran on lethality of Nigerian isolates of Campylobacter jejuni in mice. Author(s): Faculty of Science, Department of Biological Sciences, University of Lagos, Nigeria. Source: Coker, A O Obi, C L Cent-Afr-J-Med. 1991 January; 37(1): 20-3 0008-9176
•
Effects of the clearing-heat and nourishing-stomach method in the treatment of chronic gastritis with positive Campylobacter pylori. Author(s): Hangzhou Hospital of Integrated Chinese and Western Medicine, Zhejiang Province. Source: Wu, D Sun, B Sun, L Chai, K Ye, C J-Tradit-Chin-Med. 1995 March; 15(1): 28-30 0254-6272
•
Epidemiological typing of Campylobacter isolates from meat processing plants by pulsed-field gel electrophoresis, fatty acid profile typing, serotyping, and biotyping. Source: Steele, M. McNab, B. Fruhner, L. DeGrandis, S. Woodard, D. Odumeru, J.A. Appl-environ-microbiol. Washington : American Society for Microbiology. July 1998. volume 64 (7) page 2346-2349. 0099-2240
•
Epidemiology and treatment of gastric Campylobacter pylori infection: more questions than answers. Author(s): Dept. of Gastroenterology and Hepatology, Medizinische Hochschule Hannover. Source: Iserhard, R Freise, J Wagner, S Bokemeyer, B Weissbrodt, H Fritsch, R S Soudah, B Schmidt, F W Hepatogastroenterology. 1990 December; 37 Suppl 238-44 0172-6390
•
Eradication of Campylobacter pylori and recurrence of duodenal ulcer. A six-month follow-up study. Author(s): Gastroenterology Department, NIMTS Hospital, Athens, Greece. Source: Mouzas, I A Kalantzis, N Gabriel, P Kallimanis, G Papantoniou, P Mavrogiannis, H Acta-Gastroenterol-Latinoam. 1990; 20(3): 159-61 0300-9033
•
Evaluation of Campylobacter jejuni colonization of the domestic ferret intestine as a model of proliferative colitis. Source: Bell, J.A. Manning, D.D. Am-J-Vet-Res. Schaumburg, Ill. : American Veterinary Medical Association. June 1991. volume 52 (6) page 826-832. 0002-9645
•
Expression of Campylobacter hyoilei lipo-oligosaccharide (LOS) antigens in Escherichia coli. Source: Korolik, V. Fry, B.N. Alderton, M.R. Zeijst, B.A.M. van der. Coloe, P.J. Microbiol. Reading, U.K. : Society for General Microbiology, c1994-. November 1997. volume 143 (pt. 11) page 3481-3489. 1350-0872
•
Fate of Campylobacter jejuni in butter. Author(s): Center for Food Safety and Quality Enhancement, Department of Food Science and Technology, University of Georgia, Griffin 30223-1797, USA. Source: Zhao, T Doyle, M P Berg, D E J-Food-Prot. 2000 January; 63(1): 120-2 0362-028X
•
Host signal transduction and endocytosis of Campylobacter jejuni. Author(s): Department of Genetics, University of Leicester, UK.
Nutrition
115
Source: Wooldridge, K G Williams, P H Ketley, J M Microb-Pathog. 1996 October; 21(4): 299-305 0882-4010 •
Identification and molecular cloning of a gene encoding a fibronectin-binding protein (CadF) from Campylobacter jejuni. Source: Konkel, M.E. Garvis, S.G. Tipton, S.L. Anderson, D.E. Jr. Cieplak, W. Jr. Molmicrobiol. Oxford : Blackwell Scientific Publications,. June 1997. volume 24 (5) page 953963. 0950-382X
•
Identification of Campylobacter jejuni on the basis of a species-specific gene that encodes a membrane protein. Source: Stucki, U. Frey, J. Nicolet, J. Burnens, A. J-clin-microbiol. Washington : American Society for Microbiology,. April 1995. volume 33 (4) page 855-859. 0095-1137
•
Impairment of Na+, K+-ATPase activity following enterotoxigenic Campylobacter jejuni infection: changes in Na+, Cl- and 3-O-methyl-D-glucose transport in vitro, in rat ileum. Source: Kanwar, R.K. Ganguly, N.K. Kanwar, J.R. KuMarch, L. Walia, B.N.S. FEMSmicro-biol-lett. Amsterdam, The Netherlands : Elsevier Science Publishers. December 15, 1994. volume 124 (3) page 381-385. 0378-1097
•
In vitro binding of Campylobacter jejuni surface proteins to murine small intestinal cell membranes. Author(s): Institut fur Mikrobiologie und Tierhygiene, Fachbereich Veterinarmedizin, Freie Universitat Berlin. Source: Moser, I Hellmann, E Med-Microbiol-Immunol-(Berl). 1989; 178(4): 217-28 03008584
•
In vitro study on the effect of organic acids on Campylobacter jejuni/coli populations in mixtures of water and feed. Author(s): Department of Science and Food of Animal Origin, Faculty of Veterinary Medicine, Utrecht University, The Netherlands.
[email protected] Source: Chaveerach, P Keuzenkamp, D A Urlings, H A Lipman, L J van Knapen, F Poult-Sci. 2002 May; 81(5): 621-8 0032-5791
•
In vitro susceptibility of Campylobacter pyloridis to cimetidine, sucralfate, bismuth and sixteen antibiotics. Source: Andreasen, J J Andersen, L P Acta-Pathol-Microbiol-Immunol-Scand-[B]. 1987 April; 95(2): 147-9 0108-0180
•
Incidence of thermotolerant Campylobacter in foods assessed by NF ISO 10272 standard: results of a two-year study. Source: Federighi, M. Magras, C. Pilet, M.F. Woodward, D. Johnson, W. Jugiau, F. Jouve, J.L. Food-microbiol. London; Orlando : Academic Press, c1984-. April 1999. volume 16 (2) page 195-204. 0740-0020
•
Iron-regulated proteins in outer membranes of Campylobacter jejuni diarrhoea isolates and immune response to the proteins in patients. Author(s): Microbiology Laboratory, Sourasky (Ichilov Medical Center), Tel-Aviv, Israel. Source: Schwartz, D Konforti, N Perry, R Goossens, H Butzler, J P Williams, P Goldhar, J Zentralbl-Bakteriol. 1994 January; 280(3): 338-47 0934-8840
•
Lectin agglutination of thermophilic Campylobacter species. Author(s): Ministry of Agriculture, Fisheries and Food, Central Veterinary Laboratory, Surrey, Gt. Britain. Source: Corbel, M J Gill, K P Vet-Microbiol. 1987 October; 15(1-2): 163-73 0378-1135
116
Campylobacter
•
Methods for recovery of campylobacter jejuni from foods. Source: Stern, Norman J. J-Food-Prot. Ames : International Association of Milk, Food, and Environmental Sanitarians. December 1982. volume 45 (14) page 1332-1337, 1341. ill., charts. 0362-028X
•
Molecular characterization of a Campylobacter jejuni 29-kilodalton periplasmic binding protein. Source: Garvis, S.G. Puzon, G.J. Konkel, M.E. Infect-immun. Washington, D.C., American Society for Microbiology. Sept 1996. volume 64 (9) page 3537-3543. 0019-9567
•
Occurrence of Campylobacter jejuni in free-living wild birds from Japan. Author(s): Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Japan. Source: Ito, K Kubokura, Y Kaneko, K Totake, Y Ogawa, M J-Wildl-Dis. 1988 July; 24(3): 467-70 0090-3558
•
Production of hyperimmune bovine colostrum against Campylobacter jejuni. Source: Husu, J. Syvaoja, E.L. Ahola Luttila, H. Kalsta, H. Sivela, S. Kosunen, T.U. Jappl-bacteriol. Oxford; New York : Blackwell Scientific, 1954-. May 1993. volume 74 (5) page 564-569. 0021-8847
•
Protection of breast-fed infants against Campylobacter diarrhea by antibodies in human milk. Source: Ruiz Palacios, G.M. Calva, J.J. Pickering, L.K. Lopez Vidal, Y. Volkow, P. Pezzarossi, H. West, M.S. J-Pediatr. St. Louis, Mo. : C.V. Mosby. May 1990. volume 116 (5) page 707-713. charts. 0022-3476
•
Quorum sensing and production of autoinducer-2 in Campylobacter spp., Escherichia coli O157:H7, and Salmonella enterica serovar Typhimurium in foods. Author(s): Eastern Regional Research Center, Agricultural Research Service, U.S. Department of Agriculture, Wyndmoor, Pennsylvania 19038, USA. Source: Cloak, O M Solow, B T Briggs, C E Chen, C Y Fratamico, P M Appl-EnvironMicrobiol. 2002 September; 68(9): 4666-71 0099-2240
•
Risk factors for campylobacter infection in infants and young children: a matched case-control study. Author(s): Brisbane Southside Public Health Unit, Queensland Health, Australia. Source: Tenkate, T D Stafford, R J Epidemiol-Infect. 2001 December; 127(3): 399-404 0950-2688
•
Risk factors for indigenous campylobacter infection: a Swedish case-control study. Author(s): Department of Communicable Disease Control and Prevention, Boras, Sweden. Source: Studahl, A Andersson, Y Epidemiol-Infect. 2000 October; 125(2): 269-75 09502688
•
Structural analysis of the lipid A component of Campylobacter jejuni CCUG 10936 (serotype O:2) lipopolysaccharide. Description of a lipid A containing a hybrid backbone of 2-amino-2-deoxy-D-glucose and 2,3-diamino-2,3-dideoxy-D-glucose. Author(s): Forschungsinstitut Borstel, Institut fur Experimentelle Biologie und Medizin, Federal Republic of Germany. Source: Moran, A P Zahringer, U Seydel, U Scholz, D Stutz, P Rietschel, E T Eur-JBiochem. 1991 June 1; 198(2): 459-69 0014-2956
Nutrition
117
•
Survival of Campylobacter jejuni and pathogenic Escherichia coli in mahewu, a fermented cereal guel. Source: Simango, C. Rukure, G. Trans-R-Soc-Trop-Med-Hyg. London : The Society. 1991. volume 85 (3) page 399-400. 0035-9203
•
The bactericidal activity of tea against Campylobacter jejuni and Campylobacter coli. Source: Diker, K.S. Akan, M. Hascelik, G. Yurdakok, M. Lett-Appl-Microbiol. Oxford : Blackwell Scientific Publications. February 1991. volume 12 (2) page 34-35. 0266-8254
•
The minimum inhibitory concentrations of various bismuth salts against Campylobacter pylori. Author(s): Institut fur Medizinische Mikrobiologie der Freien Universitat Berlin. Source: Vogt, K Warrelmann, M Hahn, H Zentralbl-Bakteriol. 1989 September; 271(3): 304-10 0934-8840
•
The O-specific polysaccharide chain of Campylobacter fetus serotype B lipopolysaccharide is a D-rhamnan terminated with 3-O-methyl-D-rhamnose (Dacofriose). Author(s): N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russia. Source: Senchenkova, S N Shashkov, A S Knirel, Y A McGovern, J J Moran, A P Eur-JBiochem. 1996 July 15; 239(2): 434-8 0014-2956
•
Treatment of Campylobacter pylori gastritis: a pilot study using pirenzepine dihydrochloride (Gastrozepin) and three formulations of colloidal bismuth subcitrate (De-Nol). Author(s): Department of Microbiology, Middlemore Hospital, Otahuhu, Auckland. Source: Morris, A Brown, P Ali, M R Lane, M Palmer, R N-Z-Med-J. 1988 October 26; 101(856 Pt 1): 651-4 0028-8446
•
Yeast treatment to reduce Salmonella and Campylobacter populations associated with broiler chickens subjected to transport stress. Source: Line, J.E. Bailey, J.S. Cox, N.A. Stern, N.J. Poultry-sci. Savoy, IL : Poultry Science Association, Inc. Sept 1997. volume 76 (9) page 1227-1231. 0032-5791
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
118
Campylobacter
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMDHealth: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
119
CHAPTER 3. CAMPYLOBACTER
ALTERNATIVE
MEDICINE
AND
Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to campylobacter. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to campylobacter and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “campylobacter” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to campylobacter: •
A comparative study of the rod and coccoid forms of Campylobacter jejuni ATCC 29428. Author(s): Moran AP, Upton ME. Source: The Journal of Applied Bacteriology. 1986 February; 60(2): 103-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2422149
•
A point of view: The need to identify an antigen in psyconeuroimmunological disorders. Author(s): Covelli V, Pellegrino NM, Jirillo E. Source: Current Pharmaceutical Design. 2003; 9(24): 1951-5. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12871180
120
Campylobacter
•
Aetiological factors of infantile diarrhoea: a community-based study. Author(s): Loening WE, Coovadia YM, van den Ende J. Source: Annals of Tropical Paediatrics. 1989 December; 9(4): 248-55. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2482008
•
Antagonistic activities of several bacteria on in vitro growth of 10 strains of Campylobacter jejuni/coli. Author(s): Chaveerach P, Lipman LJ, van Knapen F. Source: International Journal of Food Microbiology. 2004 January 1; 90(1): 43-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14672829
•
Antibiotic and deoxycholate resistance in Campylobacter jejuni following freezing or heating. Author(s): Humphrey TJ, Cruickshank JG. Source: The Journal of Applied Bacteriology. 1985 July; 59(1): 65-71. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3928571
•
Antimicrobial activity of Terminalia macroptera root. Author(s): Silva O, Duarte A, Pimentel M, Viegas S, Barroso H, Machado J, Pires I, Cabrita J, Gomes E. Source: Journal of Ethnopharmacology. 1997 August; 57(3): 203-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9292414
•
Antimicrobial use and resistance in animals. Author(s): McEwen SA, Fedorka-Cray PJ. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 June 1; 34 Suppl 3: S93-S106. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11988879
•
Bacterial food poisoning: what to do if prevention fails. Author(s): Goldfrank L, Weisman R. Source: Postgraduate Medicine. 1982 September; 72(3): 171-5, 178-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=6812033
•
Bactericidal activities of plant essential oils and some of their isolated constituents against Campylobacter jejuni, Escherichia coli, Listeria monocytogenes, and Salmonella enterica. Author(s): Friedman M, Henika PR, Mandrell RE. Source: J Food Prot. 2002 October; 65(10): 1545-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12380738
•
Basis for serological heterogeneity of thermostable antigens of Campylobacter jejuni. Author(s): Mills SD, Bradbury WC, Penner JL.
Alternative Medicine 121
Source: Infection and Immunity. 1985 October; 50(1): 284-91. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2412962 •
Campylobacter fetus adheres to and enters INT 407 cells. Author(s): Graham LL. Source: Canadian Journal of Microbiology. 2002 November; 48(11): 995-1007. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12556127
•
Campylobacter pylori and gastroduodenal ulcer disease. A prospective study in a Swedish population. Author(s): Gad A, Hradsky M, Furugard K, Malmodin B. Source: Scandinavian Journal of Gastroenterology. Supplement. 1989; 167: 81-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2575789
•
Campylobacter pylori and non-ulcer dyspepsia. 2. A prospective study in a Swedish population. Author(s): Gad A, Hradsky M, Furugard K, Malmodin B, Nyberg O. Source: Scandinavian Journal of Gastroenterology. Supplement. 1989; 167: 44-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2617168
•
Campylobacter pylori infection in biopsy specimens of gastric antrum: laboratory diagnosis and estimation of sampling error. Author(s): Morris A, Ali MR, Brown P, Lane M, Patton K. Source: Journal of Clinical Pathology. 1989 July; 42(7): 727-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2474579
•
Cell association and invasion of Caco-2 cells by Campylobacter jejuni. Author(s): Russell RG, Blake DC Jr. Source: Infection and Immunity. 1994 September; 62(9): 3773-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8063393
•
Characterization of the porins of Campylobacter jejuni and Campylobacter coli and implications for antibiotic susceptibility. Author(s): Page WJ, Huyer G, Huyer M, Worobec EA. Source: Antimicrobial Agents and Chemotherapy. 1989 March; 33(3): 297-303. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2543277
•
Characterization of urease from Campylobacter pylori. Author(s): Mobley HL, Cortesia MJ, Rosenthal LE, Jones BD. Source: Journal of Clinical Microbiology. 1988 May; 26(5): 831-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3384908
122
Campylobacter
•
Comparison of methods used to separate the inner and outer membranes of cell envelopes of Campylobacter spp. Author(s): Page WJ, Taylor DE. Source: J Gen Microbiol. 1988 November; 134 ( Pt 11): 2925-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=2474628
•
Comparison of weep and carcass rinses for recovery of Campylobacter from retail broiler carcasses. Author(s): Musgrove MT, Cox NA, Berrang ME, Harrison MA. Source: J Food Prot. 2003 September; 66(9): 1720-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14503734
•
Difficulty in recovering inoculated Campylobacter jejuni from dry poultry-associated samples. Author(s): Cox NA, Berrang ME, Stern NJ, Musgrove MT. Source: J Food Prot. 2001 February; 64(2): 252-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11271776
•
Domestic poultry-raising practices in a Peruvian shantytown: implications for control of Campylobacter jejuni-associated diarrhea. Author(s): Harvey SA, Winch PJ, Leontsini E, Torres Gayoso C, Lopez Romero S, Gilman RH, Oberhelman RA. Source: Acta Tropica. 2003 April; 86(1): 41-54. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12711102
•
Effects of the clearing-heat and nourishing-stomach method in the treatment of chronic gastritis with positive Campylobacter pylori. Author(s): Wu D, Sun B, Sun L, Chai K, Ye C. Source: J Tradit Chin Med. 1995 March; 15(1): 28-30. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7783456
•
Evaluation of an avian-specific probiotic to reduce the colonization and shedding of Campylobacter jejuni in broilers. Author(s): Morishita TY, Aye PP, Harr BS, Cobb CW, Clifford JR. Source: Avian Dis. 1997 October-December; 41(4): 850-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9454918
•
Fate of Campylobacter jejuni in butter. Author(s): Zhao T, Doyle MP, Berg DE. Source: J Food Prot. 2000 January; 63(1): 120-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10643781
Alternative Medicine 123
•
Human antibody response to outer membrane proteins of Campylobacter jejuni during infection. Author(s): Mills SD, Bradbury WC. Source: Infection and Immunity. 1984 February; 43(2): 739-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=6198286
•
In vitro inhibitory activity of Chinese leek extract against Campylobacter species. Author(s): Lee CF, Han CK, Tsau JL. Source: International Journal of Food Microbiology. 2004 July 15; 94(2): 169-74. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15193803
•
Infection with Campylobacter jejuni induces tyrosine-phosphorylated proteins into INT-407 cells. Author(s): Biswas D, Niwa H, Itoh K. Source: Microbiology and Immunology. 2004; 48(4): 221-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15107531
•
Invasion of human epithelial cells by Campylobacter upsaliensis. Author(s): Mooney A, Byrne C, Clyne M, Johnson-Henry K, Sherman P, Bourke B. Source: Cellular Microbiology. 2003 November; 5(11): 835-47. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14531898
•
Investigation on the inhibition of Campylobacter jejuni growth with the applications of some preservatives, medicines, herbs and herb preparations. Author(s): Uradzinski J, Szteyn J, Kafel S. Source: Pol J Vet Sci. 2002; 5(4): 223-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12512554
•
Isolation of Campylobacter spp. from semen samples of commercial broiler breeder roosters. Author(s): Cox NA, Stern NJ, Wilson JL, Musgrove MT, Buhr RJ, Hiett KL. Source: Avian Dis. 2002 July-September; 46(3): 717-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12243539
•
Major outer membrane protein of Campylobacter fetus: physical and immunological characterization. Author(s): McCoy EC, Wiltberger HA, Winter J. Source: Infection and Immunity. 1976 April; 13(4): 1258-65. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=819374
•
Microcapsule of Campylobacter fetus: chemical and physical characterization. Author(s): Winter AJ, McCoy EC, Fullmer CS, Burda K, Bier PJ.
124
Campylobacter
Source: Infection and Immunity. 1978 December; 22(3): 963-71. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=730387 •
Occurrence of Campylobacter jejuni in vegetables. Author(s): Kumar A, Agarwal RK, Bhilegaonkar KN, Shome BR, Bachhil VN. Source: International Journal of Food Microbiology. 2001 July 20; 67(1-2): 153-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11482564
•
Passive hemagglutination technique for serotyping Campylobacter fetus subsp. jejuni on the basis of soluble heat-stable antigens. Author(s): Penner JL, Hennessy JN. Source: Journal of Clinical Microbiology. 1980 December; 12(6): 732-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=6796598
•
Rapid detection of Campylobacter coli, C. jejuni, and Salmonella enterica on poultry carcasses by using PCR-enzyme-linked immunosorbent assay. Author(s): Hong Y, Berrang ME, Liu T, Hofacre CL, Sanchez S, Wang L, Maurer JJ. Source: Applied and Environmental Microbiology. 2003 June; 69(6): 3492-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12788755
•
Rapid methods for detection and enumeration of Campylobacter spp. in foods. Author(s): Wang H. Source: J Aoac Int. 2002 July-August; 85(4): 996-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12180699
•
Role of the beta-lactamase of Campylobacter jejuni in resistance to beta-lactam agents. Author(s): Lachance N, Gaudreau C, Lamothe F, Lariviere LA. Source: Antimicrobial Agents and Chemotherapy. 1991 May; 35(5): 813-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1854162
•
Simple extraction of Campylobacter lipopolysaccharide and protein antigens and production of their antibodies in egg yolk. Author(s): Chandan V, Fraser AD, Brooks BW, Yamazaki H. Source: International Journal of Food Microbiology. 1994 May; 22(2-3): 189-200. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8074971
•
Specific detection and confirmation of Campylobacter jejuni by DNA hybridization and PCR. Author(s): Ng LK, Kingombe CI, Yan W, Taylor DE, Hiratsuka K, Malik N, Garcia MM.
Alternative Medicine 125
Source: Applied and Environmental Microbiology. 1997 November; 63(11): 4558-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9361442 •
Survival of Campylobacter jejuni in biofilms isolated from chicken houses. Author(s): Trachoo N, Frank JF, Stern NJ. Source: J Food Prot. 2002 July; 65(7): 1110-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12117243
•
Susceptibility of Campylobacter jejuni to strain-specific bactericidal activity in sera of infected patients. Author(s): Pennie RA, Pearson RD, Barrett LJ, Lior H, Guerrant RL. Source: Infection and Immunity. 1986 June; 52(3): 702-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3710581
Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •
Alternative Medicine Foundation, Inc.: http://www.herbmed.org/
•
AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com: http://www.drkoop.com/InteractiveMedicine/IndexC.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
•
MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine
•
Open Directory Project: http://dmoz.org/Health/Alternative/
•
HealthGate: http://www.tnp.com/
•
WebMDHealth: http://my.webmd.com/drugs_and_herbs
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
126
Campylobacter
The following is a specific Web list relating to campylobacter; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
General Overview Food Poisoning Source: Integrative Medicine Communications; www.drkoop.com Proctitis Source: Integrative Medicine Communications; www.drkoop.com Rectal Inflammation Source: Integrative Medicine Communications; www.drkoop.com Reiter's Syndrome Source: Integrative Medicine Communications; www.drkoop.com
•
Herbs and Supplements Astragalus Mem Alternative names: Huang-Qi; Astragalus membranaceus Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Cinnamomum Alternative names: Cinnamon; Cinnamomum zeylanicum Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Eugenia Clove Alternative names: Cloves; Eugenia sp. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Taraxacum Alternative names: Dandelion; Taraxacum officinale (Dhudhal) Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Thymus Alternative names: Thyme; Thymus vulgaris Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
127
CHAPTER 4. DISSERTATIONS ON CAMPYLOBACTER Overview In this chapter, we will give you a bibliography on recent dissertations relating to campylobacter. We will also provide you with information on how to use the Internet to stay current on dissertations. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical dissertations that use the generic term “campylobacter” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on campylobacter, we have not necessarily excluded non-medical dissertations in this bibliography.
Dissertations on Campylobacter ProQuest Digital Dissertations, the largest archive of academic dissertations available, is located at the following Web address: http://wwwlib.umi.com/dissertations. From this archive, we have compiled the following list covering dissertations devoted to campylobacter. You will see that the information provided includes the dissertation’s title, its author, and the institution with which the author is associated. The following covers recent dissertations found when using this search procedure: •
An investigation of the structural and antigenic properties of cell envelope components from Campylobacter species by Preston, Martin Alfred; PhD from University of Toronto (Canada), 1989 http://wwwlib.umi.com/dissertations/fullcit/NL51111
•
Characterization of the hippurate hydrolase enzyme of Campylobacter jejuni by Steele, Marina Lynn; PhD from University of Guelph (Canada), 2003, 198 pages http://wwwlib.umi.com/dissertations/fullcit/NQ75994
•
Characterization of the macrophage response to Campylobacter jejuni: Implications for C. jejuni-mediated enteritis by Siegesmund, Amy Marie; PhD from Washington State University, 2003, 155 pages http://wwwlib.umi.com/dissertations/fullcit/3096899
128
Campylobacter
•
Ecological modeling of the bacterial pathogens, Vibrio cholerae and Campylobacter jejuni by Louis, Valerie R.; PhD from University of Maryland College Park, 2003, 269 pages http://wwwlib.umi.com/dissertations/fullcit/3112589
•
In-package heat pasteurization combined with biocide-impregnated packaging films for inhibition of Escherichia coli O157:H7 and Campylobacter jejuni by HughesHollar, LaVonda Ann; PhD from North Carolina State University, 2003, 174 pages http://wwwlib.umi.com/dissertations/fullcit/3107770
•
Isolation and characterization of Campylobacter coli and Campylobacter jejuni by Ng, Lai-King; PhD from University of Alberta (Canada), 1987 http://wwwlib.umi.com/dissertations/fullcit/NL37651
•
Isolation and characterization of cell surface antigens from Campylobacter jejuni and Campylobacter coli by Mills, Sharon Dawn; PhD from University of Toronto (Canada), 1986 http://wwwlib.umi.com/dissertations/fullcit/NL34165
•
Molecular analysis of the surface antigens of campylobacter jejuni by Logan, Susan M; PhD from University of Victoria (Canada), 1986 http://wwwlib.umi.com/dissertations/fullcit/NL34521
•
Pathogenic mechanisms of Campylobacter jejuni : Characterization and identification of the role of CadF in Campylobacter-mediated enteritis by Monteville, Marshall Reno; PhD from Washington State University, 2003, 284 pages http://wwwlib.umi.com/dissertations/fullcit/3096893
•
The association between Campylobacter jejuni infection and Guillain Barre syndrome by Murphy, Gailene Ann; MSc from University of Prince Edward Island (Canada), 2003, 111 pages http://wwwlib.umi.com/dissertations/fullcit/MQ82383
•
Ultrastructure and atpase nature of polar membrane in Campylobacter jejuni by Brock, Frances Marguerite; PhD from The University of Western Ontario (Canada), 1988 http://wwwlib.umi.com/dissertations/fullcit/NL40759
Keeping Current Ask the medical librarian at your library if it has full and unlimited access to the ProQuest Digital Dissertations database. From the library, you should be able to do more complete searches via http://wwwlib.umi.com/dissertations.
129
CHAPTER 5. PATENTS ON CAMPYLOBACTER Overview Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.8 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical patents that use the generic term “campylobacter” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on campylobacter, we have not necessarily excluded non-medical patents in this bibliography.
Patents on Campylobacter By performing a patent search focusing on campylobacter, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We will tell you how to obtain this information later in the chapter. The following is an 8Adapted
from the United States Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
130
Campylobacter
example of the type of information that you can expect to obtain from a patent search on campylobacter: •
Amplification and detection of Campylobacter jejuni and Campylobacter coli Inventor(s): Fort; Thomas L. (Finksburg, MD), McMillian; Ray A. (Timonium, MD), You; Qimin (Lutherville, MD) Assignee(s): Becton Dickinson and Company (Franklin Lakes, NJ) Patent Number: 6,066,461 Date filed: April 12, 1999 Abstract: Amplification primers and methods for specific amplification and detection of a Campylobacter jejuni and C. coli target are disclosed. The primer-target binding sequences are useful for amplification and detection of C jejuni and C. coli target in a variety of amplification and detection reactions. Excerpt(s): The present invention relates to methods for determining the presence or absence of Campylobacter jejuni and C. coli in patients. The method involves using nucleic acid primers to amplify specifically the C. jejuni and C. coli superoxide dismutase (sodB) gene, preferably using one of the techniques of Strand Displacement Amplification (SDA), thermophilic Strand Displacement Amplification (tSDA) or fluorescent real time thermophilic Strand Displacement Amplification, and optionally using a microelectronic array. C. jejuni and C. coli are recognized as important causes of acute diarrheal disease in humans throughout the world. Nucleic acid amplification is a powerful technology that allows rapid detection of specific target sequences. It is therefore a promising technology which allows rapid detection and identification of C. jejuni and C. coli. The oligonucleotide primers of the present invention are applicable to nucleic acid amplification and detection of the C. jejuni- and C. coli-specific regions of the superoxide dismutase (sodB) gene. The sodB gene is approximately 900 base pairs in size and is important in the survival of C. jejuni and C. coli in air and during infection. An amplification primer is a primer for amplification of a target sequence by extension of the primer after hybridization to the target sequence. Amplification primers are typically about 10-75 nucleotides in length, preferably about 15-50 nucleotides in length. The total length of an amplification primer for SDA is typically about 25-50 nucleotides. The 3' end of an SDA amplification primer (the target binding sequence) hybridizes at the 3' end of the target sequence. The target binding sequence is about 10-25 nucleotides in length and confers hybridization specificity on the amplification primer. The SDA amplification primer further comprises a recognition site for a restriction endonuclease 5' to the target binding sequence. The recognition site is for a restriction endonuclease which will nick one strand of a DNA duplex when the recognition site is hemimodified, as described by G. Walker, et al. (1992. Proc. Natl. Acad. Sci. USA 89:392-396 and 1992 Nucl. Acids Res. 20:1691-1696). The nucleotides 5' to the restriction endonuclease recognition site (the "tail") function as a polymerase repriming site when the remainder of the amplification primer is nicked and displaced during SDA. The repriming function of the tail nucleotides sustains the SDA reaction and allows synthesis of multiple amplicons from a single target molecule. The tail is typically about 10-25 nucleotides in length. Its length and sequence are generally not critical and can be routinely selected and modified. As the target binding sequence is the portion of a primer which determines its target-specificity, for amplification methods which do not require specialized sequences at the ends of the target the amplification primer generally consists essentially of only the target binding sequence. For example, amplification of a
Patents 131
target sequence according to the invention using the Polymerase Chain Reaction (PCR) will employ amplification primers consisting of the target binding sequences of the amplification primers described herein. For amplification methods that require specialized sequences appended to the target other than the nickable restriction endonuclease recognition site and the tail of SDA (e.g., an RNA polymerase promoter for Self-Sustained Sequence Replication (3SR), Nucleic Acid Sequence-Based Amplification (NASBA) or the Transcription-Based Amplification System (TAS)), the required specialized sequence may be linked to the target binding sequence using routine methods for preparation of oligonucleotides without altering the hybridization specificity of the primer. Web site: http://www.delphion.com/details?pn=US06066461__ •
Campylobacter jejuni antigens and methods for their production and use Inventor(s): Blaser; Martin J. (Nashville, TN), Pei; Zhiheng (Nashville, TN) Assignee(s): Enteric Research Laboratories () Patent Number: 5,874,300 Date filed: March 13, 1995 Abstract: The present invention provides an isolated nucleic acid encoding an approximately 26 kilodalton antigen, PEB1A, of Campylobacter jejuni, or an antigenic fragment thereof, wherein the antigen is associated with diarrheal disease. The present invention also provides methods of detecting the presence of a Campylobacter jejuni strain possessing the PEB1A antigen in a subject. Vaccines and treatments for C. jejuni infection are provided, as is a mutant C. jejuni not expressing a functional PEB1A antigen. Excerpt(s): This invention relates to the Campylobacter jejuni antigen PEB1A, to nucleic acid encoding the antigen, to various methods of detecting Campylobacter jejuni infection, and to vaccines and treatments for Campylobacter jejuni enteritis. In particular, the interaction of the PEB1A antigen with its receptor can be beneficially controlled by a number of techniques described herein. Campylobacter jejuni is now recognized as one of the leading causes of diarrheal diseases worldwide. Approximately two million cases of C. jejuni enteritis occur in the United States each year, and the actual incidence may be even higher for at least two reasons. First, C. jejuni is a fastidious bacterium which requires microaerobic environment (5% O.sub.2, 3-10% CO.sub.2) to grow, a condition that is not available in many clinical microbiology laboratories. Second, treatment of diarrheal patients with antibiotics for any reason may kill C. jejuni, thus causing conventional diagnostic methods based on culturing viable bacteria to yield false negative results. Thus, a new diagnostic technique is needed to detect C. jejuni bacteria, whether viable or not. Prior art attempts at vaccines and therapy for C. jejuni enteritis have suffered from incomplete knowledge of the important antigen and receptor interactions discussed herein regarding PEB1A. Web site: http://www.delphion.com/details?pn=US05874300__
132
•
Campylobacter
Campylobacteri jejuni flagellin-escherichia coli LT-B fusion protein Inventor(s): Khoury; Christian A. (Philadelphia, PA), Meinersmann; Richard J. (Lithonia, GA) Assignee(s): The United States of America as represented by the Secretary of (Washington, DC) Patent Number: 5,888,810 Date filed: January 16, 1997 Abstract: A fusion protein which comprises the B subunit of the labile toxin (LT-B) of E. coli and part of the flagellin (flaA) protein of C. jejuni is antigenic and is useful for decreasing colonization in chickens by Campylobacter species. The protein is produced by E. coli cells, transformed by the plasmid pBEB into which DNA sequences encoding the novel protein have been introduced. Excerpt(s): Approximately 3 billion chickens are raised in the United States every year, and virtually all are contaminated with Campylobacter jejuni (C. jejuni). Currently, there is no vaccine or any other method available to the poultry industry for the prevention of colonization, therefore there exists a need to develop a product which will provide protection from C. jejuni contamination. This invention relates to a novel fusion protein which, upon administration to a poultry population, will decrease the incidence of colonization by C. jejuni. The protein is relatively simple to produce and purify, and it is expressed in large quantities and can be used without further treatment (beyond purification) for vaccination. In recent years, C. jejuni has been recognized as a major human enteropathogen and is the species implicated in more than 95% of the cases of campylobacteriosis in the United States (Karmali et al. 1983. J. Infect. Dis., vol. 147, pp. 243-246). C. jejuni has also been recognized as a common cause of gastroenteritis worldwide (Georges-Courbot et al. 1989. Res. Microbiol. vol. 140, pp. 292-296) with twothirds of the reported cases found in the United States (Bokkenheuser and Sutter. 1981. pp.301-310. In Diagnostic Procedures for Bacterial, Mycotic and Parasitic Infections. Ed. Balows and Hausler. 6th edition, American Public Health Association, Washington, D.C.). Several reports indicate that C. jejuni enteritis is associated with eating in restaurants (Genigeorgis, C. 1987. pp. 111-145. In Elimination of Pathogenic Organisms from Meat and Poultry. Ed. F. J. M. Smulders, Elsevier, Amsterdam), drinking raw milk or unchlorinated water (Hutchinson et al. J. Hyg. Cam., vol. 94, pp. 204-215; Schmid et al. 1987. J. Infect. Dis., vol, 156, pp. 218-222), eating under-cooked poultry meat (Harris et al. 1986. Am. J. Pub. Health, vol. 76, pp. 407-411; Izat and Gardner. 1986. Poultry Science, vol. 67, pp. 1431-1435), and living in a household with pets (Genigeorgis, supra; Vandenberghe et al. 1982. Br. Vet. J., vol. 138, pp. 356-361). C. jejuni is common in the intestine of most domestic and many wild animals and is present in high numbers in most birds (Bokkenheuser, supra). Species of Camplyobacter enter into a nonpathological, commensal relationship in the intestine of the chicken (Juven et al. 1991. Eur. J. Clin. Microbiol., v. 70, pp. 95-103). Chickens carry the organism as part of the indigenous intestinal flora, and for this reason they have been suspected as an important vehicle in the transmission or Campylobacter spp. to humans (Izat and Gardner, supra; Juven et al., supra). Poultry has been implicated as the major reservoir of human campylobacteriosis in the developed world (Genigeorgis, supra). As many as 90% of broiler chickens may harbor this organism (Lam et al. 1992. Av. Dis., v. 36, pp. 359-363). The pathogen can survive the chicken processing procedures and may be present on the product in retail outlets (Hood et al. 1988. Epidem. Inf., vol. 100, pp. 17-25). In a study at a live poultry market in New York City, more than 80% of broiler chickens sold yielded the organism. In another study, 68% of the retail broiler carcasses tested had C. jejuni
Patents 133
(Izat et al., supra). Undercooked or improperly handled poultry has been implicated in 50 to 70% of Campylobacter spp. infections in humans (Hood et al., supra). In a study on university students in Georgia infected with Campylobacter, 70% of the cases were accounted for by eating chicken, often undercooked or raw, and 30% by contact with cats ›Tauxe et al. 1988. CDC Surveillance Summaries, vol. 37(SS-2), pp. 1-13!. Web site: http://www.delphion.com/details?pn=US05888810__ •
Chicken meat product and method of making Inventor(s): Glabe; Elmer F. (1354 Westwood Ct., Northbrook, IL 60062), Shubert; Victor H. (3846 State Rte. 153, Washington County, Coulterville, IL 62237) Assignee(s): none reported Patent Number: 6,329,003 Date filed: July 7, 2000 Abstract: A chicken meat product rendered substantially free of pathogenic bacterial species by having an external coating of sodium diacetate substantially free of an adhesive material. The wet coating is retained on the external surfaces of the dressed chicken meat by the surface tension of the sodium diacetate solution after the chicken meat is coated with the solution and is hung freely to permit excess liquid to drain away. The amount of sodium diacetate present in the product of the invention depends upon the degree of pathogenic bacterial contamination of the chicken meat. The sodium diacetate is included in each case in sufficient quantity to preserve the meat from growth of all pathogenic bacteria of the order and species of salmonella, E. coli, and campylobacter. Excerpt(s): This invention relates to a packaged chicken meat product--either a dressed whole chicken or dressed chicken parts--that is coated with a water solution of sodium diacetate, or solid sodium diacetate in a specified form, to combat and eliminate certain pathogenic bacteria, and to the process of making such a product. Chicken production and processing for meat is a large and growing U.S. industry. Profit for processors, however, is not more than a few cents per pound of dressed chicken. The intense competition often leads to hazardous cost cutting that is contrary to good processing practices as prescribed by government oversight agencies such as the Food and Drug Administration, the U.S. Department of Agriculture and the Food Safety Inspection Service. Salmonella, E. coli, and campylobacter have been clearly identified by many studies made by these government agencies, and by meat processors, as species of pathogenic bacteria that have often been found in chicken meat and have been the cause of food poisoning outbreaks that have affected large numbers of the population, often with many fatalities. Web site: http://www.delphion.com/details?pn=US06329003__
134
•
Campylobacter
Composition for treatment of a bacterial infection of the digestive tract Inventor(s): Fischetti; Vincent (West Hempstead, NY), Loomis; Lawrence (Columbia, MD) Assignee(s): New Horizons Diagnostics Corporation (Columbia, MD) Patent Number: 6,399,097 Date filed: September 1, 2000 Abstract: An enteric coated pill for treating bacterial infections of the digestive tract, wherein the bacteria to be treated are selected from the group consisting of Listeria, Salmonella, E. coli, Campylobacter and combinations thereof, said pill comprising an effective amount of at least one lytic enzyme genetically coded by a bacteriophage specific for said bacteria of the digestive tract, whereby said enzyme has the ability to digest the cell wall of said bacteria; and a carrier for said enzyme. Excerpt(s): The present invention discloses a method and composition for the treatment of bacterial infections by the use of a lysing enzyme blended with an appropriate carrier suitable for the treatment of the infection. In the past, antibiotics have been used to treat various infections. The work of Selman Waksman in the introduction and production of Streptomycetes and Dr. Fleming's discovery of penicillin, as well as the work of numerous others in the field of antibiotics, are well known. Over the years, there have been additions and chemical modifications to the "basic" antibiotics in attempts to make them more powerful, or to treat people allergic to these antibiotics. Others have found new uses for these antibiotics. U.S. Pat. No. 5,260,292 (Robinson et al.) discloses a topical treatment of acne with aminopenicillins. The method and composition for topically treating acne and acneiform dermal disorders includes applying an amount of an antibiotic selected from the group consisting of ampicillin, amoxicillin, other aminopenicillins, and cephalosporins, and derivatives and analogs thereof, effective to treat the acne and acneiform dermal disorders. U.S. Pat. No. 5,409,917 (Robinson et al.) discloses the topical treatment of acne with cephalosporins. Web site: http://www.delphion.com/details?pn=US06399097__
•
Detection and speciation of Campylobacter Inventor(s): Fox; Andrew John (Manchester, GB), Jones; Dennis Mackay (Stockport, GB) Assignee(s): Public Health Laboratory Service Board (London, GB) Patent Number: 6,080,547 Date filed: July 30, 1999 Abstract: Method for detecting Campylobacter by PCR detection of DNA sequence highly conserved between species lari, coli, jejuni and upsaliensis. Speciation between these four is possible as the PCR product is differentially cleaved by restriction endonucleases. Excerpt(s): This invention relates to the detection and speciation of Campylobacter bacteria, for example in clinical, environmental and food samples. In particular, this invention relates to a method of detecting whether a sample contains Campylobacter and to a method of differentiating between the main Campylobacter species jejune, coli, upsaliensis and lari. Campylobacter species are recognised as the most frequent cause of bacterial gastroenteritis in the United Kingdom and many other countries throughout the world. In the U.K. approximately 90% and 10% of case isolates are identified as
Patents 135
Campylobacter jejuni and Campylobacter coli respectively, plus a small number of other species such as Campylobacter upsaliensis and lari. The majority of the infections are sporadic the source of which remains largely unknown although the importance of several vehicles is now recognised. There is a known desire to be able to detect and differentiate species of Campylobacter. However, it is also known that present Campylobacter enrichment culture techniques lack sensitivity, making detection difficult. Campylobacter jejuni does not multiply in foodstuffs and low numbers may be present together with a high background of indigenous microflora. Also, surface viable counts of Campylobacter can decrease rapidly and cells that are potentially culturable are often lost before samples reach a laboratory for analysis. Another factor making detection problematic is that antibiotics used in culture enrichment media may damage already weakened Campylobacter. Web site: http://www.delphion.com/details?pn=US06080547__ •
DNA probes for campylobacter, arcobacter and helicobacter Inventor(s): Al Rashid; Shahnaz Tahihra (36 Highland Hill, North York, Ontario, CA), Chan; Voon Loong (93 Elm Ridge Drive, Toronto, Ontario, CA) Assignee(s): none reported Patent Number: 6,245,516 Date filed: December 7, 1999 Abstract: Nucleic acid probes and a method for their use in detecting and identifying Campylobacter, Helicobacter, and Arcobacter spp. bacterial pathogens are described. A method for prepg. specific nucleic acid probes for the detection of identification of any other bacterial pathogens is also provided. Excerpt(s): The invention relates to nucleotide probes that are useful in detecting and identifying bacterial pathogens. More particularly, the invention relates to nucleotide probes that are useful in detecting and identifying Campylobacter, Helicobacter and Arcobacter spp. bacterial pathogens. Campylobacter, Helicobacter, and Arcobacter spp. are examples of common human and animal pathogens (Thomas, C. A. et al., 1966). Although the pathogenicity of such bacteria has long been known, their phylogenetic relationships, isolation, detection, identification, and classification by traditional biochemical tests, have been variable and difficult. This is largely due to their fastidious growth requirements, inability to ferment carbohydrates, and diverse growth characteristics which vary, not only between genera and species, but also within species. Thus, their large phenotypic variations have made biochemical tests unreliable as a sole method for identifying and differentiating these bacteria. Many of the species in the genera Helicobacter and Arcobacter were once classified under the genus Campylobacter. However, the phylogenetic relationships of these bacteria have been reevaluated based on information from DNA-DNA hybridization, 23S rRNA-DNA hybridization (Vandamme et al., 1991; Vandamme et al., 1993), and partial 16S rRNA sequences (Li et al., 1993; Patton et al., 1991; Totten et al., 1987). These phylogenetic studies have led to the formation of the current classification of the Campylobacter and Vibrio organisms into Campylobacter, Helicobacter, and Arcobacter. Web site: http://www.delphion.com/details?pn=US06245516__
136
•
Campylobacter
Gene encoding invasion protein of campylobacter species Inventor(s): Chan; Voon Loong (93 Elm Ridge Drive, Toronto, Ontario, CA), Hong; Yuwen (300 Regina Street North, Waterloo, Ontario, CA), Joe; Angela (#1122, 341 Bloor Street West, Toronto, Ontario, CA) Assignee(s): none reported Patent Number: 6,087,105 Date filed: April 8, 1998 Abstract: A protein associated with adherence and invasion of Campylobacter spp. including C. jejuni and C. coli is provided. Methods are disclosed for detecting Campylobacter spp. including C. jejuni and C. coli in a biological sample by determining the presence of the protein or a nucleic acid molecule encoding the protein in the sample. Compositions for treatment of infections diseases and vaccines are also described. Excerpt(s): The invention relates to novel nucleic acid molecules encoding a protein involved in the virulence of bacteria and more particularly of Campylobacter jejuni; the novel proteins encoded by the nucleic acid molecules; and, uses of the proteins and nucleic acid molecules. Campylobacter jejuni (C. jejuni), a gram-negative microaerophilic bacterium, is a leading cause of bacterial diarrhea and enterocolitis in children and adults in both developing and developed countries (Walker R I et al, Microbiol. Rev. 50(1): 81-94, 1986; Kim N W et al, J. Bacteriol. 174(11):3494-3498, 1992; Chan V L and Bingham H L, Gene 101:51-58, 1991). Clinical symptoms of Campylobacter infections range from watery diarrhea to inflammatory dysentery and bloody diarrhea (Cover T L and Blaser N J, Ann. Rev. Ned. 40:269-285, 1989; Walker R I et al, supra). Complications from C. jejuni infections have included Guillain-Barre syndrome, a neurological disease which may lead to respiratory paralysis and death, toxic megacolon, acute mesenteric adenitis syndrome, and reactive arthritis (Kaldor J and Speed B R, British Medical J. 288:1867-1870, 1984; Johnson K et al, Acta. Med. Scand. 214:165-168, 1983; Walker R I et al, supra). C. jejuni is commonly found in surface water, in animals such as cattle, sheep, goats, swine and poultry, in industrial wastes, and in many different types of foods including unpasteurized dairy products. Human pets such as dogs, cats and birds may also be infected with C. jejuni and may transmit the bacterium to humans. (Cover T L and Blaser M J, Ann. Rev. Med. 40:269-285, 1989; and Penner, J. L., Clin. Micro. Rev. 1:157-172, 1988). Web site: http://www.delphion.com/details?pn=US06087105__
•
Identification and molecular cloning of a gene encoding a fibronectin binding protein (CadF) from Campylobacter coli and Campylobacter jejuni Inventor(s): Garvis; Steven G. (Pullman, WA), Konkel; Michael E. (Pullman, WA) Assignee(s): Washington State University Research Foundation (Pullman, WA) Patent Number: 6,156,546 Date filed: May 15, 1998 Abstract: A novel gene encoding a 37 kDa outer membrane protein from Campylobacter coli M275 has been cloned and sequenced. This protein has been named CadF and is expressed in a large number of clinical isolates of Campylobacter species. The invention also provides assays for detecting the presence of pathogenic Campylobacter species
Patents 137
based on the antibody-based detection of CadF, or the polymerase chain reaction (PCR)based amplification of a segment of the C. coli cadF gene. Excerpt(s): Gene encoding an outer membrane protein found in Campylobacter coli and Campylobacter jejuni isolates and methods for detecting virulent Campylobacter spp. This work was supported in part by a grant from the National Institute of Health of the United States government (1R01 DK50567-01A1). The government has certain rights in the invention. Campylobacter species, primarily C. jejuni and C. coli, are recognized as a major cause of gastrointestinal disease (Skirrow and Blaser, 1992), with between 2 to 8 million cases of campylobacteriosis, and an estimated 200 to 800 deaths per year in the United States. Infection with C. jejuni or C. coli is characterized by the sudden onset of fever, abdominal cramps, and diarrhea with blood and leukocytes. These two species of Campylobacter are very closely related. Though they can be differentiated by a biochemical test, clinically they are associated with virtually the same symptoms, and generally are treated with the same antibiotics. In addition to acute gastrointestinal disease, infection with C. jejuni has been shown to be a frequent antecedent to the development of Guillain-Barre-type polyneuropathy (Kuroki et al., 1991; Yuki et al., 1993). Despite the prevalence and complications associated with Campylobacter infections worldwide, relatively few rapid tests are available for the detection of these organisms. Web site: http://www.delphion.com/details?pn=US06156546__ •
Lipopolysaccharide.alpha.-2,3 sialyltransferase of Campylobacter jejuni and its uses Inventor(s): Gilbert; Michel (Hull, CA), Wakarchuk; Warren W. (Gloucester, CA) Assignee(s): National Research Council of Canada (Ottawa, CA) Patent Number: 6,689,604 Date filed: March 18, 1999 Abstract: The structure and specificity of a recombinant.alpha.2,3-sialyltransferase from Campylobacter spp., is disclosed. Also provided are methods for using the.alpha.2,3sialyltransferase in the production of desired carbohydrate structures and nucleic acids that encode the sialyltransferase. Excerpt(s): This invention relates to the field of cloning and expression of sialyltransferase enzymes. In particular, the preferred sialyltransferases are bacterial transferases obtained from, for example, Campylobacter jejuni. Carbohydrates are now recognized as being of major importance in many cell-cell recognition events, notably the adhesion of bacteria and viruses to mammalian cells in pathogenesis and leukocyteendothelial cell interaction through selectins in inflammation (Varki (1993) Glycobiology 3: 97-130). Moreover, sialylated glycoconjugates that are found in bacteria (Preston et al. (1996) Crit. Rev. Microbiol. 22:139-180; Reuter et al. (1996) Biol. Chem. Hoppe-Seyler 377:325-342) are thought to mimic oligosaccharides found in mammalian glycolipids to evade the host immune response (Moran et al. (1996) FEMS Immunol. Med. Microbiol. 16:105-115). Molecular mimicry of host structures by the saccharide portion of lipopolysaccharide (LPS) is considered to be a virulence factor of various mucosal pathogens, which use this strategy to evade a host immune response (Moran et al. (1996) FEMS Immunol. Med. Microbiol. 16: 105-115; Moran et al. (1996) J. Endotoxin Res. 3: 521-531). One such pathogen, Campylobacter jejuni, is an important cause of acute gastroenteritis in humans (Skirrow (1977) Brit. Med. J. 2: 9-11). Epidemiological studies have shown that Campylobacter infections are more common in developed countries
138
Campylobacter
than Salmonella infections, and they are also an important cause of diarrheal diseases in developing countries (Ketley (1997) Microbiol. 143: 5-21). Moreover, C. jejuni infection has been implicated as a frequent antecedent to the development of Guillain-Barre syndrome, a form of neuropathy that is the most common cause of generalized paralysis (Ropper (1992) N. Engl. J. Med. 326: 1130-1136). The C. jejuni serotype most commonly associated with Guillian-Barre syndrome is O:19 (Kuroki et al. (1993) Ann. Neurol. 33: 243-247). The core oligosaccharides of low molecular weight LPS of O:19 strains exhibit molecular mimicry of several gangliosides (Aspinall et al. (1994) Biochemistry 33: 241249; Aspinall et al. (1994) Biochemistry 33: 250-255). Terminal oligosaccharide moieties identical to those of GD.sub.1a, GD.sub.3, GM.sub.1 and GT.sub.1a gangliosides have been found in various O:19 strains. The significance of molecular mimicry as a virulence factor makes the identification of the genes involved in LPS synthesis and the study of their regulation of considerable interest for a better understanding of the pathogenesis mechanisms used by these bacteria. Web site: http://www.delphion.com/details?pn=US06689604__ •
Livestock mucosal competitive exclusion culture to reduce enteropathogenic bacteria Inventor(s): Bailey; J. Stan (Athens, GA), Cox; Nelson A. (Athens, GA), Cray; Paula J. (Ames, IA), Stern; Norman J. (Athens, GA) Assignee(s): The United States of America as represented by the Secretary of Agriculture (Washington, DC) Patent Number: 6,214,335 Date filed: June 26, 1998 Abstract: A preparation from the scrapings of healthy animals is cultured and administered to animals. This preparation confers a strong measure of protection against the subsequent colonization by enteropathogenic bacteria, including Salmonella species, Campylobacter species and Escherichia coli 0157:H7, which currently cause an unacceptably high incidence of morbidity and mortality in humans and reduce productivity in livestock populations. Excerpt(s): This invention relates to a bacterial culture prepared from the intestinal tract of pathogen-free mammalian animals. It also relates to subcultures of such cultures and to methods of using the subcultures to protect livestock from colonization by enteropathogenic bacteria. Enteropathogens, such as Salmonella and Escherichia coli 0157:H7, cause an unacceptably high incidence of morbidity and mortality in humans and may reduce productivity in livestock populations. Gastrointestinal pathogens in humans are typically derived from intestinal contamination of meats that humans consume. At a symposium on Tracking Foodborne Pathogens from Farm to Table: Data Needs to Evaluate Control Groups held in January, 1995, a question asked was "How important are foodborne diseases?" (Tracking Foodborne Pathogens from Farm to Table: Data Needs to Evaluate Control Groups, Washington, D.C., 3-29, 1995). It was stated that in the United States, there are an estimated 6.5 million to 33 million cases of foodborne diseases each year, resulting in up to 9,000 deaths. The USDA Economic Research Service estimates U.S. medical costs and productivity losses for seven foodborne pathogens at $5.6 billion to $9.4 billion annually. Menning estimates that there are over 5 million cases of meat and poultry foodborne diseases in the United States per year and a large percentage is attributable to Salmonella and Campylobacter infections (J. Am. Vet. Med. Assoc., Volume 192, 494-497, 1988). Roberts estimates that each case of salmonellosis costs $700 (Amer. J. Agr. Econ., Volume 71, 468-474, 1989).
Patents 139
Based on surveys estimating foodborne disease in other countries, it would not be unreasonable to project that the number of worldwide foodborne diarrheas per year attributable to Salmonella probably exceeds 100 billion with an estimated cost exceeding 25 billion dollars. These pathogens also account for pain, suffering and loss of life. In addition, enteropathogenic bacteria may also cause substantial economic loss through infection of livestock. Competitive exclusion (CE) techniques are used for decreasing colonization of enteropathogenic bacteria in poultry. Nurmi et al (Nature, Volume 241, 210-211 1973) found that preparations from mature, healthy chickens conferred protection to young chicks, whose microflora had not yet been established, against Salmonella colonization. Administration of undefined CE preparations to chicks speeds the maturation of gut flora in newly-hatched birds and provides a substrate for the natural process of transmission of microflora from the adult hen to its offspring. Web site: http://www.delphion.com/details?pn=US06214335__ •
Method for detecting enteric disease Inventor(s): Moore; Norman (North Berwick, ME), Tarr; Phillip I. (Seattle, WA) Assignee(s): Binax, Inc. (Portland, ME) Patent Number: 6,727,073 Date filed: November 19, 1999 Abstract: A method for determining and diagnosing inflammatory enteric disease using an immunochromatographic test device having a multiplicity of test zones. The method tests for the presence of at least one enteric pathogen and at least one of certain inflammatory enteric disease markers. The enteric pathogens tested for can be any number of enteric pathogens such as the pathogens E. coli O157, Campylobacter, Salmonella, Listeria, Shigella, and Yersinia. The inflammatory enteric disease markers tested for are fecal lactoferrin, a bacteria marker, a virus marker, and a protozoa marker. Positive results for any one of the pathogens indicates that pathogen as the cause of the inflammatory enteric disease. Positive results for fecal lactoferrin indicate an inflammatory condition of the intestines. Positive results for the bacteria, virus, protozoa markers indicate respectively a bacterial, viral, or protozoan cause of infection as the cause of the disease. Liquid fecal sample is mixed with a mixture containing antibodies to the pathogens and the markers. These antibodies are conjugated to a label. Each test zone on the test device has immovably fixed upon it a complementary antibody that binds specifically with one of the labeled antibodies in the mixture. Positive results appear as a stripe across the corresponding test zone. Excerpt(s): The present invention relates to the field of immunochromatographic assays. More particularly, the present invention relates to a method for detecting enteric pathogens in fecal specimens. More particularly yet, the present invention relates to a method for detecting the presence of one or more specific enteric pathogens from the simultaneous assay for several enteric pathogens. Most particularly, the present invention relates to a method for detecting the presence or absence of several enteric pathogens and concurrently applying one or more general tests for an inflammatory condition of the intestines. Enteric pathogens can cause severe illness in people and affect a large number of people within a short period of time. The U.S. Centers for Disease Control estimates that there are five million cases of foodborne illnesses per year in the United States with up to 5,000 deaths. Campylobacter jejuni and Salmonella are the leading causes of foodborne illnesses; E. coli O157 is less frequent, but is significant in disease control because this strain of E. coli, the most noted of the enterohemorrhagic
140
Campylobacter
E. coli bacteria, causes the majority of severe disease from E. coli and is also a cause of large epidemics. Other strains of E. coli, such as O111, have also been implicated in foodborne outbreaks. Although the number of illnesses from E. coli O157 is low relative to the numbers of cases of Campylobacter jejuni or Salmonella, this E. coli pathogen is significant because the rate of mortality is much higher and the treatment significantly different. Some antibiotics can have a detrimental effect on patient health if the patient is suffering from an illness caused by an enterohemorrhagic E. coli that has not been diagnosed. For this reason, before prescribing antibiotics for a patient apparently suffering from an illness caused by a pathogen, it is important to determine whether E. coli bacteria is the cause in order to avoid prescribing medication detrimental to the health of the patient. Rapid determination of the cause of the illness is thus a critical factor in providing the timely and proper care of the ill. Moreover, it is critical to determine the possible sources of contamination as quickly as possible in order to take appropriate steps to eliminate them. A method to rapidly screen patients for enteric illnesses would greatly increase the ability of medical personnel to accurately diagnose the cause of the illness and provide appropriate treatment, thus accelerating the rate of patient recovery. Furthermore, a method for rapid screening for enteric pathogens also has great economic value because it can focus valuable resources. For example, rapid screening can be used to rule out certain pathogens as a cause of illness before making the decision to use the more costly methods of culturing a specimen for a pathogen that cannot be readily detected by a rapid screening device. Use of a method for rapidly screening patients for enteric illnesses that can be performed reliably by unskilled persons is also a more cost-effective use of personnel resources than the use of a method that requires the attention of skilled personnel. Web site: http://www.delphion.com/details?pn=US06727073__ •
Method for the culture of microorganisms of the genera helicobacter, campylobacter and arcobacter employing culture media comprising cyclodextrins Inventor(s): Bugnoli; Massimo (Monteriggioni, IT), Figura; Natale (Monteriggioni, IT), Olivieri; Roberto (Costalpino, IT), Rappuoli; Rino (Monteriggioni, IT) Assignee(s): Chiron S.p.A. (IT) Patent Number: 5,866,375 Date filed: June 6, 1995 Abstract: Method for the culture of microorganisms of the genera Helicobacter, Campylobacter and Arcobacter, wherein culture media are employed, which comprise, in place of blood or its derivative, cyclodextrins. Excerpt(s): The present invention relates to a method for the culture of microorganisms of the genera Helicobacter, Campylobacter and Arcobacter, wherein culture media are employed which comprise cyclodextrins. The culture on industrial scale of microorganisms of the genera Helicobacter, Campylobacter and Arcobacter is getting more and more important both for the production of relevant amounts of the same microorganisms and because of the importance of the products which can be produced during the fermentation culture or still for the manufacture of cheap media suitable for the primary isolation of microorganisms belonging to the aforementioned genera. With regard to the importance attained by the above cited microorganisms, it should be considered, for instance, that the Helicobacter pylori is recognized as the aetiological agent of type B gastritis, likely the second most disseminated chronic infection in the world after dental caries, and as co-agent of peptic ulcer. Infection with Helicobacter
Patents 141
pylori has also been associated with increased risk for gastric carcinoma, a disease which may be responsible for one million deaths annually. Forman, et al., Br. Med. J., 302: 1302-1305, 1991. The microbial etiology of these diseases indicates that they might be prevented through vaccination. It is therefore evident that a more developed knowledge of the physiological and pathological properties of said microorganism, knowledge that at present is still very poor due to the difficulty involved in the cultivation, and the large scale cultivation of such microorganism, should be of extreme importance. The cultures of H. pylori are usually carried out by adding to the culture media blood or derivatives thereof (serum, red cells etc.), yolk in concentration ranging between 5% and 20%. Said additives, obviously, cannot be employed on industrial scale because of the drawbacks deriving therefrom for the purification of the culture products, drawbacks which moreover involve high costs for the industry. It is therefore extremely interesting to avail a culture media wherein blood and derivatives thereof are replaced, entirely or partially, by products which do not bring about the above cited disadvantages, without compromising the culture yield though. Web site: http://www.delphion.com/details?pn=US05866375__ •
Methods for detecting and enumerating Campylobacter jejuni in environmental samples and for identifying antibiotic-resistant strains Inventor(s): Kaneene; John B. (East Lansing, MI), Linz; John E. (East Lansing, MI), Mansfield; Linda S. (Bath, MI), Newman; Thomas C. (Haslett, MI), Walker; Robert D. (Laurel, MD), Wilson; David L. (Grand Ledge, MI) Assignee(s): Board of Trustees of Michigan State University (East Lansing, MI) Patent Number: 6,355,435 Date filed: September 6, 2000 Abstract: The present invention provides a process for detecting and enumerating Campylobacter jejuni in an environmental sample. The present invention further provides a process which can distinguish antibiotic resistant strains of Campylobacter jejuni from wild-type strains, in particular, antibiotic-resistant strains resistant to high levels of ciprofloxacin. Both processes use PCR primers which flank a target sequence unique to Campylobacter jejuni in combination with one or more dual-labeled oligonucleotide probes complementary to the target sequence wherein the dual-labeled probes enable detection of PCR amplification by fluorescence detection means. Excerpt(s): Not applicable. The present invention relates to a process for detecting and enumerating Campylobacter jejuni in an environmental sample. The present invention further relates to a process which can distinguish antibiotic resistant strains of Campylobacter jejuni from wild-type strains, in particular, antibiotic-resistant strains resistant to high levels of ciprofloxacin. Both processes relate to PCR primers which flank a target sequence unique to Campylobacter jejuni in combination with one or more dual-labeled oligonucleotide probes complementary to the target sequence wherein the dual-labeled probes enable detection of PCR amplification by fluorescence detection means. Campylobacter spp. is the leading cause of gasterial enteritis in the United States, affecting millions of people annually. Of the people affected, Campylobacter jejuni represents the etiological agent for a large proportion of the clinical cases of Campylobacter infections in human patients. Campylobacter is a gram negative microaerophilic pathogen of both humans and animals. In humans, Campylobacter infection is characterized by acute diarrheal disease, and more recently, has been associated with Guillain Barre Syndrome, a peripheral neuropathy
142
Campylobacter
characterized by limb weakness, and other neurological and systemic sequelae (Hughs et al., J. Infect. Dis. 176(Suppl. 2): S92-S98 (1997); Blaser, J. Infect. Dis. 176(Suppl.): S103S105 (1997)). Web site: http://www.delphion.com/details?pn=US06355435__ •
Nucleotide sequence hybridizing specifically with a genomic nucleic sequence of campylobacter Inventor(s): Guesdon; Jean-Luc (Sevres, FR), Stonnet; Veronique (Asnieres, FR) Assignee(s): Institut Pasteur (Paris Cedex, FR) Patent Number: 5,998,138 Date filed: July 1, 1997 Abstract: The present invention relates to a nucleic acid sequence isolated from C. coli which hybridizes specifically with the genomic nucleic acid of strains belonging to the species C. coli and which does not hybridize under the usual conditions with the nucleic acids of campylobacteria which do not belong to this species, nor with the genomic nucleic acids of bacteria related to the genus Campylobacter. Excerpt(s): The present invention relates to a specific nucleic sequence of Campylobacter coli, as well as to applications of this sequence as specific nucleotide probe for the detection of sequences of Campylobacter coli or of fragments of this sequence as nucleotide primers for the amplification of DNA or RNA of Campylobacter coli in a biological specimen. Campylobacter infections are very common all over the world, affecting man as well as wild or domestic animals. Although discovered at the start of the twentieth century, the bacteria now called Campylobacter were unrecognized for a long time, because their characteristics rendered their identification and their culture difficult. First isolated in sheep and cattle and called Vibrio fetus and then, later, Campylobacter fetus, it was not until the start of 1946 that the first cases of human campylobacterioses were described, but it was not until the start of 1972, when selective media for Campylobacter had begun to be perfected, that the importance of Campylobacter infections had been able to be proved and recognized. Web site: http://www.delphion.com/details?pn=US05998138__
•
Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastrointestinal diseases Inventor(s): Athanikar; Narayan (Irvine, CA) Assignee(s): Josman Laboratories (Irvine, CA) Patent Number: 6,379,651 Date filed: July 29, 1999 Abstract: The invention relates to concomitant treatment with bismuth compounds, other antibacterial compounds, and/or antibiotics in oral-topical and peroral dosage forms to eradicate H. pylori from its niches both in the dental plaque and in the gastric mucosa in order to improve the ulcer cure rate and prevent ulcer relapse. The invention also provides oral topical dosage forms with pharmaceutically usable bismuth compounds, other antibacterial compounds, and/or antibiotics that eradicate or reduce
Patents 143
H. pylori in dental plaque. The invention further provides for treatment with bismuth compounds, other antibacterial compounds, and/or antibiotics which are effective against Campylobacter rectus and Treponema denticola which are responsible for causing halitosis. The invention also provides bismuth compounds which have applications in wound healing, particularly in ocular and dermal wound healing. Excerpt(s): Until recently, excessive gastric acidity and mental stress were thought to be major pathophysiological reasons for occurrence of peptic ulcers. In the early 1980s, Marshall and Warren (Warren, Lancet, 1:1273-1275, 1983 and Marshall et al., Lancet, 2:1311-1315, 1984) first reported an unidentified curved bacilli in the stomach of patients with gastritis and peptic ulcers. These bacilli, which later were identified as gram negative spiral bacteria and named Helicobacter pylori (Goodwin et al., Int. J. Syst. Bacteriol. 39:397-405, 1989), have been demonstrated to be associated with gastritis and peptic ulcers (Buck et al., J. Infect. Dis. 153:664-669, 1986 and Graham, Gastroenterology 96:615-625, 1989), and are thought to be transmitted by person-to-person contact. Recent clinical investigations have shown a definite presence of H. pylori in the dental plaque (Nguyen et al., Journal of Clinical Microbiology 31(4):783-787, 1993; Desai et al., Scandinavian Journal of Gastroenterology 26:1205-1208, 1991; and Lambert et al., Lancet 341(8850):957, 1993), and have also shown that standard oral hygiene practice does not help reduce H. pylori presence in the oral cavity (Nguyen et al., Journal of Clinical Microbiology 31(4):783-787, 1993). As a result of these recent discoveries associating bacterial infection in the causation of peptic ulcer disease, questions regarding the previously established paradigms of ulcer treatment and healing processes have been raised. H.sub.2 receptor blockers which suppress acid secretion, such as cimetidine (Tagamet.RTM.) and ranitidine (Zantac.RTM.), have been used to treat and heal duodenal ulcers (Jones et al., Gut. 28:1120-1127, 1987; McIsaac et al., Aliment. Pharmacol. Therap. 1:369-381, 1987; and Boyed et al., Amsterdam:Excerpta Medica, 1442, 1984). Recently, however, a number of clinical investigations have demonstrated that 70-80% of healed duodenal ulcers reoccur within the next year (Goodwin et al., Int. J. Syst. Bacteriol 39:397407, 1989), and that these drugs do not reverse the tendency for ulcers to form (Wormsley, British Medical Journal 293:1501, 1986; Gudman et al., British Medical Journal i:1095-1097, 1978; and Bardhan et al., British Medical Journal 284:621623, 1982). Web site: http://www.delphion.com/details?pn=US06379651__ •
Polynucleic acid sequences for use in the detection and differentiation of prokaryotic organisms Inventor(s): Giesendorf; Belinda (Nijmegen, NL), Quint; Wilhelmus (Nootdorp, NL), Van Doorn; Leendert-Jan (Ridderkerk, NL) Assignee(s): Delft Diagnostic Laboratory B.V. (Delft, NL), Innogenetics N.V. (Ghent, BE) Patent Number: 6,221,582 Date filed: August 7, 1997 Abstract: The invention relates to the use of the GTPase gene family as a target for nucleic acid based assays for the detection and differentiation of prokaryotic organisms. The invention relates to polynucleic acids derived from gene sequences encoding prokaryotic GTPase (=GTP-binding) proteins, as well as their use in the detection and identification of prokaryotic organisms; primers and probes derived from said polynucleic acid sequences, for specific amplification and detection of prokaryotic DNA in a biological sample; as well as methods and kits allowing the detection and
144
Campylobacter
identification of at least one micoroorganism, and preferentially several microorganisms simultaneously in a sample. More specifically, the invention relates to new polynucleic acid sequences encoding GTPase proteins from Campylobacter species, primers and probes derived from them, and methods and kits comprising these reagents for the detection and differentiation of species belonging to the genus Campylobacter. Excerpt(s): The present invention relates to the use of the GTPase gene family as a target for nucleic acid based assays for the detection and differentiation of prokaryotic organisms. The present invention relates to polynucleic acids derived from gene sequences encoding prokaryotic GTPase (=GTP-binding) proteins, as well as their use in the detection and identification of prokaryotic organisms; primers and probes derived from said polynucleic acid sequences, for specific amplification and detection of prokaryotic DNA in a biological sample; as well as methods and kits allowing the detection and identification of at least one micro-organism, and preferentially several micro-organisms simultaneously in a sample. More specifically, the invention relates to new polynucleic acid sequences encoding GTPase proteins from Campylobacter species, primers and probes derived from them, and methods and kits comprising these reagents for the detection and differentiation of species belonging to the genus Campylobacter. Web site: http://www.delphion.com/details?pn=US06221582__ •
Poultry house litter treatment Inventor(s): Bartlett; Stephen L. (5310 Cendronella Rd., Chapel Hill, NC 27514), Logan; Walter T. (Postal Rte. 1, Box 160, Buena Vista, VA 24416) Assignee(s): none reported Patent Number: 6,017,525 Date filed: March 30, 1998 Abstract: A dry composition containing large numbers of beneficial bacteria and enzymes for the digestion of poultry manure is used to treat poultry litter. The growth of the beneficial bacteria, activated by moisture in poultry droppings prevents the growth of pathogenic bacteria such as E. coli, Salmonella and Campylobacter by competitive exclusion. Excerpt(s): The present invention is directed to a dry mixture of bacteria and enzyme used in poultry house litter treatment floor ammonia control and increased growout productivity of the poultry. Poultry house litter is treated with acidic material which neutralize basic ammonium compound to prevent the release of ammonia. While useful for the intended purpose, acidic materials have harmful side effects. To eliminate the harmful side effects, the present inventors developed a bacteria-enzyme mixture that is suspended in water and sprayed onto the chicken litter at frequent intervals to digest the ammonia compounds and reduce the ammonia emissions. The composition of the liquid product is a trade secret. Web site: http://www.delphion.com/details?pn=US06017525__
Patents 145
•
Process for producing GM1 specific antibodies Inventor(s): Old; Lloyd J. (New York, NY), Ritter; Gerd (New York, NY) Assignee(s): Ludwig Institute For Cancer Research (New York, NY) Patent Number: 5,854,007 Date filed: April 24, 1997 Abstract: The invention relates to the production of ganglioside specific antibodies. These antibodies are produced following immunization with lipopolysaccharide antigen of Campylobacter jejuni. The antibodies bind to monosialogangliosides, including GM2 and GM1. Excerpt(s): This invention relates to the making of antibodies against glycolipids, and the uses of these antibodies. More particularly, it relates to processes for making antibodies specific to the monosialogangliosides known as "GM2" and "GM1", as well as the uses of these antibodies. The uses include diagnostic and screening applications, as well as therapeutic modalities. Gangliosides are a class of molecules which are glycolipids. Different gangliosides have been identified as prominent cell surface constituents of various transformed cells, including melanoma, as well as other tumors of neuroectodermal origin. See, e.g., Ritter and Livingston, et al., Sem. Canc. Biol. 2: 401409 (1991). Oettgen, VCH Verlags Gesellschaft (Weinheim Germany 1989), incorporated by reference in their entirety. Gangliosides are known as mono-, di-, tri or polysialogangliosides, depending upon the degree of glycosylation with sialic acid residues. Abbreviations employed to identify these molecules include "GM1", "GD3", "GT1", etc., with the "G" standing for ganglioside, "M", "D" or "T", etc. referring to the number of sialic acid residues, and the number or number plus letter (e.g., "GT1a"), referring to the binding pattern observed for the molecule. See Lehninger, Biochemistry, pg. 294-296 (Worth Publishers, 1981); Wiegandt, in Glycolipids: New Comprehensive Biochemistry (Neuberger et al., ed., Elsevier, 1985), pp. 199-260. Web site: http://www.delphion.com/details?pn=US05854007__
•
Saccharomyces boulardii treatment to diminish campylobacter and salmonella in poultry Inventor(s): Bailey; J. Stan (Athens, GA), Cox; Nelson A. (Athens, GA), Line; J. Eric (Athens, GA), Stern; Norman J. (Athens, GA) Assignee(s): The United States of America, as represented by the Secretary of (Washington, DC) Patent Number: 6,010,695 Date filed: August 9, 1996 Abstract: A preparation of Saccharomyces strains is used for reducing colonization by human enteropathogenic bacteria in poultry. This is referred to as a defined competitive exclusion preparation. It is especially effective for both Salmonella and Campylobacter. Excerpt(s): This invention relates to a method for reducing the presence of human enteropathogenic bacteria in poultry. The consumption of improperly prepared poultry products has resulted in numerous cases of human intestinal diseases. It has long been recognized that Salmonella spp. are causative agents of such diseases, and more recently Campylobacter spp., especially Campylobacter jejuni, has also been implicated. As many as two million cases of salmonellosis occur annually in the United States (Stavric
146
Campylobacter
et al., Journal of Food Protection, Volume 56, No. 2, 173-180, February 1993); twice as many cases of campylobacteriosis are thought to occur (Krienberg et al., Food Technology, pages 77, 80, 81, and 98, July 1987). Both microorganisms may colonize poultry gastrointestinal tracts without any deleterious effects on the birds and, although some colonized birds can be detected, asymptomatic carriers can freely spread the microorganisms during production and processing, resulting in further contamination of both live birds and carcasses. Poultry serves as the primary reservoir for Salmonella and Campylobacter in the food supply (Jones et al., Journal of Food Protection, Volume 54, No. 4, 259-262, April 1991; Jones et al., Journal of Food Protection, Volume 54, No. 7, 502-507, July 1991). The intestinal contents of chickens may harbor up to 10.sup.7 Campylobacter and/or Salmonella per gram, and cross contamination during processing is frequent (Oosterom et al., Journal of Food Protection, Volume 46, No. 4, 339-344, April 1983). Studies have demonstrated that fecal material constitutes the major source from which edible parts of chickens are contaminated in processing plants. Therefore, to significantly reduce the level of contamination on processed poultry, pathogen-free or nearly pathogen-free birds must be delivered to the processing plant, (Bailey, Poultry Science, Volume 72, 1169-1173, 1993). Better control measures are needed to minimize the spread of these and other human enteropathogenic bacteria; and the most promising approach to achieve this end has been to decrease the incidence and level of colonization by these microorganisms in poultry gastrointestinal tracts. To date, the most effective means for controlling Salmonella colonization is competitive exclusion (CE). Although the exact mechanism of CE protection is unclear, it is likely to be influenced by factors such as pH, Eh, production of inhibitory substances such as H.sub.2 S, bacteriocins, fatty acids, and conjugated bile acids; competition for nutrients and receptor sites; and local immunity (Mead et al., Letters in Applied Microbiology, Volume 10, 221-227, 1990). Competitive exclusion treatment involves introduction of intestinal flora from pathogen-free adult birds into newly hatched chicks. A study by Nurmi et al. (Nature, Volume 241, 210-211, Jan. 19, 1973), first reported the use of the competitive exclusion technique. The reference discloses inoculation of 1 to 2 day old chicks by oral gavage with a 1:10 dilution of normal intestinal contents from healthy adult birds. One day later, the chicks were challenged with Salmonella. After 8-22 days, the birds were examined for the presence of Salmonella. It was found that only 33% of the treated birds were colonized with Salmonella whereas 100% of the untreated birds were colonized with Salmonella. Originally, a suspension of crop and intestinal tract materials obtained from healthy, adult birds was used. In later studies, cecal content was cultured anaerobically in a liquid medium. It was found that preparations of subcultured intestinal contents from healthy, adult birds conferred protection to young chicks whose intestinal or gut microflora had not yet been established. Administration of undefined CE preparations to chicks speeds up the maturation of the gut flora in the newly-hatched birds and also provides a substitute for the natural process of transmission of microflora from the adult hen to its offspring. Snoeyenbos et al., U.S. Pat. No. 4,335,107 (1982) developed a technique designed to reduce salmonellae in poultry where the source of CE microflora was lyophilized fecal droppings which were propagated by anaerobic culture. Mikkola et al., U.S. Pat. No. 4,657,762 (1987) discloses the use of intestinal fecal and cecal contents as a source of CE microflora. Treatment with their culture required media to be anaerobic and pH balanced. Neither of these CE treatments addressed Campylobacter. Web site: http://www.delphion.com/details?pn=US06010695__
Patents 147
•
Selective media for recovery and enumeration of campylobacters Inventor(s): Garrish; Johnna Kennedy (Hull, GA), Glassmoyer Pearson; Kirsten Elizabeth (Athens, GA), Line; John Eric (Watkinsville, GA) Assignee(s): The United States of America, as represented by the Secretary of (Washington, DC) Patent Number: 6,368,847 Date filed: June 1, 2000 Abstract: A composition for recovery and enumeration of Campylobacter species that includes a selective Campylobacter medium plus an indicator, 2,3,5triphenyltetrazolium chloride. Improved selective media including the indicator, contains a nutrient medium with an energy source, agar, a reducing agent, and selective agents. The selective agents are a mixture of agents selected from cycloheximide, cefoperazone, vancomycin, trimethoprim, polymyxin B; rifampicin, amphotericin, cefoperazone, vancomycin, trimethoprim, and nystatin. The salts of these agents are also useful. Excerpt(s): This invention relates to media containing an indicator, 2,3,5triphenyltetrazolium chloride, and a selective agent composition; and methods for the recovery and enumeration of Campylobacter species. Campylobacter species have been recognized as important causative agents of foodborne illness. There is a strong association of foods of animal origin in the transmission of disease to humans. Poultry is one such food with high carriage rates of Campylobacter contamination. Campylobacter jejuni, C. coli and C. lari are known to cause an estimated 2.2 million cases of foodborne gastroenteritis per year in the United States alone (Tauxe et al., American J. Public Health, Volume 77, 1219-1221, 1987). The vast majority of these cases are associated with the consumption of improperly prepared or handled foods. Although the origin of this disease in humans is primarily linked to poultry, the food microbiology and poultry communities have been slow in directing substantive attention toward the organism. This has been due, in part, to the unique physiological requirements of these organisms, impairing their culture and identification from foods and clinical specimens. A variety of enrichment and culture media have been proposed for the isolation of Campylobacter species (Park et al., Campylobacter, In: Compendium of Methods for the Microbiological Examination of Foods, second ed., M. L. Speck (ed.), Am. Pub. Hlth. Assoc., Wash., D.C., 386-404, 1984--the contents of which are herein incorporated by reference). Because Campylobacter can be overgrown by other organisms present in sources, the use of selective media, incorporating antibiotics and/or antimicrobial agents, is essential for their isolation. Ideally, any culture medium selected should also be differential, allowing the characterization of the Campylobacter by distinctive colonial appearances in culture. Web site: http://www.delphion.com/details?pn=US06368847__
148
•
Campylobacter
Vaccine containing a campylobacter bacterium having an enhanced antigenic property Inventor(s): Frey; Steven Michael (Germantown, MD), Pace; John Lee (Germantown, MD), Walker; Richard Ives (Gaithersburg, MD) Assignee(s): Antex Biologics Inc. (Gaithersburg, MD) Patent Number: 5,869,066 Date filed: May 30, 1997 Abstract: This invention relates generally to in vitro methods for inducing or enhancing expression of enteric bacterial antigens and/or virulence factors thereby producing antigenically enhanced enteric bacteria, to methods for using antigenically enhanced enteric bacteria and to vaccines comprising antigenically enhanced enteric bacteria. Further, a vaccine comprising a Campylobacter bacterium having en enhanced antigenic property is disclosed. The culture medium conditions comprise 0.05% to 3% bile or 0.025% to 0.6% of one or more bile acids or salts. In addition a divalent cation chelator can also be included in the culture medium. The bacteria culture is in a growth phase at early log phase and between early log phase and stationary phase. The enhanced antigenic property is a higher level of an immunogenic antigen when compared to the antigenic property of the same bacteria grown on brain heart infusion broth. Excerpt(s): It is widely recognized that bacteria cultured in vitro using conventional media and conditions express characteristics that are different from the characteristics expressed during growth in their natural habitats, which includes in vivo growth of normal microflora or pathogens in an animal host. Therefore, such in vitro grown pathogenic bacteria might not be good for use as vaccine components. However, if it were possible to define conditions that trigger or enhance expression of virulence factors, relevant physiology, or antigens including outer-surface antigens then important products and therapeutics (e.g., new antigens for vaccines, new targets for antibiotics, and novel bacterial characteristics for diagnostic applications) could be rapidly identified. Several environmental factors have been identified which influence expression of virulence determinants in bacteria (Mekalanos, J. J., J. Bacteriol. 174:1-7, 1992). For instance, there is a long history of research on the relationship between iron and virulence of bacteria, in particular Shigella (Payne, Mol. MicroBiol., 3:101-1306, 1989), Neisseria (Payne and Finkelstein, J. Clin. Microbiol., 6:293-297, 1977) and Pasteurella (Gilmour, et al., Vaccine, 9:137-140, 1991). Web site: http://www.delphion.com/details?pn=US05869066__
Patent Applications on Campylobacter As of December 2000, U.S. patent applications are open to public viewing.9 Applications are patent requests which have yet to be granted. (The process to achieve a patent can take several years.) The following patent applications have been filed since December 2000 relating to campylobacter:
9
This has been a common practice outside the United States prior to December 2000.
Patents 149
•
Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens Inventor(s): Lin, Angeline Seah Huay; (Singapore, SG), Meng, Tan Hai; (Singapore, SG), Teo, Alex Yeow-Lim; (Singapore, SG) Correspondence: Kent A. Herink; The Financial Center, Suite 2500; 666 Walnut Street; Des Moines; IA; 50309-3993; US Patent Application Number: 20040101525 Date filed: November 27, 2002 Abstract: Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens. A novel strain of Bacillus subtilis was isolated from the gastrointestinal tract of poultry and was found to produce a factor or factors that have excellent inhibitory effects on Clostridium perfringens, Clostridium difficile, Campylobacter jejuni, Campylobacter coli, and Streptococcus pneumoniae. The factor(s) retain full viability and antimicrobial activity after heat treatment. The invention provides a method of treatment of pathogenic microorganisms including C. perfringens. Excerpt(s): This invention relates generally to antimicrobial compounds and, more specifically, to antimicrobial compounds from Bacillus subtilis PB6 for use against animal and human pathogens. Necrotic enteritis, an enterotoxemic disease caused by Clostridium perfringens leads to the development of necrotic lesions in the gut wall resulting in mortality of poultry (Paulus and Ruckebusch, 1996; Tsai and Tung, 1981). It is also a multifactorial disease with complex and partly unknown epidemiology and pathogenesis (Kaldhusdal, 2000). The bacterium, C. perfringens is commonly found in the gastrointestinal tract of poultry (Tshirdewahn et al. 1991), the occurrence of necrotic enteritis, is however sporadic (Cowen et al., 1987). Nevertheless, feed contaminated with C. perfringens has been implicated in outbreaks of necrotic enteritis in chickens (Kaldhusdal, 2000). Studies have also shown that healthy chickens have a relatively low number of C. perfringens in their gastrointestinal tracts, while an increase in the concentration of the bacteria can result in a necrotic enteritis condition (Craven et al., 1999). The use of bacitracin, linocomycin and other growth promoting antibiotics are commonly used to treat poultry suffering from necrotic enteritis (Craven et al., 1999). However, due to the isolation of antibiotic-resistant strains of C. perfringens from chickens and turkeys (Devriese et al., 1993; Kondo, 1988; Watkins et al., 1997), poultry health authorities and producers are increasingly interested in the development and application of probiotic products to replace antibiotics. Probiotics have been defined as a live microbial feed supplement that beneficially affects the host by improving its intestinal microbial balance. Some researchers believe that this normalization of the intestinal microbiota will confer the following benefits: (a) protection against pathogens by competitive exclusion (also termed colonization resistance); (b) provision of certain nutrients and enzymatic/detoxification reactions; (c) involvement in tissue morphogenesis and peristaltic activity; and (d) interaction with the immune and endocrine systems of the host. Furthermore, in the light of rising necrotic enteritis in poultry and the progressive ban of various feed antibiotics by many countries (Council of the European Communities, 1998), there is a shift towards alternative growth promoters (AGP) to enhance animal performance. Beneficial microorganisms, such as yeast or lactic acid bacteria have been used in animal production for the last two decades. Bacteria with probiotic attributes have the primary function of maintaining healthy gut microflora by replacing or displacing the pathogenic bacteria in the intestinal tract. It has been known that probiotics could maintain "normal" intestinal
150
Campylobacter
microflora through competitive exclusion (Toumot, 1989) and antagonistic action against pathogenic bacteria in the animal intestine (Fuller, 1989). Generally, probiotic microorganisms could proliferate in large numbers within the gut, thus inhibiting the multiplication of pathogenic bacteria. Probiotic microorganisms that have potential uses in humans or animals include Bacillus spp., Lactobacillus spp., Enterococcus spp. and Streptococcus spp. (Lee et al., 1999). Various microorganisms have been reported to be able to colonize different parts of the gastrointestinal tract (Jin et al., 1997). Generally, the duodenum portion of the gastrointestinal tract has the lowest population of bacterial microflora compared to the cacca, which has the highest concentration of microorganisms (Mead and Adams, 1975; Salanitro et al., 1974). Microorganisms, such as Lactobacillus spp., Streptococcus spp. and Escherichia coli have been isolated from the duodenum, jejunum and ileum portions of the small intestine (Shapiro and Sarles, 1949). The general microbial population of the caeca comprises obligate anaerobes such as Streptococcus spp., Staphylococcus spp., Lactobacillus spp., Fusobacterium spp. and Bacteroides (Barnes et al., 1972; Mead, 1997). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Anti-sigma28 factors in Helicobacter pylori, Campylobacter jejuni and Pseudomonas aeruginosa and applications thereof Inventor(s): Colland, Frederic; (Fosses, FR), De Reuse, Hilde; (Paris, FR), Labigne, Agnes; (Bures-sur-yvette, FR), Legrain, Pierre; (Paris, FR), Rain, Jean-Christophe; (Puteaux, FR) Correspondence: Lerner, David, Littenberg,; Krumholz & Mentlik; 600 South Avenue West; Westfield; NJ; 07090; US Patent Application Number: 20020192796 Date filed: January 31, 2002 Abstract: Disclosed are polypeptides named HP1122, Cj1464 and PA3351 which are the anti-.sigma.sup.28 factor of Helicobacter pylori, Campylobacter jejuni and Pseudomonas aeruginosa, respectively and fragments and variants thereof. Also disclosed is a polypeptide named SID1122 which is the domain of Helicobacter pylori's HP1122 polypeptide involved in a specific interaction with Helicobacter pylori.sigma.sup.28 (HP1032) and which has an anti-.sigma.sup.28 factor activity. Further disclosed are a SID1122 polypeptide that interacts with HP1032, identification of the HP1032 interacting domain (SID1032) that is specifically involved in the interaction with HP1122, complexes of two polypeptides such as HP1122-HP1032, or SID1122SID1032, fragments and variants of the SID1122 and SID1032 polypeptides, antibodies to the SID1122 and SID1032 polypeptides, methods for screening drugs or agents which modulate the interaction of Helicobacter pylori's polypeptides encoded by HP1122 and HP1032, and pharmaceutical compositions for treating or preventing Gram negative flagellated bacteria infection in a human or mammal, more specifically Helicobacter sp. or Campylobacter jejuni or Pseudomonas aeruginosa infection, in particular Helicobacter pylori infection in a human or a mammal. Excerpt(s): The present application claims priority to U.S. provisional application No. 60/265,465 filed Jan. 31, 2001. Helicobacter pylon (H. pylori) is a microaerophilic, Gram negative, slow growing spiral shaped and flagellated organism. H. pylori has first been isolated in 1984 from a gastric biopsy specimen of a patient with chronic gastritis (Marshall and Warren, 1984). The organization of the physical structure of the H. pylori flagellum is similar to that of enteric organisms Escherichia coli and Salmonella
Patents 151
typhimurium. The flagellum is composed of three structural elements: a basal body, a flexible hook and a flagellar filament. The mechanism of gene expression involved in flagellar assembly was extensively studied in the model organisms mentioned above (for review, see Macnab et al., 1996). In E. coli and S. typhimurium genes involved in flagellar biosynthesis are expressed in a hierarchical order and divided into three classes: (i) the class 1 genes, flhC and flhD, are regulated by the.sigma.sup.70 factor of RNA polymerase. The FlhC and FlhD proteins act as transcriptional activators to stimulate transcription from class 2 genes; (ii) the class 2 genes encode the early components required for flagellar assembly such as the basal body and flexible hook (HBB complex) as well as the.sigma.sup.28 factor of RNA polymerase; and (iii) the expression of the class 3 genes, which encode proteins involved in the final stages of flagellar assembly, is controlled by the.sigma.sup.28 factor. Completion of the HBB complex is required to result in class 3 gene expression. This tight regulation is due to the presence of the anti-.sigma.sup.28 factor, FIgM, which binds to.sigma.sup.28 and prevents its association with RNA polymerase core enzyme (Ohnishi et al., 1992; for review, see Hughes & Mathee, 1998). It has been shown that FIgM is secreted from the cell through the HBB structures thus allowing RNA polymerase associated with.sigma.sup.28 to transcribe class 3 genes (Gillen & Hughes, 1991a; 1991b; Hughes et al., 1993; Kutsukake, 1994). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics Inventor(s): Gilbert, Michel; (Hull, CA), Wakarchuk, Warren W.; (Gloucester, CA) Correspondence: Townsend And Townsend And Crew; Two Embarcadero Center; Eighth Floor; San Francisco; CA; 94111-3834; US Patent Application Number: 20020042369 Date filed: March 21, 2001 Abstract: This invention provides prokaryotic glycosyltransferases, including a bifunctional sialyltransferase that has both an.alpha.2,3- and an.alpha.2,8-activity. A.beta.1,4-GaINAc transferase and a.beta.1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS). The glycosyltransferases can be obtained from, for example, Campylobacter species, including C. jejuni. In additional embodiments, the invention provides nucleic acids that encode the glycosyltransferases, as well as expression vectors and host cells for expressing the glycosyltransferases. Excerpt(s): This application claims benefit of U.S. Provisional Application No. 60/118,213, which was filed on Feb. 1, 1999, and is a continuation-in-part of U.S. Application Ser. No. 09/495,406 filed Jan. 31, 2000, both of which are incorporated herein by reference for all purposes. This invention pertains to the field of enzymatic synthesis of oligosaccharides, including gangliosides and ganglioside mimics. Gangliosides are a class of glycolipids, often found in cell membranes, that consist of three elements. One or more sialic acid residues are attached to an oligosaccharide or carbohydrate core moiety, which in turn is attached to a hydrophobic lipid (ceramide) structure which generally is embedded in the cell membrane. The ceramide moiety includes a long chain base (LCB) portion and a fatty acid (FA) portion. Gangliosides, as well as other glycolipids and their structures in general, are discussed in, for example, Lehninger, Biochemistry (Worth Publishers, 1981) pp. 287-295 and Devlin, Textbook of
152
Campylobacter
biochemistry (Wiley-Liss, 1992). Gangliosides are classified according to the number of monosaccharides in the carbohydrate moiety, as well as the number and location of sialic acid groups present in the carbohydrate moiety. Monosialogangliosides are given the designation "GM", disialogangliosides are designated "GD", trisialogangliosides "GT", and tetrasialogangliosides are designated "GQ". Gangliosides can be classified further depending on the position or positions of the sialic acid residue or residues bound. Further classification is based on the number of saccharides present in the oligosaccharide core, with the subscript "I" designating a ganglioside that has four saccharide residues (Gal-GalNAc-Gal-Glc-Ceramide), disaccharide (Gal-Glc-Ceramide) and monosaccharide (Gal-Ceramide) gangliosides, respectively. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Campylobacter vaccine Inventor(s): Bosch, Johannes Franciscus Van Den; (Boxmeer, NL), Jacobs, Antonius Arnoldus Christiaan; (Kessel, NL), Nuijten, Petrus Johannes Maria; (Boxmeer, NL) Correspondence: Intervet Inc; 405 State Street; PO Box 318; Millsboro; DE; 19966; US Patent Application Number: 20030072766 Date filed: July 10, 2002 Abstract: The present invention relates to vaccines comprising antiserum raised against a flagellaless Campylobacter strain for the prevention of Campylobacter colonisation in animals. The invention also relates to antigenic Campylobacter proteins visible in a Western blot of Campylobacter jejuni protein after incubation of said Western blot with antibodies against a flagellaless mutant of Campylobacter jejuni and not visible after incubation of said blot with antibodies against wild type Campylobacter jejuni, and to their use in vaccines and the manufacturing thereof. The invention further relates to vaccines comprising such proteins and antibodies against such proteins. The invention further relates to the use of such Campylobacter proteins and to antiserum and antibodies raised against Campylobacter antigens for the preparation of vaccines. Finally, the invention relates to methods for the preparation of such vaccines. Excerpt(s): The present invention relates to vaccines against Campylobacter colonisation, to the use of Campylobacter proteins and anti-Campylobacter antibodies for the preparation of such vaccines and to methods for the preparation of such vaccines. Bacteria of the genus Campylobacter are Gram-negative spiral shaped pathogenic bacteria, with a high motility and carrying a flagellum at one or both poles of the cell. Several Campylobacter species have been found. Campylobacter jejuni is very often found in poultry. Frequently Campylobacter coli and (to a lesser extent) the recently found Campylobacter hyoilei are found in pigs. Next to active vaccination as described above, passive vaccination has been tested as a means of decreasing Campylobacter infection. Tsubokura et al (1997, Clin. Exp. Immunol. 108: 451-455) have orally administered antibodies against whole Campylobacter jejuni cells followed by challenge with Campylobacter jejuni. They claim a 1-2 log reduction in the number of bacteria found in the faeces of thus vaccinated chickens. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 153
•
Cattle reproductive disease vaccines Inventor(s): Dominowski, Paul Joseph; (Hickorg Corners, MI) Correspondence: Scully Scott Murphy & Presser, PC; 400 Garden City Plaza; Garden City; NY; 11530 Patent Application Number: 20040081666 Date filed: August 26, 2003 Excerpt(s): The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI.sub.3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo-prajitno, Leptospira icterohaemmorrhagiae, Leptospira borgpetersenii hardjo-bovis and Leptospira interrogans pomona by administering to the animal an effective amount of a combination vaccine. The combination vaccine can be a whole or partial cell inactivated or modified live preparation. Five viral agents associated with the bovine respiratory disease (BRD) complex--Bovine Herpes Virus Type-1 (BHV-1), also known as infectious bovine rhinotracheitis virus (IBR), Bovine viral diarrhea virus (BVDV) Types 1 and 2, Bovine Respiratory Syncytial Virus (BRSV), and Parainfluenza Virus (PI.sub.3), cause respiratory and reproductive system infections of great economic importance to the cow-calf and dairy industries worldwide. BRD causes a broad array of clinical syndromes including acute onset respiratory disease and abortion. The respiratory form of BRD is characterized by inflammation, swelling, hemorrhage, and necrosis of the mucous membranes of the respiratory tract and may be accompanied by high fever, anorexia, depression, nasal discharge, labored breathing, and inflamed muzzle. Abortions induced by IBR and BVDV virus can occur in all three trimesters, but chiefly during the last half of gestation, and often without evidence of other clinical signs (Ellis et al. (1996) JAVMA 208:393-400; Ellsworth et al. (1994) In: Proceedings, 74.sup.th Conference of Research Workers in Animal Disease:34). Bovine Herpes Virus Type-1 (BHV-1), is a member of the alphaherpesviridae subfamily, and produces a variety of clinical forms of disease in cattle, including respiratory and genital infections, conjunctivitis, encephalitis, and abortions. Previous attempts at controlling BHV-1 infection have utilized vaccines comprising live attenuated virus (Gerber, J. D., et al., 1978, Am. J. Vet. Res. 39:753-760; Mitchell, D., 1974, Can. Vet. Jour. 15:148-151), inactivated virus (Frerichs, G. N., et al., 1982, Vet. Rec. 111:116-122), and viral subunits such as, e.g., one of the three major BHV-1 glycoproteins, which have been designated in the art as gI, gIII, and gIV (Babiuk, L. A., et al., 1987, Virology 159:57-66; van Drunen, S., et al., 1993, Vaccine 11:25-35). In addition, the ability of a recombinant, truncated version of the BHV-1 gIV glycoprotein (designated in the art as BHV-1 tgIV) to induce mucosal immunity against BHV-1 has been demonstrated (van Drunen, S., et al., 1994, Vaccine, 12:1295-1302). However, the art-recognized BHV-1 vaccines are contraindicated for use in pregnant cattle, seropositive or seronegative, and also contraindicated for use in calves nursing pregnant cows. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
154
•
Campylobacter
Detection of antibacterial activity in excretory secretory product of adult trichuris suis Inventor(s): Abner, Sheila R; (Atlanta, GA), Mansfield, Linda S; (Bath, MI) Correspondence: Mcleod & Moyne, P.C.; 2190 Commons Parkway; Okemos; MI; 48864; US Patent Application Number: 20040029802 Date filed: April 25, 2003 Abstract: The present invention provides a heat-stable and protease-resistant antibacterial activity in excretory-secretory products (ESP) of Trichuris suis. The antibacterial activity is not more than 10,000 MW; is resistant to boiling, trypsin, and pronase E; has a bactericidal mode of action; and is effective against Gram positive and Gram negative bacteria, including Escherichia coli, Campylobacter jejuni, Campylobactercoli, and Staphylococcus aureus. The antibacterial activity is useful in applications for killing or inhibiting the growth of microorganisms, in particular bacteria. Excerpt(s): This application claims priority to Provisional Application No. 60/246,203, which was filed Nov. 6, 2000. Not Applicable. The present invention relates to heatstable and protease-resistant antibacterial activity in excretory-secretory products (ESP) of Trichuris suis. The antibacterial activity is not more than 10,000 MW; is resistant to boiling, trypsin, and pronase E; has a bactericidal mode of action; and is effective against Gram positive and Gram negative bacteria, including Escherichia coli, Campylobacter jejuni, Campylobacter coli, and Staphylococcus aureus. The antibacterial activity is useful in applications for killing or inhibiting the growth of microorganisms, in particular bacteria. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Flagellin gene, flaC of Campylobacter Inventor(s): Chan, Voon Loong; (Toronto, CA), Louie, Helena; (Markham, CA) Correspondence: Sim & Mcburney; 330 University Avenue; 6th Floor; Toronto; ON; M5g 1r7; CA Patent Application Number: 20040006037 Date filed: April 29, 2003 Abstract: Purified and isolated nucleic acid molecules are provided which encode a FlaC flagellin protein of a strain of Campylobacter, particularly C. jejuni, or a fragment or an analog of the FlaC flagellin protein. The nucleic acid molecules may be used to produce proteins free of contaminants derived from bacteria normally containing the FlaA or FlaB proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecules, proteins encoded thereby and antibodies raised against the proteins, may be used in the diagnosis of infection. Excerpt(s): The present invention is related to the molecular cloning of a gene encoding a flagellin protein, identified herein as FlaC, of the flagellar filament from a strain of Campylobacter. Campylobacter jejuni is a Gram-negative spiral microaerophilic bacterium that has been recognized as a cause of secretory type diarrhea and enteritis (Ref. 1). Throughout this application, various references are referred to in parenthesis to more fully describe the state of the art to which this invention pertains. Full bibliographic information for each, citation is found at the disclosed end of the
Patents 155
specification immediately preceding the claims. These references are hereby incorporated by reference into the present disclosure). The flagellum of C. jejuni is responsible for bacterial motility which enhances the organism's pathogenicity. The flagellum consists of three major components; the filament, the hook, and the basal body (Ref. 2). A campylobacter cell carries a single unsheathed flagellum at one or both poles of the body. The flagella are responsible for the high motility of the organisms as aflagellate mutants are nonmotile (Refs. 3, 4, 5, 6, 7, 8, 9). A number of studies indicated that the polar flagellum plays an important role in colonization of the viscous mucus lining of the gastric intestinal tract and that it is an important virulence determinant (Refs. 3,4,7,10,11). The basic structure of the bacterial flagellum consists of a propeller (filament) connected via a universal joint (hook) to a transmission shaft, motor and brushings (basal body) embedded in the cell envelope (Ref. 12). The flagellar filament consists of several thousand self-assembling protein (flagellin) monomers arranged in a helix. These form a hollow tube of relatively constant diameter and variable length with an over corkscrew morphology. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Lipopolysaccharide alpha-2,3 sialyltransferase of Campylobacter jejuni and its uses Inventor(s): Gilbert, Michel; (Quebec, CA), Wakarchuk, Warren W.; (Ontario, CA) Correspondence: Townsend And Townsend And Crew, Llp; Two Embarcadero Center; Eighth Floor; San Francisco; CA; 94111-3834; US Patent Application Number: 20030049270 Date filed: January 29, 2002 Abstract: The structure and specificity of a recombinant.alpha.2,3-sialyltransferas- e from Campylobacter spp., is disclosed. Also provided are methods for using the.alpha.2,3-sialyltransferase in the production of desired carbohydrate structures and nucleic acids that encode the sialyltransferase. Excerpt(s): This application claims benefit of U.S. Provisional Application No. 60/078,891, filed Mar. 20, 1998, which application is incorporated herein by reference for all purposes. This invention relates to the field of cloning and expression of sialyltransferase enzymes. In particular, the preferred sialyltransferases are bacterial transferases obtained from, for example, Campylobacter jejuni. Carbohydrates are now recognized as being of major importance in many cell-cell recognition events, notably the adhesion of bacteria and viruses to mammalian cells in pathogenesis and leukocyteendothelial cell interaction through selectins in inflammation (Varki (1993) Glycobiology 3: 97-130). Moreover, sialylated glycoconjugates that are found in bacteria (Preston et al. (1996) Crit. Rev. Microbiol. 22:139-180; Reuter et al. (1996) Biol. Chem. Hoppe-Seyler 377:325-342) are thought to mimic oligosaccharides found in mammalian glycolipids to evade the host immune response (Moran et al. (1996) FEMS Immunol. Med. Microbiol. 16:105-115). Molecular mimicry of host structures by the saccharide portion of lipopolysaccharide (LPS) is considered to be a virulence factor of various mucosal pathogens, which use this strategy to evade a host immune response (Moran et al. (1996) FEMS Immunol. Med. Microbiol. 16: 105-115; Moran et al. (1996) J. Endotoxin Res. 3: 521-531). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
156
•
Campylobacter
METHODS AND VACCINES FOR PROTECTION AGAINST CAMPYLOBACTER INFECTIONS Inventor(s): NACHAMKIN, IRVING; (NEWTON SQUARE, PA) Correspondence: Jane Massey Licata; Law Offices OF Jane Massey Licata; 66 E Main Street; Marlton; NJ; 08053 Patent Application Number: 20010038844 Date filed: April 28, 1999 Abstract: Methods and vaccines for protection of animals against Campylobacter infection are provided. Excerpt(s): This application claims the benefit of U.S. provisional patent application No. 60/084,170, filed May 4, 1998. Campylobacter jejuni is a major cause of gastrointestinal infection in man and is estimated to be the most common cause of sporadic bacterial diarrheal illness with approximately 2 million cases per year in the United States alone (Tauxe, R. V. 1992. Campylobacter jejuni: Current Status and Future Trends, pp. 9-19). C. jejuni typically causes an acute enterocolitis accompanied by fever and abdominal cramping lasting 3 to 5 days. Although complications are infrequent, Campylobacter infection may be confused with acute appendicitis resulting in unnecessary surgery, and may also cause serious extraintestinal infections (Nachamkin, I. 1993. Curr. Opin. Infect. Dis. 6:72-76). There is now substantial evidence that Campylobacter is a major cause of a serious paralytic illness, Guillain-Barre Syndrome (GBS; Mishu, B. and M. J. Blaser. 1993. Clin. Infect. Dis. 17:104-108), including both demyelinating and axonal forms of the disease (McKann, G. M. et al. 1993. Ann. Neurol. 33:333-342). Although rare, deaths have been associated with Campylobacter infection. The morbidity due to the disease is significant and results in substantial economic costs (Tauxe, R. V. 1992. Campylobacter jejuni: Current Status and Future Trends, pp. 9-19). Most of the cases of Campylobacter infection in the U.S. occur sporadically, although common source outbreaks are also seen. Campylobacter infection is essentially a food-borne illness acquired by ingestion of contaminated water, milk, and/or food products. A number of animal reservoirs serve as vehicles for transmission of Campylobacter, with poultry being the single most important vehicle for transmission of human infection (Stern, N. J. 1992. Campylobacter jejuni: Current Status and Future Trends, pp. 49-60). Other reservoirs for the organism include ducks, turkeys, cattle, goats, sheep, and swine. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Monoclonal antibodies against campylobacter jejuni and campylobacter coli outer membrane antigens Inventor(s): Bates, Anna H.; (Lafayette, CA), Brandon, David L.; (Berkeley, CA), Mandrell, Robert E.; (Sonoma, CA) Correspondence: Usda-Ars-Office OF Technology Transfer; Patent Advisors Office; Western Regional Research Center; 800 Buchanan ST; Albany; CA; 94710; US Patent Application Number: 20020106383 Date filed: March 16, 2001 Abstract: The present invention is directed to a method of producing monoclonal antibodies that are highly specific for (1) unique epitopes of Campylobacter jejuni (Cj) only and (2) epitopes conserved between Campylobacter jejuni and Campylobacter coli
Patents 157
(Cc) outer membranes; to specific monoclonal antibodies made by the methods of the instant invention; and uses thereof The invention is drawn further to immunogens comprising the outer membrane complexes of Cj and Cc. Excerpt(s): This application claims the benefit of U.S. Provisional Application No. 60/080,166, filed Mar. 31, 1998. The disclosure of said provisional application is incorporated herein by reference. The present invention relates generally to a method of preparing an immunogen comprising outer membranes from Campylobacter jejuni (hereafter designated Cj) and Campylobacter coli (hereafter designated Cc), inoculating animals with the immunogen, and detecting the desired hybridoma-producing antibodies; and to a composition comprising the immunogen. The invention is drawn further to hybridoma cell lines developed by this method to produce (1) monoclonal antibodies specific to Cj only and (2) monoclonal antibodies that recognize both Cj and Cc exclusively, and uses thereof. Campylobacters cause more human gastroenteritis than any other food-borne pathogen. Campylobacter enteritis is caused by two closely related species, Cj and Cc, but Cj is responsible for greater than 98% of human disease and produces more severe symptoms. Cj, has been further subdivided into Cj subspecies jejuni (Cjj) and Cj subspecies doylei (Cjd). (In the remainder of this application, the term Cjj will be used to designate C. jejuni subspecies jejuni and Cjd to designate C. jejuni subspecies doylei. The term Cj (Campylobacter jejuni) will be used to describe both C. jejuni subspecies jejuni and C. jejuni subspecies doylei collectively.) Cjj and Cjd are closely related; however, Cjj is the predominant subspecies causing human illness and isolated from food sources. Cj and Cc cause acute diarrhea in humans with associated enteritis, particularly in developing countries. These infections are prevalent in infants under 1 year in age and rank as the third most common cause of acute diarrhea after Rotavirus and enterotoxigenic Escherichia coli. The various clinical patterns of disease suggest that Campylobacter spp. and, more specifically, Cj strains are diverse and may possess more than one type of virulence factor. In addition, Cj, unlike Cc, are more often associated with symptomatic infections and with bloody diarrhea. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Rapid and specific detection of campylobacter Inventor(s): Czajka, John W.; (West Grove, PA) Correspondence: E I DU Pont DE Nemours And Company; Legal Patent Records Center; Barley Mill Plaza 25/1128; 4417 Lancaster Pike; Wilmington; DE; 19805; US Patent Application Number: 20030113757 Date filed: August 8, 2002 Abstract: The present invention provides a method for specifically detecting pathogenic Campylobacter species in a complex sample. The target pathogenic Campylobacter species can be Campylobacter jejuni or Campylobacter coli. The complex sample can be a food sample, water sample, or selectively enriched food matrix. The method of detection utilizes PCR amplification with, or without, an internal positive control, and appropriate primer pairs. Multiple species can be detected in the same reaction. The reagents necessary to perform the method can be supplied as a kit and/or in tablet form. Excerpt(s): This application claims the priority benefit of U.S. Provisional Application 60/310,882 filed Aug. 8, 2001, the disclosure of which is hereby incorporated by reference in its entirety. This invention relates to a rapid method for detection of Campylobacter bacteria, oligonucleotide molecules and reagents kits useful therefor.
158
Campylobacter
Specifically the target bacteria are detected with PCR in a homogeneous or gel-based format by means of labeling DNA amplification products with a fluorescent dye. Campylobacter species are the most common bacteria associated with foodborne gastroenteritis worldwide. The vast majority (in some areas, approximately 90%) of cases are associated with Campylobacter jejuni, and the remaining cases are caused by C. coli, although a minority of cases are associated with other species such as C. upsaliensis and C. lari. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
System for the control of enteropathogenic bacteria in the crops of poultry Inventor(s): Byrd, James A. II; (Bryan, TX), Corrier, Donald E.; (US), Corrier, Juanita P.; (College Station, TX), Stanker, Larry H.; (Livermore, CA) Correspondence: Usda-Ars-Office OF Technology Transfer; National Ctr For Agricultural Utilization Research; 1815 N. University Street; Peoria; IL; 61604; US Patent Application Number: 20020136706 Date filed: February 8, 2001 Abstract: The invention provides a method and compositions for controlling food borne enteric bacterial pathogens in poultry populations. The incidence of the colonization of poultry by enteropathogenic bacteria, and/or the populations of enteropathogenic bacteria within colonized poultry, may by substantially reduced by providing particles of an expanded matrix material to the locus or vicinity of the animals, particularly during the period of feed removal prior to slaughter. The method and compositions are particularly useful for the control of Salmonella species, enteropathogenic Escherichia coli, and Campylobacter species. Excerpt(s): This invention relates to a process for the control of enteric bacterial pathogens in animals using expanded matrix materials. Despite the efforts of researchers and public health agencies, the incidence of human infections from enteropathogenic bacteria such as Salmonella, E. coli 0157:H7, and Campylobacter has increased over the past 20 years. For example, the number of actual reported cases of human Salmonella infection exceeds 40,000 per year. However, the Communicable Disease Center estimates that the true incidence of human Salmonella infections in the United States each year may be as high as 2 to 4 million. The USDA Economic Research Service has recently reported that the annual cost of the food borne illnesses caused by six common bacterial pathogens, Campylobacter spp., Clostridium perfringens, Escherichia coli 0157:H7, Listeria monocytogenes, Salmonella spp., and Staphylococcus aureus, ranges from 2.9 billion to 6.7 billion dollars (Food Institute Report, USDA, AER, December, 1996). In addition to the impact of enteric pathogens on human health, many of these bacteria also cause significant infections in animals. For example, Salmonella infections in swine alone cost the United States swine industry more than 100 million dollars annually (Schwartz, 1990, "Salmonellosis in Midwestern Swine", In: Proceedings of the United States Animal Health Assoc., pp. 443-449). Animal food products remain a significant source of human infection by these pathogens. Contamination of meat and poultry products with many bacterial food-borne pathogens, including the particularly onerous pathogens Campylobacter spp., Escherichia coli 0157:H7, and Salmonella spp., often occurs as a result of exposure of the animal carcass to ingesta and/or fecal material during or after slaughter. Any of the above-mentioned pathogens can then be transmitted to humans by consumption of meat and poultry contaminated in this manner.
Patents 159
Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Use of an enzyme for the manufacture of an agent for controlling bacterial infection Inventor(s): Bedford, Michael R.; (Wiltshire, GB), Fernandez, Fresie; (Wiltshire, GB) Correspondence: Fitch Even Tabin And Flannery; 120 South LA Salle Street; Suite 1600; Chicago; IL; 606033406 Patent Application Number: 20010046494 Date filed: January 18, 2000 Abstract: Provided is the use of a xylanane or a cellulase for the manufacture of an agent for the treatment and/or prophylaxis of bacterial infection in an animal caused by Salmonella, Campylobacter or Clostridium perfringens.It is preferred that xylanase is used in combination with wheat to form an animal feed. Such a diet is particularly effective in controlling Campylobacter and Salmonella in chickens.The use provided by the present invention affords an alternative to antibiotics when controlling bacterial infection in animals. This leads to considerable health, environmental and economic benefits. Excerpt(s): The present invention is directed to the use of an enzyme for the manufacture of an agent for the treatment and/or prophylaxis of a bacterial infection. The farming of many different types of animals is important throughout the world for the production of food for human consumption. When the animals are reared, they come into contact with a variety of infection-causing bacteria, such as Campylobacter and Salmonella. In some cases these bacteria may spread directly from animals to humans (zoonosis). Accordingly, it is necessary from an economic, environmental and health perspective that such bacterial infection is prevented or eradicated in the animal prior to human consumption to prevent the spread of the disease to humans. The domestic animal of particular, but not exclusive, concern with regard to zoonosis is the chicken. Campylobacter and Salmonella are particularly prevalent in the chicken. The bacteria are transmitted to the bird in a variety of ways, including through feed, water, litter and vermin. The bacteria initially infect the caecae of the chicken. The disease then progresses to the small intestine where infestation may cause loss of weight in the bird. A particular problem with the chicken is that it is almost impossible to eviscerate in a sterile manner with the result that bacteria inhabiting the intestines will invariably be transmitted to the saleable carcass. Accordingly the potential for zoonosis is great, unless the carcass is handled or cooked properly. The cost of human infection caused by eating improperly treated chicken is significant in terms of both time and lives. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Keeping Current In order to stay informed about patents and patent applications dealing with campylobacter, you can access the U.S. Patent Office archive via the Internet at the following Web address: http://www.uspto.gov/patft/index.html. You will see two broad options: (1) Issued Patent, and (2) Published Applications. To see a list of issued patents, perform the following steps: Under “Issued Patents,” click “Quick Search.” Then, type “campylobacter” (or synonyms) into the “Term 1” box. After clicking on the search button, scroll down to see the various patents which have been granted to date on campylobacter.
160
Campylobacter
You can also use this procedure to view pending patent applications concerning campylobacter. Simply go back to http://www.uspto.gov/patft/index.html. Select “Quick Search” under “Published Applications.” Then proceed with the steps listed above.
161
CHAPTER 6. BOOKS ON CAMPYLOBACTER Overview This chapter provides bibliographic book references relating to campylobacter. In addition to online booksellers such as www.amazon.com and www.bn.com, excellent sources for book titles on campylobacter include the Combined Health Information Database and the National Library of Medicine. Your local medical library also may have these titles available for loan.
Book Summaries: Federal Agencies The Combined Health Information Database collects various book abstracts from a variety of healthcare institutions and federal agencies. To access these summaries, go directly to the following hyperlink: http://chid.nih.gov/detail/detail.html. You will need to use the “Detailed Search” option. To find book summaries, use the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer. For the format option, select “Monograph/Book.” Now type “campylobacter” (or synonyms) into the “For these words:” box. You should check back periodically with this database which is updated every three months. The following is a typical result when searching for books on campylobacter: •
1997 Red Book: Report of the Committee on Infectious Diseases. 24th ed Source: Elk Grove Village, IL: American Academy of Pediatrics. 1997. 764 p. Contact: Available from American Academy of Pediatrics. Publications, P.O. Box 747, Elk Grove Village, IL 60009-0747. (800) 433-9016 or (847) 228-5005. Fax (847) 228-1281. Email:
[email protected]. PRICE: Single copy free to members, with additional copies $74.95 each; $79.95 for nonmembers. ISBN: 091076185x. Publication number MA0001. Summary: This monograph contains the 24th edition of the report of the Committee on Infectious Diseases, the group responsible for formulating and revising guidelines of the American Academy of Pediatrics for the control of infectious diseases in children. Five sections present guidelines in the areas of active and passive immunization; recommendations for the care of children in special circumstances, including children in day care, infection control for hospitalized children, and medical evaluation of
162
Campylobacter
internationally adopted children; summaries of infectious diseases; antimicrobial prophylaxis; and antimicrobials and related therapy. Infectious diseases that can affect the digestive system include amebiasis, campylobacter infections, cholera, Escherichia coli, diarrhea, giardia lamblia, helicobacter pylori, hepatitis, HIV, malaria, parasitic diseases, salmonellosis, schistosomiasis, shigellosis, vibrio infections, and yersinia infections. A summary of major changes in the 1997 edition is provided; changes include the addition of recent information on Escherichia coli diarrhea (E coli 0157:H7 infection) and its complication of hemolytic-uremic syndrome, and expanded information about Hepatitis A, B, and C. A subject index concludes the volume. 9 appendices.
Book Summaries: Online Booksellers Commercial Internet-based booksellers, such as Amazon.com and Barnes&Noble.com, offer summaries which have been supplied by each title’s publisher. Some summaries also include customer reviews. Your local bookseller may have access to in-house and commercial databases that index all published books (e.g. Books in Print). IMPORTANT NOTE: Online booksellers typically produce search results for medical and non-medical books. When searching for “campylobacter” at online booksellers’ Web sites, you may discover non-medical books that use the generic term “campylobacter” (or a synonym) in their titles. The following is indicative of the results you might find when searching for “campylobacter” (sorted alphabetically by title; follow the hyperlink to view more details at Amazon.com): •
Gastroduodenal pathology and Campylobacter pylori: Proceedings of the First Meeting of the European Campylobacter Pylori Study Group, held in Bordeaux, France, 7-8 October 1988 (International congress series) by European Campylobacter Pylori Study Group; ISBN: 0444811591; http://www.amazon.com/exec/obidos/ASIN/0444811591/icongroupinterna
Chapters on Campylobacter In order to find chapters that specifically relate to campylobacter, an excellent source of abstracts is the Combined Health Information Database. You will need to limit your search to book chapters and campylobacter using the “Detailed Search” option. Go to the following hyperlink: http://chid.nih.gov/detail/detail.html. To find book chapters, use the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Book Chapter.” Type “campylobacter” (or synonyms) into the “For these words:” box. The following is a typical result when searching for book chapters on campylobacter: •
Food-Borne Illness Source: in Hagan, P.T., ed. Mayo Clinic Guide to Self-Care: Answers for Everyday Health Problems. New York, NY: Kensington Publishers. 1999. p. 26-27. Contact: Available from Mayo Clinic. 200 First Street, S.W., Rochester, MN 55905. (800) 291-1128 or (507) 284-2511. Fax (507) 284-0161. Website: www.mayo.edu. PRICE: $16.95 plus shipping and handling. ISBN: 0962786578. Summary: Foodborne illness is a growing problem in the U.S. This chapter on foodborne illness is from a self care handbook on everyday health problems published by the Mayo
Books
163
Clinic. The handbook offers readers a guide to symptoms, diagnosis, and treatment for common problems (particularly self care strategies and tips for handling these problems in children). All foods naturally contain small amounts of bacteria. When food is poorly handled, improperly cooked, or inadequately stored, bacteria can multiply in great enough numbers to cause illness. Parasites, viruses, and chemicals can also contaminate food, but foodborne illness from these sources is less common. Eating contaminated food can result in illness, depending on the organism, the amount of exposure, one's age, and health status. As people age, their immune cells may not respond as quickly and effectively to infectious organisms. Young children are at increased risk of illness because their immune systems haven't developed fully. Conditions such as diabetes, AIDS, and cancer treatment also reduce the immune response, making one more susceptible to foodborne illness. The chapter briefly lists self care strategies, particularly for handling short lived (less than 12 hours) food poisoning. One section cautions readers about botulism, a potentially fatal food poisoning. A side bar reviews how to handle food safely. The chapter concludes with a chart of common troublesome bacteria, how each is spread, the symptoms caused by infection, and prevention strategies. Bacteria included are Campylobacter jejuni, Clostridium perfringens, Escherichia coli 0157:H7, Salmonella, Staphylococcus aureus, and Vibrio vulnificus. The book is focused on how to prevent illness, how to detect illness before it becomes a serious and costly problem, and how to avoid unnecessary trips to the clinic or emergency room. 1 table. •
Bacterial Infections of the Colon Source: in Textbook of Gastroenterology. 4th ed. [2-volume set]. Hagerstown, MD: Lippincott Williams and Wilkins. 2003. p. 1864-1882. Contact: Available from Lippincott Williams and Wilkins. P.O. Box 1600, Hagerstown, MD 21741. (800) 638-6423. Fax: (301) 223-2400. Website: www.lww.com. PRICE: $289.00. ISBN: 781728614. Summary: This chapter on bacterial infections of the colon is from a comprehensive gastroenterology textbook that provides an encyclopedic discussion of virtually all the disease states encountered in a gastroenterology practice. The author of this chapter covers Shigella, Campylobacter, Clostridium difficile, pathogenic Escherichia coli that causes colitis, and sexually transmitted infections of the anus and rectum. Individuals with bacterial colitis who seek medical attention tend to have more severe symptoms, such as bloody diarrhea, fever, and abdominal pain. The nonspecific nature of symptoms associated with infectious colitis requires that stool cultures and examination for parasites be performed to identify a specific pathogen. Colonic biopsies may be necessary to exclude the diagnosis of ulcerative or ischemic colitis. For each of the five major bacterial pathogens that affect the colon, the author discusses classification, epidemiological aspects, pathogenesis, clinical features, complications, and treatment. 2 figures. 4 tables. 218 references.
•
Food-Related Illnesses and Allergies Source: in Townsend, C.E. and Roth, R.A. Nutrition and Diet Therapy. 7th ed. Albany, NY: Delmar Publishers. 1999. 171-187 p. Contact: Available from Delmar Publishers. 3 Columbia Circle, Albany, NY 12212. (800) 865-5840. E-mail:
[email protected]. PRICE: $44.95 plus shipping and handling. ISBN: 0766802965. Summary: This chapter on food related illnesses and allergies is from an undergraduate textbook on nutrition and diet therapy. The chapter identifies the diseases caused by
164
Campylobacter
contaminated food, along with their signs and the means by which they are spread; lists the signs of food contamination; reviews precautions for protecting food from contamination; and covers allergies and elimination diets and their uses. Foodborne illnesses covered include Campylobacter jejuni, Clostridium botulinum, Clostridium perfringens, Cyclospora, Escherichia coli (O157:H7), Listeria monocytogenes, Salmonella, Shigella, and Staphylococcus aureas. The authors stress that infection or poisoning traced to food is usually caused by human ignorance or carelessness. Food should not be prepared by anyone who has or carries a contagious disease. All fresh fruits and vegetables should be washed before being eaten. Meats, poultry, fish, eggs, and dairy products should be refrigerated. Food should be covered to prevent contamination by dust, insects, or animals. Food allergies can cause many different and unpleasant symptoms, and elimination diets are used to determine their causes. Some of the most common food allergens are milk, chocolate, eggs, tomatoes, fish, citrus fruit, legumes, strawberries, and wheat. The chapter includes lists of key terms to learn, recommended discussion topics, and suggested supplemental activities, and a section of review questions so readers can test their comprehension of the material. Two illustrative case studies are appended. 1 figure. 4 tables. •
Infectious Agents as Aggravating Factors in Inflammatory Bowel Disease Source: in Bayless, T.M. and Hanauer, S.B. Advanced Therapy of Inflammatory Bowel Disease. Hamilton, Ontario: B.C. Decker Inc. 2001. p. 95-98. Contact: Available from B.C. Decker Inc. 20 Hughson Street South, P.O. Box 620, L.C.D. 1 Hamilton, Ontario L8N 3K7. (905) 522-7017 or (800) 568-7281. Fax (905) 522-7839. Email:
[email protected]. Website: www.bcdecker.com. PRICE: $129.00 plus shipping and handling. ISBN: 1550091220. Summary: This chapter on infectious agents as aggravating factors is from the second edition of a book devoted to the details of medical, surgical, and supportive management of patients with Crohn's disease (CD) and ulcerative colitis (UC), together known as inflammatory bowel disease (IBD). When patients present with diarrhea, one of the first questions is whether it is an infection or an attack of IBD. Initial symptoms may be very similar, including diarrhea (with or without blood), abdominal pain or cramps, fever, and even arthralgias (pain in the joints). Clinical features that favor infection are acute onset of diarrhea (often greater than 10 bowel movements per day) and fever early in the course. Conversely, IBD usually has a more insidious onset, fewer than 6 bowel movements daily, and early fever is uncommon. Colonoscopic features can suggest infection or UC, but are rarely diagnostic. Mucosal biopsy, however, can be useful in distinguishing acute self-limited colitis or infectious-type colitis from IBD. However, to further complicate matters, infections sometimes can precipitate IBD, and intercurrent (happening at the same time) infections can mimic or induce flares of IBD. This chapter considers infections that mimic IBD, including amebic colitis and chronic infectious colitides (including Entamoeba histolytica and Yersinia); and infections that aggravate IBD, including Campylobacter jejuni, Salmonella, Shigella, Escherichia coli, Clostricium difficile, Cytomegalovirus, Herpes simplex virus, parasites, and mycobacterium. 1 table. 22 references.
•
Infectious Diarrhea and Bacterial Food Poisoning Source: in Feldman, M.; Friedman, L.S.; Sleisenger, M.H. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management. 7th ed. [2-volume set]. St. Louis, MO: Saunders. 2002. p. 1864-1913.
Books
165
Contact: Available from Elsevier. 11830 Westline Industrial Drive, St. Louis, MO 63146. (800) 545-2522. Fax (800) 568-5136. Website: www.us.elsevierhealth.com. PRICE: $229.00 plus shipping and handling. ISBN: 0721689736. Summary: This chapter on infectious diarrhea and bacterial food poisoning is from a comprehensive and authoritative textbook that covers disorders of the gastrointestinal tract, biliary tree, pancreas, and liver, as well as the related topics of nutrition and peritoneal disorders. Topics include changes in normal flora caused by diarrhea; classification of bacterial diarrhea; toxigenic diarrheas, including cholera, other vibrios, Aeromonas, Plesiomonas shigelloides, and Escherichia coli; invasive pathogens, including Shigella, nontyphoidal Salmonellosis, typhoid fever, Campylobacter, and Yersinia; viral diarrhea, including that due to rotavirus, calicivirus, enteric andenovirus, astrovirus, and torovirus; traveler's diarrhea, including microbiology, epidemiology, clinical features, and prevention; diarrhea in the elderly; diagnosis of infectious diarrheal disease; treatment of infectious diarrhea, including with fluid therapy, diet, antimicrobial drugs, and nonspecific therapy; tuberculosis of the gastrointestinal tract; and bacterial food poisoning, including that from Clostridium perfringers, Saphylococcus auerus, Listeria, Bacillus cereus, botulism, and Bacillus anthracis. The chapter includes a mini-outline with page citations, illustrations, and extensive references. 8 figures. 16 tables. 329 references. •
Approach to Patients with Gastrointestinal Tract Infections and Food Poisoning Source: in Feigin, R.D. and Cherry, J.D., eds. Textbook of Pediatric Infectious Diseases. 4th ed. Volume 1. Philadelphia, PA: W.B. Saunders Company. 1998. p. 567-601. Contact: Available from W.B. Saunders Company. Order Fulfillment, 6277 Sea Harbor Drive, Orlando, FL 32887. (800) 545-2522. Fax (800) 874-6418 or (407) 352-3445. PRICE: $315.00. ISBN: 0721664482. Summary: This chapter on managing young patients with gastrointestinal (GI) tract infections and food poisoning is from a textbook on pediatric infectious diseases. The authors stress that the approach to patients must begin with a thorough medical history, including information about epidemiologic factors, a physical examination, and knowledge of the pathophysiology of various enteropathogens. GI tract infections can include a wide range of symptoms and can be caused by a variety of agents and organisms. However, most infectious diarrhea illness can be classified into a category based on its cause, its pathophysiology, and the clinical response. This information can then be used to determine the appropriate diagnostic and monitoring tests and to decide which therapy to use. All patients with diarrhea require some degree of fluid and electrolyte therapy, a few need other nonspecific support, and for some, specific antimicrobial therapy is indicated to shorten the illness. The authors consider epidemiology and etiology, including outbreaks in child care centers and hospitals, foodborne or waterborne diarrhea, antimicrobial-associated diarrhea, travelers' diarrhea, and diarrhea in immunocompromised patients, including those with AIDS; bacterial organisms that cause gastroenteritis, including Aeromanas hydrophila, Bacillus cereus, Campylobacter, Clostridium difficile, Clostridium perfringens, Escherichia coli, Plesiomonas shigelloides, Salmonella, Shigella, Staphylococcus aureus, Vibrio cholerae, Vibrio parahaemolyticus, and Yersinia enterocolitica; viral agents, including rotaviruses, astroviruses, calciviruses, and enteric adenoviruses; and parasites, including Cryptosporidium, Entamoeba histolytica, Giardia lamblia, Strongyloides stercoralis, Isospora belli, microsporidia, and Cyclospora. Diagnostic considerations, including laboratory testing, are reviewed. The authors also discuss treatment options, including fluid and electrolyte therapy, dietary manipulation, nonspecific therapy with
166
Campylobacter
antidiarrheal compounds, and specific therapy with antimicrobial agents. 5 figures. 18 tables. 392 references. (AA-M). •
Gastrointestinal Disease and Hepatitis Source: in Andersen, R.D., et al. Infections in Children: A Sourcebook for Educators and Child Care Providers. Aspen Publishers, Inc. 1994. p. 137-146. Contact: Available from Aspen Publishers, Inc. 7201 McKinney Circle, Frederick, MD 21701. (800) 638-8437 or (301) 417-7500. PRICE: $36. ISBN: 0834203871. Summary: This chapter, from a handbook for educators and child care providers on infections in children, addresses gastrointestinal disease and hepatitis. The chapter covers vomiting; diarrhea; common causes of infectious diarrhea, including rotavirus, Escherichia coli, campylobacter species, salmonella, and shigella; hepatitis A; hepatitis B; and hepatitis C. In each section, the authors review the illness and its symptoms, consider etiology, review transmission and its prevention, and remind readers of the situations in which consultation of a health care provider is indicated. 3 references.
167
CHAPTER 7. MULTIMEDIA ON CAMPYLOBACTER Overview In this chapter, we show you how to keep current on multimedia sources of information on campylobacter. We start with sources that have been summarized by federal agencies, and then show you how to find bibliographic information catalogued by the National Library of Medicine.
Video Recordings An excellent source of multimedia information on campylobacter is the Combined Health Information Database. You will need to limit your search to “Videorecording” and “campylobacter” using the “Detailed Search” option. Go directly to the following hyperlink: http://chid.nih.gov/detail/detail.html. To find video productions, use the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Videorecording (videotape, videocassette, etc.).” Type “campylobacter” (or synonyms) into the “For these words:” box. The following is a typical result when searching for video recordings on campylobacter: •
Peptic Ulcer Source: Timonium, MD: Milner Fenwick. 1990. Contact: Available from Milner Fenwick. 2125 Greenspring Drive, Timonium, MD 21093. (800) 432-8433. PRICE: $250. Summary: An introduction for the patient with duodenal or gastric ulcers, this film helps the patient identify ulcer symptoms, explains tests that may be required, and discusses medications. It also covers side effects of medications and possible complications of ulcers. It also provides an explanation of the bacteria campylobacter pylori recently found to be associated with ulcers. (AA-M).
•
Food Borne Illnesses and Their Prevention Source: Charleston, WV: Cambridge Educational. 1995. (videocassette).
168
Campylobacter
Contact: Available from Cambridge Educational. P.O. Box 2153, Dept. D23, Charleston, WV 25328-2153. (800) 468-4227. Fax (800) FAX ON US. Website: www.cambridgeeducational.com. PRICE: $79.00 plus shipping and handling. Summary: This videotape program takes an indepth look at the recommended practices for food handlers (at home or commercially) to follow in order to prevent the spread of bacteria and other pathogens that can cause foodborne illness. The program investigates the causes, symptoms, and treatment of foodborne illnesses, with emphasis placed on their prevention. The program discusses the more common and severe illnesses in some detail. These include Salmonella, Campylobacter jejuni, Escherichia coli, Botulism, and Listeriosis. For each infectious organism, the narrator describes why the pathogen causes illness, how long the illness should be expected to last, safe and proper treatments, and when to contact a health care provider. The program then reviews shopping, food preparation, and hygiene issues that can help prevent foodborne illness. The final section of the videotape reviews the recommended internal cooking temperatures for a variety of foods. The program stresses that almost all foodborne illnesses can be avoided if people who handled food are educated about causes and the proper procedures to avoid contamination. The USDA Food Hotline number (800-5354555) is provided for viewers who would like to obtain additional information.
169
CHAPTER 8. PERIODICALS CAMPYLOBACTER
AND
NEWS
ON
Overview In this chapter, we suggest a number of news sources and present various periodicals that cover campylobacter.
News Services and Press Releases One of the simplest ways of tracking press releases on campylobacter is to search the news wires. In the following sample of sources, we will briefly describe how to access each service. These services only post recent news intended for public viewing. PR Newswire To access the PR Newswire archive, simply go to http://www.prnewswire.com/. Select your country. Type “campylobacter” (or synonyms) into the search box. You will automatically receive information on relevant news releases posted within the last 30 days. The search results are shown by order of relevance. Reuters Health The Reuters’ Medical News and Health eLine databases can be very useful in exploring news archives relating to campylobacter. While some of the listed articles are free to view, others are available for purchase for a nominal fee. To access this archive, go to http://www.reutershealth.com/en/index.html and search by “campylobacter” (or synonyms). The following was recently listed in this archive for campylobacter: •
UK study reveals Campylobacter sources Source: Reuters Medical News Date: September 19, 2001
170
Campylobacter
•
Navy to help study Campylobacter vaccine Source: Reuters Health eLine Date: August 17, 2000
•
Navy to complete studies of Antex's oral Campylobacter vaccine Source: Reuters Industry Breifing Date: August 17, 2000
•
Antex Biologics Phase I Campylobacter Vaccine Trial Positive Source: Reuters Medical News Date: October 27, 1997
•
New Techniques Identify More Campylobacter Species In AIDS Patients Source: Reuters Medical News Date: June 23, 1997
•
Microcarb Announces Testing Of Campylobacter Vaccine With US Navy Source: Reuters Medical News Date: June 29, 1995 The NIH
Within MEDLINEplus, the NIH has made an agreement with the New York Times Syndicate, the AP News Service, and Reuters to deliver news that can be browsed by the public. Search news releases at http://www.nlm.nih.gov/medlineplus/alphanews_a.html. MEDLINEplus allows you to browse across an alphabetical index. Or you can search by date at the following Web page: http://www.nlm.nih.gov/medlineplus/newsbydate.html. Often, news items are indexed by MEDLINEplus within its search engine. Business Wire Business Wire is similar to PR Newswire. To access this archive, simply go to http://www.businesswire.com/. You can scan the news by industry category or company name. Market Wire Market Wire is more focused on technology than the other wires. To browse the latest press releases by topic, such as alternative medicine, biotechnology, fitness, healthcare, legal, nutrition, and pharmaceuticals, access Market Wire’s Medical/Health channel at http://www.marketwire.com/mw/release_index?channel=MedicalHealth. Or simply go to Market Wire’s home page at http://www.marketwire.com/mw/home, type “campylobacter” (or synonyms) into the search box, and click on “Search News.” As this service is technology oriented, you may wish to use it when searching for press releases covering diagnostic procedures or tests. Search Engines Medical news is also available in the news sections of commercial Internet search engines. See the health news page at Yahoo (http://dir.yahoo.com/Health/News_and_Media/), or
Periodicals and News
171
you can use this Web site’s general news search page at http://news.yahoo.com/. Type in “campylobacter” (or synonyms). If you know the name of a company that is relevant to campylobacter, you can go to any stock trading Web site (such as http://www.etrade.com/) and search for the company name there. News items across various news sources are reported on indicated hyperlinks. Google offers a similar service at http://news.google.com/. BBC Covering news from a more European perspective, the British Broadcasting Corporation (BBC) allows the public free access to their news archive located at http://www.bbc.co.uk/. Search by “campylobacter” (or synonyms).
Newsletter Articles Use the Combined Health Information Database, and limit your search criteria to “newsletter articles.” Again, you will need to use the “Detailed Search” option. Go directly to the following hyperlink: http://chid.nih.gov/detail/detail.html. Go to the bottom of the search page where “You may refine your search by.” Select the dates and language that you prefer. For the format option, select “Newsletter Article.” Type “campylobacter” (or synonyms) into the “For these words:” box. You should check back periodically with this database as it is updated every three months. The following is a typical result when searching for newsletter articles on campylobacter: •
Food Safety Guide Source: Nutrition Action Healthletter. 26(8): 1, 3-9. October 1999. Contact: Available from Center for Science in the Public Interest. 1875 Connecticut Avenue, N.W., Suite 300, Washington, DC 20009-5728. (202) 332-9110. Fax (202) 2654954. Website: www.cspinet.org. Summary: This newsletter article offers a food safety guide to help consumers avoid episodes of food poisoning. The authors first review some of the changes in the food safety field, including new pathogens to deal with, a more centrally produced and global food supply, and changes in the ways food animals are raised. The authors then review the two families of bacteria of concern: spoilage bacteria that cause foods to smell and taste bad; and disease causing bacteria that do not usually change the taste, smell, or appearance of food, but can make people sick. The body of the article discusses each category of food, including poultry, seafood, dairy, eggs, fruits and vegetables, juice and cider, prepared foods and salads, hot dogs and deli meats. In each category, the authors describe the food handling issues, the types of infections that are possible, and experiences of people who got sick. Sections headed What to Do offer specific strategies for shopping, handling fresh fruits, preparing foods, cooking meats, staying informed, avoiding raw foods, traveling, and eating at restaurants. One sidebar lists the symptoms of food poisoning and how to know when to contact a health care provider. The authors recommend the website that refers readers to the government food safety sites (www.foodsafety.gov). The article concludes with a chart summarizing the pathogens, their possible symptoms, foods that have caused outbreaks, how soon the symptoms typically strike, and how long the illness lasts. Pathogens covered are Campylobacter, Ciguatera, Clostridium botulinum, Cyclospora, E. coli O157:H7, hepatitis A, Listeria,
172
Campylobacter
Norwalk virus, Salmonella, Scombrotoxin, Vibrio parahaemolyticus, and Vibrio vulnificus. 1 table.
Academic Periodicals covering Campylobacter Numerous periodicals are currently indexed within the National Library of Medicine’s PubMed database that are known to publish articles relating to campylobacter. In addition to these sources, you can search for articles covering campylobacter that have been published by any of the periodicals listed in previous chapters. To find the latest studies published, go to http://www.ncbi.nlm.nih.gov/pubmed, type the name of the periodical into the search box, and click “Go.” If you want complete details about the historical contents of a journal, you can also visit the following Web site: http://www.ncbi.nlm.nih.gov/entrez/jrbrowser.cgi. Here, type in the name of the journal or its abbreviation, and you will receive an index of published articles. At http://locatorplus.gov/, you can retrieve more indexing information on medical periodicals (e.g. the name of the publisher). Select the button “Search LOCATORplus.” Then type in the name of the journal and select the advanced search option “Journal Title Search.”
173
APPENDICES
175
APPENDIX A. PHYSICIAN RESOURCES Overview In this chapter, we focus on databases and Internet-based guidelines and information resources created or written for a professional audience.
NIH Guidelines Commonly referred to as “clinical” or “professional” guidelines, the National Institutes of Health publish physician guidelines for the most common diseases. Publications are available at the following by relevant Institute10: •
Office of the Director (OD); guidelines consolidated across agencies available at http://www.nih.gov/health/consumer/conkey.htm
•
National Institute of General Medical Sciences (NIGMS); fact sheets available at http://www.nigms.nih.gov/news/facts/
•
National Library of Medicine (NLM); extensive encyclopedia (A.D.A.M., Inc.) with guidelines: http://www.nlm.nih.gov/medlineplus/healthtopics.html
•
National Cancer Institute (NCI); guidelines available at http://www.cancer.gov/cancerinfo/list.aspx?viewid=5f35036e-5497-4d86-8c2c714a9f7c8d25
•
National Eye Institute (NEI); guidelines available at http://www.nei.nih.gov/order/index.htm
•
National Heart, Lung, and Blood Institute (NHLBI); guidelines available at http://www.nhlbi.nih.gov/guidelines/index.htm
•
National Human Genome Research Institute (NHGRI); research available at http://www.genome.gov/page.cfm?pageID=10000375
•
National Institute on Aging (NIA); guidelines available at http://www.nia.nih.gov/health/
10
These publications are typically written by one or more of the various NIH Institutes.
176
Campylobacter
•
National Institute on Alcohol Abuse and Alcoholism (NIAAA); guidelines available at http://www.niaaa.nih.gov/publications/publications.htm
•
National Institute of Allergy and Infectious Diseases (NIAID); guidelines available at http://www.niaid.nih.gov/publications/
•
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); fact sheets and guidelines available at http://www.niams.nih.gov/hi/index.htm
•
National Institute of Child Health and Human Development (NICHD); guidelines available at http://www.nichd.nih.gov/publications/pubskey.cfm
•
National Institute on Deafness and Other Communication Disorders (NIDCD); fact sheets and guidelines at http://www.nidcd.nih.gov/health/
•
National Institute of Dental and Craniofacial Research (NIDCR); guidelines available at http://www.nidr.nih.gov/health/
•
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); guidelines available at http://www.niddk.nih.gov/health/health.htm
•
National Institute on Drug Abuse (NIDA); guidelines available at http://www.nida.nih.gov/DrugAbuse.html
•
National Institute of Environmental Health Sciences (NIEHS); environmental health information available at http://www.niehs.nih.gov/external/facts.htm
•
National Institute of Mental Health (NIMH); guidelines available at http://www.nimh.nih.gov/practitioners/index.cfm
•
National Institute of Neurological Disorders and Stroke (NINDS); neurological disorder information pages available at http://www.ninds.nih.gov/health_and_medical/disorder_index.htm
•
National Institute of Nursing Research (NINR); publications on selected illnesses at http://www.nih.gov/ninr/news-info/publications.html
•
National Institute of Biomedical Imaging and Bioengineering; general information at http://grants.nih.gov/grants/becon/becon_info.htm
•
Center for Information Technology (CIT); referrals to other agencies based on keyword searches available at http://kb.nih.gov/www_query_main.asp
•
National Center for Complementary and Alternative Medicine (NCCAM); health information available at http://nccam.nih.gov/health/
•
National Center for Research Resources (NCRR); various information directories available at http://www.ncrr.nih.gov/publications.asp
•
Office of Rare Diseases; various fact sheets available at http://rarediseases.info.nih.gov/html/resources/rep_pubs.html
•
Centers for Disease Control and Prevention; various fact sheets on infectious diseases available at http://www.cdc.gov/publications.htm
Physician Resources
177
NIH Databases In addition to the various Institutes of Health that publish professional guidelines, the NIH has designed a number of databases for professionals.11 Physician-oriented resources provide a wide variety of information related to the biomedical and health sciences, both past and present. The format of these resources varies. Searchable databases, bibliographic citations, full-text articles (when available), archival collections, and images are all available. The following are referenced by the National Library of Medicine:12 •
Bioethics: Access to published literature on the ethical, legal, and public policy issues surrounding healthcare and biomedical research. This information is provided in conjunction with the Kennedy Institute of Ethics located at Georgetown University, Washington, D.C.: http://www.nlm.nih.gov/databases/databases_bioethics.html
•
HIV/AIDS Resources: Describes various links and databases dedicated to HIV/AIDS research: http://www.nlm.nih.gov/pubs/factsheets/aidsinfs.html
•
NLM Online Exhibitions: Describes “Exhibitions in the History of Medicine”: http://www.nlm.nih.gov/exhibition/exhibition.html. Additional resources for historical scholarship in medicine: http://www.nlm.nih.gov/hmd/hmd.html
•
Biotechnology Information: Access to public databases. The National Center for Biotechnology Information conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information for the better understanding of molecular processes affecting human health and disease: http://www.ncbi.nlm.nih.gov/
•
Population Information: The National Library of Medicine provides access to worldwide coverage of population, family planning, and related health issues, including family planning technology and programs, fertility, and population law and policy: http://www.nlm.nih.gov/databases/databases_population.html
•
Cancer Information: Access to cancer-oriented databases: http://www.nlm.nih.gov/databases/databases_cancer.html
•
Profiles in Science: Offering the archival collections of prominent twentieth-century biomedical scientists to the public through modern digital technology: http://www.profiles.nlm.nih.gov/
•
Chemical Information: Provides links to various chemical databases and references: http://sis.nlm.nih.gov/Chem/ChemMain.html
•
Clinical Alerts: Reports the release of findings from the NIH-funded clinical trials where such release could significantly affect morbidity and mortality: http://www.nlm.nih.gov/databases/alerts/clinical_alerts.html
•
Space Life Sciences: Provides links and information to space-based research (including NASA): http://www.nlm.nih.gov/databases/databases_space.html
•
MEDLINE: Bibliographic database covering the fields of medicine, nursing, dentistry, veterinary medicine, the healthcare system, and the pre-clinical sciences: http://www.nlm.nih.gov/databases/databases_medline.html
11
Remember, for the general public, the National Library of Medicine recommends the databases referenced in MEDLINEplus (http://medlineplus.gov/ or http://www.nlm.nih.gov/medlineplus/databases.html). 12 See http://www.nlm.nih.gov/databases/databases.html.
178
Campylobacter
•
Toxicology and Environmental Health Information (TOXNET): Databases covering toxicology and environmental health: http://sis.nlm.nih.gov/Tox/ToxMain.html
•
Visible Human Interface: Anatomically detailed, three-dimensional representations of normal male and female human bodies: http://www.nlm.nih.gov/research/visible/visible_human.html
The NLM Gateway13 The NLM (National Library of Medicine) Gateway is a Web-based system that lets users search simultaneously in multiple retrieval systems at the U.S. National Library of Medicine (NLM). It allows users of NLM services to initiate searches from one Web interface, providing one-stop searching for many of NLM’s information resources or databases.14 To use the NLM Gateway, simply go to the search site at http://gateway.nlm.nih.gov/gw/Cmd. Type “campylobacter” (or synonyms) into the search box and click “Search.” The results will be presented in a tabular form, indicating the number of references in each database category. Results Summary Category Journal Articles Books / Periodicals / Audio Visual Consumer Health Meeting Abstracts Other Collections Total
Items Found 9616 62 927 72 11 10688
HSTAT15 HSTAT is a free, Web-based resource that provides access to full-text documents used in healthcare decision-making.16 These documents include clinical practice guidelines, quickreference guides for clinicians, consumer health brochures, evidence reports and technology assessments from the Agency for Healthcare Research and Quality (AHRQ), as well as AHRQ’s Put Prevention Into Practice.17 Simply search by “campylobacter” (or synonyms) at the following Web site: http://text.nlm.nih.gov.
13
Adapted from NLM: http://gateway.nlm.nih.gov/gw/Cmd?Overview.x.
14
The NLM Gateway is currently being developed by the Lister Hill National Center for Biomedical Communications (LHNCBC) at the National Library of Medicine (NLM) of the National Institutes of Health (NIH). 15 Adapted from HSTAT: http://www.nlm.nih.gov/pubs/factsheets/hstat.html. 16 17
The HSTAT URL is http://hstat.nlm.nih.gov/.
Other important documents in HSTAT include: the National Institutes of Health (NIH) Consensus Conference Reports and Technology Assessment Reports; the HIV/AIDS Treatment Information Service (ATIS) resource documents; the Substance Abuse and Mental Health Services Administration's Center for Substance Abuse Treatment (SAMHSA/CSAT) Treatment Improvement Protocols (TIP) and Center for Substance Abuse Prevention (SAMHSA/CSAP) Prevention Enhancement Protocols System (PEPS); the Public Health Service (PHS) Preventive Services Task Force's Guide to Clinical Preventive Services; the independent, nonfederal Task Force on Community Services’ Guide to Community Preventive Services; and the Health Technology Advisory Committee (HTAC) of the Minnesota Health Care Commission (MHCC) health technology evaluations.
Physician Resources
179
Coffee Break: Tutorials for Biologists18 Coffee Break is a general healthcare site that takes a scientific view of the news and covers recent breakthroughs in biology that may one day assist physicians in developing treatments. Here you will find a collection of short reports on recent biological discoveries. Each report incorporates interactive tutorials that demonstrate how bioinformatics tools are used as a part of the research process. Currently, all Coffee Breaks are written by NCBI staff.19 Each report is about 400 words and is usually based on a discovery reported in one or more articles from recently published, peer-reviewed literature.20 This site has new articles every few weeks, so it can be considered an online magazine of sorts. It is intended for general background information. You can access the Coffee Break Web site at the following hyperlink: http://www.ncbi.nlm.nih.gov/Coffeebreak/.
Other Commercial Databases In addition to resources maintained by official agencies, other databases exist that are commercial ventures addressing medical professionals. Here are some examples that may interest you: •
CliniWeb International: Index and table of contents to selected clinical information on the Internet; see http://www.ohsu.edu/cliniweb/.
•
Medical World Search: Searches full text from thousands of selected medical sites on the Internet; see http://www.mwsearch.com/.
18 Adapted 19
from http://www.ncbi.nlm.nih.gov/Coffeebreak/Archive/FAQ.html.
The figure that accompanies each article is frequently supplied by an expert external to NCBI, in which case the source of the figure is cited. The result is an interactive tutorial that tells a biological story. 20 After a brief introduction that sets the work described into a broader context, the report focuses on how a molecular understanding can provide explanations of observed biology and lead to therapies for diseases. Each vignette is accompanied by a figure and hypertext links that lead to a series of pages that interactively show how NCBI tools and resources are used in the research process.
181
APPENDIX B. PATIENT RESOURCES Overview Official agencies, as well as federally funded institutions supported by national grants, frequently publish a variety of guidelines written with the patient in mind. These are typically called “Fact Sheets” or “Guidelines.” They can take the form of a brochure, information kit, pamphlet, or flyer. Often they are only a few pages in length. Since new guidelines on campylobacter can appear at any moment and be published by a number of sources, the best approach to finding guidelines is to systematically scan the Internet-based services that post them.
Patient Guideline Sources The remainder of this chapter directs you to sources which either publish or can help you find additional guidelines on topics related to campylobacter. Due to space limitations, these sources are listed in a concise manner. Do not hesitate to consult the following sources by either using the Internet hyperlink provided, or, in cases where the contact information is provided, contacting the publisher or author directly. The National Institutes of Health The NIH gateway to patients is located at http://health.nih.gov/. From this site, you can search across various sources and institutes, a number of which are summarized below. Topic Pages: MEDLINEplus The National Library of Medicine has created a vast and patient-oriented healthcare information portal called MEDLINEplus. Within this Internet-based system are “health topic pages” which list links to available materials relevant to campylobacter. To access this system, log on to http://www.nlm.nih.gov/medlineplus/healthtopics.html. From there you can either search using the alphabetical index or browse by broad topic areas. Recently, MEDLINEplus listed the following when searched for “campylobacter”:
182
Campylobacter
Bacterial Infections http://www.nlm.nih.gov/medlineplus/bacterialinfections.html E. Coli Infections http://www.nlm.nih.gov/medlineplus/ecoliinfections.html Food Contamination and Poisoning http://www.nlm.nih.gov/medlineplus/foodcontaminationandpoisoning.html Food Safety http://www.nlm.nih.gov/medlineplus/foodsafety.html Salmonella Infections http://www.nlm.nih.gov/medlineplus/salmonellainfections.html
Within the health topic page dedicated to campylobacter, the following was listed: •
Diagnosis/Symptoms Diarrhea Source: American Academy of Family Physicians http://familydoctor.org/534.xml Nausea and Vomiting Source: American Academy of Family Physicians http://familydoctor.org/529.xml Stool Tests Source: Nemours Foundation http://kidshealth.org/parent/general/sick/labtest8.html
•
Children Amebiasis Source: Nemours Foundation http://kidshealth.org/parent/infections/parasitic/amebiasis.html Campylobacter Infections Source: Nemours Foundation http://kidshealth.org/parent/infections/stomach/campylobacter.html Ground Meat and Food Poisoning Source: National Resource Center for Health and Safety in Child Care http://nrc.uchsc.edu/TIPS/food.htm Mushroom Poisoning in Children Source: American Academy of Family Physicians http://familydoctor.org/129.xml Yersinia Enterocolitica Source: Nemours Foundation http://kidshealth.org/parent/infections/bacterial_viral/yersinia.html
Patient Resources
•
183
From the National Institutes of Health Bacteria and Foodborne Illness Source: National Institute of Diabetes and Digestive and Kidney Diseases http://digestive.niddk.nih.gov/ddiseases/pubs/bacteria/index.htm Foodborne Diseases Source: National Institute of Allergy and Infectious Diseases http://www.niaid.nih.gov/factsheets/foodbornedis.htm
•
Latest News FDA Investigating Illnesses Associated with School Lunches Served in Massachusetts Source: 06/02/2004, Food and Drug Administration http://www.fda.gov/bbs/topics/news/2004/NEW01074.html FDA Issues Alert on Foodborne Illness Associated with Certain Basil and Mesculin/Spring Mix Salad Products Source: 05/21/2004, Food and Drug Administration http://www.fda.gov/bbs/topics/news/2004/NEW01071.html
•
Law and Policy What to Do If You Have a Problem with Food Products Source: Dept. of Agriculture, Food Safety and Inspection Service http://www.fsis.usda.gov/oa/pubs/illness.htm
•
Organizations CDC Health Topics: Foodborne Illnesses Source: Centers for Disease Control and Prevention http://www.cdc.gov/health/foodill.htm Food and Drug Administration http://www.fda.gov/ Food Safety and Inspection Service Source: Dept. of Agriculture http://www.fsis.usda.gov/ National Institute of Allergy and Infectious Diseases http://www.niaid.nih.gov/ Partnership for Food Safety Education http://www.fightbac.org www.FoodSafety.gov Source: Center for Food Safety and Applied Nutrition http://www.foodsafety.gov/
•
Pictures/Diagrams Foodborne Illness: Ten Least Wanted Foodborne Pathogens Source: Partnership for Food Safety Education http://www.fightbac.org/10least.cfm
184
•
Campylobacter
Prevention/Screening Everyone Can Fight BAC! Source: Partnership for Food Safety Education http://www.fightbac.org/factsht.cfm Hock Locks and Other Accoutrements Source: Dept. of Agriculture, Food Safety and Inspection Service http://www.fsis.usda.gov/OA/pubs/hocklock.htm Unwelcome Dinner Guest: Preventing Foodborne Illness Source: Food and Drug Administration http://vm.cfsan.fda.gov/%7Edms/fdunwelc.html
•
Research High Levels of Arsenic in Chicken May Require Adjustment in Consumption Source: National Institute of Environmental Health Sciences http://ehp.niehs.nih.gov/press/achicken.html
•
Statistics Foodborne-Disease Outbreaks Reported to CDC January 1, 1990 Through March 15, 2002 Source: National Center for Infectious Diseases, Division of Bacterial and Mycotic Diseases http://www.cdc.gov/foodborneoutbreaks/outbreak_satistics/cdc_reported.htm
•
Women During Your Pregnancy: Food Safety Source: March of Dimes Birth Defects Foundation http://www.marchofdimes.com/pnhec/159_826.asp Food-Borne Risks in Pregnancy Source: March of Dimes Birth Defects Foundation http://www.marchofdimes.com/professionals/681_1152.asp
You may also choose to use the search utility provided by MEDLINEplus at the following Web address: http://www.nlm.nih.gov/medlineplus/. Simply type a keyword into the search box and click “Search.” This utility is similar to the NIH search utility, with the exception that it only includes materials that are linked within the MEDLINEplus system (mostly patient-oriented information). It also has the disadvantage of generating unstructured results. We recommend, therefore, that you use this method only if you have a very targeted search. The Combined Health Information Database (CHID) CHID Online is a reference tool that maintains a database directory of thousands of journal articles and patient education guidelines on campylobacter. CHID offers summaries that describe the guidelines available, including contact information and pricing. CHID’s general Web site is http://chid.nih.gov/. To search this database, go to http://chid.nih.gov/detail/detail.html. In particular, you can use the advanced search
Patient Resources
185
options to look up pamphlets, reports, brochures, and information kits. The following was recently posted in this archive: •
Questions and Answers About Reactive Arthritis Source: Bethesda, MD: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Information Clearinghouse. 2002. 24 p. Contact: Available from National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Information Clearinghouse. 1 AMS Circle, Bethesda, MD 20892-3675. (877) 226-4267 toll-free or (301) 495-4484. Fax (301) 718-6366. TTY (301) 565-2966. E-mail:
[email protected]. Website: www.niams.nih.gov. PRICE: 1 to 25 copies free. Order Number: AR-253 QA (booklet), or AR-253L QA (large print fact sheet). Summary: This booklet uses a question and answer format to provide people who have reactive arthritis with information about the causes, symptoms, diagnosis, and treatment of this form of arthritis, which occurs as a reaction to an infection elsewhere in the body. Reactive arthritis, or Reiter's syndrome, usually begins 1 to 3 weeks after infection. Chlamydia trachomatis, the bacterium most often associated with reactive arthritis, is usually acquired through sexual contact. Infections in the digestive tract caused by Salmonella, Shigella, Yersinia, and Campylobacter may also trigger reactive arthritis. A genetic factor, human leukocyte antigen, increases the risk of developing reactive arthritis. Although reactive arthritis itself is not contagious, the bacteria that trigger it can be passed from person to person. Men aged 20 to 40 are most likely to develop reactive arthritis. Symptoms include inflammation of the urogenital tract, the joints, and the eyes. Mouth ulcers and skin rashes are less common symptoms. Diagnosis is based on clinical presentation, laboratory tests, and imaging studies. There is no cure for reactive arthritis, but some treatments relieve symptoms. Treatment options include nonsteroidal antiinflammatory drugs, corticosteroid injections, topical corticosteroids, antibiotics, immunosuppressive medicines, tumor necrosis factor inhibitors, and exercise. Most people with reactive arthritis recover fully within 2 to 6 months after the first symptoms appear. Researchers are investigating the causes and treatments for reactive arthritis. The booklet identifies sources of additional information and provides a glossary of medical terms.
•
Is Your Food Safe? Source: Santa Cruz, CA: ETR Associates. 1998. 6 p. Contact: Available from ETR Associates. 4 Carbonero Way, Scotts Valley, CA 950664200. (800) 321-4407. Fax (800) 435-8433. Website: www.etr.org. PRICE: Single copy free; bulk copies available. Order number: R027. Summary: This brochure describes foodborne illnesses and their prevention. If food is poorly handled or not cooked or stored properly, bacteria can multiply and cause illness. Not everyone who eats contaminated food will become sick. The symptoms depend on which organism was eaten, how much was eaten, and what the age and general health of the person are. Symptoms of food poisoning are similar to those of stomach flu and include nausea, vomiting, diarrhea, stomach pain or cramps, and fever, fatigue, and feelings of weakness. The brochure lists nine organisms and how they are usually transmitted; organisms and diseases discussed are botulism, Campylobacter, Crytosporidiosis, cyclospora, E. coli (0157:H7), hepatitis A, listeriosis, Salmonella, and Vibrio vulnificus. The brochure notes that mild illness usually gets better on its own and provides basic strategies for handling symptoms of mild food poisoning. The brochure also lists symptoms that would indicate the need to contact a health care provider and
186
Campylobacter
notes people more at risk for problems from food poisoning. The centerpiece of the brochure offers U.S. Department of Agriculture strategies for keeping food safe: the six areas covered are buying, storing, preparing, cooking, and serving food, and eating out. A chart summarizes the time that fresh meat, fish, poultry, cheese, eggs, and milk will last in the refrigerator or in the freezer. One sidebar lists safe kitchen tips (primarily relating to hygiene). •
About Keeping Safe from Waterborne Pathogens Source: South Deerfield, MA: Channing L. Bete Co., Inc. 1997. 15 p. Contact: Available from Channing L. Bete, Co., Inc. 200 State Road, South Deerfield, MA 01373-0200. (800) 628-7733. PRICE: $1.72 each for 1-24 copies; $1.47 each for 25-99 copies. Summary: This brochure educates readers about waterborne pathogens, disease-causing organisms that can